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Abstract	1	
Transcatheter	heart	valve	replacements	avoid	the	main	risks	associated	with	conventional	
open	 heart	 surgery	 and	 so	 is	 the	 preferred	 replacement	 technique	 for	 high-risk	 patients	
with	aortic	stenosis.	Due	to	technical	challenges,	adaptation	for	the	mitral	position	is	still	in	
early	stages	of	research.	
The	 aim	 of	 this	 project	 was	 to	 develop	 the	 novel	 UCL	 transcatheter	 mitral	 valve	 (TMV)	
based	on	a	prior	conceptual	design.	The	UCL	TMV	is	designed	to	treat	mitral	regurgitation	
(MR)	 and	 is	 based	 on	 the	 UCL	 transcatheter	 aortic	 valve	 (TAV)	 which	 is	 retrievable,	
repositionable	and	has	enhanced	anchoring	and	sealing.		
The	 UCL	 TMV	 leaflets,	 which	 ensure	 unidirectional	 blood	 flow,	 are	 novel	 because	 they	
mimic	native	mitral	valve	morphology	by	having	two	leaflets,	being	D-shaped	and	conical.	
Their	optimal	design	criterion	and	two	key	design	parameters	were	identified	using	a	failure	
mode	 and	 effects	 analysis	 and	 numerical	 simulations	 were	 used	 to	 select	 a	 design	 with	
acceptable	 stress	 levels	 and	 maximum	 coaptation	 area.	 The	 optimal	 leaflets	 were	
prototyped	as	a	surgical	valve	to	evaluate	their	performance	against	available	commercial	
device	 designs	 and	 were	 then	 incorporated	 in	 TMV	 prototypes,	 and	 assessed	 for	
hydrodynamic	performance,	both	of	which	exceeded	international	standard	requirements.	
Durability	assessment	of	the	TMV	is	ongoing	and	very	encouraging;	currently	withstanding	
>	80	million	cardiac	cycles.	
In	 conclusion,	 the	 results	presented	and	ongoing	durability	assessments	 for	 the	UCL	TMV	
indicate	 it	 could	 be	 a	 new	 and	 effective	 treatment	 option	 for	 severe	 MR	 in	 high-risk	
patients	whom	are	declined	surgical	interventions.		
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Thesis	Aim		
There	 are	 approximately	 eight	 million	 people	 worldwide	 with	 symptomatic	 mitral	
regurgitation	 (Lloyd-Jones	et	al	2010,	Nkomo	et	al	2006,	 Lung	et	al	2003)	and	due	 to	 the	
prevalence	 increasing	 with	 age	 and	 the	 presence	 of	 an	 aging	 population	 the	 number	 of	
cases	is	expected	to	rise	significantly	in	the	future.	Up	to	50%	of	patients	with	severe	mitral	
regurgitation,	whom	would	 advisably	 have	 a	 replacement,	 are	 currently	 declined	 surgery	
because	they	are	judged	too	ill	or	weak	to	withstand	the	stress	of	the	open	heart	procedure	
required	(Taramasso	et	al	2010,	Mirabel	et	al	2007,	Lung	et	al	2003)	(3).	
Transcatheter	 aortic	 valves	 (TAV)	 have	 provided	 a	 treatment	 option	 for	 similar	 patients	
with	 aortic	 valve	 disease;	 however	 these	 devices	 are	 not	 suitable	 for	 the	mitral	 position.	
The	UCL	TAV	was	developed	 for	 the	 treatment	of	 calcified	aortic	 valves	and	 improves	on	
the	 first	generation	of	 commercially	available	devices	by	being	 retrievable,	 repositionable	
and	has	enhanced	anchoring	and	sealing.	Following	successful	animals	trials	of	the	UCL	TAV,	
it	was	adapted	for	the	mitral	position,	to	have	two-leaflets	and	be	D-shaped	(Chapter	2).	
The	 aim	 of	 this	 project	 was	 to	 develop	 a	 proof	 of	 concept	 prototype	 of	 the	 UCL	
transcatheter	mitral	valve	 (TMV)	by	completing	an	 initial	design	cycle	consisting	of	design	
(Chapter	3	and	4),	prototyping	and	testing	(Chapter	6	and	7).		
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Chapter	1 Background	
The	transcatheter	mitral	valve	developed	 in	 this	project	 is	designed	to	treat	severe	mitral	
regurgitation	 in	 high-risk	 patients.	 Therefore,	 the	 aim	 of	 this	 chapter	 is	 to	 explain	 the	
anatomy	 and	 function	of	 healthy	mitral	 valves,	 define	mitral	 regurgitation	 in	 terms	of	 its	
statistical	 significance	 and	 pathology,	 and	 introduces	 the	 current	 surgical	 and	 minimally	
invasive	treatment	options	as	well	as	the	emerging	UCL	solutions.	
1.1 Mitral	valve	
This	 section	describes	 the	mitral	 valve	anatomy	and	kinetics	associated	with	 the	annulus,	
leaflets,	chordae	tendineae	and	papillary	muscles	and	describes	the	associated	left	ventricle	
(LV)	dynamics.	
1.1.1 Anatomy	
The	mitral	valve	is	located	in	the	left	side	of	the	heart.	It	regulates	the	flow	of	oxygenated	
blood	from	the	left	atrium	(LA)	into	the	LV	(Figure	1.1),	which	pumps	the	blood	through	the	
aortic	valve	and	around	the	circulatory	system.		
	
MV	open	(a)	 (b)	
Figure	 1.1:	2D	 echocardiogram	of	 a	 healthy	mitral	 valve	 (a)	direction	 of	 blood	 flow	
through	 open	mitral	 valve	 (MV),	 papillary	muscles	 (PM)	 (b)	 left	 atrium	 (LA),	 closed	
mitral	valve	(MV),	left	ventricle	(LV)	(acknowledgements:	Gibbons	R,	Brunel	University	
London).	
LV	
MV	closed	
LA		blood	flow	
PM	
MV	open	
(a)	 (b)	
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1.1.1.1	Annulus	
The	mitral	valve	is	essentially	part	of	the	LV	and	is	often	described	as	having	an	annulus.	In	
fact	it	is	a	saddle	D-shaped	orifice	called	the	left	atrioventricular	junction,	formed	between	
the	 walls	 of	 the	 LV	 and	 the	 supporting	 LV	 structures	 (Van	 Mieghem	 et	 al	 2010),	 that	
supports	the	thin	tissue	leaflets.		
	
1.1.1.2	Leaflets	
The	vascularized	 leaflets	are	made	 from	fibrous	 tissue	 (collagen	 type	 I,	 III	and	V),	 smooth	
muscle	 cells	 and	nonmylinated	nerve	 fibres.	 The	 conical	 leaflet	 structure	 is	 formed	of	 an	
aortic	 leaflet,	 which	 is	 in	 fibrous	 continuity	 with	 two	 of	 the	 aortic	 valve	 leaflets,	 and	 is	
divided	 into	 three	 regions;	 A1	 (lateral),	 A2	 (middle)	 and	 A3	 (medial),	 connected	 via	 the	
anterolateral	 and	 posteromedial	 commissures	 to	 the	 opposing	 mural	 leaflet	 similarly	
divided	 into	 three	 regions	P1,	P2	and	P3	and	has	 two	scallops	 (indentations)	 (Figure	1.2).	
The	aortic	 leaflet	 is	 relatively	 longer	and	covers	one-third	of	 the	atrioventricular	 junction,	
compared	to	the	shorter	and	less	extensible	mural	leaflet	which	covers	the	remaining	two	
thirds.	The	leaflets	are	described	by	three	regions;	the	base	(closest	to	the	annulus),	belly	
(central	 region)	 and	 the	 free	 edge	 (distal	 to	 the	 annulus),	 the	 latter	 being	 the	 most	
extensible.	The	leaflets	are	further	described	by	two	zones;	clear	and	rough.	The	clear	zone	
occurs	 between	 the	 annulus	 and	 line	 of	 coaptation,	 which	 have	 minimal	 chordae	
attachment,	are	thin	with	regular	texture	and	translucent.	The	rough	zones	have	numerous	
chordal	 insertions,	 with	 a	 higher	 density	 in	 the	 mural	 leaflet,	 and	 therefore	 are	 thicker,	
irregular	and	textured.		
	
	
	
	 	
Figure	 1.2:	Mitral	 valve	 leaflet	 regions:	 (posterior	 leaflet)	
lateral	 (P1),	middle	 (P2)	 and	medial	 (P3)	 (anterior	 leaflet)	
similarly	A1,	A2	and	A3	(Fedak	et	al	2008).	
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1.1.1.3	Chordae	tendineae	
The	 fibrous	 tendinous	 cords	 extend	down	 from	 the	 rough	 zones	 connecting	 the	edges	of	
the	leaflets	to	the	LV	wall	by	gathering	them	into	two	papillary	muscles;	posteromedial	and	
anterolateral,	anchoring	them	in	the	cardiac	muscle	(Figure	1.3).		
	
	
	
	
	
	
	
	
	
	
	
	
1.1.2 Dynamic	behaviour	of	mitral	valve	components	
The	mitral	valve	opens	and	closes	throughout	the	cardiac	cycle.	During	diastole,	when	the	
atrial	pressure	 is	greater	than	 in	the	ventricle,	 the	mitral	valve	opens,	a	 jet	 is	 formed	and	
the	 valve	 reaches	 its	maximum	open	position	 (Figure	 1.4.a).	 Vortices	 begin	 to	 form	once	
peak	flow	has	been	achieved	(Figure	1.4.b),	the	mitral	flow	then	diminishes	and	the	leaflets	
gradually	 start	 to	close	under	 the	action	of	vortices	and/or	an	adverse	pressure	gradient,	
the	mitral	 jet	becomes	 slower	and	narrower	 (Figure	1.4.c).	Atrial	 contraction	 then	causes	
acceleration	of	 flow	reopening	the	mitral	valve,	but	without	convective	vortex	generation	
(Figure	 1.4.d).	 The	 ventricle	 begins	 to	 contract	 reversing	 the	 atrio-ventricular	 pressure	
gradient	 causing	 the	 valve	 to	 close	 (Figure	 1.4.e).	 Once	 the	 mitral	 valve	 is	 fully	 closed	
isovolumic	 contraction	 occurs	 rising	 the	 ventricular	 pressure	 above	 the	 aorta	 pressure	
opening	the	aortic	valve	(Figure	1.4.f).	
	
Below	 are	 detailed	 descriptions	 of	 the	 mitral	 valve	 components,	 including	 the	 mitral	
annulus,	leaflets,	chordae	tendineae	and	papillary	muscles.		
Figure	1.3:	Morphology	of	the	left	heart	(a)	dissected	left	ventricle	with	intact	mitral	valve	(b)	
dissected	left	ventricle	and	mitral	valve	(acknowledgements:	Cook	A,	UCL).	
aortic	valve	
leaflets	
chordae	
tendineae	
anterolateral	
papillary	
muscle	
(a)	
posteromedial	
papillary	muscle	
posteromedial	commissures	
aortic	leaflet	 mural	
leaflet	
(b)	
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1.1.2.1	Annulus	
The	mitral	annulus	contracts	and	bends	 throughout	 the	cardiac	cycle	 (Figure	1.5),	varying	
the	mitral	orifice	area	and	circumference	by	as	much	as	26%	and	13%,	respectively	(Rabbah	
et	 al	 2013).	 The	 saddle	 shape,	 defined	 by	 the	 annular	 height	 to	 commissural	width	 ratio	
(AHCWR)	 (Figure	 1.6),	 can	 vary	 by	 as	 much	 as	 30%	 (Rabbah	 et	 al	 2013)	 throughout	 the	
cardiac	 cycle	 and	has	 an	essential	 role	 in	 reducing	 the	 stresses	 in	 the	 leaflets	 and	evenly	
distributing	the	forces	among	the	chordae,	the	flattening	of	which	has	been	associated	with	
an	increase	in	the	severity	of	mitral	regurgitation	(Jensen	et	al	2013).	
	
	
	
	
	
	
	
Figure	1.4:	Six	main	stages	of	the	mitral	valve	cardiac	cycle	dynamics	
(adapted	from	Reul	et	al	1981).	
(a) diastole	
begins	
(d)	re-opening	
(b)	peak	flow	
(e)	closing	
(c)	initial	closing	
(f)	systole	begins	
Figure	 1.5:	 3D	 echocardiogram	 of	 a	 healthy	 mitral	 valve	 (a)	 more	 circular	 in	
diastole	 (blood	 flow	 into	 the	 page)	 (b)	 more	 kidney-shaped	 in	 systole	
(acknowledgements:	Pantazis	A,	The	Heart	Hospital,	London).	
location	of	aortic	valve	
(a) open	 (b)	closed	
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1.1.2.2	Leaflets	
The	 passive	 membrane	 leaflets	 undergo	 membrane	 deformation,	 more	 specifically,	 the	
coapting	force	on	the	leaflets	is	caused	by	the	apically	contracting	papillary	muscles	and	the	
basally	directed	pressure	forces	(Figure	1.7).	The	mobility	and	redundancy	of	the	aortic	and	
mural	 leaflets	 respectively	 (Kunzelman	 et	 al	 1994),	 combined	 with	 the	 presence	 of	 the	
commissures	provides	an	optimal	seal	to	withstand	the	transmitral	pressure	gradient.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
1.1.2.3	Chordae	tendineae	
The	collagenous	chordae	(Padala	et	al	2010)	exert	restraining	tensile	forces	during	systole	
preventing	 the	 upward	 displacement	 of	 the	 leaflets	 into	 the	 LA	 and	 have	 recently	 been	
measured	 in	 vivo	 (Askov	 et	 al	 2013).	 They	 also	 facilitate	 leaflet	 opening,	 along	 with	 the	
commissures,	during	diastole.	
Figure	1.6:	Mitral	valve	saddle	shape	defined	as	the	ratio	of	annular	height	
(H)	to	commissural	width	(W)	(adapted	from	Padala	et	al	2009).	
Figure	 1.7:	 Forces	 (F)	 acting	 on	 the	 mitral	 apparatus	 (FLAP)	 left	 atrium	
pressure	 (FLVP)	 left	 ventricle	 pressure	 (FC)	 chordae	 (FPM)	papillary	 muscles	
(FAC)	 annular	 contraction	 (FAF)	 apical-basal	 force	 (LA)	 left	 atrium	 (LV)	 left	
ventricle	(Rabbah	et	al	2013).	
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1.1.2.4	Papillary	muscles	
The	 papillary	muscles	 stabilise	mitral	 valve	 function	 by	 adjusting	 the	 tension	 on	 chordae	
and	 leaflets.	 They	 contract	 apically	 by	 as	 much	 as	 2-5	 mm	 during	 systole,	 thereby	
maintaining	valvular-ventricular	force	continuity,	then,	before	diastole	the	crimped	collagen	
fibrils	straighten	and	the	high	crosslinking	of	collagen	prevent	creep	during	valve	closure.	
	
There	 are	 various	 pathologies	 associated	with	 the	mitral	 valve	which	 alter	 these	 healthy	
anatomies,	dynamics	and	kinetics,	the	most	common	pathology	being	mitral	regurgitation	
(MR).	
1.2 Mitral	regurgitation	
This	section	summarises	the	statistics	associated	with	MR,	one	of	the	most	common	forms	
of	heart	valve	disorder,	and	describes	the	pathology	 in	terms	of	anatomical	abnormalities	
and	their	subsequent	effect	on	the	pressures	and	volumes	within	the	LV.	
1.2.1 Statistics		
It	 is	 estimated	 that	 symptomatic	 MR	 affects	 over	 four	 million	 Europeans	 and	 a	 similar	
number	of	Americans	(Lloyd-Jones	et	al	2010,	Nkomo	et	al	2006,	Lung	et	al	2003)	and	due	
to	the	continuous	ageing	of	the	western	population;	the	number	of	cases	is	expected	to	rise	
significantly	 in	 the	 future.	 In	 fact,	MR	prevalence	 increases	with	age,	 rising	 from	0.5%	 for	
young	 patients	 (18-44	 year	 olds)	 to	 9.3%	 for	 patients	 older	 than	 75	 years	 (Nkomo	 et	 al	
2006).	Therefore,	a	significant	proportion	of	symptomatic	patients	are	in	their	late	age,	with	
relevant	co-morbidities	and	previous	surgery	(Lung	et	al	2003,	Edwards	et	al	2003,	Roques	
et	al	1999,	Körfer	et	al	1995).	As	a	result,	up	to	50%	of	them	are	currently	declined	surgery	
because	they	are	 judged	too	 ill	or	weak	to	withstand	the	stress	of	 the	 invasive	treatment	
(Taramasso	et	al	2010,	Mirabel	et	al	2007,	Lung	et	al	2003).	
1.2.2 Pathology	
MR	is	the	flow	of	blood	in	the	wrong	direction	from	the	LV	through	the	mitral	valve	into	the	
LA	 and	 results	 in	 additional	 turbulence	 in	 the	 LA	 during	 systole	 (Dyverfeldt	 et	 al	 2011).	
Degenerative	 MR	 is	 associated	 with	 alterations	 of	 the	 mitral	 valve	 leaflet	 structure,	
whereas	functional	MR,	classified	by	Carpentier’s	four	functional	classes	(Figure	1.8),	occurs	
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due	to	changes	 in	shape	of	the	heart	chambers	or	damage	to	the	heart	muscle	(e.g.	 from	
myocardial	 infarction)	 resulting	 in	 annular	 dilatation	 and	 papillary	 muscle	 displacement,	
which	compromises	correct	leaflet	coaptation.		
	
	
	
	
	
	
MR	 alters	 the	 healthy	 pressures	 and	 flows	 that	 occur	 in	 the	 LV	 during	 the	 cardiac	 cycle,	
which	 are	 commonly	 represented	 by	 pressure-volume	 diagrams	 (Figure	 1.9).	 Firstly,	 MR	
prevents	 isovolumetric	contraction	and	relaxation;	which	can	be	observed	in	Figure	1.9	as	
volumetric	changes	between	2	and	3	and	between	4	and	1	respectively.	MR	also	increases	
the	 afterload	 i.e.	 the	 pressure	 in	 the	 LV	 during	 ejection,	which	 can	 cause	 a	 smaller	 than	
normal	 end-systolic	 volume	 (point	 1,	 Figure	 1.9).	 The	 elevated	 pressure	 in	 the	 atrium,	
caused	 by	 the	 regurgitant	 flow,	 is	 transmitted	 to	 the	 ventricle	 during	 diastole,	when	 the	
mitral	 valve	 is	 open,	 causing	 the	 end-diastolic	 pressure	 and	 volume	 in	 the	 ventricle	 to	
increase	(point	2,	Figure	1.9),	the	latter	is	exacerbated	by	increased	compliance	associated	
with	dilated	ventricles	in	the	case	of	chronic	MR.	This	means	that	despite	the	stroke	volume	
increasing	 the	 volume	 ejected	 into	 the	 aorta	 reduces.	 In	 addition	 to	 raising	 the	 systolic	
pressure	and	volumetric	capacity	 the	cardiac	system	also	uses	systemic	vasoconstriction2,	
increased	 blood	 volume	 and	 heart	 rate	 and	 inotropy3	 in	 order	 to	 compensate	 for	 loss	 of	
blood	flow.	Therefore	Figure	1.9	is	only	one	example	of	what	a	given	set	of	conditions	for	
MR	may	look	like.	
																																								 																				
2	Systemic	vasoconstriction	is	the	narrowing	of	blood	vessel	throughout	the	circulatory	system.	
3	Inotropy	is	cardiac	contractility.	
Figure	 1.8:	 Carpentier’s	 functional	 classification	 of	 mitral	 regurgitation	 (Type	 I)	
annular	 dilation	 or	 leaflet	 perforation	 (Type	 II)	 leaflet	 prolapse	 (Type	 III)	
restricted	 leaflet	 motion	 (a)	 subvalvular	 involvement	 (b)	 ventricular	 dilation.	
Dashed	 arrow:	 undesired	 regurgitant	 flow;	 solid	 arrow:	desired	 flow	 into	 aorta	
(adapted	from	Cohn	et	al	2003).	
Type	I	 Type	 II Type	 IIIa Type	 IIIb
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The	 area	 of	 the	 pressure-volume	 diagram	 is	 equivalent	 to	 the	 energy	 generated	 by	 the	
pumping	 action	 of	 the	 LV	 during	 one	 cardiac	 cycle.	 All	 healthy	 circulatory	 systems	 have	
energy	 losses,	 which	 occur	 when	 mechanical	 energy	 in	 the	 form	 of	 static	 pressure	
(generated	by	ventricular	contraction),	 is	 irreversibly	converted	 to	 frictional	energy	 in	 the	
form	of	heat	 (via	viscosity	and	flow	separation)	during	the	desirable	conversion	to	kinetic	
energy	(Akins	et	al	2008).	Pathologies	are	sources	of	additional	energy	loss	and	in	the	case	
of	 MR,	 cause	 abnormal	 remodelling	 of	 the	 LV	 and	 circulatory	 system,	 resulting	 in	 an	
undesirable	 increase	 in	stress	on	the	myocardium.	 In	 fact,	 this	concept	of	energy	 loss	has	
been	used	to	assess	MR	in	symptomatic	patients	(MacIsaac	et	al	1992).	
If	 untreated,	 MR	 increases	 the	 risk	 of	 heart	 failure	 and	 leads	 to	 a	 deterioration	 in	 life	
expectancy	and	quality	of	life.	In	severe	cases,	the	leaking	native	valve	can	be	replaced	by	a	
prosthetic	 device;	 optimal	 devices	 being	 those	 with	 minimal	 energy	 losses	 (Akins	 et	 al	
2008).	
1.3 Surgical	treatments	
In	severe	cases	of	mitral	heart	valve	disease,	the	clinician	may	suggest	the	patients’	native	
valve	 to	 be	 replaced	 by	 a	 prosthetic	 device.	 Current	 options	 include	 mechanical	 and	
stentless	or	stented	bioprosthetic	heart	valves	(Figure	1.10).		
	
Figure	1.9:	Pressure-volume	diagram	for	a	healthy	heart	compared	 to	one	
with	 mitral	 regurgitation	 (1-2)	 mitral	 valve	 open	 (2-3)	 “isovolumic”	
contraction	 (3-4)	 aortic	 valve	 open	 (4-1)	 “isovolumic”	 relaxation	 (adapted	
from	Klabunde	2011).	
healthy	
mitral	regurgitation	
1	 2	
3	
4	
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Mechanical	valves	have	the	best	durability;	 lasting	30-40	years	compared	to	bioprosthetic	
valves	which	only	last	15	years	(Hoffmann	et	al	2008).	However,	the	synthetic	materials	of	
mechanical	valves	require	anticoagulation	therapy,	 the	side	effects	of	which	decrease	the	
patients’	 quality	of	 life.	 Such	 therapy	 is	 not	 required	 for	bioprosthetic	 valves,	made	 from	
biological	 tissue	 and	 furthermore	 they	 have	more	 favourable	 hemodynamic	 performance	
(Hulsmann	et	al	2012),	therefore	in	some	cases	are	the	best	treatment	option.		
The	 Pericarbon	 MORE	 Mitral	 (Figure	 1.10)	 successfully	 mitigated	 the	 early	 mechanical	
failures	 that	hampered	 the	durability	of	 first-generation	pericardial	 valves	and	 is	 the	only	
bioprosthetic	device	specifically	adapted	from	its	initial	aortic	version	for	the	mitral	position	
(Caimmi	 et	 al	 1998).	 In	 general,	manufacturers	 design	devices	 for	 the	 aortic	 position,	 for	
which	 there	 is	 a	higher	 commercial	demand,	and	assess	 them	according	 to	 the	minimum	
performance	requirements	for	the	mitral	position,	with	higher	pressure	gradients	than	the	
aortic	 position.	 Therefore,	 these	 circular	 three	 leafleted	 aortic	 valves	 can	 be	 used	 in	 the	
opposite	orientation	 in	 the	mitral	position;	a	 typical	 sizer	used	 to	 select	 the	correct	 sized	
device	is	shown	in	Figure	1.11.	Subsequently	all	bioprosthetic	heart	valves	implanted	in	the	
mitral	position	force	the	natural	D-shape,	see	Figure	1.5,	to	become	circular	and	replace	the	
native	two	leaflets	with	three,	the	effect	of	which	is	unknown.		
Figure	 1.10:	 Surgical	 mitral	 valve	 replacements	 (top)	mechanical;	 left:	 bi-
leaflet,	middle:	tilting	disk,	right:	ball	and	cage	(bottom)	bioprosthetic;	left:	
stentless,	right:	stented	(Pericarbon	MORE	Mitral).	
	
	
32	
	
	
	
	
	
	
	
Prosthetic	heart	valves	present	a	greater	resistance	to	blood	flow	compared	to	the	native	
valve	 and	 therefore	 cause	 additional	 energy	 losses,	 dependant	 on	 valve	 type,	 size,	
orientation	 and	 position,	 consequently	 affecting	 ventricular	 function.	 Stentless	
bioprostheses	provide	the	least	resistance,	followed	by	bileaflet	and	tilting	disk	mechanical	
valves	and	stented	bioprostheses	present	the	greatest	resistance,	as	tested	 in	vitro	 (Akins	
et	al	2008,	Yoganathan	et	al	2002).		
All	of	the	above	mitral	valve	replacements	require	open	heart	surgery	which	presents	too	
many	 risks	 for	 half	 the	 patients	 that	 require	 a	 replacement	 (Mirabel	 et	 al	 2007).	 These	
patients	 are	 currently	 treated	with	 limited	medical	 alternatives,	 i.e.	 drugs,	 which	merely	
aim	to	relieve	their	symptoms	and	in	fact	in	some	cases	have	no	benefit	at	all	(Nishimura	et	
al	2014).	Therefore,	there	is	a	clinical	need	for	a	minimally	invasive	alternative.	
1.4 Minimally	invasive	treatments		
In	 recent	years,	 the	growing	need	 for	 less	 invasive	 therapeutic	approaches	has	 led	 to	 the	
development	 of	 a	 number	 of	 reconstructive	 percutaneous	 treatments	 for	MR.	 However;	
these	procedures	generally	only	relieve	the	symptoms	of	very	specific	forms	of	mitral	valve	
disease	and	anatomic	subset,	and	are	still	surpassed	in	efficacy	by	surgical	repair	(Herrmann	
2009,	Masson	et	al	2009).	A	minimally	 invasive	mitral	valve	functional	replacement	would	
allow	 the	 treatment	 of	 a	 broader	 spectrum	 of	 patients,	 disease	 etiology	 and	 anatomical	
variations,	 with	 significant	 benefits	 for	 the	 substantial	 patient	 population	 unable	 to	
undergo	 invasive	 surgery	 (Davidson	 et	 al	 2006,	 Lung	 et	 al	 1996).	 This	 approach	 would	
reduce	 both	 the	 procedural	 and	 recovery	 time	 for	 heart	 valve	 replacements	 (Modi	 et	 al	
Figure	 1.11:	 Sizer	 in	 a	 native	 mitral	 valve	 to	 determine	 the	 size	 of	 the	
surgical	mitral	valve	replacement	required	(25	mm)	(adapted	from	Edwards	
website:	www.edwards.com	5/5/16).	
sizer	
chordae	tendineae	
left	ventricle	wall	
aortic	valve	
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2008),	with	significant	potential	for	cost	saving	(Osnabrugge	et	al	2013)	as	well	as	being	a	
more	 accessible	 procedure	 both	 in	 terms	 of	 patient	 populations,	 pathologies	 and	 global	
location	 (Claramunt	 et	 al	 2012),	 surpassing	 the	 relatively	 excessive	 risk	 factors	 and	
resource-intensive	 requirements	 of	 conventional	 open	 heart	 surgical	 replacements.	
Moreover,	 as	 shown	 in	 the	 case	of	 the	pulmonary	 valve,	 they	 can	 represent	 an	excellent	
bridge	treatment	before	surgery	for	children.		
The	 first	 minimally	 invasive	 heart	 valve	 replacement	 for	 the	 pulmonary	 valve	 in	 2000	
(Bonhoeffer	 et	 al	 2000),	 was	 developed	 into	 the	 current	 transcatheter	 aortic	 valve	
implantation	(TAVI)	technology	and	has	been	in	the	European	market	since	2007,	approved	
for	use	in	high-risk	patients	unfit	for	open	heart	surgery	(Steinberg	et	al	2014).		
1.4.1 Percutaneous	mitral	valve	repair		
The	first	percutaneous	mitral	valve	procedure	 is	dated	back	to	the	early	 ‘80s,	when	Inoue	
and	 colleagues	 performed	 the	 first	 balloon	 valvuloplasty	 for	 treatment	 of	mitral	 stenosis	
(Inoue	et	al	1984),	accessing	the	valve	region	via	antegrade	venous	route	(with	transseptal	
puncture).	This	approach	has	quickly	become	the	solution	of	choice	for	congenital	stenotic	
mitral	 valves	 (Block	et	 al	 1988,	Mckay	1991)	 in	patients	with	 isolated	mitral	 stenosis	 and	
suitable	 anatomy	 (Vahanian	 et	 al	 2004).	 However,	 this	 disease	 is	 now	 uncommon	 in	
developed	countries	and	the	procedure	is	not	free	from	complications,	including	failure	to	
relieve	stenosis,	 formation	of	mitral	regurgitation	and	systemic	embolization	(Vahanian	et	
al	 2004,	 Axford	 et	 al	 2004).	Mitral	 valve	 regurgitation	 represents	 a	much	more	 common	
disease	in	the	western	world	(Davidson	et	al	2008),	which	affects	patients	often	untreatable	
surgically	(Lung	et	al	2003,	Mirabel	et	al	2007,	Taramasso	et	al	2010).	Hence,	a	number	of	
minimally	 invasive	procedures	have	recently	been	developed	to	target	this	disease.	These	
are	 essentially	 reconstructive	 treatments	 (valve	 repair)	 that	 aim	 to	 improve	 the	 leaflets	
apposition	 by	 remodelling	 one	 of	 the	 functional	 substructures.	 Hence,	 below	 they	 are	
classified	in	terms	of	the	substructure	they	target	to	achieve	their	function.		
1.4.1.1	Leaflets	plication	procedures		
The	main	percutaneous	approach	currently	adopted	for	mitral	repair	is	based	on	the	edge-
to-edge	technique	(Figure	1.12).	This	consists	in	the	apposition	of	the	central	portion	of	the	
anterior	 and	 posterior	mitral	 valve	 leaflets	 to	 create	 a	 double-orifice	 valve	with	 reduced	
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leaflet	 excursion	 and	 reduced	 regurgitation	 (Alfieri	 et	 al	 2001).	 This	 is	 achieved	 by	
manipulating	 a	 grasping	 clip	 (MitraClip,	 Abbott	 Vascular)	 (Coats	 et	 al	 2007)	 or	 suturing	
device	 (Mobius,	Edwards)	 (Chiam	et	al	2011,	Davidson	et	al	2006).	The	main	 limitation	of	
this	procedure	is	it	being	restricted	to	patients	without	severe	dilatation	of	mitral	annulus,	
relatively	 normal	 leaflets,	 mitral	 valve	 prolapse	 and	 central	 regurgitation	 (Block	 2005).	
Moreover,	clinical	 results	 indicate	the	 inability	of	the	technique	to	eliminate	regurgitation	
in	all	patients	(Feldman	et	al	2005).	 In	fact,	the	edge-to-edge	technique	was	developed	as	
an	adjunct	to	standard	surgical	repair	procedures,	and	its	use	as	a	stand-alone	technique	is	
still	debated	(Block	2005,	Cohn	2001).		
	
	
	
	
	
In	2008	the	Abbott’s	MitraClip	percutaneous	repair	device	obtained	CE	marking,	 followed	
by	 FDA	 approval	 in	 2013.	 This	 remains	 the	 only	 percutaneous	 reconstructive	 device	
currently	available	on	the	market.		
1.4.1.2	Annulus	reshaping	procedures		
Other	 popular	 approaches	 aim	 to	 restore	 the	 leaflets	 coaptation	 by	 reshaping	 the	mitral	
annulus.	 In	 the	 first	 solutions,	 this	was	 achieved	 by	 implanting	 into	 the	 coronary	 sinus	 a	
stent-like	device	(such	as	the	Carillon,	Cardiac	Dimensions	and	the	Monarc,	Edwards)	that	
forces	the	reshaping	of	the	posterior	region	of	the	annulus,	producing	an	approximation	of	
the	mitral	valve	 leaflets	 (Kaye	et	al	2003,	Liddicoat	et	al	2003).	However,	 this	approach	 is	
considerably	 limited	 by	 the	 great	 anatomical	 variability	 of	 the	 coronary	 sinus,	 and	 is	 not	
applicable	in	about	half	of	the	patients.	Lastly,	the	consequence	of	long-term	placement	of	
such	 an	 aggressive	 prosthesis	 into	 the	 coronary	 sinus,	 whose	 walls	 are	 very	 thin,	 is	 still	
unknown	and	raises	some	concern	(Coats	et	al	2007,	Block	2005,	Axford	et	al	2004).		
sutures	 aortic	leaflet	
Figure	 1.12:	 The	 edge-to-edge	 technique	 for	 mitral	 valve	 repair	 resulting	 in	 a	
“double-orifice”	 (*)	 (left)	 suturing	method	 (surgical)	 (adapted	 from	De	 Bonis	 2002)	
(right)	 3D	 transesophageal	 echocardiogram	 of	 a	 MitraClip®	 (Abbott	 Laboratories)	
(transcatheter)	(adapted	from	Bartel	et	al	2014).	
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Other	 devices	 achieve	 the	 reduction	 of	 the	 anteroposterior	 diameter	 by	 applying	 an	
epicardial	 pressure	 that	 modifies	 the	 shape	 of	 the	 left	 ventricle	 and,	 consequently,	 the	
annulus.	This	is	obtained	by	tethering	cords	passed	into	the	ventricle	(iCoapsys,	Myocor)	or	
inflating	silicone	bands	placed	around	the	atrioventricular	groove	(BACE,	Mardil).		
Alternative	 recent	 methodologies	 replicate	 more	 closely	 surgical	 annuloplasty,	 which	
achieve	 leaflet	 coaptation	 by	 undersizing	 the	 annulus	 perimeter.	 These	 are	 based	 on	
transannular	or	 subannular	cinching	by	means	of	 sutures	 that	are	anchored	and	 tethered	
(e.g.	Mitralign	 System,	Mitralign	 and	 Accucinch	 System,	 Guided	 Delivery	 Systems),	 or	 by	
anchored	Dacron	bands	of	adjustable	 length	(Cardioband,	Valtech).	The	main	limitation	of	
these	approaches	is	that	they	only	allow	partial	cinching	(posterior	leaflet	only)	(Chiam	et	al	
2011,	Herrmann	et	al	2009).		
Other	 solutions	 achieve	 the	 annulus	 undersizing	 by	 shrinking	 its	 collagen	 fibres	 with	 the	
heat	generated	by	radio	frequencies	or	ultrasound	(e.g.	QuantumCor	Device,	QuantumCor	
and	 ReCor	 Device,	 ReCor	Medical).	 The	 drawback	 of	 this	 approach	 is	 the	 potential	 over-
constriction	or	undercorrection,	as	well	as	possible	damage	to	 the	surrounding	structures	
(Chiam	 et	 al	 2011).	 The	 long-term	 outcome	 for	 these	 devices	 is	 still	 unknown,	 and	 their	
development	has	been	discontinued.		
1.4.2 History	of	pulmonary	and	aortic	valves	
The	first	human	valve	replacement	using	a	percutaneous	procedure	was	reported	 in	2000	
by	 Professor	 Philipp	 Bonhoeffer	 (Bonhoeffer	 et	 al	 2000),	 who	 successfully	 implanted	 a	
stented	valve	in	the	pulmonary	artery	prosthetic	conduit	of	a	12-year-old	boy	with	stenosis	
and	insufficiency.	The	valve	was	an	18	mm	bovine	jugular	vein	valve,	sutured	to	a	Numed	
CP	platinum	stent.	The	prosthesis,	Contegra®	(Medtronic),	received	CE	marking	in	2006	and	
FDA	approval	under	Humanitarian	Device	Exemption	in	2010,	and	is	now	widely	used.		
The	 approach	 was	 soon	 adopted	 for	 treating	 the	 aortic	 valve,	 with	 the	 first	 human	
implantation	described	by	Dr	Alain	Cribier	and	colleagues	in	2002.	They	delivered	a	bovine	
pericardial	 valve	 sewn	 into	 a	 stainless	 steel	 stent	 using	 a	 venous	 transseptal	 (antegrade)	
approach.	 The	 patient,	 who	 had	 been	 judged	 to	 be	 too	weak	 to	withstand	 the	 stress	 of	
open-heart	surgery,	was	a	57-year-old	man	who	presented	with	cardiogenic	shock	due	to	
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severe	calcific	aortic	stenosis	with	a	bicuspid	aortic	valve.	Since	then,	 transcatheter	aortic	
valve	implantation	(TAVI)	has	been	established	as	the	treatment	of	preference	for	calcified	
aortic	 valves	 in	 high	 risk	 patients	 (Helton	 et	 al	 2011,	 Ghanbari	 et	 al	 2009,	 Zajarias	 et	 al	
2009).	 Two	 valve	 devices,	 the	 balloon-expandable	 Edwards	 SAPIEN	 (a	 direct	 evolution	 of	
the	prosthesis	 implanted	by	Dr	Cribier)	and	the	self-expanding	Medtronic	CoreValve,	with	
bovine	 and	 porcine	 pericardium	 leaflets	 respectively,	 have	 been	 in	 the	 European	market	
since	 2007	 (FDA	 approval	was	 granted	 in	 2011	 and	 2014,	 respectively)	 and	 a	 number	 of	
second	 generation	 devices	 are	 already	 emerging;	 such	 as	 Boston	 Scientific’s	 LOTUS	 Edge	
and	the	Medtronic	Evolut	R	(Table	1.1).		The	SAPIEN	has	an	advantageously	shorter	length,	
best	for	causing	minimal	vascular	damage	during	delivery	and	they	are	both	limited	by	their	
inability	to	reposition	once	deployed	and	are	similarly	subject	to	paravalvular	leakage	(PVL).	
The	major	limitations	are	discussed	in	more	detail	in	the	following	sections.	
Table	1.1:	Commercially	available	transcatheter	aortic	valves	(up	to	date	at	time	of	writing).	
Company	
	 	  
Models	
	
	
	
	
	
	
	
	
	
	
	
	
	 	
Stent	type	
(material)	
Balloon-expandable	
(stainless-steel,	Co-Cr)	 Self-expanding	(nitinol)	
Mechanically	
expanded	(braided	
nitinol)	
Leaflets	(material)	 Bioprosthetic	(bovine	pericardium)	
Bioprosthetic	(porcine	
pericardium)	
Bioprosthetic	
(bovine	
pericardium)	
Device	size	
(annulus	size)	 20,	23,	26,	29	(18-27)	mm	 23,	26,	29,	31	(18-29)	mm	
23,	25,	27	(19-23	
and	23-27)	mm	
Length	 14-19	mm	 45-55	mm	(62	collapsed)	 -	
Delivery	diameter	 16-18	Fr	 18	Fr	 18-20	Fr	
[1]	www.edwards.com,	12/9/16.	[2]	www.corevalve.com,	12/9/16.		
[3]	www.bostonscientific.com,	2/3/17.	
[2]	[1]	
CoreValve	 Evolute	R	
SAPIEN	3	
SAPIEN	XT	
LOTUS	EdgeTM	
[3]	
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1.4.2.1	Fluid	dynamic	requirement	
TAVIs	push	 the	native	 leaflets	 to	 the	 side	 restricting	 the	 formation	of	oval	 vortices	 in	 the	
sinus	(Ducci	et	al	2013),	which,	when	present,	induce	an	even	pressure	on	the	leaflets.	This	
means	the	native	leaflets	act	as	a	wall,	reducing	the	area	in	which	a	vortex	can	form	causing	
the	blood	to	flow	in	a	more	vertical	manner;	creating	a	greater	force	on	the	belly	(i.e.	the	
middle)	of	the	leaflets	than	in	other	areas,	instigating	the	characteristic	belly-first	behaviour	
during	 both	 closure	 and	 opening,	 which	 is	 more	 prominent	 in	 TAVI	 valves	 such	 as	 the	
SAPIEN	XT	 (Edwards	 Lifescience)	 and	CoreValve	 (Medtronic)	 compared	 to	 surgical	 valves.	
Namely	because	when	the	latter	are	implanted	the	native	leaflets	are	removed	and	so	more	
natural	 sinus	 hemodynamics	 occur,	 resulting	 in	more	 natural	 leaflet	 opening	 and	 closing	
morphology.	
1.4.2.2	Conformity	
The	calcified	deposits	on	stenotic	aortic	valves	prevent	TAVIs	from	conforming	to	the	native	
annulus	and	so	a	small	gap	often	remains	between	the	native	diseased	leaflets	and	stent	of	
the	 device,	 causing	 paravalvular	 leakage	 (PVL).	Medtronic	 have	 recently	 released	 a	 new	
version;	CoreValve®	EvolutTM	(Medtronic	CoreValve	Evolut)	(Table	1.1,	Figure	1.13),	which	
is	 designed	 to	 address	 this	 problem	 by	 virtue	 of	 new	 stent	 geometry,	 size	 and	material	
properties	improving	its	conformability,	fit	and	radial	force	for	minimal	PVL.			
	
	
	
	
1.4.2.3	Applicable	patients	
Initially	TAVIs	were	only	implanted	in	elderly	high-risk	patients.	For	example;	the	patients	in	
the	Placement	of	AoRTic	TraNscathetER	valve	(PARTNER)	trial,	were	aged	83.1	±	8.6	years	
(Leon	 et	 al	 2010).	 Then,	 six	 years	 later,	 once	 their	 efficacy	 and	 safety	 had	 been	
demonstrated,	 the	 SAPIEN	 XT	 and	 SAPIEN	 3	 were	 granted	 U.S.	 Food	 and	 Drug	
Administration	(FDA)	approval	for	use	in	intermediate	risk	patients.	
Figure	 1.13:	 Conformability	 of	 CoreValve	 Evolut	 to	 the	
native	aortic	annulus	(www.corevalve.com,	12/9/16.)	
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A	similar	initial	patient	population	will	have	to	be	used	for	the	trial	of	transcatheter	mitral	
valve	 implants	 (TMVI).	 Then	 it	 is	 predicated	 that	 similar	 to	 TAVIs,	 their	 target	 patient	
population	will	be	expanded	to	include	medium	and	eventually	also	low	risk	patients.		
1.4.3 The	UCL	transcatheter	aortic	valve		
The	 transcatheter	 aortic	 valve	 (TAV)	designed	and	manufactured	at	UCL,	 the	TRISKELE,	 is	
retrievable,	repositionable	and	has	enhanced	anchoring	and	sealing	(Figure	1.14)	(Burriesci	
et	 al	 2012,	 Burriesci	 et	 al	 2010,	 Ghanbari	 et	 al	 2008),	 thereby	 overcomes	 the	 main	
limitations	 associated	 with	 some	 of	 the	 commercially	 available	 devices.	 The	 leaflets	 are	
currently	made	 from	 a	 novel	 synthetic	 functional	 nanocomposite	 polymer,	 developed	 by	
the	group	of	Professor	Seifalian	at	UCL	(Rahmani	et	al	2013).	
	
	
	
	
	
According	 to	 in	 vitro	 tests,	 the	 UCL	 TAV	 has	 a	 similar	 effective	 orifice	 area	 and	 smaller	
regurgitant	fraction	compared	to	first	generation	TAVI	devices	in	the	market	at	the	time	of	
testing	in	2012	(Rahmani	et	al	2012).	The	UCL	TAV	resulted	in	lower	ventricular	energy	loss	
during	the	cardiac	cycle	and	therefore	was	deemed	to	have	better	overall	performance.	
In	2013	the	UCL	TAV	was	implanted	into	sheep	by	Mike	Mullen	and	John	Yap	(UCLH	Heart	
Hospital),	 at	 IMM	 Recherche,	 Paris	 (Mullen	 et	 al	 2014).	 All	 prototypes	 were	 successfully	
implanted,	 retrieved	 back	 into	 the	 catheter	 and	 repositioned.	 Their	 hemodynamic	
performance	 was	 assessed	 for	 their	 optimal	 position,	 demonstrating	 good	 acute	 valve	
function	with	no	significant	regurgitation	(Mullen	et	al	2014).	
Despite	 the	 pertinent	 clinical	 need	 (Block	 et	 al	 2006,	 Block	 2005),	 the	 translation	 of	
transcatheter	valve	technologies	to	the	mitral	position	has	been	hindered	by	the	need	for	
Figure	1.14:	The	UCL	transcatheter	aortic	valve	‘TRISKELE’.	
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alternative	 engineering	 strategies,	 taking	 into	 account	 the	 complex	 morphology	 of	 the	
valve,	higher	transvalvular	pressure	and	larger	sized	devices	(Siminiak	et	al	2007).	Also,	this	
application	 necessitates	 adaptation	 of	 the	 delivery	 and	 deployment	 methods,	 sizing	
algorithms,	 intraprocedural	 imaging,	 failure	 modes	 and	 post	 procedural	 assessment	
parameters,	all	of	which	are	unique	to	the	mitral	position.		
1.4.4 The	UCL	transcatheter	mitral	valve		
The	 in	 vitro	 and	 in	 vivo	 data	 for	 the	 UCL	 TAV	 proved	 the	 effectiveness	 of	 its	 wireframe	
design	 in	 enabling	 retrieval,	 repositioning,	 good	 anchoring	 and	 low	 paravalvular	 leakage	
(PVL)	 in	absence	of	calcification.	Therefore	a	similar	 retrievable	and	repositionable	design	
was	used	 for	 the	wireframe	of	 the	UCL	 transcatheter	mitral	 valve	 (TMV);	GEMINI	 (Figure	
1.15).	Furthermore,	it	is	novel	in	mimicking	the	morphology	of	the	native	mitral	valve;	being	
D-shaped	and	having	two	leaflets.	
	
	
	
	
	
	
The	 TMV	 frame	 has	 three	 functions;	 it	 facilitates	 folding	 of	 the	 device	 for	 transapical	
minimally	 invasive	 delivery,	 is	 a	 structure	 supporting	 the	 leaflets	 and	 is	 a	 means	 for	
anchoring	 the	device	 in	situ.	The	word	 ‘frame’,	 rather	 than	stent	 is	used	to	emphasise	 its	
intricate	relationship	with	the	function	of	the	leaflets,	namely	as	an	axis	for	their	hinge-like	
motion.	 This	 is	 contrary	 to	 the	metallic	 stent	 components	of	 other	devices	 that	have	 the	
primary	 function	 of	 exerting	 a	 radial	 force	 on	 surrounding	 anatomy.	 The	 medial	 crown	
(Figure	 1.15)	 acts	 as	 a	 webbed	 spring	 which	 can	 deform	 and	 then	 return	 to	 its	 former	
shape.	 This	 harbours	 the	 classical	 physics	 of	 springs	 in	 a	 non-coiled	 form,	 predicted	 to	
Figure	 1.15:	 Initial	 concept	 for	 the	 UCL	 TMV	 (left)	 perspective	 view	 (leaflets	 open)	
(middle)	 atrial	 view	 (leaflets	 open)	 (right)	 atrial	 view	 (artist’s	 impression	 of	 leaflets	
closed	position).	
closed	open	
medial	crown	
1	of	4	wire	
loops	
1	of	4	petal	
shaped	
hoops	
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enable	 the	proposed	device	 to	 adapt	 to	 a	mobile	 environment	 (previously	 described	 and	
depicted	in	Figure	1.5),	absorbing	load,	whilst	providing	a	constant	radial	force	securing	the	
device	against	the	mitral	annulus,	thus	creating	a	seal.	
The	implantation	procedure	for	the	proposed	device	would	take	place	in	a	catheterisation	
laboratory	using	a	delivery	system	similar	to	that	for	the	UCL	TAV	(Burriesci	et	al	2012).	Just	
prior	 to	 the	procedure,	a	 set	of	 tethers	would	be	 threaded	 through	 the	delivery	 catheter	
and	 attached	 to	 four	wire	 loops.	 The	 device	would	 then	 be	 submerged	 in	water	 at	 4	 oC	
whilst	 the	 tethers	 are	 pulled	 together,	 folding	 the	 wireframe	 as	 it	 is	 pulled	 inside	 the	
catheter.	To	minimise	the	catheter	diameter,	the	aortic	and	mural	loops	were	designed	to	
lay	side-by-side	when	folded,	thereby	reducing	risk	of	damage	to	surrounding	tissues	as	it	is	
inserted.	 The	 loaded	 catheter	 would	 then	 be	 guided	 towards	 the	 mitral	 orifice	 using	
fluoroscopic	and	transesophageal	echocardiography	(TEE).		
The	current	position	of	 the	 loops	necessitates	a	 transapical	 implantation	procedure;	once	
the	 device	 is	 positioned	 in	 the	 mitral	 orifice	 the	 deployment	 can	 begin	 (Figure	 1.16.a).	
Firstly,	 the	 three	 crown	 sections	 of	 the	 frame	 would	 be	 released	 inside	 the	 atrium;	
generating	one	 side	of	 the	clamping	 force	 (Figure	1.16.b).	The	petal	 shaped	hoops	would	
then	expand	inside	the	ventricle	and	project	radially	into	the	native	leaflets,	pushing	them	
to	 the	 side,	 generating	 the	 other	 side	 of	 the	 clamping	 force,	 securing	 the	 device	 to	 the	
native	mitral	annulus	(Figure	1.16.c)	and	once	the	loop	sections	are	released	they	will	keep	
the	 native	 leaflets	 taut,	 preventing	 left	 ventricular	 outflow	 tract	 obstruction	 (LVOTO)	
(Figure	1.16.d).		
The	correct	positioning	of	the	device	 is	vital	 to	anchor	the	device	securely.	 In	anticipation	
that	 the	 device	 does	 not	 deploy	 in	 the	 correct	 position,	 the	 tethers	 are	 designed	 so	 the	
device	can	be	drawn	back	 inside	the	catheter,	moved	to	a	more	optimal	position,	and	re-
deployed,	 this	 could	 be	 done	 several	 times.	 Once	 the	 device	 is	 deployed	 in	 the	 correct	
position	the	tethers	would	then	be	cut	and	removed,	after	which	the	loops	would	function	
as	springs,	absorbing	motions	that	occur	in	the	light	frame	structure.	
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1.5 Summary	
This	 background	 chapter	 expounded	 relevant	 information	 regarding	 the	 anatomy	 and	
dynamic	 behaviours	 of	 the	mitral	 valve	 components.	 The	 disease	 state	 being	 addressed,	
namely	 mitral	 regurgitation	 was	 described	 and	 current	 surgical	 and	 minimally	 invasive	
treatments	 were	 explained,	 including	 the	 UCL	 transcatheter	 solutions	 which	 are	 at	 both	
working	 prototype	 (UCL	 TAV,	 TRISKELE)	 and	 conceptual	 stages	 of	 design	 (UCL	 TMV,	
GEMINI).	 This	has	provided	 the	 required	background	 information	 to	 form	 the	 context	 for	
the	following	literature	review	and	thesis.	
	
	
(a)	 (b)	 (c)	 (d)	
Figure	 1.16:	 Transapical	 implantation	 for	 the	 UCL	 transcatheter	 mitral	
valve	(a)	wireframe	collapsed	in	catheter	 in	the	mitral	orifice	(b)	crowns	
released	 (c)	 petal	 shaped	 hoops	 released	 (d)	 final	 configuration	 keeps	
native	leaflets	taut.	
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Chapter	2 	Literature	review	
The	UCL	transcatheter	mitral	valve	(TMV)	aims	to	mimic	the	conical	bileaflet	native	mitral	anatomy	
(previously	described	 in	section	1.1.1).	Therefore,	the	first	section	of	this	chapter	reviews	previous	
attempts	to	do	this	for	surgical	devices	and	the	evolutionary	development	into	the	initial	concept	for	
the	 UCL	 TMV.	 The	 other	 TMVs	 in	 development	 are	 then	 reviewed	 in	 terms	 of	 their	 structural	
components,	 anchoring	 approaches,	 regurgitation	 prevention,	 delivery	 methods	 and	 in	 vivo	
evaluations.	 Implications	 for	 the	 regulations	 specifically	 for	 minimally	 invasive	 heart	 valves	
implanted	 in	 the	 mitral	 position	 are	 discussed;	 namely	 the	 devices	 diastolic	 and	 systolic	
performance,	 risk	 management	 issues	 and	 the	 choice	 of	 a	 relevant	 reference	 valve,	 which	 is	
followed	 by	 a	 summary	 and	 the	 future	 work	 required	 for	 the	 evolution	 of	 TMV	 implantation	
technology.		
2.1 Bileaflet	and	quadrileaflet	bioprosthetic	mitral	valves	
There	 have	 been	 several	 attempts	 to	 mimic	 the	 native	 mitral	 valve	 morphology	 in	 bioprosthetic	
valves,	 although	 none	 have	 achieved	 technology	 transfer.	 All	 of	 the	 stented	 and	 stentless	 mitral	
valves	discussed	below	were	made	from	bovine	pericardium	with	either	two	or	four	leaflets.	
2.1.1 Stented		
2.1.1.1	The	bubble	valve	
In	 1983	 a	 circular	 bileaflet	 stented	 surgical	mitral	 valve	 (SMV)	was	developed	 at	 the	University	 of	
Victoria,	Canada	(Walker	et	al	1983),	the	leaflets	for	which	were	designed	to	form	two	symmetrical	
bubbles	when	in	the	closed	position,	as	would	occur	for	the	stent	profile.	The	shape	of	the	bubbles	
was	 initially	 measured	 experimentally	 from	 a	 five	 times	 scale	 model	 and	 later	 a	 computational	
technique	was	used,	which	defined	 the	stent	boundary	as	shown	 in	Figure	2.1.	This	 ‘bubble	valve’	
successfully	achieved	comparable,	and	in	some	cases	exceeded,	the	performance	of	the	Bjork-Shiley	
convexo-concave	tilting-disc	and	the	Ionescu-Shirley	three	leaflet	pericardial	xenograft	valves	i.e.	the	
commercially	available	mitral	valves	at	the	time.	
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2.1.1.2	The	Sheffield	valve		
Later	in	1986,	another	circular	bileaflet	stented	SMV	was	developed	at	Sheffield	University	(Black	et	
al	1986),	the	open	shape	for	which	is	slightly	conical	(i.e.	“the	fustrum	of	a	cone,	with	a	small	cone	
angle”	(Black	et	al	1991,	Figure	2.2).	Both	two	(Huang	et	al	1990)	and	three-dimensional	(Black	et	al	
1991)	 finite	 element	 analyses	 have	 been	 completed.	 An	 investigation	 into	 the	 influence	 of	
orthotropy	 in	 pericardium	on	 its	mechanical	 behaviour	 (Burriesci	 et	 al	 1999)	 and	was	 reported	 to	
have	endured	a	peak	maximum	principal	stress	of	approximately	2	MPa,	associated	with	the	critical	
loading	mode	when	the	leaflets	are	fully	closed,	formed	in	a	pattern	of	contours	traversing	the	belly	
from	 the	 commissures	 to	 peaks	 at	 the	 base.	 The	 prototypes	 withstood	 more	 than	 400	 million	
opening	and	closing	cycles	(5	years)	 in	vitro	as	well	as	 in	vivo	function	in	calves,	with	survival	times	
that	met	the	Food	and	Drug	Administration	requirements	(Black	et	al	1986).	
	
	
	
	
	
	
	
	
	
	 Figure	 2.2:	 Stented	 bileaflet	 surgical	 mitral	 valve	 (left)	 Sheffield	 valve	
(adapted	from	Black	et	al	1991)	(right)	Cylindrical	surface	developments	
of	the	Sheffield	valve	(Black	et	al	1986).	
Figure	2.1:	Stented	bileaflet	surgical	mitral	valve	(left)	‘bubble	valve’	developed	at	the	University	of	
Victoria,	 Canada	 (adapted	 from	 Walker	 et	 al	 1983)	 (right)	 co-ordinate	 system	 used	 for	 bubble	
surface:	 ellipse	 (short	 side	 (a)	 long	 side	 (b))	 is	 an	 idealised	 projection	 of	 stent	 boundary	 on	 x-y	
plane,	α	is	angle	between	plane	of	the	stent	and	the	x-y	plane	and	D	denotes	the	symmetry,	i.e.	the	
half	of	the	ellipse	calculated	(Walker	et	al	1983).	
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2.1.1.3	The	California	valve		
A	bileaflet	SMV	was	developed	at	 the	University	of	California,	which	had	a	 flexible	 saddle	annulus	
(Kheradvar	et	al	2012)	 (Figure	2.3	and	Figure	2.4)	and	two	diverging	supporting	prongs	 to	prevent	
leaflet	 	 prolaspse,	 the	 latter	 being	 in	 direct	 contrast	 to	 the	 slightly	 conical	 design	 of	 the	 Sheffield	
valve.	The	computational	analyses	and	in	vitro	hemodynamic	studies	showed	leaflet	length	and	the	
dynamic	saddle	annulus	were	critical	in	minimising	stress	distribution	at	leaflet	tips	(Kheradvar	et	al	
2012).	
	
	
	
	
	
2.1.2 Stentless	
2.1.2.1	The	QuattroTM	valve	
The	first	D-shaped	quadrileaflet	stentless	bovine	pericardial	SMV;	QuattroTM	(St.	Jude	Medical	Inc.),	
was	 implanted	 into	 a	 total	 of	 76	 patients	between	1998	 and	 2005	 and	used	 a	 different	 approach	
which	requires	the	device’s	papillary	flaps	(Figure	2.5)	to	be	attached	to	the	native	papillary	muscles.	
Although	the	initial	results	were	promising	(Middlemost	et	al	2003,	Walther	et	al	2003,	Hofmann	et	
al	 2001,	 Aybek	 et	 al	 2000,	Middlemost	 et	 al	 2000,	Middlemost	 et	 al	Mar	 1999,	Middlemost	Mar	
1999,	Middlemost	et	al	Oct	1999,	Walther	et	al	Oct	1999,	Walther	et	al	Dec	1999),	it	was	later	shown	
to	be	associated	with	a	high	risk	of	endocarditis,	reoperations,	valve	degeneration	and	malfunction	
Figure	2.3:	The	California	bileaflet	mitral	valve	with	a	dynamic	saddle	shaped	
annulus	(a)	front	view	(b)	side	view	(adapted	from	Kheradvar	et	al	2012).	
(b)	(a)	
supporting	prongs	
Figure	2.4:	The	California	bileaflet	mitral	bioprosthetic	with	saddle	shape	annulus	(A)	mid-section	of	
the	 valve	 showing	 the	 Nitinol	 core	 surrounded	 by	 pericardial	 tissue	 (B)	 open	 configuration	 from	
convex	side,	depicting	valve	dimensions	and	angle	of	motion	(C)	schematic	from	the	top	when	 the	
valve	is	fully	open	(Kheradvar	et	al	2012).	
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due	to	the	papillary	flap	attachment	to	the	ventricle	leading	to	insufficiency	or	subvalvular	stenosis	
(Alsoufi	et	al	2010,	Goldberg	et	al	2002).	Due	to	the	 joining	of	 the	papillary	 flaps,	 the	QuattroTM	 is	
effectively	conical	and	therefore,	more	similar	to	the	Sheffield	stented	SMV	than	the	California	SMV.	
	
	
	
	
	
	
	
	
	
	
Despite	the	failure	of	the	quadrileaflet	QuattroTM	mitral	valve,	similar	designs	have	continued	to	be	
researched	 across	 China	 using	 both	 finite	 element	 analyses	 and	 in	 vitro	 assessments	 (Wang	 et	 al	
2013,	Huang	et	al	2013,	Kuai	et	al	2008,	Kuai	et	al	2006).	The	foremost,	the	Beijing	valve	being	the	
only	D-shaped	valve,	similar	to	the	QuattroTM,	in	contrast	to	the	Hunan	and	Xiamen	valves,	which	are	
circular	(Figure	2.6).	
	
	
	
	
	
2.1.2.2	The	Cleveland	valves		
The	 Cleveland	 valves	 are	 stentless	 kidney-shaped	 bileaflet	mitral	 valves	 (Figure	 2.7)	 based	 on	 the	
morphology	 of	 the	 native	 valve	 and,	 therefore,	 designed	 to	 similarly	 form	 a	 “continuous	 veil	 as	 a	
muff	 to	 the	circumference	of	 the	mitral	annulus”	 (Navia	et	al	2010).	 In	2010,	 two	of	 these	devices	
were	 tested	 in	 12	 sheep	 (Navia	 et	 al	 2010);	 one	with	 and	 one	without	 chordae	 (Figure	 2.7).	 The	
foremost	required	the	surgical	removal	of	both	the	native	leaflets	and	chordae	tendinae;	however,	
Figure	 2.5:	 QuattroTM	 surgical	 mitral	 valve	 (left)	 lateral	 view	 (adapted	 from	
Hofmann	et	al	2001)	(right)	inflow	side	of	valve	(adapted	from	Walther	et	al	2003).	
papillary	flaps	
Figure	 2.6:	Quadrileaflet	 valves	 researched	 in	 China:	 (left)	Hunan	 valve:	 (A)	
inflow	 (B)	 outflow	aspects	 of	 valve	 (adapted	 from	 Kuai	 et	 al	 2008)	 (middle)	
Xiamen	 quadrileaflet	 valve	 (adapted	 from	 Huang	 et	 al	 2013)	 (right)	 Beijing	
quadrileaflet	valve	(adapted	from	Wang	et	al	2013).	
tear	
A	 B	
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for	the	latter	the	native	chordae	and	leaflet	free	edge	to	which	they	attach	were	not	removed	but	
sutured	 to	 the	 free	edge	of	 the	prosthesis.	Both	designs	achieved	good	performance,	with	 further	
chronic	studies	suggested.		
	
	
	
	
	
	
	
2.1.3 Evolution	to	the	UCL	bileaflet	transcatheter	mitral	valve	
The	 UCL	 TMV	 presents	 an	 evolution	 of	 the	 aforementioned	 two	 and	 four	 leafleted	 SMVs,	 by	
combining	 the	 successful	 features	 which	 replicate	 the	 native	 morphology	 into	 a	 transcatheter	
device.	In	particular,	it	has	two	leaflets,	similar	to	the	California,	Sheffield	and	Cleveland	valves,	but	
moves	 away	 from	 the	 circular	 design	 of	 the	 former	 two,	 employing	 a	 D-shape	more	 akin	 to	 the	
latter.	 Furthermore,	 it	 improves	 on	 the	 very	 angular	 D-shape	 of	 the	 QuattroTM	 and	 other	
quadrileaflet	 valves,	which	would	 result	 in	 a	 quadrangular	 orifice,	 by	 having	 two	 rather	 than	 four	
leaflets	resulting	 in	an	elliptical	orifice,	making	 it	more	representative	of	a	healthy	native	orifice	 in	
the	 open	 state	 (Figure	 1.5).	 In	 addition	 to	 these	 morphological	 improvements	 to	 the	 previous	
designs,	 the	 UCL	 TMV	 also	 incorporates	 them	 into	 a	 frame	 which	 is	 suitable	 for	 transcatheter	
delivery,	 thereby	 significantly	 advancing	 the	 development	 of	 mitral	 valve	 replacements	 which	
replicate	the	native	morphology,	aiming	to	produce	more	physiological	function.	
2.2 Transcatheter	mitral	valves	in	development	
A	 number	 of	 research	 groups	 and	 companies	 are	 currently	 working	 on	 the	 adaptation	 of	
percutaneous	valve	solutions	specifically	for	the	mitral	position.	In	this	section,	the	TMVs	known	at	a	
most	 advanced	 stage	 of	 development	 and	 the	 technical	 solutions	 on	 which	 they	 are	 based	 are	
described	and	discussed	(Table	2.1	and	Figure	2.8).	
A	
B	
C	
D	
Figure	2.7:	The	Cleveland	stentless	bileaflet	valves:	no	chordae	(left)	A:	atrial	and	
B:	 ventricular	 surfaces,	with	 chordae	 (right)	C:	atrial	 and	D:	ventricular	surfaces	
(adapted	from	Navia	et	al	2010).	
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Table	2.1:	Transcatheter	mitral	valves	at	the	most	advanced	stage	of	development	and	description	of	their	main	features.	
Product	name	 Company	 Frame	 Leaflets	 Anchoring	 Delivery	 Trials	
AccuFit	 Sino	Medical	Science	Technology	Inc.,	Tianjin,	China	 SE	NiTi	 P	 Atrial	&	ventricular	flanges	 Transapical,	RPR	 Animals	only	
Caisson	TMVR	 Caisson	 Not	specified	 Atrial	flange	and	native	valve	anchors	 Transseptal	 Preclinical		
CardiAQ	Prosthesis	 Edwards	Lifesciences,	California,	US	
SE	NiTi	
GA	fixed	PP	 Atrial	&	ventricular	flanges	 Transseptal/Transapical	 First-in-human	in	2012	
Cardiovalve	 Valtech	Cardio	Ltd,	Or	Yehuda,	Israel	 GA	fixed	P	 Atrial	flange	(full	details	not	currently	available)	 Not	specified	 Animals	only	
Direct	Flow	Mitral	 Direct	Flow	Medical	Inc.,	California,	US	 Polyester		 GA	fixed	BP	
Atrial	&	ventricular	flanges	
Transapical,	RPR	 First-in-man	expected	Q4	2016	
Double-Crowned	Mitral	
Valve	Implantation	
Zhejiang	University,	Hangzhou,	China	&	Centre	Hospitalier	
Universitaire	Vaudois	(CHUV),	Lausanne,	Switzerland	
SE	NiTi	
Porcine	pulmonary	&	
aortic	homografts	 Left	atriotomy	 Animals	only	
Endovalve	 Micro	Interventional	Devices,	Langhorne,	Pennsylvania,	US	 GA	fixed	P	 Arrow-head	anchors	
Transapical	
Fortis	 Edwards	Lifesciences,	California,	US	 GA	fixed	BP	 Atrial	flange	and	native	valve	anchors	
First-in-human	in	
2014	
Gorman	 The	Trustees	of	The	University	of	Pennsylvania,	Philadelphia,	US	
GA	fixed	P	
Atrial	&	ventricular	flanges	
Left	atriotomy	 Animals	only	HighLife	 HighLife	Medical	Inc.,	California,	US	
Medtronic	TMVR	 Medtronic	Inc.,	Minneapolis,	US	 Atrial	flange	&	native	anchors	
MitraCath	 Emory	University,	Georgia,	US	 Prototype	under	development	
MitralSeal	 Avalon	Medical	Ltd.,	Stillwater,	Minneapolis,	US	
SE	NiTi	
GA	fixed	P	
Atrial	flange	&	ventricular	
tethers	 Transapical	
Animals	only	MitrAssist	 MitrAssist	Medical	Ltd,	Misgav,	Israel	 Atrial	flange	&	native	valve	anchors	 Not	specified	
MiVAR	 Trinity	College	Dublin,	EIRE	 Atrial	cage	
NaviGate	TMVR	 NaviGate	Cardiac	Structures	Inc.,	Cleveland,	Ohio,	US	 BE	CoCr	 Atrial	&	ventricular	flanges	 Transseptal	 None	currently	reported	
Tendyne	 Abbott	Laboratories,	US	
SE	NiTi	
GA	fixed	BP	
Atrial	flange	&	ventricular	
tethers	
Transapical	
First-in-human	in	
2013	
Tiara	 NeoVasc	Inc.,	Richmond,	British	Columbia,	Canada	
Atrial	flange	&	native	valve	
anchors	
First-in-human	in	
2013	
Tresillo	 Transcatheter	Technologies	GmbH,	Regensburg,	Germany	
Not	specified	
Transseptal,	RPR	 None	currently	reported	
Twelve	Intrepid	 Medtronic,	US	 SE	 Transapical		 First-in-human	in	2016	
Key:	GA	=	Glutaraldehyde,	BP	=	bovine	pericardium,	PP	=	porcine	pericardium,	P	=	pericardium	(animal	not	specified),	SE	=	self-expandable,	BE	=	balloon	expandable,	NiTi	=	superelastic	
alloy,	CoCr	=	cobalt	chromium	alloy,	RPR	=	repositionable	and	retrievable.	
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	 Figure	2.8:	Transcatheter	mitral	valves	in	development:	1(Abdelghani		et	al	2015),	2(Hacohen	et	al	2011),	
3(www.dicardiolody	.com),	4(De	Backer	et	al	2014),	5(Kheradvar	et	al	2015),	6(Ma	et	al	2005),	7(Chiam	et	al	2011),	
8(Maisano	et	al	2015),	9(www.avalonmed.com),	10(www.atlanticpediatricdeviceconsortium.org),	
11(www.knowledgetransferireland.com),	12(www.health.clevelandclinic.org),	
13(www.transcathetertechnologies.com),	14(www.2015.icimeeting.com).	(All	websites	accessed	13/06/16).	
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As	 in	all	prosthetic	heart	valves,	 in	order	 to	restore	unidirectional	blood	flow	through	the	
cardiac	 chambers,	 the	 devices	 are	 comprised	 of	 an	 occluding	 component,	 a	 supporting	
structure	 and	 a	 securing	means	 that	 avoids	 valve	 dehiscence.	 The	 presence	 of	 a	 sealing	
component	 to	minimise	paravalvular	 leakage	 is	also	preferable,	especially	 for	mitral	valve	
applications.		
The	 occluding	 component	 of	 all	 described	 solutions	 consists	 of	 three	membrane	 leaflets	
(apart	from	the	MitrAssist	which	has	two	asymmetrical	leaflets)	made	from	glutaraldehyde	
fixed	bovine	or	porcine	pericardium,	sewn	onto	a	supporting	frame.	This	functional	solution	
is	optimal	for	percutaneous	valves	because	the	flexibility	of	the	membranes	allows	them	to	
be	 folded	 easily.	 Moreover,	 membrane	 valves	 can	 operate	 in	 different	 configurations,	
accommodating	 specific	 anatomical	 shapes	 and	 dimensions.	 This	 feature	 offers	 the	
possibility	 for	 the	 valve	 to	 adapt	 to	 an	 implantation	 site	 with	 dimensions	 and	 tissue	
elasticity	 which	 cannot	 be	 accurately	 determined	 and	 are	 likely	 to	 change	 during	 the	
device’s	life.		
All	of	 the	supporting	 frames,	excluding	 the	NaviGate	TMVR,	are	self-expanding	structures	
made	from	nitinol;	a	near-equiatomic	Ni-Ti	alloy	that	exhibits	enhanced	recoverable	elastic	
strains	up	to	8%	(about	20	times	 larger	 than	 for	stainless	steel),	commonly	referred	to	as	
super-elastic	 behaviour.	 Thanks	 to	 this	 property,	 the	 valves	 are	 delivered	 after	 crimping	
them	inside	a	covering	sheath,	which	once	the	prosthesis	has	reached	the	anatomical	site,	
is	pulled	back	allowing	the	frame	to	re-expand	 into	 its	unstressed	configuration.	This	self-
expanding	approach	provides	the	ability	 to	better	adapt	to	geometrical	changes	that	may	
occur	in	the	implantation	site	during	the	valve	life.	
In	 the	 case	 of	 the	 NaviGate	 TMVR	 the	 frame	 is	 made	 from	 a	 balloon-expandable	 Co-Cr	
alloy.	During	implantation,	the	valve	is	collapsed	around	an	empty	balloon	with	a	crimping	
device,	which	plastically	deforms	the	 frame	by	producing	plastic	hinges.	The	valve	 is	 then	
re-deformed	to	the	expanded	configuration	by	 inflating	the	balloon	with	a	 liquid	solution.	
Balloon-expandable	approaches	allow	the	operator	to	administer	the	deployment	pressure,	
but	 in	 the	 case	 of	 the	 mitral	 valve	 they	 require	 particular	 care	 to	 avoid	 excessive	
deformation	of	the	neighbouring	aortic	valve.	Moreover,	they	are	typically	less	suitable	for	
the	implementation	of	retrievable	devices.	
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2.2.1 Anchoring	approach	
The	 anchoring	 methods	 required	 for	 percutaneous	 mitral	 valves	 are	 distinct	 from	 those	
used	 in	TAVI	devices	due	 to	 the	more	 irregular	and	dynamic	morphology.	The	substantial	
amount	 of	 calcium	present	 in	 a	 stenotic	 native	 aortic	 valve	 can	 generate	 the	 large	 radial	
reaction	 forces	 that	are	commonly	used	 to	 fix	aortic	prostheses.	 In	 the	case	of	 the	mitral	
valve,	the	stiffening	mineral	is	normally	insufficient	to	provide	radial	forces	able	to	secure	a	
device.	Moreover,	high	 levels	of	 radial	 forces	would	not	be	advisable	as	 they	could	cause	
left	ventricular	outflow	obstruction	 (LVOTO)	 (Ducas	et	al	2009)	due	to	the	native	anterior	
leaflet	being	pushed	radially	into	the	LVOT,	as	well	as	possible	aortic	valve	impairment,	due	
to	the	device	extending	into	the	aorto-mitral	curtain	(Timek	et	al	2003).	
Hence,	 anchoring	 in	 percutaneous	 mitral	 valves	 is	 commonly	 achieved	 by	 application	 of	
counteracting	 axial	 forces	 and/or	 tensioning	 the	 device	 between	 proximal	 and	 distal	
constraints.	 In	 the	 case	 of	 the	 Tendyne	 and	 MitralSeal	 the	 proximal	 constraint	 is	
represented	 by	 a	 flange,	 which	 lies	 flat	 against	 the	 atrial	 surface	 of	 the	 native	 mitral	
annulus,	while	 the	valve	 is	 fixed	distally	 to	 the	apex	of	 the	 left	ventricle,	 through	a	set	of	
tensioned	threads	(Figure	2.9.a).	Although	these	threads	look	similar	to	chordae	tendineae,	
they	have	the	function	to	anchor	the	frame,	with	no	direct	action	on	the	valve	leaflets.	This	
solution	 may	 contribute	 to	 the	 reduction	 of	 paravalvular	 leakage	 (PVL),	 thanks	 to	 the	
presence	 of	 the	 atrial	 flange,	 pressed	 on	 the	 inlet	 wall.	 A	 potential	 drawback	 might	 be	
represented	by	possible	variations	in	the	tension	applied	to	the	distal	threads	in	the	event	
of	left	ventricle	remodelling.		
	
Figure	 2.9:	 Percutaneous	mitral	 valve	 anchoring	 systems	 (a)	 atrial	 flange	 and	 ventricular	
tethers	 (b)	 atrial	 flange	 and	 native	 valve	 anchors	 (c)	 atrial	 and	 ventricular	 flanges	 (d)	
subannular	hooks	(e)	atrial	cage.	
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An	 alternative	 approach	 is	 adopted	 in	 the	 Fortis,	 Gorman,	 Medtronic	 TMVR,	 MitrAssist,	
Tiara	 and	 Tresillo	which,	 instead	of	 threads,	 use	 ventricular	 distal	 anchors	 that	 grasp	 the	
free	margins	of	 the	native	 leaflets	 (Figure	2.9.b).	 The	 Fortis	 is	 secured	by	 two	ventricular	
tabs	that	capture	the	aortic	and	mural	leaflets,	combined	with	an	atrial	flange.	The	Gorman	
valve	is	secured	using	upper	and	lower	wire-weave	flanges.	The	Tiara	uses	ventricular	tabs	
that	capture	the	aortic	and	mural	 leaflets,	combined	with	three	atrial	 flanges	that	anchor	
the	device	on	the	right	and	left	fibrous	trigones	and	native	posterior	leaflet.	An	additional	
feature	of	the	Tiara	anchoring	system	is	its	saddle-shape,	designed	to	better	conform	to	the	
native	 annulus	 (Jensen	 et	 al	 2013).	 However,	 this	 makes	 the	 implantation	 of	 the	 device	
more	challenging,	as	the	saddle	shaped	device	demands	accurate	orientation.	The	Tresillo,	
also	uses	ventricular	anchors	to	restrain	the	native	 leaflets,	although	are	longer	and	more	
numerous	 than	 in	 the	 Tiara	 valve.	 A	 potential	 advantage	 of	 clamping	 the	 native	 leaflets	
could	be	derived	by	 reducing	 the	 risk	of	LVOTO,	 though	the	 long-term	effect	of	 the	 force	
acting	on	the	subvalvular	components	still	needs	to	be	ascertained	(Rabbah	et	al	2013).	
The	 Double-Crowned	 Mitral	 Valve	 and	 the	 HighLife	 adopt	 clamping	 mechanisms	 that	
engage	 with	 the	 upstream	 and	 downstream	 sides	 of	 the	 mitral	 annulus,	 reducing	 the	
interaction	with	the	subvalvular	apparatus	(Figure	2.9.c).	This	is	achieved	by	squeezing	the	
mitral	annulus	between	two	Z-stents.	The	deployment	of	the	Double-Crowned	Mitral	Valve	
Implantation	 requires	 the	 presence	 of	 an	 annuloplasty	 ring	 in	 the	 mitral	 annulus,	 thus	
making	 its	 application	 limited	 to	 only	 a	 sub-set	 of	 patients.	 The	 HighLife	 relies	 on	 the	
alignment	of	a	groove	with	the	annulus	 to	anchor	 the	device	and	provide	a	seal	between	
the	left	atrium	and	ventricle.	The	same	securing	principle	is	used	by	the	CardiAQ	Prosthesis,	
Cardiovalve	and	NaviGate	TMVR,	which	incorporate	two	sets	of	barbs	or	‘wings’	protruding	
from	 the	main	 body	 to	 improve	 the	 grasp.	 The	 advantage	 of	 this	 approach	 is	 a	 reduced	
interference	with	the	subvalvular	apparatus,	which	avoids	potential	 issues	associated	with	
re-modelling.	However,	 the	 solution	does	not	prevent	 LVOTO,	 and	 the	presence	of	barbs	
may	represent	a	risk	for	surrounding	structures	such	as	the	coronary	sinus	
In	the	case	of	the	Endovalve,	fixation	is	provided	by	a	series	of	anchors	around	the	edge	of	
the	valve	consisting	of	a	solid	core	and	flexible	barb	 (Figure	2.9.d).	The	 flexible	barb	hugs	
the	 core,	 thereby	 enabling	 the	 anchors	 to	 pierce	 the	mitral	 valve	 tissue	 as	 the	 device	 is	
deployed.	Once	inserted	inside	the	tissue,	the	barb	springs	away	from	the	core,	forming	an	
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arrowhead	 which	 prevents	 retraction	 and	 ensures	 the	 anchors	 do	 not	 disengage.	 This	
anchoring	method	could	be	effective	 in	preventing	PVL,	but	 it	does	not	 facilitate	multiple	
deployment	or	retrieval.	Therefore,	incorrect	release	would	foreseeably	require	open-heart	
surgery.		
An	alternative	approach	 is	provided	by	the	MiVAR	valve,	which	relies	on	an	atrial	 fixation	
system	 (Figure	 2.9.e);	 based	 on	 a	 nitinol	 cage	 that	 conforms	 to	 the	 atrial	 chamber,	
preventing	axial	displacement	of	the	valve.	A	potential	disadvantage	of	this	design	is	that,	
every	time	the	left	ventricle	contracts,	the	associated	apical-basal	motion	(Lung	et	al	1996)	
and	pressure	gradient	may	cause	the	device	to	move	relative	to	the	wall	of	the	left	atrium,	
the	consequences	of	which	are	to	be	determined.	This	solution	makes	the	valve	operation	
totally	 independent	from	any	remodelling	that	may	occur	to	the	subvalvular	apparatus	or	
left	ventricle,	and	could	help	to	reduce	PVL.	However,	 its	presence	could	 impair	the	atrial	
function,	as	well	as	the	aortic	valve.		
2.2.2 Regurgitation	prevention	
Contrary	 to	 standard	 surgical	 valves,	which	 are	 normally	 sutured	 onto	 the	 annulus	 (after	
dissection	of	the	native	leaflets),	transcatheter	valves	are	expanded	into	the	diseased	valve	
leaflets.	 This	 may	 result	 in	 gaps	 between	 the	 prosthesis	 and	 surrounding	 native	 tissues,	
with	consequent	PVL.		
PVL	has	been	identified	as	a	major	shortcoming	of	TAVI,	and	its	impact	is	potentially	more	
prominent	 in	 the	mitral	 position	 due	 to	 the	 higher	 transvalvular	 pressure	 difference	 (De	
Bonis	 et	 al	 2012).	 Therefore	 it	 is	 of	 paramount	 importance	 that	 any	 leakage	 around	 the	
edge	 of	 the	 device	 is	 actively	mitigated	 in	 the	 design.	Most	 of	 the	 devices,	 including	 the	
Cardiovalve,	 Endovalve,	 Fortis,	HighLife,	Medtronic	 TMVR,	MitralSeal,	 Tendyne,	 Tiara	 and	
Tresillo	prevent	PVL	using	a	fabric	flange	sutured	onto	the	atrial	portion	of	the	metal	frame.	
A	 unique	 method	 is	 employed	 by	 the	 Gorman	 valve,	 which	 relies	 on	 the	 flexibility	 of	 a	
nitinol	wire-weave	stent	body	to	conform	to	the	complex	host	geometry	and	create	a	seal.	
The	other	valves	do	not	report	any	specific	measure	taken	to	mitigate	PVL.		
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2.2.3 Delivery	
TMVIs	 need	 to	 conform	 to	more	 irregular	 anatomical	 sites	 and	 larger	 orifices	 than	 TAVI.	
This	 requires	 more	 material	 for	 the	 valve	 components,	 which	 translates	 into	 larger	
diameters	of	the	collapsed	device	and	subsequently	wider	access	routes	are	required.	With	
sufficiently	 low	valve	profiles	an	endovascular	retrograde	approach	allows	to	conveniently	
reach	 the	 aortic	 valve	 from	 the	 femoral	 vein,	 after	 puncturing	 of	 the	 inter-atrial	 septum	
(Figure	 2.10.a).	 This	 approach	 has	 been	 very	 popular	 in	 the	 early	 experience	 with	 TAVI	
devices,	 because	 the	 larger	 dimensions	 and	 greater	 elasticity	 of	 the	 veins	 allows	 the	
passage	of	relatively	large	collapsed	stents.	In	the	case	of	the	mitral	valve,	this	is	the	most	
favourable	 access,	 because	 it	 does	 not	 require	 navigation	 through	 the	 subvalvular	
apparatus.	However,	this	procedure	requires	the	device	to	fit	inside	a	catheter	equal	to	or	
smaller	 than	 24	 Fr	 (8	 mm	 diameter),	 while	 current	 valves	 still	 require	 relatively	 larger	
catheters	of	30-33	Fr	(10-11	mm	diameter),	with	the	exception	of	the	MitrAssist,	for	which	
a	delivery	system	of	18	Fr	(6	mm	diameter)	is	declared.	Currently,	only	four	of	the	devices	
have	achieved	a	percutaneous	delivery;	Caisson,	CardiAQ	Prosthesis,	NaviGate	TMVR	and	
MiVAR,	 all	 but	 the	 later	use	 transseptal	 approaches	 (Maisano	et	 al	 2015,	De	Backer	et	 al	
2014)	and	this	approach	is	also	claimed	to	be	achievable	for	the	Tresillo.	
	
	
	
	
	
	
	
	
	
	
The	 transapical	 route	 (Figure	 2.10.b),	 widely	 used	 for	 the	 implantation	 of	 aortic	 valves,	
allows	the	passage	of	larger	valves;	and	therefore	is	currently	the	most	adopted	approach.	
However,	 access	 to	 the	mitral	 valve	 requires	 navigating	 the	 delivery	 system	 through	 the	
subvalvular	 apparatus.	 To	 prevent	 the	 device	 becoming	 entangled	 in	 the	 chordae	
tendineae,	 expert	 interpretation	 of	 the	 fluoroscopic	 and	 transesophageal	
echocardiographic	 guidance	 (TEE)	 is	 required.	 Despite	 this	 challenge,	 the	 transapical	
Figure	2.10:	Percutaneous	mitral	valve	delivery	(a)	transseptal	(b)	transapical	
(c)	left	atriotomy	(d)	transaortic.	
(a)	 (b)	 (c)	 (d)	
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approach	has	been	used	 for	 implanting	the	CardiAQ	Prosthesis,	Direct	Flow	Mitral,	Fortis,	
Tiara	and	Twelve	Intrepid	(Banai	et	al	2014)	and	is	necessary	for	the	anchoring	systems	of	
the	Tendyne,	MitralSeal	and	Endovalve.		
A	 left	 atriotomy	 (Figure	 2.10.c)	 is	 required	 to	 implant	 the	 Double-Crowned	Mitral	 Valve	
Implantation,	 Gorman,	 HighLife	 and	 Medtronic	 TMVR	 valves.	 This	 approach	 involves	 an	
incision	of	approximately	10	cm,	making	it	the	most	invasive	access	for	transcatheter	valve	
implantation.		
A	unique	choice	of	surgical	approach	is	adopted	for	the	MitrAssist,	which	currently	uses	a	
transaortic	 implant	 (Figure	 2.10.d)	 where	 a	 minimally	 invasive	 surgical	 incision	 into	 the	
aorta	is	made	to	insert	the	device.		
2.2.4 In	vivo	evaluation	
Evaluation	of	transcatheter	prosthetic	mitral	valves	in	large	animals	has	been	reported	for	
the	 CardiAQ	 Prosthesis,	 Cardiovalve,	 Double-Crowned	 Mitral	 Valve	 Implantation,	
Endovalve,	 Fortis,	 Gorman,	 HighLife,	 Medtronic	 TMVR,	 MitrAssist,	 Tendyne	 and	 Tiara,	
similarly	 indicating	 the	 approach	 is	 feasible	 and	 promising,	 whilst	 highlighting	 current	
deficiencies	(De	Backer	et	al	2014,	Banai	et	al	2014,	Gillespie	et	al	2013,	Zou	et	al	2013,	Iino	
et	 al	 2012,	Banai	et	 al	 2012,	Ma	et	 al	 2005).	A	 common	 failure	mode	of	 the	devices	was	
inadequate	anchoring	mechanisms,	 resulting	 in	device	migration,	which	 is	also	one	of	 the	
main	causes	of	LVOTO.	However,	some	of	these	failure	modes	may	be	due	to	inappropriate	
sizing.	 For	 example,	 the	 relatively	 high	 rate	 of	 PVL	 in	 chronic	 in	 animal	 evaluation	of	 the	
Tiara	was	attributed	to	only	one	size	device	being	available	 for	 the	range	of	native	valves	
(De	Backer	et	al	2014).	The	MitralSeal	 is	routinely	employed	for	veterinary	applications	 in	
dogs,	which	are	characterised	by	similar	mitral	valve	pathologies	to	humans	(Pedersen	et	al	
2000)	and	acute	animal	studies	for	AccuFit	are	currently	in	their	final	stages	(Abdelghani	et	
al	2015).	
Generally,	 in	 animals,	 experience	 with	 TMVIs	 indicate	 that	 current	 devices	 require	
substantial	 design	 improvements,	 namely	 to	 position	 and	 anchor	 them.	 These	
improvements	may	partly	be	achieved	by	developing	appropriate	algorithms	 for	 selecting	
device	size	 to	be	 implanted	 for	a	particular	native	valve.	For	 the	Tiara	device,	 implants	 in	
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human	 cadavers	 are	 reported	 (Banai	 et	 al	 2014),	 which	 demonstrated	 appropriate	
geometric	positioning.		
In	humans,	evaluation	of	minimally	 invasive	mitral	valve	 replacements	has	occurred	since	
2012	when	the	CardiAQ	prosthesis	was	the	first	 to	be	 implanted	 in	a	human,	 followed	by	
the	 Tendyne	 in	 2013,	 the	 Tiara	 and	 Fortis	 in	 2014	 and	most	 recently	 in	 2016	 the	 Twelve	
Intrepid.	 The	 AccuFit	 and	 Direct	 Flow	Mitral	 were	 expected	 to	 achieve	 their	 first-in-man	
later	 in	 2016	 (Abdelghani	 et	 al	 2015).	 The	 Cardiovalve,	 Double-Crowned	 Mitral	 Valve	
Implantation,	 Endovalve,	 Gorman,	 HighLife,	 Medtronic	 TMVR,	 MitrAssist	 and	 MiVAR	 all	
remain	in	animal	trials,	whilst	no	in	vivo	data	are	yet	reported	for	the	NaviGate	TMVR.		
The	first-in-man	experience	of	the	CardiAQ	Prosthesis	was	performed	by	the	team	of	Lars	
Søndergaard	 at	 the	 Heart	 Centre	 in	 Copenhagen,	 Denmark,	 in	 June	 2012.	 The	 valve	was	
implanted	 into	 an	 86-year-old	 high-risk	 patient	 suffering	 from	 severe	mitral	 regurgitation	
(MR).	The	device	successfully	alleviated	the	patient’s	severe	regurgitation,	although	some	
remained	 and	 three	 days	 later	 the	 patient	 died	 from	 multi-organ	 failure	 (Sondergaard	
2012).	More	 recently,	 in	 2014,	 three	 elderly	 patients	 aged	 78-89	 years,	 with	 severe	MR	
were	 given	 the	 CardiAQ	mitral	 valve	 on	 compassionate	 grounds.	 All	were	 positioned	 and	
deployed	 accurately,	 successfully	 eliminating	 MR,	 two	 of	 the	 patients	 made	 full	 clinical	
recovery	with	good	valve	function	monitored	up	to	60	days	post-procedure	and	the	other	
patient	died	nine	days	after	the	operation	from	pneumonia	(Sondergaard	et	al	2015).	
In	2013	two	Tendyne	valves	were	 implanted	at	the	French	Hospital	 in	Asuncion,	Paraguay	
(De	 Backer	 et	 al	 2014).	 The	 57	 year-old	 man	 and	 55	 year-old	 woman,	 with	 severe	 MR,	
agreed	 to	have	 the	Tendyne	 valve	 implanted	 for	 2	hours	prior	 to	 removal	of	 their	 native	
valves	 for	 conventional	 surgical	 replacement.	 The	 severity	 of	 their	 MR	 grade	 was	
successfully	 reduced	 from	 four	 to	 one	 in	 one	 patient	 and	 completely	 eliminated	 in	 the	
other	(Lutter	et	al	2014).	
The	 Tiara	 was	 implanted	 into	 a	 73-year-old-man	 and	 a	 61-year-old-woman	 with	 severe	
functional	MR	at	St.	Paul’s	Hospital,	Vancouver,	British	Columbia,	Canada	(De	Backer	et	al	
2014)	 at	 the	 beginning	 of	 2014	 and	 successfully	 eliminated	 MR	 as	 well	 as	 achieving	
improved	LV	stroke	volumes	 (Cheung	et	al	2014),	according	 to	data	up	 to	2	months	after	
the	procedure.	
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Later	 in	 2014,	 a	 total	 of	 five	 Fortis	 valves	were	 implanted,	 four	by	 the	Heart	 Team	at	 St.	
Thomas’	Hospital	in	London,	UK	and	one	at	St	Michael’s	Hospital	in	Toronto,	Canada	(Bapat	
et	 al	 2014).	 The	 patients	 had	 presented	 with	 severe	 mitral	 valve	 disease	 and	 showed	
promising	 initial	 recovery	 after	 the	 implantation	 of	 Fortis,	 although	 three	 patients	 died	
between	four	and	76	days	after	the	procedure.	Failure	modes	and	causes	of	death	have	not	
been	reported.	More	recently	in	2015,	three	patients	with	functional	MR	(mean	age	71	±	9	
years,	2	men)	had	the	Fortis	implanted	under	a	compassionate	use	program	(Altisent	et	al	
2015).	The	devices	were	implanted	with	no	complications	and	successfully	removed	MR	in	
one	patient	with	trace	residual	MR	in	the	other	two	and	remained	alive	at	6-month	follow-
up	 (Altisent	 et	 al	 2015).	 However,	 thrombus	 formation	 was	 a	 significant	 issue	 with	 the	
Fortis	 device,	which	 signifies	 that	 a	well-tailored	 anticoagulation	 regime	may	be	 required	
after	TMVIs.		
Most	recently,	 in	February	2016	results	were	presented	for	a	pilot	study	of	eleven	Twelve	
Intrepid	 valves	 (NHS,	 UK),	 for	 which	 three	 patients	 died,	 one	 of	 which	 was	 due	 to	
deployment	failure	and	one	of	the	patients	still	experiences	symptoms	as	per	NYHA4	class	II	
heart	failure	(Wood	2016).		
These	 human	 trials	 have	 demonstrated	 the	 clinical	 need,	 reflected	 by	 elderly	 patients	
agreeing	to	the	implantation,	and	the	potential	of	TMVIs	to	diminish	MR	to	a	similar	 level	
achieved	 by	 surgical	 replacements.	 However,	 only	 with	 larger	 numbers	 of	 patients	 and	
longer	 follow-up	 times	 can	 the	 effectiveness	 of	 TMVI	 technology	 be	 assessed	 as	 a	 truly	
compassionate	 treatment	 option	 for	 elderly	 patients	with	 severe	MR	 at	 too	 high	 risk	 for	
surgical	replacements.	
2.3 Regulatory	issues	for	transcatheter	mitral	valves	
Prior	 to	 reaching	 the	 market,	 the	 safety	 and	 efficacy	 of	 any	 prospective	 heart	 valve	
substitute	must	be	ascertained	by	means	of	 in	vitro	 and	 in	vivo	 investigations.	Guidelines	
and	 recommendations	 for	 the	 qualification	of	 the	 design	 and	manufacture	 of	 permanent	
prosthetic	 valve	devices	 are	provided	by	 International	 Standards	 ISO	5840-Cardiovascular	
implants-Cardiac	 valve	 prostheses.	 This	 imposes	 the	 design	 and	 minimum	 performance	
																																								 																				
4	 New	 York	 Heart	 Association	 (NYHA)	 Functional	 Classification	 class	 II	 has	 the	 following	 mild	
symptoms;	mild	shortness	of	breath	and/or	angina	and	slight	limitation	during	ordinary	activity.	
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specifications	for	aortic	and	mitral	valves,	and	outlines	the	approach	required	to	assess	the	
properties	of	prostheses	and	their	materials,	and	those	for	in	vivo	evaluation.	The	standard,	
first	enforced	 in	1984	and	 initially	based	on	a	 ‘requirement	based’	approach,	has	recently	
adopted	 a	 ‘risk	 based’	 approach	 (ISO	 5840:2005),	 more	 in	 line	 with	 FDA	 guidance	 and	
better	suited	for	recent	transformative	developments	of	the	technologies.	The	substantial	
technological	 and	 functional	 differences	 between	 surgical	 and	 minimally	 invasive	 valve	
prostheses	 have	driven	 the	drafting	 and	publication	of	 an	 additional	 updated	part	 of	 the	
standard,	ISO	5840-3:2013,	specifically	created	for	qualification	of	transcatheter	heart	valve	
substitutes	and	valid	since	March	2013.	
Most	 of	 the	 specifications	 and	 assessment	 approaches	 described	 in	 the	 International	
Standards	 ISO	5840:2005	and	 ISO	5840-3:2013	are	applicable	 to	minimally	 invasive	mitral	
valve	 replacements.	 However,	 as	 they	 are	 based	 on	 existing	 clinical	 evidence,	 mainly	
available	only	 for	surgical	valves	and	TAVI,	 revision	may	be	needed	to	better	address	 this	
emerging	class	of	devices.		
2.3.1 Diastolic	performance	
The	current	standards	prefer	measurement	of	the	effective	orifice	area	(EOA)	to	assess	the	
hydrodynamic	 performance	 of	 valves,	 during	 the	 forward	 flow	 phase	 (diastolic	 phase	 for	
the	mitral	valve).	However,	due	to	its	larger	orifice,	the	EOA	is	a	less	critical	parameter	for	
the	healthy	function	of	the	mitral	valve	compared	to	the	aortic	valve,	and	is	often	sacrificed	
in	 favour	of	better	 leaflet	 coaptation.	 For	example,	 in	 the	edge-to-edge	 repair	 technique,	
the	EOA	of	the	mitral	valve	can	be	reduced	by	as	much	as	60%	after	an	edge-to-edge	repair,	
without	detrimental	 consequences.	 Therefore,	 assessment	based	on	 the	effective	 surface	
area	 using	 the	 proximal	 isovelocity	 surface	 area	 (PISA)	 method	 (Lancellotti	 et	 al	 2010,	
Recusani	 et	 al	 1998)	 may	 be	 more	 relevant	 for	 the	 intraoperative	 evaluation	 of	 mitral	
devices.		
2.3.2 Systolic	performance	
The	performance	of	the	valve	during	the	closing	and	closed	phase	is	verified	and	controlled	
by	limiting	the	regurgitant	fraction.	The	ISO	5840-3:2013	acknowledges	the	inevitability	of	
higher	 degrees	 of	 paravalvular	 leakage	 in	 transcatheter	 devices,	 accepting	 larger	
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regurgitant	 fractions	 (for	 large	 sizes,	up	 to	25%	at	a	CO	of	5	 lpm)	 than	 for	 corresponding	
surgical	valves.	This	is	compensated	by	more	severe	demands	in	terms	of	EOA.	
As	discussed	above,	though	this	approach	is	acceptable	for	TAVIs,	in	the	case	of	the	mitral	
valve	 increases	 in	 EOA	 would	 possibly	 be	 unnecessary	 and	 insufficient	 to	 compensate	
significant	levels	of	leakage,	which	should	instead	be	mitigated.	
2.3.3 Risk	management	aspects	
The	 potential	 hazards,	 associated	 failure	 modes	 and	 subsequent	 evaluation	 methods	
currently	described	in	ISO	5840-3:2013	(Annex	G)	are	defined	based	on	TAVI	experience.	In	
order	to	better	reflect	lessons	learnt	from	current	in	vivo	experiences	with	TMVIs,	the	risks	
associated	 with	 unintended	 anatomical	 interactions	 should	 also	 consider	 failure	 modes	
such	as:	left	ventricular	out	flow	tract	obstruction	(LVOTO),	which	can	lead	to	heart	failure	
and	death;	left	circumflex	(LCx)	artery	compression,	which	would	inhibit	blood	supply	to	the	
posterolateral	 left	 ventricle	 and	 anterolateral	 papillary	 muscle;	 and	 coronary	 sinus	 (CS)	
compression,	which	would	hinder	deoxygenated	blood	flow	from	the	heart	muscles	to	the	
right	atrium.	
2.3.4 Reference	valve	predicament	
The	standards	require	that	a	heart	valve	substitute	with	known	clinical	experience	is	used	
for	 comparative	 preclinical	 and	 clinical	 evaluations.	 No	 such	 reference	 valve	 for	
transcatheter	mitral	valves	(TMV)	has	been	suggested	in	the	literature	to	date.		
The	 clinical	 experience	 most	 similar	 to	 a	 TMV	 is	 evidence	 of	 transcatheter	 aortic	 valves	
(TAV)	 performing	well	 in	 the	mitral	 position	when	 implanted	 inside	 existing	 annuloplasty	
rings	or	valvular	prosthesis	(Tang	et	al	2013).	However,	these	valve-in-mitral-valves	are	not	
appropriate	 reference	 valves	 because	 they	 are	 not	 specifically	 designed	 for	 the	 mitral	
position	and	have	an	unfair	 advantage	 in	 terms	of	 likely	 lower	 regurgitation	and	 reduced	
risk	 of	 migration	 due	 to	 being	 implanted	 inside	 existing	 devices.	 For	 similar	 reasons,	
comparison	with	 balloon-expandable	 aortic	 valve	 systems,	 used	 in	 patients	with	 severely	
calcified	mitral	valves	(Fassa	et	al	2014,	Guerrero	et	al	2014,	Himbert	et	al	2014,	Ribeiro	et	
al	2014,	Hasan	et	al	2013,	Sinning	et	al	2013)	are	not	appropriate	either.		
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The	 next	 most	 similar	 device	 to	 a	 TMV	 is	 a	 bio-prosthetic	 surgical	 mitral	 valve	 (SMV)	
replacement.	 There	 are	 four	 commercially	 available	 pericardial	 valves	 used	 in	 the	mitral	
position.	Edwards	Lifesciences	Corporation	manufactures	three	of	them;	the	Magna	Mitral	
Ease,	 Perimount	 Plus	 and	 Perimount	 Theon,	 and	 Sorin	 Group	 (now	 LivaNova	 PLC)	
manufacture	 the	 Pericarbon	 MORE	 Mitral,	 all	 of	 which	 are	 circular	 devices	 with	 three	
leaflets.	 The	 latter	 being	 the	 only	 bio-prosthetic	 valve	 to	 be	 specifically	 adapted	 for	 the	
mitral	position	from	its	initial	aortic	version,	with	successful	clinical	experience	(Caimmi	et	
al	1998).	In	fact	nearly	all	bioprosthetic	heart	valves	are	suitable	for	the	mitral	position	even	
though	in	general	they	are	not	specifically	designed	for	it.	
However,	direct	 comparison	between	a	 surgical	and	 transcatheter	mitral	 valve	would	not	
be	 valid	 due	 to	 different	 minimum	 device	 performance	 requirements	 made	 by	 ISO	
5840:2009	 and	 5840-3:2013	 respectively	 (Table	 2.2	 and	 Table	 2.3).	 Namely,	 the	 latter	
standard	 for	 transcatheter	 valves	 accounts	 for	 inevitably	 greater	 leakage	 compared	 to	
surgical	 valves	 by	 allowing	 more	 regurgitation	 for	 a	 given	 device	 size	 but	 demanding	 a	
greater	 effective	 orifice	 area	 to	 compensate	 for	 the	 additional	 work	 required	 by	 left	
ventricle	 to	 maintain	 normal	 cellular	 metabolism.	 For	 example;	 a	 size	 25	 mm	 (tissue	
annulus	 diameter)	 SMV	must	 have	 a	 regurgitant	 fraction	 (RF)	 less	 than	 or	 equal	 to	 15%	
(Table	2.2)	but	a	size	25	mm	(deployed	valve	diameter	within	implant	site)	TMV	can	have	a	
RF	as	high	as	20%	(Table	2.3),	however,	it	must	have	an	effective	orifice	area	(EOA)	greater	
than	or	equal	to	1.25	cm2	(Table	2.3)	compared	to	only	1.2	cm2	for	a	SMV	(Table	2.2).	
Table	 2.2:	 Minimum	 device	 performance	 requirements	 for	 surgical	 mitral	 valve	
replacements	(adapted	from	ISO	5840:2009).	
Valve	size	 Tissue	Annulus	Diameter	(mm)	 25	 27	 29	 31	
Effective	orifice	area	(cm2)	≥	 1.2	 1.4	 1.6	 1.8	
Regurgitant	fraction	(%)	≤	 15	 15	 20	 20	
	
Table	 2.3:	 Minimum	 device	 performance	 requirements	 for	 transcatheter	 mitral	 valve	
replacements	(adapted	from	ISO	5840-3:2013).	
Valve	size	 Deployed	valve	diameter	within	implant	site	(mm)	 23	 25	 27	 29	 31	 33	
Effective	orifice	area	(cm2)	≥	 1.05	 1.25	 1.45	 1.65	 1.90	 2.15	
Regurgitant	fraction	(%)	≤	 20	 20	 20	 25	 25	 25	
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At	 this	 early	 stage	 in	 the	 development	 of	 TMVs,	 and	 therefore	 in	 absence	 of	 a	 relevant	
reference	 valve	 to	 date,	 they	 have	 been	 assessed	 in	 vivo	 in	 reference	 to	 improving	 the	
previously	 untreated	 disease	 state	 (Sondergaard	 et	 al	 2012,	 Sondergaard	 et	 al	 2015,	 De	
Backet	et	al	2014,	Lutter	et	al	2014,	Cheung	et	al	2014,	Bapat	et	al	2014,	Altisent	et	al	2015,	
Wood	2016).	
2.4 Summary	of	transcatheter	mitral	valve	technology	
After	 the	 rapid	 development	 of	 pulmonary	 and	 aortic	 transcatheter	 heart	 valve	
implantations,	the	advantages	of	percutaneous	procedures	are	finally	being	transferred	to	
the	 functional	 replacement	 of	 mitral	 valves.	 The	 experience	 gained	 with	 TAVI	 devices	 is	
fundamental	 to	 the	 development	 of	 this	 approach,	 which	 presents	 unique	 challenges	
requiring	 new	 technical	 solutions,	 due	 to	 the	more	 complex	morphology	 and	 function	 of	
the	mitral	valve.	
Similarly	 to	 the	 first	 generation	 of	 percutaneous	 aortic	 valves,	 PVL	 and	 embolisation5	
remain	 major	 hurdles,	 the	 impact	 of	 which	 is	 amplified	 by	 more	 severe	 transvalvular	
pressures	 and	 valve	 dynamics.	 The	 accuracy	 of	 medical	 imaging	 technologies	 and	 sizing	
criteria	will	play	a	major	role	in	reducing	these	complications,	by	allowing	selection	of	the	
most	suitable	TMVI	for	each	patient.	In	fact,	for	a	correct	fitting,	most	of	the	valves	under	
development	 require	 proper	 geometrical	 matching	 with	 the	 irregular	 mitral	 annulus	
(normally	characterised	by	an	asymmetric	bean-shape,	laying	on	a	saddle-shape	surface),	as	
well	 as	 the	 subvalvular	 structures	 and	 heart	 chambers.	 All	 these	 components	 are	
characterised	by	significant	variations	of	their	dimensions	during	the	cardiac	cycle,	due	to	
the	dynamic	nature	of	the	mitral	valve	apparatus	and	surrounding	anatomy.	Therefore,	for	
each	prosthetic	valve,	 it	 is	essential	to	identify	what	parameters	are	the	most	relevant	for	
ensuring	proper	anchoring	and	sealing.	Accurate	and	comprehensive	sizing	algorithms	will	
need	 to	 be	 developed,	 to	 ensure	 the	 safety	 and	 proper	 functionality	 of	 TMVIs.	 This	 will	
necessarily	require	continuous	revision	and	refining,	based	on	both	in	vivo	experience	and	
in	vitro	assessment.	
Future	designs	will	also	need	to	focus	on	reducing	the	device’s	collapsed	profile,	enabling	
endovascular	 access	 with	 minimal	 incision	 size.	 This	 will	 foreseeably	 follow	 the	
																																								 																				
5	Embolisation	is	the	lodging	of	an	embolus	(a	blood	clot)	within	the	bloodstream.	
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developmental	 trend	 that	 has	 characterised	 aortic	 solutions,	 which	 have	 achieved	
substantial	 advances	 in	 reducing	 the	 loaded	 valve	 size	 and	 delivery	 system,	 offering	 new	
alternative	implantation	approaches	with	reduced	vascular	injury.	An	important	feature	to	
inherit	from	the	latest	generation	of	TAVIs	will	be	the	ability	to	reposition	valves	during	the	
implantation	 procedure.	 In	 fact,	 as	 most	 of	 the	 anchoring	 approaches	 adopted	 for	 the	
mitral	 application	 require	a	precise	axial	 and	angular	positioning,	 inappropriate	 release	 is	
more	likely	to	lead	to	functional	complications	and	increased	PVL.	
Concerns	about	safety	and	durability	 in	the	functionally	more	stressed	mitral	position	will	
be	revealed	only	after	medium	and	 long	term	clinical	outcome,	but	the	positive	results	of	
TAVI	 devices	 suggest	 that	 metal	 frames	 can	 be	 suitable	 to	 withstand	 heavy	 loading	
conditions.	Also,	as	 for	TAVIs,	TMVs	might	result	 in	a	high	rate	of	silent	cerebral	 ischemic	
lesions.	 These,	 in	 fact,	 appear	 to	 be	 independent	 from	 catheter	 manipulation	 and	 the	
severity	 of	 calcification	 (Rodes-Cabau	 et	 al	 2010),	 and	 are	 possibly	 associated	 with	 the	
hemodynamic	disturbance6	produced	by	the	valve-in-valve	configuration	(Ducci	et	al	2013).		
In	 order	 to	 be	 established	 as	 a	 sustainable	 therapy,	 it	 is	 essential	 that	 TMV	 replacement	
fully	demonstrates	its	safety	and	efficacy,	guaranteeing	at	the	same	time	affordable	costs.	
In	 fact,	 contrary	 to	 TAVI	 devices,	which	only	 compete	with	other	 replacement	 strategies,	
mitral	valves	will	have	to	operate	in	a	more	aggressive	commercial	climate,	contending	the	
role	to	a	range	of	surgical	and	transcatheter,	replacement	and	repair	solutions,	with	various	
degrees	of	invasivity.	However,	it	can	be	envisaged	that,	similarly	to	what	has	happened	for	
aortic	 valve	 therapies,	 currently	 established	 mitral	 treatments	 will	 strongly	 benefit	 from	
novel	 technical	 solutions	 developed	 for	 TMVIs.	 In	 fact,	 dimensional	 reduction	 of	 the	
supportive	 structure	 of	 the	 leaflets	 and	 the	 availability	 of	 collapsible	 sutureless	 mitral	
valves	may	contribute	 to	 the	development	of	procedurally	safer	and	 less	 invasive	surgical	
applications.		
In	 summary,	 first	 experiences	 with	 TMV	 replacements	 have	 been	 very	 encouraging,	
demonstrating	 the	 feasibility	 and	 potential	 benefit	 of	 the	 approach.	 However,	 due	 to	
anatomical	 variations	between	animals,	 comparison	of	 in	 vivo	 data	 for	 current	devices	 in	
development	 (Table	 2.1)	 would	 be	 insufficient	 to	 determine	 the	 best	 solution;	 in	 vitro	
																																								 																				
6	Disturbance	here	meaning	alteration	of	physiological	flow,	thereby	including	stagnation	of	flow.	
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assessment	 is	 required	 to	 obtain	 comparative	 data,	 which	 may	 consequently	 better	
determine	an	optimal	anchoring	method	for	 the	mitral	position.	Undoubtedly,	substantial	
progress	will	be	needed	in	order	to	overcome	current	limitations	and	establish	this	solution	
as	 a	 competitive	 treatment.	 The	process	will	 have	 to	be	 assisted	by	 regulatory	 standards	
that	better	reflect	the	specific	clinical	needs	and	recent	experiences	with	this	approach.	
2.5 Summary	of	key	findings	
There	were	 two	main	 findings	 from	 the	 background	 and	 literature	 review	which	 directly	
influenced	the	design	and	form	the	context	of	the	work	presented.	
1. Conical	Design	
The	background	research	regarding	the	anatomy	of	a	healthy	native	mitral	valve	indicated	
that	 conicity	would	make	 the	 proposed	UCL	 bileaflet	 design	more	 physiologically	 similar.	
This	 feature	 can	 be	 seen	 clearly	 in	 Figure	 1.5,	which	 depicts	 the	mitral	 valve	 in	 its	 open	
position,	 and	 shows	 the	 leaflets	 acting	 as	 a	 funnel	 for	 transporting	 blood	 from	 the	 left	
atrium	 into	 the	 left	 ventricle.	 This	 novel	 design	 feature	 was	 consequently	 added	 to	 the	
initial	UCL	TMV	concept	(section	1.4.4).	
2. Annulus	size	
It	was	clear	from	current	 in	vivo	data	for	developmental	TMVs,	that	 implantation	site	size	
had	a	significant	impact	on	the	device’s	performance.	Therefore,	it	was	chosen	as	the	focus	
for	 the	 in	 vitro	 tests,	 and	 thereby	 instigated	 the	design	and	manufacture	of	 various	 sized	
mock	native	mitral	valve	holders	 in	which	the	UCL	TMV	prototypes	were	tested.	There	by	
resulting	in	a	novel	contribution	to	the	experimental	design	for	TMVs.	
2.6 Thesis	outline	
This	 thesis	 describes	how	 the	materials	 used	 to	make	 the	UCL	 TMVs	were	 characterised;	
namely	pericardium,	polyester	mesh	and	nitinol	wire,	the	requirements	for	which	are	also	
outlined	 in	Chapter	3.	Chapter	4	then	discusses	the	 leaflet	design	and	how	finite	element	
analyses’	were	used	as	a	design	tool	resulting	in	the	selection	of	a	conical	bileaflet	design,	
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uniquely	defined	by	two	parameters;	its	scale	factor	and	coaptation	length.	Chapter	5	then	
describes	the	equipment	used	and	made	to	assess	the	prototypes.	This	includes	the	design	
and	manufacture	of	 surgical	mitral	 valves,	designed	 to	provide	a	 relevant	 reference	valve	
for	 the	UCL	TMV.	Furthermore,	 it	describes	 the	experimental	 conditions	used	 to	simulate	
the	 left	 side	 of	 a	 normal	 healthy	 adult	 heart	 and	 the	 parameters	 measured	 to	 assess	
prosthetic	 heart	 valve’s	 performance.	 The	 minimum	 performance	 requirements	 are	 also	
expounded	as	well	as	the	limitations	of	these	methods.	
Chapter	 6	 outlines	 the	 main	 aim	 of	 the	 UCL	 TMVs,	 that	 is,	 to	 assess	 its	 potential	 as	 a	
treatment	option	for	high-risk	patients	with	severe	mitral	regurgitation.	The	design	of	the	
prototypes	 and	 their	 functional	 assessment	 are	 then	 described	 and	 the	 results	 are	 then	
presented	 and	 discussed.	 Chapter	 7	 describes	 how	 and	 why	 the	 1st	 generation	 device	
(Chapter	6)	was	developed	into	a	2nd	generation	device,	for	which	preliminary	results	and	a	
discussion	are	provided.	
Chapter	 8	 discusses	 current	 and	 future	 work	 to	 develop	 the	 UCL	 TMV;	 including	
development	 of	 the	 surgical	 version	 as	 well	 as	 functional	 assessment	 methods,	 delivery	
system	 and	 durability	 assessments.	 Lastly,	 chapter	 9	 concludes	 design	 and	 functional	
performance	and	the	appendices	contain	numerical	codes	and	graphs,	unnecessary	in	the	
main	body	of	the	thesis	and	are	all	referred	to	where	relevant.	
To	summaries,	the	aim	of	this	project	was	to	develop	a	proof	of	concept	prototype	of	the	
UCL	 transcatheter	 mitral	 valve	 (TMV)	 by	 completing	 the	 following	 objectives;	 an	 initial	
design	 cycle	 consisting	 of	 design	 of	 both	 devices	 and	 testing	 equipment	 (Chapter	 3-5),	
prototyping	(Chapter	6)	and	testing	(Chapter	6	and	7).	This	aim	was	achieved,	and	the	main	
findings,	limitations	and	recommendations	for	future	work	required	to	further	develop	the	
UCL	TMV	are	outlined	in	Chapter	8.		
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Chapter	3 Material	characterisation		
The	UCL	TMV	has	two	pericardial	leaflets,	a	self-expanding	nitinol	wireframe	and	polyester	
mesh	skirt	 sections	 (Figure	3.1).	Characterisation	of	 these	materials	 is	crucial	 in	 the	 initial	
stage	of	 the	design	cycle,	 therefore,	 contained	within	 this	chapter	are	 their	 requirements	
and	characterisation.	More	specifically,	 the	thermo-mechanical	properties	of	pericardium,	
the	nominal	Poisson’s	ratio	of	a	mesh	structure	and	the	effect	of	variable	strain	history	on	
the	cyclic	tensile	mechanical	properties	of	nitinol	wire	are	discussed.	
	
	
	
	
	
	
	
3.1 Pericardium	
This	 section	explains	why	pericardium	was	chosen	 for	 the	prosthetic	mitral	 valve	 leaflets,	
describes	 characterisation	 of	 its	 thermo-mechanical	 behaviour	 and	 identification	 of	 four	
parameters	for	an	Ogden	equation	to	model	its	constitutive	stress-strain	relationship,	both	
in	relation	to	developing	bioprosthetic	heart	valves.	
3.1.1 Requirements	
The	 leaflets	 for	 the	 prototype	 prosthetic	 mitral	 valves	 had	 to	 be	 constructed	 from	 a	
material	 which	 has	 known	 successful	 clinical	 experience.	 Therefore	 glutaraldehyde	 (GA)	
fixed	 bovine	 pericardium	 (BP)	 soft	 tissue	 was	 chosen	 due	 to	 its	 common	 use	 in	
bioprosthetic	 heart	 valves	 and	 favourable	 hemodynamic	 performance	 (Hulsmann	 et	 al	
Figure	 3.1:	 The	 UCL	 transcatheter	 mitral	 valve	 made	 from	 bovine	 pericardium	
(BP),	nitinol	(NiTi)	wire	and	polyester	knitted	mesh	(PETKM2004).	
thread	(nylon)	
skirt	(PETKM2004)	
2	leaflets	(BP)	
mural	leaflet	
aortic	leaflet	
sealing	cuff	(BP)	
wireframe	(NiTi)	
blood	flow	
left	atrium	
	
blood	flow	
left	ventricle	
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2012).	 In	general,	prosthetic	heart	valves	are	required	to	withstand	and	perform	well	at	a	
healthy	 body	 temperature7	 of	 approximately	 37	 oC	 and	 must	 not	 be	 damaged	 when	 at	
room	temperature,	21	oC	nor	when	folded	 into	a	catheter	at	4	oC,	 the	 latter	 temperature	
being	 required	 to	 collapse	 the	 nitinol	 frame.	 Therefore,	 these	 temperatures	 are	 highly	
relevant	for	modelling	and	testing.	
3.1.2 Characterisation	
The	mechanical	 behavior	 of	 pericardium	 tissue	 is	 complex;	 nonlinear,	 with	 nearly	 elastic	
behaviors	over	 small	 strains,	hysteresis	over	 cyclic	 loads,	 creep	under	 constant	 loads	and	
stress	relaxation	at	fixed	deformations.	The	aim	of	this	section,	which	describes	the	uniaxial	
characterisation	 of	 BP,	 is	 firstly	 to	 describe	 and	 quantify	 its	 thermo-mechanical	 behavior	
and	 secondly	 to	 provide	 data	 to	 identify	 four	 parameters	 for	 an	 Ogden	 hyperelastic	
material	model	for	use	in	finite	element	analyses	later.			
Technically,	pericardium	 is	orthotropic	and,	 therefore,	 in	order	 to	 investigate	 its	direction	
dependant	 properties,	 a	 biaxial	 tensile	 test	 would	 be	 required;	 for	 example	 Baek	 et	 al	
(2005)	 presented	 the	 first	 biaxial	 study	on	 the	 stress	 relaxation	behaviour	of	 collagenous	
tissue	before	and	after	thermal	damage.	However,	a	uniaxial	 tensile	test	was	sufficient	to	
provide	 information	 for	 average	 behaviour,	 accurate	 enough	 to	 achieve	 aims	 previously	
described.	
3.1.2.1	Thermo-mechanical	behaviour	
Cyclic	uniaxial	tensile	tests	have	previously	been	conducted	on	GA	fixed	BP	(Claramunt	et	al	
2012,	Trowbridge	et	al	1985)	and	its	mechanical	properties	have	been	described	as	having	a	
transition	 point	 (TP)	 between	 a	 more	 extensible	 and	 stiffer	 region	 (Black	 et	 al	 1991,	
Trowbridge	et	al	1985)	with	various	amounts	of	hysteresis	(Claramunt	et	al	2012).	However,	
the	thermo-mechanical	properties	have	not	been	reported	and	the	strain	at	which	the	TP	
occurs	has	not	been	quantified,	both	of	which	are	addressed	in	the	study	described	below.	
The	 thermo-mechanical	 behaviour	 of	 BP	 can	 be	 quantitatively	 described	 by	 changes	 in	
strain	 at	 a	 TP	 between	 an	 approximately	 linear	 region	 at	 small	 strains	 and	 non-linear	
(transition)	region	at	higher	strains	(Figure	3.2).	To	 identify	the	TP	 in	an	objective	manner	
																																								 																				
7	According	to	ISO	5840	the	patient’s	body	temperature	may	vary	between	34	oC	and	42	oC.	
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we	defined	 it	as	 the	strain	at	 the	maximum	of	 the	second	derivative	of	a	 four	parameter	
equation,	 which	 models	 the	 stress-strain	 relationship	 for	 BP	 (Figure	 3.2	 and	 3.3	 and	
Equation	3.1).		
	
	
	
Figure	3.2:	Definition	of	transition	point	for	pericardium	shown	on	original	data	
(top)	 real	 data/soft	 tissue	 equation	 3.1:	 definition	 of	 linear	 region	 1	 (LR1),	
transition	point	(TP)	and	theoretical	linear	region	2	(LR2)	(middle)	derivative	of	
soft	tissue	equation	3.1	(bottom)	second	derivative	of	soft	tissue	equation	3.1.	
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The	engineering	stress	is	defined	as;	
	 σ = 	A ln 1 +	e*+-- + Dϵ	 (3.1)	
	
where;	
A	=	y-direction	stretch/compression	 transformation	of	 the	 integral	of	 the	 logistic	 function	
(Equation	3.2)	for	A	>	1	and	A	<	1	respectively,	
B	=	x-direction	stretch/compression	 transformation	of	 the	 integral	of	 the	 logistic	 function	
for	0	<	B	<	1	and	B	>	1	respectively,	
ϵ	=	engineering	strain,	
C	=	translation	in	the	positive	x-direction	of	the	integral	of	the	logistic	function,	and	
D	=	constant	to	multiply	strain	by	to	provide	an	initial	straight	line	with	a	(0,	0)	intercept.	
This	proposed	‘soft	tissue	equation’	is	based	on	graphical	transformations	of	the	integral	of	
the	logistic	function	(Equations	3.2	and	3.3).	
								 y = 	 11 +	e-1	 (3.2)			
	
Figure	3.3:	Characterisation	of	the	strain	vs	stress	relationship	for	pericardium	
using	a	transition	point	between	an	approximately	 linear	region	and	the	non-
linear	 transition	 region	 which	 occurs	 prior	 to	 the	 theoretical	 second	 linear	
region	which	is	not	actually	reached	in	the	tests	conducted.	
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When	integrated	becomes;	
	 2 = 	ln	(1 + e1)	 	(3.3) 		
The	 logistic	 function	 being	 the	 most	 common	 sigmoid	 function	 (Equation	 3.4),	 chosen	
because	it	is	a	bound	differential	real	function	that	is	defined	for	real	input	values	and	has	a	
positive	derivative	at	each	point.	
	 f x = 	 L1 +	e-8(1-19)	 (3.4)	
Where;	
xo	=	x-value	of	the	sigmoid’s	midpoint	(0	for	logistic	function),	
L	=	curve’s	maximum	value	(1	for	logistic	function),	and	
k	=	the	steepness	of	the	curve	(1	for	logistic	function).	
	
3.1.2.1.1	Protocol	
A	total	of	three	dumbbells8	were	extracted	from	GA	fixed	BP	patches	using	a	die	cutter	and	
fixed	 in	 the	 clamps	 of	 a	 Zwick	 Z5.0	mechanical	 testing	machine,	 with	 the	 aid	 of	 acetate	
templates	 (Figure	 3.4),	 then	 submerged	 in	 a	 water	 bath	 at	 4	 oC	 and	 subjected	 to	 a	
mechanical	 cyclic	 test,	 with	 10foot	 note	 9	 conditioning	 and	 full	 cycles	 up	 to	 3	 and	 6	 N	
respectively.		The	conditioning	cycles	were	done	to	remove	the	variation	that	occurs	in	the	
first	 cycles	 (Claramunt	 et	 al	 2012)	 and	 the	 latter	 force	 was	 chosen	 because	 it	 induced	
stresses	 (approximately	 3	 MPa)	 similar	 to	 that	 experienced	 by	 bioprosthetic	 heart	 valve	
leaflets	(Burriesci	et	al	1999,	Black	et	al	1986).	These	cyclic	tests	were	repeated	a	total	of	
eight	 times	 on	 each	 of	 the	 three	 dumbbells	 according	 to	 the	 three	 temperature	 cyclic	
history	shown	in	Figure	3.45.	Then	one	of	the	samples	was	tested	again	a	total	of	19	times	
according	to	the	ten-temperature	cyclic	history	shown	in	Figure	3.4.	
																																								 																				
8	A	dumbbell	shape	was	chosen	as	it	had	previously	been	used	by	the	research	group.	
9	The	number	of	conditioning/full	cycles,	i.e.	10,	was	chosen	based	on	the	current	protocol	used	by	
the	research	group.	
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The	 temperatures	 chosen	 for	 the	 three	 temperature	 cyclic	 history	were	 4,	 21	 and	 37	 oC,	
corresponding	to	the	temperature	at	which	the	device	is	crimped,	prepared	and	functions	
at	respectively.	The	ten	temperatures	chosen	for	the	ten	temperature	test	were	chosen	to	
provide	an	even	number	of	data	points	between	4	and	37	oC.	
	
	
	 	
Figure	3.4:	Cyclic	temperature	histories;	three	and	ten	temperature	tests.	
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Figure	 3.5:	 Uniaxial	 tensile	 test	 set	 up	 for	 measuring	 thermo-mechanical	 properties	 of		
pericardium	(a)	dumbbell	die	cutter	(b)	acetate	template	and	dumbbell	pericardium	sample	
and	 template	 clamped	 in	 a	 Zwick	 Z5.0	 (c)	 equipment;	 Zwick	 Z5.0,	 water	 bath,	 immersion	
thermostat	and	refrigerated	circulator.	
Die	cutter	
with	
dumbbell	
shaped	
cutter.	
(a)	
(b)	
(c)	
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3.1.2.1.2	Analysis		
A	MATLAB	script	was	written	to	find	the	parameters	for	the	soft	tissue	equation	3.1	which	
fit	 the	 data	 for	 the	 10	 full	 cycles	 (approximately	 6000	 data	 points	 per	 loading/unloading	
cycle)	in	a	least-squares	sense	i.e.	the	fit	which	minimised	the	sum	of	squared	residuals	(the	
difference	 between	 the	 observed	 value	 and	 the	 value	 predicted	 by	 the	model);	 achieved	
using	 the	 ‘lsqcurvefit’	 function.	Provided	 that	 initial	estimates	≤	5	 integers	 from	the	
final	 values	 were	 given,	 then	 the	 scrip	 (Appendix	 A)	 worked	 well.	 Test	 cycles	 with	
parameters	greater	than	1.5	standard	deviations	(Equation	3.5)	from	the	associated	mean	
were	considered	outliers	and	therefore	excluded	from	further	analysis.	This	criterion	meant	
in	each	test	there	was	an	average	of	5	and	not	less	than	3	cycles	used	for	the	analysis.	The	
parameters	 for	 these	 loading	and	unloading	cycles	were	then	averaged	to	represent	each	
cycle	with	one	curve	 (Figures	3.2,	3.3	and	3.6),	 the	maximum	of	 the	 second	derivative	of	
which	 indicated	the	TP.	The	mean	and	standard	deviation	of	the	hysteresis	 (Equation	3.6)	
was	 also	 calculated;	 the	 integrals	 for	 which	 were	 computed	 numerically	 using	 adaptive	
Simpson	quadrature.	
	 s = 	 1N-1 (x<-	x)=><?@ 	
(3.5)			
	
	 h = 	 loading	curve- unloading	curve	∈LMNO 	∈LMNO 	 		(3.6)	
	
	
where	∈PQ1	is	the	maximum	strain	and	h	is	the	hysteresis.		
	
	
3.1.2.1.3	Results	and	discussion	
The	four	parameter	soft	tissue	equation	3.1	fitted	the	data	very	well	for	both	loading	and	
unloading	cycles	(Appendix	B,	Figure	B.2),	with	‘adjusted	R2’	(Equation	3.7)	values	of	at	least	
0.999,	which	on	visual	comparison	was	much	better	 than	the	 fit	achieved	by	Zioupos	and	
Barbenel	 (1994)	and	Rabkin	et	al	 (1975),	however	 they	did	not	 report	R2	 values	 so	direct	
comparison	 is	 not	 possible.	 	 Although	 the	 parameters	 A,	 B,	 C	 and	 D	 did	 not	 correlate	
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significantly	with	changes	in	temperature,	the	gradient	of	the	linear	region	and	TP	did	and	
are	discussed	later.		
	
	
	
	
	
	
	
	
	 adj. R= = 1-	SSVWX n-kSSZ[Z n-1	 (3.7)		
		
Where;	
SSres	=	sum	of	squares	of	residuals,	
SStot	=	total	sum	of	squares,	
k	=	number	of	parameters,	and	
n	=	number	of	data	points.	
There	 was	 no	 statistically	 significant	 variation	 in	 the	 gradient	 of	 the	 initial	 highly	 elastic	
linear	 region	 for	 the	 three-temperature	 and	 the	 first	 increasing	 temperature	 cycle	 of	 the	
ten-temperature	tests.	However,	there	was	a	non-linear	(3rd	order	polynomial)	relationship	
for	 the	 second,	 decreasing,	 temperature	 cycle	 for	 the	 ten-temperature	 test	 (Appendix	 B,	
Figure	B.3	and	Table	B.1).	
Figure	 3.6:	 Example	 of	 soft	 tissue	 equation	 curve	 fit	 for	 loading	 and	
unloading	curves	of	bovine	pericardium	dumbbell	1,	test	1	at	4	oC,	cycle	1.	
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All	 samples	 demonstrated	 that	 on	 average	 for	 1	 oC	 increase	 in	 temperature	 there	was	 a	
statistically	 significant	 increase	 in	 the	TP	of	0.0004	 (Appendix	B,	 Figure	B.4-B.6	and	Table	
B.2).	The	average	TP	for	dumbbell	2	was	0.2978	and	was	on	average	6%	and	43%	higher	for	
dumbbells	1	and	3	respectively	(Appendix	B,	Figure	B.5).	This	variation	between	dumbbells	
and	even	greater	 variation	between	patches	was	 confirmed	as	 significant	 at	 the	5%	 level	
using	Student’s	t-tests	(Appendix	B,	Table	B.3)	and	the	linear	relationship	was	confirmed	by	
the	ten-temperature	test	(Appendix	B,	Figure	B.6).	
Furthermore,	 for	all	dumbbells	 the	 rate	of	change	of	TP	with	 temperature	decreased	and	
remained	 constant	 after	 the	 first	 temperature	 cycle,	 for	 which	 the	 null	 hypothesis	 was	
rejected	by	a	Student’s	t-test	with	a	p-value	of	0.04,	and	is	therefore	statistically	significant	
at	 the	5%	 level	 (Appendix	B,	 Figure	B.4-B.6).	However,	 the	actual	 increase	 in	TP	between	
the	 first	and	remaining	cycles	was	only	significant	at	4	and	21	 oC	 (Appendix	B,	Table	B.4).	
There	was	also	a	significant	increase	of	the	TP	after	21	days	storage	at	4	oC	in	phosphate-
buffered	saline	(PBS)	(Appendix	B,	Table	B.5).	
The	calculation	of	hysteresis	was	based	on	curves	with	‘adjusted	R2’	values	of	at	least	0.999,	
and	 therefore	 was	 a	 more	 accurate	 method	 compared	 to	 that	 used	 in	 Claramunt	 et	 al	
(2012),	which	achieved	various	coefficients	of	determination	between	0.916	and	0.993.	The	
three	 and	 ten-temperature	 tests	 revealed	 no	 significant	 variation	 in	 hysteresis	 with	
temperature	or	stress	history,	the	 later	concurring	with	previous	findings	(Claramunt	et	al	
2012).	 However,	 the	 three-temperature	 test	 did	 successfully	 indicate	 the	 natural	 and	
significant	variation	in	hysteresis	between	patches	ranging	between	0.2	and	5.1	kPa,	which	
was	on	average	24%	lower	for	dumbbell	1	and	98%	lower	for	dumbbell	3,	the	latter	being	
from	a	different	patch,	when	compared	to	dumbbell	2	(Appendix	B,	Table	B.6).	There	was	
also	 a	 decrease	 in	 the	 hysteresis	 of	 dumbbell	 2	 after	 21	 days	 storage	 in	 PBS	 at	 4	 oC,	
although	only	significant	at	21	and	36	oC	with	p-values	of	0.005	and	0.0007	respectively.	
3.1.2.1.4	Summary	
1. Thermo-mechanical	properties	of	pericardium	
The	stress-strain	relationship	for	pericardium	soft	tissue	can	be	modelled	as	approximately	
linear	for	small	strains	followed	by	a	non-linear	region	using	the	four	parameter	‘soft	tissue	
equation	3.1,	the	maximum	of	the	second	derivative	of	which	can	determine	the	strain	at	
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the	 transition	 (TP)	 between	 the	 two	 regions	 and	 enables	 quantification	 of	 hysteresis	
between	loading	and	unloading	curves.	More	specifically:	
	
• The	 linear	 region	 only	 varied	with	 temperature	 after	 an	 initial	 temperature	 cycle	
from	4	to	40	oC	(3rd	order	polynomial).	
• In	general	the	TP	increased	linearly	with	temperature	at	a	rate	of	0.0004	per	oC	and	
more	specifically	it:	
o varied	between	dumbbells	and	even	more	so	between	patches,	
o increased	at	21	oC	and	4	oC	after	an	initial	temperature	cycle	up	to	37	oC,	
o increased	with	storage	at	4	oC	in	PBS.	
	
• The	hysteresis	varied	between	dumbbells	and	even	more	so	between	patches	and	
storage	at	4	oC	in	PBS	decreased	the	hysteresis	at	21	and	37	oC.	
2. Implications	for	in	vitro	testing	of	bioprosthetic	heart	valves	
Although	 the	 TP	 of	 pericardium	 is	 affected	 by	 temperature,	 on	 average	 the	 standard	
deviation	of	the	transition	point	at	4,	21	and	37	oC	was	0.007	±0.0007	which	is	a	factor	of	
ten	 smaller	 than	 between	 patches;	 0.06.	 Therefore,	 in	 terms	 of	 the	 TP,	 changes	 in	 the	
mechanical	properties	of	pericardium	due	to	temperature	differences,	in	the	range	relevant	
for	bio-prosthetic	heart	valves,	are	insignificant	compared	to	variations	that	occur	between	
patches	and	subsequently	between	prostheses.		
Consequently,	 the	 in	 vitro	 assessment	 of	 bio-prosthetic	 heart	 valves	 can	 justifiably	 be	
conducted	at	room	temperature,	rather	than	a	body	temperature	of	37	oC.	In	fact,	in	terms	
of	 using	 a	 working	 fluid,	 i.e.	 the	 fluid	 in	 the	 pulse	 duplicator,	 with	 a	 similar	 kinematic	
viscosity	to	blood	(2.8	–	3.8	m2/s	x	10-6)	water	at	21	oC	(0.98	m2/s	x	10-6)	is	more	similar	than	
if	heated	to	37	oC	(0.70	m2/s	x	10-6).	Furthermore,	any	particular	pulse	duplicator	set-up	is	
only	 accurate	 in	 providing	 comparative	 data	 (Simenauer	 et	 al	 1987),	 therefore	 the	 same	
comparative	 conclusions	would	 be	 drawn	whether	 tested	 at	 an	 elevated	 temperature	 or	
not.	 However,	 the	 impact	 of	 temperature	 on	 the	 material	 properties	 of	 the	 other	
components	of	the	bioprosthetic	valve	would	have	to	be	considered.		
	
In	 summary,	 increase	 in	 temperature,	 a	 cyclic	 temperature	 history	 and	 storage	 all	 make	
pericardium	tissue	less	stiff.	However,	due	to	variation	in	the	thermo-mechanical	properties	
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between	 patches	 used	 to	 make	 individual	 bioprosthetic	 heart	 valves,	 the	 effect	 of	
temperature	 is	negligible.	Therefore,	 in	vitro	 testing	of	bioprosthetic	heart	valves	at	room	
temperature	is	acceptable	in	terms	of	its	effect	on	the	leaflets	mechanical	properties.	
3.1.2.2	Ogden	model	
The	Ogden	constitutive	equation	was	chosen	 instead	of,	 for	example,	a	neo-Hookean10	or	
any	other	Mooney	Rivlin	equations,	because	 it	models	 the	hyperelastic,	non-linear	stress-
strain	behaviour	of	complex	materials	such	as	rubbers,	polymers	and	biological	soft	tissue.	
It	 assumes	 the	material	 behaviour	 can	 be	 described	 by	means	 of	 a	 strain	 energy	 density	
function,	from	which	the	stress-strain	relationship	can	be	derived.	The	properties	of	blood	
vessel	wall	 tissues	 can	be	approximated	as	 isotropic	 (Lally	et	al	2004)	and,	 therefore,	 the	
same	approach	has	been	followed	as	a	first	approximation.	Furthermore,	pericardium	can	
generally	 be	 approximated	 as	 incompressible	 and	 strain	 rate	 independent,	 allowing	 for	
several	simplifications	to	the	Ogden	equation.	
3.1.2.2.1	Aim	
Four	parameters	for	an	Ogden	model	were	identified	from	the	previously	described	uniaxial	
tensile	test	data	for	BP.	The	aim	was	to	implement	this	as	a	finite	element	material	model	
to	 simulate	 the	mechanical	behaviour	of	 the	proposed	bio-prosthetic	mitral	 valve	 leaflets	
described	in	Chapter	4.	
3.1.2.2.2	Calculation	
In	the	Ogden	model,	the	strain	energy	density	(W)	(Equation	3.8)	 is	expressed	 in	terms	of	
the	 principal	 stretches:	 \], \_	`ab	\c	 (Figure	 3.7)	 and	 material	 constants	 	de	 and	 fe,	
where	the	stretch/extension	ratio	(\)	is	defined	in	terms	of	the	final	and	original	lengths,	L	
and	Lo	respectively	(Equation	3.9).	
	 W λ@, λ=, λi = 	 µkαk>k?@ (λ@mn +	λ=mn +	λimn-3)	 (3.8)	
	
	 	
																																								 																				
10	 The	 neo-Hookean,	 a	 special	 case	 of	 the	 Mooney	 Rivlin,	 constitutive	 relationship	 has	 a	
characteristic	plateau	at	higher	strains	which	is	not	representative	of	pericardium.	
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	 λ = 	 LL[	 (3.9)	
	
To	identify	the	constants	for	a	four	parameter	Ogden	model	the	order	of	bulk	modulus,	N,	
was	 set	 to	 two	 in	 Equation	 3.8	 such	 that	 it	 results	 in	 Equation	 3.10	which	 requires	 four	
constants	to	be	identified.			
	 W = µ@α@ λ@mp +	λ=mp +	λimp-3 + µ=α= λ@mq +	λ=mq +	λimq-3 	 (3.	10)	
	
To	 fit	 the	 model	 to	 the	 experimental	 data	 three	 assumptions	 were	 made.	 Firstly	
pericardium	was	assumed	to	exhibit	isotropic	behaviour	(the	same	material	properties	in	all	
directions)	and	so	λ	1	and	λ	2	were	considered	to	be	equal	(Equation	3.11).		
	 λ= = 	 λi	 (3.	11)					
	
Secondly,	 it	 was	 assumed	 to	 be	 incompressible	 (i.e.	 no	 change	 in	 volume)	 such	 that	 the	
determinant	of	 the	deformation	gradient	 tensor	 F	becomes	equal	 to	 the	 Jacobian	 (J)	 and	
equal	to	1	(Equation	3.12).		
	 F = 	 λ@ 0 00 λ= 00 0 λi 	 (3.12)	
	
	 det F = 	1 = 	 λ@λ=λi	 (3.13)	
load	
Figure	 3.7:	 Direction	 of	 principal	 stretches	 for	
pericardium	dumbells	subjected	to	uniaxial	tensile	tests.	
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The	calculation	of	the	above	determinant	can	be	simplified	using	the	isotropic	assumption	
(Equation	3.11	and	3.14-3.16).		
	 λ@λ== = 1	 (3.14)	
	
	 λ= = 	 1λ@	 (3.15)	
	
	 λi = 	 λ= = 	 1λ@	 (3.16)	
	
This	results	in	simpler	equations	for	the	principal	stretches	(Equations	3.17-3.19);	
	 λ@ = 	λ	 (3.17)	
	
	 λ= = 	 1λ	 (3.18)	
	
	 λi = 	 1λ	 (3.19)				
	
which	when	substituted	into	Equation	3.8	the	strain	energy	density	becomes;	
	 W λ =	 µkαk>k?@ (λmn +	 1λ mn +	 1λ mn -3)	 (3.20)	
	
In	general,	the	shear	modulus	(µ)	(Equation	3.21)	results	from	the	constants	of	the	Ogden	
model.		
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	 2µ = 	 µkαk>k?@ 	 (3.21)	
	
Then	using	the	Ogden	material	model,	the	three	principal	Cauchy	stresses	(Equation	3.22)	
can	now	be	computed	(Equations	3.23-3.25).	
	 σ = 	 σ@@ σ@= σ@iσ=@ σ== σ=iσi@ σi= σii 	 (3.22)	
	
	 σ@@ = p +	λ@ ∂W∂λ@	 (3.23)	
	
	 σ== = p +	λ= ∂W∂λ=	 (3.24)	
	
	 σii = p +	λi ∂W∂λi	 (3.25)	
	
The	 third	 assumption	 is	 that	 pericardium	 tissue	 is	 a	 membrane	 and	 therefore	 the	 third	
principal	Cauchy	stress	is	effectively	zero	(Equation	3.26).		
	 σii = p +	λi ∂W∂λi 	= 0	 (3.26)	
	
Therefore,	a	value	for	p	can	be	obtained	(Equation	3.27).	
	 p = 	 -	λi ∂W∂λi	 (3.27)			
	
Substituting	Equation	3.27	into	Equation	3.4	gives	Equation	3.28.	
	 σ@@ = 	 λ@ ∂W∂λ@ -	λi ∂W∂λi	 (3.28)	
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The	derivatives	 for	 Equation	 3.28	 are	 calculated	 from	Equation	 3.10	 as	 in	 Equations	 3.29	
and	3.30.	
	 ∂W∂λ@ = 	µ@ λ@mp-@ +	µ= λ@mq-@ 	 (3.29)	
	
	
	 ∂W∂λi = 	µ@ λimp-@ +	µ= λimq-@ 	 (3.30)	
	
The	 extension	 of	 the	 pericardium	 dumbbells	 was	 measured	 by	 the	 Zwick	 tensile	 testing	
machine	and	so	the	first	principal	stretch	was	known	(original	length	of	the	test	section	was	
20	mm)	and	so	the	second	and	third	could	be	calculated.		
The	 above	 equations	 (Equations	 3.18-3.20	 and	 3.27-3.29)	 were	 implemented	 in	 Excel	 to	
minimise	 the	 sum	 of	 the	 difference	 squared	 (Equation	 3.31)	 between	 the	 first	 principal	
experimental	(σ@@,W1k)	and	Cauchy	true	stresses	(σ@@).		
	 Δσ= = 	 (σ@@,W1k-σ@@	)=	 (3.	31)	
	 	 	
The	resulting	 four	parameters	 for	 the	Ogden	model	are	displayed	on	Figure	3.8	and	were	
used	to	study	the	impact	of	different	aortic	valve	calcification	patterns	on	the	outcome	of	
transcatheter	aortic	valve	implantations	(Sturla	et	al	2016).	
In	 summary,	 the	 four	 parameter	 ‘soft	 tissue	 equation’	 (equation	 3.1)	 modelled	 the	
engineering	stress-strain	 relationship	 for	BP	reasonably	well	and	enabled	 the	quantitative	
study	 of	 its	 thermo-mechanical	 properties;	 becoming	 less	 stiff	 at	 higher	 temperatures,	
although	the	difference	is	not	significant	enough	to	warrant	in	vitro	testing	of	bioprosthetic	
valve	 leaflets	at	body	temperature.	Despite	 this	derived	engineering	relationship	having	a	
better	 fit	 compared	 to	 the	 four	 parameter	 Ogden	 model	 identified,	 with	 ‘adjusted	 R2’	
values	 of	 0.999	 and	 0.981	 respectively,	 the	 true	 stress-strain	 represented	 by	 the	 latter	
model	was	required	for	the	finite	element	analysis	of	the	non-linear	behaviour	because	the	
engineering	 stress-strain	 does	 not	 represent	 the	 physics	 at	 large	 strains,	 where	 the	
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instantaneous	area	of	the	cross	section	 is	significantly	different	to	the	original.	Therefore,	
the	Ogden	model	was	used	in	the	finite	element	analyses	described	in	Chapter	4.	
	
	
	
	
	
	
	
	
3.1.3 Harvesting	and	chemical	processing	of	pericardium	
To	generate	an	inert	biomaterial	from	a	xenogeneic	origin	the	xenogeneic	antigen	epitopes	
present	 in,	 for	 example,	 bovine	 pericardium	 (BP)	must	 either	 be	 removed	 or	masked	 to	
minimise	 immunological	 reactions	 from	 a	 patient’s	 body.	 This	 can	 be	 achieved	 by	
decellularisation	 or	 masked	 using	 chemical	 crosslinking	 methods	 such	 as	 glutaraldehyde	
(GA)	 treatment;	 a	 0.5%	 solution	being	 standard	 (Hulsmann	et	 al	 2012).	 The	protocol	 and	
equipment	 made	 for	 processing	 BP	 used	 to	 make	 prototype	 mitral	 valves	 is	 described	
below.		
	
BP	 sacs	were	 cut	 to	 lay	 flat	on	a	workbench	and	any	 fat	 and	parietal	 pericardium,	which	
attaches	fat	to	the	fibrous	pericardium,	were	removed	by	hand	(Figure	3.9).		
	
	
Figure	 3.8:	Ogden	material	model	 compared	 to	 experimental	 data	 for	 a	
uniaxial	tensile	test	of	bovine	pericardium.	
Four	Ogden	model	parameters	
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Number	 grid	 patches	 were	 printed	 onto	 the	 glued	 side	 of	 overhead	 projector	 acetate,	
transferred	onto	the	nearly	dry	and	smoothest	sections	of	pericardium	and	cut-out.	Their	
thickness	 was	measured	 three	 times	 at	 each	 location	 using	 a	 thickness	 gauge	 (Mitutoyo	
Corporation,	 Tokyo,	 Japan)	 specially	 adapted	 for	 pericardium;	 with	 the	 addition	 of	 a	 3D	
printed	 resin	 circular	 plunger	 head	 whilst	 submerged	 in	 saline	 (Figure	 3.10).	 The	 new	
plunger	head	being	preferable	to	the	original	metal	one	which	would	have	cut	through	the	
soft	tissue.	
Figure	 3.9:	 Bovine	 pericardium	 manual	 processing	 (a)	 whole	 sac	 (b)	
dissected	 sac	 (c)	 fat	 and	 parietal	 pericardium	 removal	 from	 fibrous	
pericardium.	
lumpy	fat		
(a)	
fat		
parietal	pericardium	
fibrous	
pericardium	
(c)	(b)	
Figure	 3.10:	 Bovine	 pericardium	 patch	 preparation	 (left)	 patch	 selection	
(right)	thickness	measurement	using	an	adapted	Mitutoyo	thickness	gauge.	
patch	
submerged	
in	saline	
1	of	12	location	
markers	per	patch	
Mitutoyo	
thickness	
gauge	
new	circular	
plunger	
head	
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Magnetic	frames,	based	on	a	design	previously	used	by	the	research	group,	were	made	by	
gluing	 together	 laser	 cut	 Perspex®	 (Universal	 Laser	 Systems	 Inc.)	 (Figure	 3.11),	were	 then	
used	to	keep	the	pericardium	taut	during	fixation	in	a	0.5%	solution	of	GA	for	48	hours.	Due	
to	this	wet	and	salty	environment	the	magnets	would	be	prone	to	rusting;	therefore	a	novel	
protective	layer	of	silicone	was	added	to	the	design	to	increase	durability	(Figure	3.11).	
	
	
	
	
	
	
	
	
The	 thickness	of	nine	pericardium	patches	was	measured	again	after	 fixation	 (Figure	3.12	
and	Appendix	C);	 average	 thickness	 becoming	0.35	 ±	 0.11	mm	and	 ranged	between	0.18	
and	0.69	mm,	 the	average	 increase	compared	 to	before	 fixation	was	0.04	±	0.03	mm	the	
average	 value	 before	 fixation	 was	 0.31	 ±	 0.06	 mm.	 Theses	 variations	 are	 statistically	
significant	because	they	are	greater	than	the	average	error	between	three	measurements	
taken	in	a	single	location,	which	was	0.01	mm.	The	thickness/location	data	for	fixed	patches	
was	later	used	to	select	regions	0.4	mm	thick	for	making	prototype	mitral	valve	leaflets.		
Figure	3.11:		Magnetic	frames	(left)	two	sides	of	frames	separate	(right)	
two	side	of	frames	holding	a	pericardium	patch	taut.	
side	1	 side	2	
attracting	magnets	 silicon	magnet	cover	
taut		
pericardium		
patch	
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3.2 Polyester	mesh	
This	 section	 describes	 the	 requirements	 and	 characterisation	 of	 polyester	 knitted	 mesh	
used	 for	 the	 skirt	 regions	 of	 the	 UCL	 TMV	 (Figure	 3.1).	 This	 research	 into	 the	
characterisation	of	mesh	structures	is	also	relevant	for	the	characterisation	of	other	meshes	
used	in	clinical	practice.	
3.2.1 Requirements	
The	 skirt	 region	 of	 the	 UCL	 TMV	 is	 required	 to	 extend	 in	 the	 axial	 direction	 by	
approximately	 65%	 when	 the	 device	 is	 fully	 crimped	 (Figure	 1.15)	 (estimated	 from	 CAD	
model).	 In	 order	 to	minimise	 the	 collapsed	diameter	 of	 the	device,	 to	 reduce	damage	 to	
surrounding	 tissue	during	 implantation,	 the	skirt	 region	would	 ideally	also	contract	 in	 the	
transverse	direction.	Therefore,	a	biocompatible	mesh	structure	was	identified	as	a	suitable	
material.		
A	 total	 of	 twelve	 biocompatible	 polyester	 knitted	 and	 woven	 meshes	 were	 considered	
(Textile	Development	Associates	 Inc.)	 (Figure	3.13).	 The	woven	meshes	were	not	 suitable	
due	to	their	 inextensibility;	therefore	one	of	the	knitted	meshes,	PETKM2004,	was	chosen	
because	 it	 had	 the	smallest	 pore	 size	 compared	 to	 the	 other	 knitted	meshes.	 There	 are	
numerous	reasons	why	the	smallest	pore	size	was	advantageous	for	the	UCL	TMV:	
Figure	3.12:	Effect	of	glutaraldehyde	 fixation	on	 the	 thickness	of	bovine	
pericardium,	patch	1	see	Appendix	B	for	results	for	patches	2	to	9	(there	
were	no	errors	in	the	locations	measured).	
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• It	better	facilitated	secure	suture	retention	for	attachment	to	the	wireframe.	
• The	more	dense	structure	of	mesh	better	distributes	the	gentle	anchoring	force	
over	the	annulus	compared	to	a	more	sparse	structure	of	meshes	with	larger	pores.		
• For	the	purpose	of	in	vitro	assessment,	and	therefore	in	the	absence	of	tissue	
ingrowth,	smaller	pore	sizes	would	be	advantageous	in	terms	of	minimising	
regurgitation.		
The	ability	of	PETKM2004	to	meet	the	required	extension	was	subsequently	characterised	
as	described	in	the	following	section.	
	
3.2.2 Characterisation	
Biocompatible	 synthetic	 meshes	 are	 commonly	 used	 to	 treat	 ventral	 hernias11	 and	 their	
general	mechanical	properties	have	been	characterised	(Ibrahim	et	al	2015).	However,	the	
nominal	Poisson’s	ratio	i.e.	that	associated	with	the	mesh	structure	has	not	previously	been	
measured	and	 is	of	critical	 importance	for	crimping	the	UCL	TMV	because	as	the	frame	 is	
folded	 the	 mesh	 must	 elongate	 in	 the	 axial	 direction	 of	 the	 device	 and	 contract	 in	 the	
transverse	direction	(Figure	3.14).	
																																								 																				
11	A	ventral	hernia	is	a	buldge	through	an	opening	in	the	muscles	of	the	abdomen.	
Figure	 3.13:	 Polyester	 meshes	 from	 Textile	 Development	 Associates,	 Inc.	 (GSM	 =	
grams	per	square	meter)	(http://www.surgicalmesh.com/pet_mesh.htm,	9/10/16).	
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3.2.2.1	Uniaxial	tensile	tests	
Initial	 uniaxial	 tensile	 tests	 were	 done	 to	 the	 required	 65%	 extension	 (section	 3.2.1)	 for	
three	orientations	of	the	PETKM2004	mesh;	0o,	45o	and	90o	(Figure	3.14Figure	3.15),	which	
identified	the	0o	orientation	to	be	the	most	extensible	and	therefore	most	suitable	for	axial	
orientation	in	the	UCL	TMV	skirt.		
	
	
	
	
	
	
Figure	 3.15:	Uniaxial	 tensile	 test	 to	 failure	 for	 3	 orientations	 of	 PETKM2004	measured	
using	a	Zwick	Z5.0	mechanical	testing	machine.	
(1)	
0o	
45o	90o	
(2)	
axial	
transverse	
Figure	 3.14:	 PETKM2004	 sample	 orientation	 (1)	 magnification	 of	 mesh	
structure	 (http://www.surgicalmesh.com/pet_mesh.htm,	 9/10/16)	 (2)	
orientation	of	skirt	cutting	pattern	on	sample.	
	
	
86	
	
To	confirm	the	PETKM2004	samples	had	not	slipped	in	the	uniaxial	clamps	and	that	it	was	
the	mesh	structure	rather	than	the	polyester	material	properties	that	were	measured	and	
to	enable	calculation	of	the	nominal	Poisson’s	ratio,	a	sample	at	0o	was	mounted	on	a	bi-
axial	mechanical	testing	machine	(BioTester,	CellScale	Biomaterials	Testing)	using	BioRakes,	
which	allowed	lateral	movement	(Figure	3.16),	and	was	extended	to	70%,	demonstrating	it	
could	in	fact	exceed	the	requirement.		
	
	
	
	
	
	
3.2.2.2	Nominal	Poission’s	ratio	
Firstly,	 it	should	be	noted	that	when	a	Poisson's	ratio	is	describing	a	material	 it	cannot	be	
greater	 than	 0.5	 due	 to	 the	 requirement	 that	 Young's	modulus,	 shear	modulus	 and	 bulk	
modulus	have	positive	values12.	However,	here	it	is	applied	to	a	mesh	structure	rather	than	
the	material	itself.	
The	 nominal	 Poisson’s	 ratio	 (Equation	 3.32)	 of	 the	 PETKM2004	mesh	 structure	 was	 2.7,	
based	on	relative	axial	and	transverse	dimensions	of	the	sample,	measured	relative	to	the	
BioRakes	 as	 indicated	 in	 Figure	 3.16	 from	 the	 BioTester	 video	 footage.	 In	 practice,	 this	
means	 that	when	 the	TMV	 is	 loaded	 into	a	 catheter,	 the	axial	 dimension	of	 the	 skirt	will	
extend	from	approximately	21	to	32	mm	and	decrease	from	33	to	26	mm	in	the	transverse	
																																								 																				
12	 Interestingly,	 some	 materials	 have	 negative	 Poission’s	 ratios,	 called	 auxetic	 materials,	 and	 are	
being	researched	by	the	UCL	Cardiovascular	Engineering	Laboratory	(Karnessis	et	al	2013,	Burriesci	
et	al	2007,	Scarpa	et	al	2003,	Smith	et	al	2002).	
Figure	3.16:	Biaxial	tensile	test	(BioTester,	CellScale	Biomaterials	Testing)	of	
PETKM2004	 cut	 at	 0o	 from	 sample	 indicating	 locations	 to	 measure	
displacements	for	nominal	Possion’s	ratio.	
0o	orientation		
BioRakes	 move	 laterally	
PETKM2004	
0%		
70%	
Displacement	at	right	angle	to	load		
Displacement	in	direction	of	load		
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direction.	Therefore,	two	sections	of	skirt	material	of	approximately	2.6	cm	wide	and	0.14	
mm	thick	need	to	fit	inside	the	catheter	along	with	the	other	components.	
	
	 ν = 	d ∈ZVQzXd ∈Q1<Q{ 	 (3.	32)	
	
Where;	
| ∈}~ÄÅ	=	strain	in	direction	of	load,	and		| ∈ÇÉÑ 	=	strain	at	right	angle	to	load.	
3.3 Nitinol	wire	
This	section	explains	how	nitinol	wire	fulfils	the	requirements	for	the	UCL	TMV	frame	and	
describes	its	characteristic	mechanical	behaviour	aided	by	an	investigation	into	the	effect	of	
cyclic	uniaxial	variable	strain	history	tensile	tests.	An	exemplar	analysis	for	determining	the	
material	properties	for	use	in	finite	element	analyses	of	the	nitinol	frame,	which	simulated	
its	 collapse	 into	 a	 catheter	 (Bozkurt	 et	 al	 2016),	 is	 provided	 as	 background	 information.	
Lastly,	the	limitations	associated	with	using	Nitinol	are	described.		
3.3.1 Requirements	
It	is	arguably	preferable	for	the	frame	of	any	TMV	to	be	self-expanding	rather	than	balloon-
expanding	because	the	radial	forces	associated	with	the	latter	are	not	appropriate	for	the	
mitral	 position.	 Furthermore	 the	 frame	 of	 a	 TMV	 should	 be	 made	 from	 a	 material	 with	
known	 successful	 clinical	 experience,	 both	 of	 which	 have	 been	 achieved	 by	 the	 nitinol	
stented	CoreValve	 (Medtronic	 Inc.)	 TAV	device	 (Liao	et	 al	 2016)	 and	 is	popular	 in	 second	
generation	 and	 investigational	 devices	 (Kheradvar	 et	 al	 2015,	 Preston-Maher	 et	 al	 2015).	
However,	 the	CoreValve	 stent	 is	 significantly	different	 to	 the	UCL	TMV	because	 it	 is	 laser	
cut	from	a	nitinol	tube,	rather	than	constructed	from	a	single	wire,	and	also	has	a	diamond	
mesh	structure	rather	than	the	relatively	light-frame	structure	of	the	UCL	TMV.	That	said;	it	
is	 also	 arguable	 that	 the	 control	 one	 has	 over	 the	 radial	 force	 produced	 by	 balloon-
expandable	 devices	 is	 advantageous	 to	 the	 uncontrolled	 and	 therefore	 variable	 radial	
forces	induced	by	self-expanding	devices.	The	superelastic	abilities	of	nitinol	enable	it	to	be	
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crimped	to	a	diameter	≤	8	mm,	smaller	diameters	being	associated	with	reduced	damage	to	
surrounding	 tissues	 during	 transcatheter	 implantation.	 Lastly,	 it	 should	 also	 be	
repositionable	 and	 possible	 to	 re-start	 the	 implantation	 procedure,	 i.e.	 retrievable,	 all	 of	
which	were	previously	 shown	to	be	 feasible	with	 the	nitinol	wireframe	design	of	 the	UCL	
TAV	(Rahmani	et	al	2013,	Burriesci	et	al	2012,	Burriesci	et	al	2010,	Ghanbari	et	al	2008),	on	
which	the	UCL	TMV	frame	is	based.	
3.3.2 Characterisation	
Nitinol	(NiTi),	a	composite	metal	of	Nickel	(Ni)	and	Titanium	(Ti),	is	characterised	by	shape	
memory	 (Huang	 et	 al	 2003),	 superelasticity,	 stress	 hysteresis	 and	 damping.	 Its	 material	
properties	 are	 non-linear,	 path	 and	 temperature	 dependant;	 determined	 by	 the	 specific	
composition	and	thermo-mechanical	processing.	Its	superelasticity	is	achieved	by	its	ability	
to	inter-change	its	crystal	structure	between	austenite	(simple	cubic)	and	martensite	(body-
centered	 tetragonal),	 this	 reversible	 solid-state	 phase	 transition	 therefore	 differs	 from	
conventional	elasticity	achieved	by	stretching	of	atomic	bonds.	In	the	absence	of	stress,	the	
martensitic	transformation	of	nitinol	can	also	be	induced	by	temperature	changes,	resulting	
in	shape	memory	(Stoeckel	et	al	2008,	Duerig	et	al	2000).		
As	in	most	biomedical	applications,	the	fatigue	behaviour	of	nitinol	is	highly	relevant	due	to	
the	 cyclic	 loads	 often	 induced	 and	 more	 specifically	 is	 relevant	 for	 the	 repeatable	
loading/deployment	of	 the	UCL	TMV.	The	highly	 complex	 fatigue	behaviour	of	nitinol	has	
recently	 been	 reviewed	 (Mahtabi	 et	 al	 2015).	 However,	 they	 do	 not	 mention	 the	
investigation	 into	 the	 effect	 of	 cyclic	 variable	 strain	 amplitudes,	 conducted	 by	 Lin	 et	 al	
(2012).	In	fact,	this	appears	to	be	the	only	research	into	the	effect	of	cyclic	variable	strain	
history	for	nitinol,	which	assessed	the	fatigue	life	of	stent-like	diamond	and	Z-shaped	nitinol	
specimens.	 The	 investigation,	described	 in	 the	 following	 sections,	 into	 the	effect	of	 cyclic	
uniaxial	 variable	 strain	 history	 tensile	 tests	 on	 the	 mechanical	 properties	 of	 nitinol	 wire	
assesses	 the	 induced	 variation	 in	mechanical	 properties	 (rather	 than	 fatigue)	 and	 uses	 a	
different	specimen	shape	(a	single	nitinol	wire)	compared	to	those	used	by	Lin	et	al	(2012)	
and	Schlun	et	al	(2011).	
	
	
	
	
89	
	
3.3.2.1	Aim	
The	aim	was	to	investigate	how	the	mechanical	properties	of	nitinol	wire	are	affected	by	a	
series	of	cyclic	uniaxial	tensile	tests	up	to	various	maximum	strains.	The	results	from	which	
also	provided	exemplar	data	for	explaining	the	material	properties	of	nitinol	wire	and	their	
derivation	for	use	in	numerical	simulations	used	to	optimise	the	UCL	TMV	frame	(Bozkurt	et	
al	2016).	
3.3.2.1	Protocol	
A	nitinol	wire13,	70	mm	long	0.45	±	0.0004	mm	diameter	was	subjected	to	5	cyclic	loads	up	
to	strains	of	2,	4,	6,	8	and	10%,	using	the	Zwick	Z5.0	mechanical	testing	machine	at	room	
temperature.	 These	 tests	 were	 done	 prior	 to	 the	 UCL	 TMV	 prototypes	 being	 made	 and	
samples	 of	 the	 optimised	 wire	 used	 for	 the	 UCL	 TAV	 were	 not	 available;	 therefore,	 the	
sample	tested	was	one	of	the	suboptimal	wires	for	the	UCL	TAV.	
	
3.3.2.1	Results	and	Discussion	
3.3.2.1.1	Hysteresis	
The	typical	stress	hysteresis	for	nitinol	(Figure	3.17)	and	associated	hyperelastic	behaviour	
was	observed	 in	 the	sample	 tested.	 Initially,	 the	stress	 increased	 linearly	with	strain	after	
which	there	was	a	 loading	plateau,	characterised	by	small	 increases	in	stress	for	relatively	
large	 increases	 in	 strain	 (Figure	3.17).	 In	 the	cases	of	 strains	≥	7%	 the	end	of	 the	 loading	
plateau	was	 reached	 and	 linear	 extension	 of	 the	martensitic	 phase	was	 observed	 (Figure	
3.18).	As	the	strain	began	to	reduce,	the	stress	decreased	rapidly	until	an	unloading	plateau	
was	reached	(Figure	3.17),	which	recovered	the	strain	with	only	small	decreases	 in	stress.	
Finally,	the	last	portion	of	strain	was	recovered	linearly,	although,	when	strained	to	10%	the	
final	 linear	region	is	no	longer	co-linear	with	the	initial	 linear	region,	which	interestingly	is	
characteristic	of	nitinol	when	tested	at	a	temperature	T,	which	 is	Mf	<	T	<	Af;	where	Mf	 is	
the	martensitic	finish	temperature	(below	this	the	nitinol	 is	fully	martensitic)	and	Af	 is	the	
austenitic	finish	temperature	(above	which	the	nitinol	is	austenitic)	(Mahtabi	et	al	2015).	
	 	
																																								 																				
13	 The	 nitinol	 wire	 (Fort	 Wayne	 Metals	 Ireland	 Limited)	 had	 the	 following	 chemical	 composition	
(percent):	 C(0.0240),	 Cr(0.0014),	 Ni(55.96),	 Fe(0.0110),	 Ti(Bal),	 Cu(0.0014),	 Co(0.004),	 H(0.0005),	
O(0.0263)	and	austenitic	peak	temperature	-17	oC.	
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3.3.2.1.2	Stress	relaxation	and	memory	
Stress	relaxation	occurred	as	the	sample	was	repeatedly	cycled	to	each	maximum	strain;	for	
example,	 the	upper	plateau	strength	(UPS)	 for	the	fifth	cycle	to	6%	strain	was	7	MPa	 less	
than	 for	 the	 first	 cycle	 (Figure	 3.18).	 The	 samples	 also	 demonstrated	 memory	 of	 the	
“relaxed”	UPS	for	the	first	cycle	of	the	consecutive	series	of	cyclic	tensile	tests	to	a	higher	
maximum	strain,	but	once	the	strain	exceeded	that	previously	experienced	there	was	a	step	
increase	 (Figure	 3.19)	 in	 the	UPS	back	 to	 the	 same	 stress	 level	 (σXÖÜ)	 associated	with	 the	
very	first	cycle	to	2%.	
	
Figure	 3.17:	 Stress-strain	 relationship	 showing	 the	 superelastic	
transformation	of	a	nitinol	wire	up	to	4%	strain,	average	of	5	cycles.	
*	=	
*	*	*	 *	 *	
stress	memory	
Figure	3.18:	Stress-strain	 relationship	 for	nitinol	wire	 for	maximum	strains	of	
2,	4,	6,	8	and	10%	showing	just	the	first	and	last	cycles	for	each,	demonstrating	
stress	relaxation	over	cyclic	loads	to	a	specific	strain,	and	stress	memory.	
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3.3.2.1	Properties	for	mathematical	modelling	
This	 section	 presents	 an	 example	 of	 how	 the	 material	 properties	 for	 nitinol	 wire	 were	
determined	for	use	 in	numerical	model	optimisation	of	 the	nitinol	 frame	which	simulated	
its	collapse	into	a	catheter	(Bozkurt	et	al	2016).	The	values	in	the	table	below	correspond	to	
nitinol	wire	strained	to	6%	(Figure	3.19).	
Table	3.1:	Exemplar	material	properties	for	nitinol	wire	strained	to	6%.	
Material	Property	 Definition	 Exemplar	values	
Upper	plateau	strength	(UPS)	 stress	at	3%	strain	during	loading	 520	MPa,	 slightly	 higher	 than	 the	 UPS	
used	 to	 model	 the	 CoreValve	 nitinol	
stent	by	Tzamtzis	et	al	(2012);	390	MPa	
Lower	plateau	strength	(LPS)	 stress	at	2.5%	strain	during	unloading	 262	MPa	
Residual	elongation	(Elr)	 difference	 between	 the	 strain	 at	 a	
stress	 of	 7	 MPa	 during	 unloading	 and	
loading	
0.014%	
Ultimate	tensile	strength	(UTS)	 maximum	stress	sustained	 just	prior	to	
necking,	or	fracture,	or	both	
The	 UTS	 and	 associated	 uniform	
elongation	(Elu)	were	not	reached.	
Young’s	 Modulus	 for	 the	 initial	
austenite	region	(EA)	
slope	of	 80%	of	 the	 stress-strain	 curve	
up	to	the	UPS	
41	GPa	
Young’s	 Modulus	 of	 the	 later	
martensitic	region	(EM)	
slope	of	80%	of	the	curve	between	the	
stress	 at	 the	 finish	 of	 transformation	
from	austenite	to	martensite	(áàâä)	and	
the	UTS	
550	MPa,	 the	 latter	 was	 not	 obtained	
for	 the	 wire	 tested	 therefore	 EM	 was	
not	calculated	
Stress	 at	 the	 start	 of	 the	
transformation	 from	 austenite	 to	
martensite	
σXÖÜ	 481	MPa	
Stress	 at	 the	 start	 of	 the	
transformation	 from	 martensite	 to	
austenite	
σXÜÖ	 270	MPa	
Stress	 at	 the	 finish	 of	 the	
transformation	 from	 martensite	 to	
austenite	
σãÜÖ	 212	MPa	
Elastic	transformation	region	 difference	 between	 the	 strain	 at	 σãÖÜ	
and	σXÖÜ	 ∈{	=	0.047	
EA	=	41	GPa	(y	=	40702x,	R²	=	0.9918)	
Figure	3.19:	Stress-strain	relationship	for	nitinol	wire	up	to	6%	strain,	average	
of	5	cycles,	indicating	the	definition	of	properties	for	mathematical	modelling	
and	simulation.	
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The	 final	 material	 properties	 for	 the	 UCL	 TMV	 frames	 were	 unknown	 at	 this	 initial	
prototyping	 stage	 because	 the	 specific	 composition	 and	 thermo-mechanical	 processes	
require	 optimisation.	 However,	 material	 properties	 resulting	 from	 the	 optimised	
manufacturing	methods	used	for	the	similar	UCL	TAV	frame	were	available	(EA	=	50	GPa,	EM	
=	12	GPa,	σXÖÜ	=	527	MPa,	σãÖÜ	=	525	MPa,	σXÜÖ	=	279	MPa,	σãÜÖ	=	297	MPa	and	∈{	=	0.075)	
and	 subsequently	 used	 as	 approximate	 inputs	 for	 the	 finite	 element	 analyses	 used	 to	
optimise	the	UCL	TMV	frame	in	terms	of	having	minimal	stresses	whilst	crimped	in	an	8	mm	
tube	and	to	adequately	match	the	mitral	valve	anatomy	(Bozkurt	et	al	2016).		
3.4 Summary	
This	chapter	characterised	and	outlined	 the	requirements	 for	 the	components	of	 the	UCL	
TMV	 prototypes;	 namely	 the	 self-expanding	 nitinol	 wireframe,	 polyester	 mesh	 skirt	 and	
pericardial	leaflets	(Figure	3.1).	The	two	main	outcomes	from	this	chapter	were;	
1. Characterisation	of	the	thermomechanical	properties	of	pericardium:		
a. Provided	input	data	for	numerically	modelling	the	mechanical	properties	of	
pericardium	tissue	for	use	in	finite	element	analyses	used	as	a	design	tool	for	
developing	the	UCL	TMV	bileaflet	design	(Chapter	4).	
b. Indicated	in	vitro	haemodynamic	assessment	of	prototypes	could	be	justifiably	
conducted	at	room	temperature,	rather	than	at	an	elevated	body	temperature	
of	37	oC	(Chapter	5).	
2. Characterisation	of	polyester	mesh:	indicated	that	PETKM2004	was	suitable	for	the	
UCL	TMV	prototypes	(Chapter	6).	
Chapter	4	will	now	discuss	the	leaflet	design	and	how	finite	element	analyses’	were	used	as	
a	design	tool	resulting	in	the	selection	of	a	conical	bileaflet	design,	uniquely	defined	by	two	
parameters;	its	scale	factor	and	coaptation	length.	
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Chapter	4 Leaflet	design	using	finite	element	analysis	
The	UCL	TMV	leaflets,	presented	 in	this	chapter,	have	an	original	combination	of	features	
being	 D-shaped,	 with	 two	 leaflets	 and	 slightly	 conical.	 Further,	 this	 is	 the	 first	 such	
morphologically	 similar	 leaflet	 design	 to	 be	 used	 in	 a	 transcatheter	 device.	 This	 chapter	
firstly	 describes	 their	 requirements	 and	 then	 the	 design	 approach	 and	 finite	 element	
simulations	used	are	expounded,	the	results	for	which	are	presented	and	discussed.		
4.1 Requirements	
The	requirements	for	the	TMV	leaflets	in	terms	of	their	material	properties	were	previously	
described	 in	section	3.1.1.	A	device	with	an	 inter-trigonal	diameter	of	26	mm	(Figure	4.1)	
was	 required	 because	 it	 is	 small	 enough	 to	 mount	 in	 the	 mitral	 position	 of	 the	 pulse	
duplicator,	 used	 to	 assess	 its	 performance,	 and	 is	 appropriate	 for	 future	 animal	 trials	 as	
well	as	for	small	human	patients,	most	likely	female	adults.		
	
	
	
	
	
	
4.2 Design	
A	 risk	 rather	 than	 requirements	 based	 design	 approach	 is	 required	 for	 the	 recent	
transformative	developments	of	 transcatheter	heart	 valves	and	 is	 in	 accordance	with	 ISO	
5840-3:2013,	 further	 described	 in	 ISO	 14971:2012	 ‘Medical	 devices	 –	 application	 of	 risk	
management	to	medical	devices’.	Therefore	a	risk	based	approach	was	used	to	select	the	
optimal	design	criteria	and	determine	 the	parametric	design.	This	 is	 summarised	 in	Table	
4.1	using	a	failure	mode	and	effects	analysis	and	described	in	detail	in	the	following	section.	
Figure	4.1:	The	26	mm	(inter-trigonal	diameter)	UCL	transcatheter	mitral	valve.	
aortic	leaflet	 annular	D-shape	
ventricular	D-shape	
mural	leaflet	
left	atrium	
left	ventricle	
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Table	4.1:	Failure	mode	and	effects	analysis	to	obtain	the	optimal	design	criteria	(mitigation/requirements)	and	parametric	design	(parameter	
for	further	investigation/evidence	of	mitigating	risk)	for	transcatheter	mitral	valves.	
Potential	
failure	
mode	
Potential	
cause(s)/mechanism	
Cardiac	
cycle	
phase	
Local	effects	
of	failure	
Next	
higher	
level	
effect	
System	
level	end	
effect	
Probability	
(estimate)	
(P)	
Severity	
(S)	
Relevance	
for	patient	
population	
(R)	
Risk	
Level	
(P+S+R)	
Mitigation	
/Requirements	
Parameter	
for	further	
investigation	
/evidence	of	
mitigating	
risk	
Structural	 Tearing,	perforations	and/or	calcification	
Systolic	 Regurgitation	
Additional	
work	
required	
by	left	
ventricle	
Reduced	
blood	flow,	
ending	in	
inadequate	
supply	of	
nutrients	
for	cellular	
metabolism.	
Risk	of	heart	
failure.	
1	(Kapadia	
SR	et	al	
2015)	
5	(worst	
case)	
2	 8	
Minimise	
excessive	
stresses	
Conicity	and	
coaptation	
length	
Functional	
Incomplete	
coaptation	and/or	
prolapse	
5	(sections	
Error!	
Reference	
source	not	
found.-
2.4)	
	
5	 15	
Maximise	
coaptation	
area	
Key:	
Probability	rating	
(meaning	based	on	
occurrences	in	
similar	devices	with	
clinical	experience)	
1	=	Extremely	unlikely	(none	known),	2	=	Remote	(relatively	few),	3	=	Occasional,	4	=	Reasonably	Possible	(repeated	failures),	5	=	
Frequent	(almost	inevitable).	
Severity	rating	
1	=	No	relevant	effect,	2	=	Minor	(may	require	use	of	pharmaceutical	drugs	to	maintain	health),	3	=	Moderate	(loss	of	optimal	
performance	of	device	resulting	in	return	of	symptoms	untreatable	with	pharmaceutical	drugs),	4	=	Critical	(loss	of	optimal	
performance	of	device	resulting	in	a	replacement	being	required),	5	=	Catastrophic	(device	no	longer	performs	required	function	
resulting	in	death).	
Relevance	rating	 1	=	None,	2	=	Little,	3	=	Considerably,	4	=	Very,	5	=	Extremely.	
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4.2.1 Optimal	design	criteria	for	leaflets	
On	 reflection	 of	 the	 failure	 mode	 and	 effects	 analysis	 (Table	 4.1),	 two	main	 risks	 were	
identified	for	the	leaflets	of	a	TMV;	structural	and	functional	failure.	Optimal	design	criteria	
associated	with	 these	 two	 failure	modes	were	 identified	 as	 the	 peak	maximum	principal	
stress	 (MPS)	 and	 coaptation	 area	 (CA)	 respectively,	 both	 of	 which	 are	 measurable	 from	
finite	element	analyses	(FEA)	and	are	unobtainable	experimentally.	The	criteria	for	the	peak	
MPS	and	CA	are	further	described	below.	
4.2.1.1	Peak	maximum	principal	stress	(MPS)	
Bioprosthetic	 heart	 valves	must	 endure	 a	 complex	 cyclic	 loading	 and	 deformation	 during	
the	 cardiac	 cycle,	 opening	 and	 closing	 more	 than	 100,000	 times	 per	 day.	 The	 resulting	
stress	states	are	multi-axial	and	their	failure	(on	average	bioprosthetic	valve	functional	life	
is	 only	 12	 years	 (Chandran	 et	 al	 2010)),	 is	 governed	 by	 a	 combination	 of	 various	 stress	
components,	including	tensile	and	compressive	in-plane,	bending	and	shear.	
There	 are	 no	 failure	 theories	 relevant	 for	 bioprosthetic	 heart	 valves.	 The	 ability	 to	
determine	why	and	how	materials	fail	i.e.	the	complete	separation	of	a	member,	has	been	
an	 area	 of	 research	 for	 several	 decades,	 continuing	 to	 the	 present	 day,	 resulting	 in	
numerous	failure	theories	some	only	for	specific	applications	and	all	with	advantages	and	
disadvantages.	 They	 all	 have	 the	 common	 theme	 that	 a	 material	 will	 fail	 when	 some	
physical	variable	reaches	a	limiting	value;	whether	this	is	a	certain	stress,	strain	or	energy	is	
specific	to	each	theory.	
There	are	two	main	failure	criteria	theories14,	one	based	on	stress,	the	maximum	principal	
stress	theory,	and	one	based	on	shear	strains,	the	maximum	distortion	energy	theory.	The	
maximum	principal	stress	theory,	is	based	on	the	idea	that	failure	will	occur	when	either	of	
the	 principal	 stresses,	 σ"	 or	 σ#,	 reaches	 or	 exceeds	 the	 yield	 strength,	 known	 as	 the	
Rankine	 failure	 criteria.	 In	 contrast,	 the	maximum	distortion	 energy	 theory	 assumes	 that	
failure	will	occur	when	the	distortional	energy	associated	with	the	principal	stress	equals	or	
exceeds	the	distortional	energy	corresponding	to	that	for	the	yield	strength	of	the	material	
in	uniaxial	tension	or	compression,	known	as	the	von	Mises	failure	criteria.	In	general,	the	
																																								 																				
14	 Other	 failure	 theories	 include	 Coulomb-Mohr,	 Beltrami	 (maximum	 strain	 energy),	 Tresca	
(maximum	shear	stress)	and	St	Venant	(maximum	principal	strain	theory)	to	name	a	few.	
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Rankine	criterion	provides	a	good	prediction	for	the	failure	of	brittle	materials,	whereas	the	
von	Mises	criterion	is	better	for	ductile	materials.		
The	von	Mises	failure	criterion	has	previously	been	used	for	designing	the	tissue	leaflets	of	
a	percutaneous	aortic	 valve	 (Smuts	et	 al	 2011).	However,	 the	Rankine	 criteria	has	 shown	
relevance	 in	 the	 structural	 failure	 in	 explanted	 bioprosthetic	 heart	 valves	 (Bernacca	 et	 al	
1992,	Thubrikar	et	al	1983),	observed	as	tearing,	perforations	and/or	calcification15,	shown	
to	be	associated	with	locations	of	peak	MPS	(Burriesci	et	al	1999).	Despite	their	theoretical	
difference,	the	peak	MPS	and	von	Mises	stresses	in	a	commercially	successful	transcatheter	
bioprosthetic	heart	 valve	 are	 shown	 in	 section	4.4.1	 to	be	 the	 same	order	of	magnitude.	
Furthermore,	pericardium	cannot	be	defined	solely	as	a	ductile	nor	brittle	material.	Whilst	
fracture	is	preceded	by	little	plastic	deformation	(Zioupos	et	al	Jan	1994,	Zioupos	et	al	Apr	
1994)	 characteristic	 of	 a	 brittle	 material,	 necking	 occurs	 before	 failure	 which	 is	
characteristic	 of	 a	 ductile	 material.	 Therefore,	 either	 the	 Rankine	 or	 von	Mises	 criterion	
may	be	relevant.	However,	it	is	the	concentration	of	principal	stresses	that	are	responsible	
for	delamination	 (Mirnajafi	 et	 al	 2010)	 and	 the	 consequent	blood	 flow	 through	 the	open	
pores	 which	 leads	 to	 calcification.	 Therefore,	 the	 Rankine	 criterion	 is	 arguably	 the	most	
relevant	for	designing	bioprosthetic	heart	valve	leaflets.	
	
A	leaflet	design	similar	to	the	UCL	TMV	leaflets	(Burriesci	et	al	1999),	was	reported	to	have	
endured	 a	 peak	MPS	 of	 approximately	 2	MPa,	 associated	with	 the	 critical	 loading	mode	
when	 the	 leaflets	 are	 fully	 closed,	 which	 withstood	 more	 than	 400	 million	 opening	 and	
closing	cycles	(5	years)	in	vitro	as	well	as	in	vivo	function	in	calves,	with	survival	times	that	
met	 the	 Food	 and	 Drug	 Administration	 requirements	 (Black	 et	 al	 1986).	 Therefore,	 the	
order	of	magnitude	of	the	peak	MPS	for	the	optimal	leaflet	design	had	to	be	2	MPa	or	less.	
This	 order	 of	 magnitude	 risk	 assessment	 for	 structural	 failure	 is	 appropriate	 for	 several	
reasons.	Firstly,	when	FEA	is	applied	to	the	design	of	bioprosthetic	heart	valve	leaflets,	the	
results	 are	 only	 relevant	 as	 a	 prediction	 for	 the	 order	 of	magnitude	 of	 stresses	 that	will	
occur.	 Secondly,	higher	accuracy	would	be	 futile	due	 to	 the	natural	 variability	 in	material	
properties	across	devices	as	well	as	within	a	single	set	of	leaflets.	Finally,	the	requirement	
																																								 																				
15	 It	 has	 been	 shown	 that	 structural	 and	 functional	 failure	 can	 occur	 in	 unison;	 calcific	 deposits	
(structural	 failure)	 can	 inhibit	 the	 full	 closure	 of	 the	 leaflet	 (functional	 failure)	 (Shah	 et	 al	 2008,	
Vesely	et	al	1988,	Thubrikar	et	al	1983).		
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of	withstanding	 400	million	 cycles	was	 revised	 in	 the	 current	 standard	 (ISO	 5840-3:2013,	
Annex	O)	to	a	minimum	of	200	million	cycles	with	no	sign	of	excessive	structural	damage	
and/or	functional	impairment,	therefore	this	order	of	magnitude	criteria	is	conservative.		
4.2.1.1	Coaptation	area	
The	 CA	 has	 previously	 been	 used	 to	 assess	 the	 effect	 of	 the	 positioning	 strategy	 for	 the	
SAPIEN	TAV	(Auricchio	et	al	2013),	which	ranged	between	3.4	and	2.6	cm2.	The	CA	for	the	
TMV	 leaflets	 is	 the	area	of	contact	between	the	aortic	and	mural	 leaflets.	This	provides	a	
surface	 seal,	 sustains	 the	 closing	 pressure	 load	 and	 provides	 a	 safety	 margin	 against	
valvular	 regurgitation.	 If	 removed	 the	 valve	 would	 be	 incompetent,	 also	 referred	 to	 as	
functional16	failure.	Therefore,	it	appeared	to	be	logical	inference	to	assume	that	larger	CAs	
would	be	associated	with	less	regurgitation	and	therefore	the	optimal	leaflet	design	would	
have	the	maximum	CA.	
4.2.2 Parametric	design	
The	 parametric	 design	 was	 developed	 after	 reflection	 of	 the	 failure	 mode	 and	 effects	
analysis	 (Table	 4.1)	 and	 therefore	 conicity	was	 added	 to	 the	 initial	 concept	 for	 the	 UCL	
TMV	 (section	 1.4.4)	 making	 it	 even	 more	 physiologically	 similar	 and	 novel	 compared	 to	
others	 in	development	 (section	2.2)	 (although	conicity	 is	 in	 fact	present	 in	 the	Cleveland,	
Sheffield,	QuattroTM	and	the	other	quadrileaflet	surgical	valves	previously	reviewed	(section	
2.1)).	 The	use	of	 a	 parametric	 design	 to	 create	 a	 bileaflet	mitral	 valve	based	on	 a	 failure	
mode	 and	 effects	 analysis	 (Table	 4.1)	 	 improves	 on	 the	 clinically	 irrelevant	 reasoning	
behind	 the	 ‘bubble	 valve’	 (section	 2.1.1,	 Walker	 et	 al	 1983)	 and	 Sheffield	 surgical	 valve	
(Black	et	al	1986)	designs.	
The	idea	for	creating	a	conical	design	was	inspired	by	the	3D	echo	of	a	healthy	mitral	valve	
(Figure	1.5)	and	the	following	section	describes	how	the	optimal	 leaflet	design	was	drawn	
using	computer-aided	design	(CAD)	3-D	modelling	software	Rhinoceros	4.0	(Robert	McNeel	
&	Associates).	
	
																																								 																				
16	The	second	functional	 failure	mode	 is	heart	 failure,	caused	by	adverse	pressure	gradients	which	
cause	the	heart	to	work	harder.	This	is	associated	with	the	diastolic	orifice	area,	which	is	taken	into	
account	in	limiting	the	scale	factor	to	not	be	less	than	0.745.		
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4.2.2.2	Design	parameters	
The	leaflets	for	the	UCL	TMV	were	drawn	in	their	assembled	configuration	as	surfaces	using	
computer-aided	 design	 (CAD)	 3-D	 modelling	 software	 Rhinoceros	 4.0	 (Robert	 McNeel	 &	
Associates)	based	on	a	standard	D-shape	(Figure	4.2	and	following	instructions).		
	
	
	
	
	
	
1	 In	the	top	view	draw	a	semi-circle	of	diameter	26	mm.	
	
2	
Draw	a	line	from	the	centre	of	the	circle	to	
the	edge.	This	is	line1.	
	
	
3	
Draw	a	quarter	circle	centred	on	the	middle	
of	line1.	
	
	
4	 Mirror	the	quarter	circle	along	the	x-axis.		
	
5	
Draw	a	straight	line	between	the	two	quarter	
circles.	
	
	
Figure	 4.2:	 Standard	 D-shape	 proportions	 constructed	 from	 a	
semi-circle	with	radius	R,	two	quarter	circles	and	a	rectangle.	
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6	
Join	the	four	sections	of	the	D-shape	
together.	
	
	
7	
Scale	the	D-shape,	using	the	centre	of	the	
semi-circle	as	the	origin	and	a	scale	factor	
(SF)	of	0.745.	
	
	
8	
In	the	front	view,	move	the	larger	and	
smaller	D-shapes	14		and	4	(CL)	mm	above	
and	below	the	origin	respectively.		
	
	
9	
In	the	top	view,	draw	a	line	between	the	
ends	of	the	two	semi-circles.	This	is	line2.	
	
	
10	 Mirror	this	line	along	the	x-axis.	This	is	line3.		
	
11	
Using	Sweep2,	use	line2	and	line3	as	the	rails	
and	the	two	D-shapes	as	the	cross-sections.	
This	is	the	conical	surface.	
	
	
12	 In	the	right	view,	display	line2	and	line3.		
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13	
Draw	a	plane,	selecting	the	tops	of	line2	and	
line3	as	the	first	two	points	and	entering	in	
10	for	the	width.	This	is	called	plane1.	
	
	
14	 Display	line1,	line2	and	line3.		
	
15	
Draw	a	plane	using;	surface/plane/3	points;	
selecting	the	top	of	line2	and	line3	and	the	
far	right	end	of	line1.	This	is	plane2.	
	
16	
Hide	the	lines.	Draw	a	vertical	line	down	2.5	
mm	(cuff	length)	from	the	bottom	left	corner	
of	plane2.	This	is	line4.	
	
	
17	 Mirror	this	line	along	the	y-axis.	This	is	line5.	
	
18	 Display	the	smaller	D-shape,	line4	and	line5.	
	
19	
Draw	a	plane,	select	the	bottom	end	of	line4	
and	line5	and	the	intercept	with	the	centre	
of	smaller	D-shape.	This	is	plane3.	
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20	
Display	the	conical	surface.	Draw	a	plane	
that	will	intersect	the	displayed	layers.	This	is	
plane4.	
	
21	 In	the	front	view,	Split	the	conical	surface	with	plane2,	plane3	and	plane4.	
	
22	
Create	a	layer	for	the	region	to	the	left	of	the	
y-axis,	this	is	the	aortic	leaflet.	Then	“hide”	
it.	
	
23	
Create	a	layer	for	the	region	to	the	right	of	
the	y-axis,	when	split	in	a	similar	way,	this	
will	be	the	mural	leaflet.	Then	“hide”	it.	
	
24	
Create	a	layer	for	the	regions	above	the	x-
axis.	Then	“hide”	them.		The	remaining	
surfaces	can	be	discarded.	
	
25	
In	the	right	view,	display	line2	and	line3.	
Draw	a	plane	selecting	the	top	ends	of	them	
and	a	width	of	10.	This	is	plane5.	
	
26	
Display	line1,	line2	and	line3.	
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27	
Draw	a	plane,	selecting	the	top	ends	of	line2	
and	line3	and	the	far	right	end	of	line1.	This	
is	plane6.	
	
	
28	
Hide	line2	and	line3.	Draw	a	vertical	line	
down	2.5	mm	from	the	bottom	left	corner	of	
plane6.	This	is	line6.	
	
	
29	 Mirror	this	line	along	the	y-axis.	This	is	line7.	
	
30	 Display	the	smaller	D-shape	and	line6	and	line7.	
	
31	
Draw	a	plane	selecting	the	bottom	ends	of	
line6	and	line7	and	the	centre	of	the	small	D-
shape.	This	is	plane7.	
	
32	
In	the	front	view,	display	the	mural	surface,	
plane6	and	plane7.	Split	the	mural	surface	
using	plane6	and	plane7.	
	
33	
Look	at	the	right	view.	Create	a	layer	for	the	
central	section,	this	is	the	mural	leaflet.	Then	
“hide”	it.	
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34	
Place	the	sections	above	the	x-axis	in	the	
commissures	layer.	The	bottom	section	can	
be	discarded.	
	
	
4.2.2.1	Aim	
The	aim	of	 the	parametric	 leaflet	design	was	to	enable	a	series	of	 incrementally	different	
designs	 to	be	created	using	parameters	 that	would	be	associated	with	 the	design	criteria	
previously	 discussed.	 Thereby	 aiming	 to	 minimise	 the	 peak	 MPS	 and	 maximise	 the	
coaptation	area,	with	the	aid	of	finite	element	simulations	(section	4.3).	
4.2.2.1.1	Scale	factor	
The	 SF17	 between	 the	 annular	 and	 ventricular	 D-shapes	 quantifies	 the	 conicity	 of	 the	
leaflets	(Figure	4.1	and	Figure	4.3).	The	addition	of	conicity	was	inspired	by	the	shape	of	a	
healthy	 native	mitral	 valve	 (Figure	 1.1	 and	 Figure	 1.3,	 Votta	 et	 al	 2008)	 and	 is	 in	 direct	
contrast	to	the	divergent	design	by	Kheradvar	et	al	 (2012)	(Figure	2.3).	The	conical	design	
was	 speculated	 to	 prevent	 excessive	 oscillation	 of	 the	 orifice	 area	 during	 diastole	 and	
thereby	reduce	potential	 turbulence	and	associated	risk	of	blood	damage18.	Furthermore,	
the	 conical	 design	 may	 prevent	 left	 ventricular	 outflow	 tract	 obstruction	 (LVOTO)	 and	
prolapse;	 by	 counter	 acting	 the	 tendency	 for	 the	 free	 leaflet	 edges	 to	diverge	 from	 their	
manufactured	 configuration	when	placed	 inside	 an	 annulus	with	 an	 interference	 fit,	 as	 is	
common	practice.		
The	SF	must	not	be	greater	than	1;	 if	 it	were	the	native	 leaflets	would	turn	outwards	and	
may	cause	LVOTO.	They	should	not	be	less	than	0.745,	which	will	ensure	the	native	mitral	
valve	 diastolic	 orifice	 area	 is	 not	 reduced	 by	 more	 than	 60%;	 for	 which	 mitral	 valves	
repaired	 using	 the	 edge-to-edge	 technique	 (Figure	 1.12)	 still	 function	 without	 adverse	
pressure	 gradients19	 (Alfieri	 et	 al	 2001).	 This	 minimum	 SF	 was	 calculated	 for	 the	 largest	
																																								 																				
17	A	scale	factor	was	used	to	place	the	leaflets	at	an	angle,	because	due	to	geometric	restrictions,	it	is	
not	possible	to	angle	the	leaflets	individually	and	have	coapting	lengths	which	can	be	formed	from	a	
flat	sheet	of	pericardium.	
18	High	turbulence	is	associated	with	high	shear	stress,	which	is	associated	with	two	types	of	blood	
damage;	hemolysis	and	platelet	activation	(Leverett	et	al	2008).	
19	Acknowledgements	The	Heart	Hospital,	London	for	allowing	me	to	observe	a	patient	undergoing	a	
transesophageal	echocardiogram	(TEE)	as	well	as	a	MitraClip®	procedure.	
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native	annulus	into	which	the	proposed	device	would	be	implanted	(25	mm,	resulting	in	an	
interference	fit	of	1	mm)	by	approximating	the	native	D-shape	to	be	similar	to	the	D-shape	
used	for	the	construction	of	the	prosthetic	leaflets	(Figure	4.2).	This	calculation	ignored	the	
conicity	of	the	native	valve,	and	therefore	was	a	conservative	estimate.		
	
	
	
	
	
	
To	enable	 the	generation	of	a	 set	of	designs	which	would	be	 incrementally	different,	 the	
following	 even	 distribution	 of	 five	 SFs,	 in	 the	 range	 described,	 were	 chosen	 for	
investigation;	0.745,	0.79875,	0.8525,	0.90625	and	0.96.	
4.2.2.1.2	Coaptation	length	
The	CL	 is	commonly	used	to	describe	the	morphology	of	a	native	mitral	valve	(Wang	et	al	
2013).	 	 For	 the	 proposed	 leaflet	 design,	 CL	 refers	 to	 the	 vertical	 distance	 from	 the	 arris	
between	the	aortic	and	mural	 leaflets	to	the	middle	of	 the	 leaflets	 free	edge	(the	 longest	
part	of	each	 leaflet).	 It	was	hypothesised	that	 longer	CLs	would	provide	better	coaptation	
between	the	 leaflets	 (Gogoladze	et	al	2010),	quantifiable	as	a	 larger	coaptation	area,	and	
would	also	allow	the	valve	to	function	in	a	larger	range	of	host	annulus	geometries.		
	
Leaflets	with	CLs	longer	than	the	cuff-length20	(CFL)	of	2.5	mm	were	cut	at	an	angle	mainly	
because	the	leaflets	have	to	be	made	from	a	single	flat	sheet	of	pericardium,	the	edges	of	
which	must	be	joined	together	and	attach	securely	to	the	frame.	Furthermore,	removal	of	
																																								 																				
20	The	cuffs	used	 for	 the	 similar	UCL	TAV	were	2.5	mm	 long	and	 therefore	 it	was	assumed	similar	
ones	would	be	used	for	the	UCL	TMV.	
Figure	4.3:	Leaflets	for	the	UCL	transcatheter	mitral	valve	and	the	conical	bileaflet	
(CB)	surgical	mitral	valve:	coaptation	length	(CL)	=	4	mm,	cuff	length	(CFL)	=	2.5	mm.	
CFL	
left	atrium	
left	ventricle	
aortic	leaflet	
mural	
leaflet	
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excess	leaflet	tissue	will	prevent	structural	and/or	functional	failure	that	may	occur	due	to	
rubbing	on	 the	 frame	and	 is	also	advantageous	 for	achieving	a	minimum	crimped	profile,	
thereby	reducing	damage	to	surrounding	tissue	during	implantation.	
There	 are	 several	 reasons	 to	 limit	 the	 maximum	 leaflet	 length;	 too	 much	 redundant	
material	 may	 cause	 premature	 degradation	 of	 the	 leaflets	 and	 would	 result	 in	 more	
localised	bending	or	folding,	such	as	buckling	or	pin	wheeling	(twisting	of	the	leaflets	free	
edges	due	to	excessive	leaflet	tissue,	ISO	5840-3:2013),	which	was	associated	with	failure	of	
pericardial	 leaflets	 (Shah	et	al	2008,	Vyavahare	et	al	1999,	Vesely	et	al	1988).	Also	 longer	
leaflets	are	more	likely	to	cause	LVOTO.	Another	reason	to	limit	their	length	is	that	viscous	
energy	losses	are	directly	proportional	to	vessel	length	(Akins	2008);	therefore	on	this	basis	
shorter	leaflets	will	have	lower	diastolic	energy	losses.	Subsequently,	the	CL	was	limited	to	
4	mm.	The	following	five	CLs	were	chosen;	0,	1,	2,	3	and	4	mm,	which	when	combined	with	
the	 five	 different	 SFs,	 resulted	 in	 25	 incrementally	 different	 bileaflet	 CAD	models.	 These	
were	then	turned	into	finite	element	models	and	their	closure	simulated.	
4.3 Finite	element	simulations	
Computational	 simulations	 of	 prosthetic	 heart	 valve	 dynamics	 play	 an	 important	 role	 in	
their	design	and	evaluation,	previously	reviewed	in	(Chandran	2010).	In	the	case	of	a	TMV,	
both	 the	 boundary	 conditions	 and	 operating	 configuration	 are	 highly	 complex,	 unknown	
and	 patient	 specific	 and	 therefore	 use	 of	 the	 finite	 element	 method	 in	 this	 context	 is	
limited	to	being	an	initial	design	tool	(Smuts	et	al	2011).	
4.3.1 Aim	
The	aim	of	using	finite	element	simulations	to	assess	the	critical	loading	mode	(fully	closed)	
of	 25	 incrementally	 different	 bileaflet	 designs	 (section	 4.2.2)	 was	 to	 select	 an	 optimal	
design	 which	 reduced	 the	 risk	 of	 functional	 and	 structural	 failure	 (section	 4.2.1),	 i.e.	
maximised	 the	 coaptation	 area	 and	 minimised	 the	 peak	 maximum	 principal	 stress	
respectively	 (Table	4.1).	 This	 subsequently	 saved	 time	and	money	 that	would	have	been	
required	 for	 prototyping	 unsuccessful	 designs	 and	 provided	 data	 unobtainable	
experimentally.	
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4.3.2 Finite	element	model	
4.3.2.1	Software	
An	explicit	code,	traditionally	used	for	 impact	and	crash	analyses,	was	chosen	rather	than	
an	implicit	code	mainly	because	of	its	superior	ability	to	deal	with	contact	problems,	which	
is	crucial	for	simulating	the	critical	loading	mode	of	heart	valve	leaflets	in	their	fully	closed	
position.	 Furthermore,	 an	 explicit	 code	 provides	 a	 cost	 effective	 analysis	 technique	 for	
short	duration	events	that	have	significant	non-linearities	with	large	deformations;	ideal	for	
simulating	 the	closure	of	pericardial	 leaflets	which	have	 large	 strains	 in	bending	of	5%	or	
greater	 at	 high	 strain	 rates	 with	 contact	 interactions	 and	 plasticity.	 LS-DYNA	 (Livermore	
Software	 Technology	 Corporation)	 is	 one	 such	 FE	 code,	 previously	 used	 successfully	 for	
simulation	of	bioprosthetic	heart	valves	(Burriesci	et	al	1999)	and	therefore	was	employed	
in	this	study	(Appendix	D).		
	
Small	time	steps	are	required	to	maintain	stability	and	provide	a	robust	solution	procedure	
even	 for	 a	 high	 degree	 of	 nonlinearities.	 Explicit	 integration	 is	 used;	 where	 a	 system	 of	
explicit	 algebraic	equations	 is	written	 for	 all	 nodes	 in	 the	mesh	at	 time	 level	 t	 +	∆t.	 Each	
equation	 is	 solved	 in-turn	 for	 the	unknown	node	point	displacements.	 The	 time	 step	 (∆t)	
must	be	less	than	the	length	of	time	it	takes	a	signal	traveling	at	the	speed	of	sound	(c)	in	
the	material	 to	 traverse	 the	 distance	 between	 the	 node	 points	 (L;	 the	 smallest	 element	
length,	Equation	4.1).	
	 ∆%	 ≤ ()	 (4.1)	
	
4.3.2.2	Material	
Despite	pericardium	being	orthotropic,	 an	 isotropic	material	model	will	 provide	 sufficient	
information	 for	 average	 behaviour	 of	 pericardial	 leaflets;	 a	 good	 approximation	 both	 in	
terms	 of	 stresses	 and	 displacements	 (Burriesci	 et	 al	 1999).	 Therefore,	 the	 constitutive	
relationship	 of	 the	 leaflets	 was	 modelled	 as	 isotropic,	 non-linear,	 hyperelastic,	
incompressible	 and	 capable	 of	 recoverable	 strain	 using	 the	 Ogden	 model	 previously	
described	(Figure	3.8).	
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4.3.2.3	Boundary	conditions	
The	 boundary	 between	 the	movable	 leaflets	 and	 stationary	 frame	was	 simplified	 i.e.	 the	
individual	stiches	which	attach	the	pericardium	to	the	nitinol	were	modelled	as	a	uniform	
hinge	 which	 allowed	 rotations	 and	 restricted	 the	 x,	 y	 and	 z	 locations	 of	 the	 nodes.	 The	
coaptation	of	the	leaflets	was	modelled	using	a	contact	boundary	condition	which	checked	
the	nodes	for	potential	contact	with	the	neighbouring	leaflet	as	well	as	self-contact	at	each	
increment	in	load	and	in	the	absence	of	a	fluid	the	wetness	of	contact	was	modelled	using	a	
zero	coefficient	of	 friction,	previously	used	 in	a	simulation	of	a	similar	mitral	valve	design	
(Burriesci	 et	 al	 1999).	 Although	 the	 boundary	 between	 blood	 and	 leaflets	 was	 not	
modelled,	 the	effect	of	blood’s	 inertia	 in	 reducing	system	oscillations	was	represented	by	
multiplying	 the	velocity	of	each	node	by	a	damping	coefficient	of	0.9965,	previously	used	
successfully	for	the	simulation	of	a	similar	pair	of	leaflets	(Burriesci	et	al	1999).	
4.3.2.4	Discretisation	
Shell	 elements	 provided	 a	 good	model	 of	 the	membrane	 structure	 of	 pericardium.	 They	
have	 previously	 been	 used	 successfully	 for	 their	 ability	 to	 model	 thin	 structures,	 with	
thickness	small	compared	to	 length,	and	efficiently	provide	accurate	results	 for	shear	and	
large	strains	in	bending,	which	can	be	greater	than	5%	in	heart	valve	leaflets,	caused	by	the	
large	and	complex	deformations	during	the	cardiac	cycle	(Howard	et	al	2003,	Burriesci	et	al	
1999,	Patterson	et	al	1996,	Black	et	al	1991,	Huang	et	al	1990).	Therefore,	an	iso-mesh	of	
quadrilateral	 (CQUAD4)	 2D	 constant	 strain	 Belytschko-Lin-Tsay	 (BLT)	 shell	 elements	 with	
grid	 points	 of	 6	 degrees	 of	 freedom,	 based	on	 the	Co-Mindlin	 shell	 formulation	with	 one	
point	 Gauss	 quadrature	 (Belytschko	 and	 Tsay	 1981),	 were	 chosen	 to	model	 the	 0.4	mm	
thick	 leaflets.	The	BLT	shell	elements	use	a	bilinear	(i.e.	first-order)	 interpolation	function,	
to	define	the	mid-surface	velocity,	angular	velocity	and	element’s	coordinates.	
The	out-of-plane	stresses	were	represented	by	one	constitutive	evaluation	for	each	of	the	
five	integration	points	through	the	thickness	of	the	shell	elements.	However,	this	geometry	
is	 limited	by	 reduced	accuracy	when	warping	 is	 involved,	 caused	by	assuming	 the	 shell	 is	
flat.	
Initially,	a	2	mm	iso-mesh	was	sufficient	to	compare	the	trends	in	behaviour	in	the	initial	25	
leaflet	designs	and	had	a	reasonable	computational	time	of	approximately	30	minutes.	This	
resulted	in,	on	average,	300	shell	elements	per	leaflet,	a	factor	of	ten	fewer	than	previously	
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used	 to	 predict	 actual	 behaviour	 of	 prosthetic	 aortic	 valve	 leaflets	 (Auricchio	 et	 al	 2014,	
Burriesci	et	al	1999).	This	mesh	was	later	refined	to	0.5	mm	for	the	optimal	leaflet	design.	
Finer	meshes	were	not	used	because	they	would	not	represent	the	physics	of	the	thin,	0.4	
mm	thick,	pericardium	leaflets,	the	elements	for	which	should	be	wider	than	they	are	thick.	
In	 fact	 a	 mesh	 refinement	 conducted	 for	 a	 similar	 valve	 revealed	 that	 finer	 meshes	
provided	an	inferior	representation	of	the	valves	closed	morphology	(section	4.4.1).	
4.3.2.5	Load	
In	general,	for	assessment	of	prosthetic	heart	valve	leaflets	the	closing	phase	dynamics	are	
the	 most	 significant	 during	 the	 cardiac	 cycle	 and	 more	 specifically,	 idealised	 models	 of	
bioprosthetic	heart	valves	 (Hamid	et	al	1986)	and	synthetic	valve	designs	 (Chandran	et	al	
1991)	have	identified	the	critical	loading	mode	to	occur	when	there	is	a	maximum	pressure	
difference	across	the	fully	closed	leaflets.	Therefore,	simulation	of	just	leaflet	closure,	using	
a	time	dependent	and	spatially	uniform	pressure	difference	applied	to	the	ventricular	side	
of	 the	 leaflets,	 was	 sufficient	 to	 enable	 selection	 of	 an	 optimal	 leaflet	 design	 based	 on	
critical	 loading	 mode	 performance.	 To	 close	 the	 leaflets	 starting	 from	 their	 fully	 open	
position	 a	 small	 opening	 pressure	 was	 applied	 prior	 to	 ramping	 to	 200	 mmHg	 (27	 kPa)	
(Figure	4.4;	based	on	pulse	duplicator	data	previously	obtained	by	the	research	group).	
	
Figure	 4.4:	 Transmitral	 pressure	 difference	 derived	 from	 pulse	 duplicator	 data,	
applied	to	the	ventricular	side	of	the	leaflets	in	their	manufactured	configuration.	
	
	
109	
	
4.4 Results	
4.4.1 Confirmation	of	peak	maximum	principal	stress	optimal	design	criteria	
The	maximum	allowable	stress	in	the	bileaflet	designs	was	set	to	be	the	same	precision	as	2	
MPa,	 for	 reasons	 previously	 discussed	 (section	 4.2.1).	 This	 design	 criterion	 was	 further	
supported	by	a	FEA	of	the	critical	loading	mode	of	a	similar	device,	the	SAPIEN,	a	pericardial	
three-leafleted	TAV21,	which	has	achieved	up	to	five	years	 implantation	without	structural	
deterioration	(Kapadia	et	al	2015).	
The	 same	 software,	material,	 boundary	 conditions	 and	 structure	 as	 previously	 described	
were	 applied	 to	 a	 FEM	 of	 the	 SAPIEN	 leaflets,	 only	 with	 two	 adjustments.	 Firstly,	 the	
pressure	applied	was	a	transaortic	pressure	derived	from	pulse	duplicator	data,	which	had	
associated	 video	 footage	 (Figure	 4.5)	 and,	 secondly	 a	 finer	mesh	of	 0.5	mm	was	 used	 to	
obtain	a	more	accurate	measure	of	stress.	Finer	meshes	were	not	used	because	they	would	
not	represent	the	physics	of	the	thin,	0.4	mm	thick,	pericardium	leaflets,	the	elements	for	
which	 should	 be	 wider	 than	 they	 are	 thick	 (discussed	 further	 in	 the	 ‘mesh	 refinement’	
section	below).	
	
	
	
	
	
																																								 																				
21	Although	designed	for	the	aortic	position,	it	has	also	been	implanted	in	the	opposite	orientation	in	
the	mitral	position	to	treat	severe	calcification	(Hasan	et	al,	2013).		
Figure	4.5:	Transaortic	pressure	difference	derived	from	pulse	duplicator	
data,	 applied	 to	 the	 aorta	 side	 of	 the	 SAPIEN	 leaflets	 in	 their	
manufactured	configuration	and	the	associated	video	frame	when	closed.	
(Data	previously	obtained	by	the	research	group).	
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The	 resulting	 FEA	 successfully	 represented	 the	 morphology	 of	 the	 fully	 closed	 SAPIEN	
leaflets,	replicating	a	similar	free-edge	curvature	as	well	as	the	characteristic	creases	in	the	
leaflet	surface,	which	combined	with	the	models	reasonable	material	description	means	it	
can	be	assumed	the	magnitude	of	the	peak	MPS	measured	from	the	FEA,	1.4	MPa,	was	also	
realistic	(Krucinski	et	al	1993,	Figure	4.6).	Thus,	this	FEA	is	validated.	Furthermore,	this	FEA	
validates	 the	 simulations	used	 to	design	 the	bileaflets	prior	 to	 experimental	 validation	of	
their	similar	FEMs.	Note	that	due	to	the	singularities	that	occurred	at	the	top	of	the	stent	
posts	and	at	 the	edge	of	 the	bases,	peak	values	 for	 the	MPS	and	von	Misses	 stress	were	
measured	one	element	away.	More	specifically,	the	peak	MPS	was	2.1	MPa	at	the	corner	of	
the	 stent	 post,	 it	 was	 1.4	MPa	 one	 element	 diagonally	 inwards;	 similarly	 the	 von	Mises	
stress	 was	 2.4	MPa	 at	 the	 very	 edge	 of	 the	 base,	 and	 was	 a	maximum	 of	 1.1	MPa	 one	
element	away.	
	
The	peak	 von	Mises	 stress	 and	MPS	were	 the	 same	order	of	magnitude,	 identical	 to	one	
significant	 figure	 and	 both	 concur	 with	 recently	 reported	 literature	 (Abbasi	 et	 al	 2015,	
MPS	[MPa]	
von	Mises	[MPa]	
3	stent	posts	
center	of	base	of	3	leaflets	 creases	
Figure	4.6:	SAPIEN	leaflets	in	their	critical	loading	mode	(top)	maximum	principal	stress	(MPS)	
peaks	 at	 top	 of	 stent	 posts	 1.4	MPa	 (bottom)	 von	Mises	 stress	 peaks	 at	 center	 of	 base	 of	
leaflets	1.1	MPa	(left	column)	views	from	aorta	(right	column)	isometric	views.	
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Auricchio	 et	 al	 2014).	 The	 location	 of	 stress	 concentrations	 for	 the	MPS	 and	 von	Misses	
stress	 differ,	 being	 located	 at	 the	 top	 of	 the	 stent	 posts	 and	 center	 of	 the	 base	 of	 each	
leaflet,	 respectively.	However,	 neither	 the	 Rankine	 nor	 von	Mises	 failure	 theories	 can	 be	
confirmed	as	applicable	without	 in	vivo	 failure	observations,	which	have	not	yet	occurred	
for	 the	 SAPIEN	 valve	 (Kapadia	 et	 al	 2015),	 there	 is	 also	no	 known	 in	 vitro	 durability	 data	
either.	Therefore,	the	MPS	and	von	Mises	stress	theories	can	equally	provide	an	estimate	
for	 the	 order	 of	magnitude	 of	 stresses	 sustainable	 for	 a	 period	 of	 5	 years	 in	 the	 SAPIEN	
valve.		
4.4.1.1	Mesh	refinement	
The	mesh	for	the	SAPIEN	valve	was	refined	(Figure	4.7)	and	although	it	did	not	converge	in	
terms	of	 stress,	 a	mesh	 size	of	 0.4	mm	was	 chosen.	Not	only	did	 this	 best	 represent	 the	
experimentally	observed	morphology	of	 the	closed	 leaflets	 it	also	meant	the	width	of	 the	
shells	 (i.e.	mesh	 size)	 remained	 at	 least	 the	 same	 size	 as	 their	 thickness.	 This	means	 the	
elements	 remained	 thin	 structures;	 if	 the	mesh	were	 smaller	 than	 0.4	mm	 the	 elements	
become	narrower	 than	 they	are	 thick,	which	no	 longer	 represents	 the	physics	of	0.4	mm	
thin	 pericardium	 tissue	 (Figure	 4.7	 and	 Figure	 4.8).	 Therefore,	 based	 on	 correctly	
representing	 the	 physics	 and	 correlations	 with	 experimental	 observations,	 rather	 than	
mesh	 convergence,	 a	mesh	of	 0.4	mm	was	used	 for	 the	 SAPIEN	and	also	 for	 the	optimal	
bileaflet	design.	
Figure	 4.7:	Mesh	 refinement	 for	 the	 SAPIEN	 valve	 leaflets,	 indicating	 the	morphology	 of	 and	
peak	maximum	principal	stress	associated	with	its	critical	operating	condition	when	fully	closed,	
highlighting	the	0.4	mm	mesh	size	chosen.	
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4.4.2 Optimal	leaflet	design	
As	previously	described,	FEMs	of	 the	25	bileaflet	designs	were	created	and	a	FEA	of	 their	
closure	simulated.	The	critical	 loading	mode	results	were	then	analysed	as	follows.	Firstly,	
each	 model	 was	 inspected	 visually	 and	 those	 which	 did	 not	 occlude	 the	 orifice	 were	
rejected	 because	 this	was	 an	 essential	 design	 requirement.	 Secondly,	 the	 stresses	 in	 the	
remaining	17	designs	were	analysed,	which	 confirmed	 they	had	a	peak	MPS	of	 the	 same	
precision	 as	 2	MPa	 (ranging	 between	 3	 and	 1	MPa)	 and,	 therefore,	 none	were	 rejected.	
Lastly,	the	CA	associated	with	each	design	was	measured	as	the	total	area	of	the	elements	
in	contact	(Figure	4.9).		
	
Figure	4.9:	Leaflet	optimisation	of	coaptation	length,	 scale	factor	and	coaptation	
area.	(Colour	variation	relates	to	changes	in	coaptation	area	and	was	included	to	
help	visualisation).	
Figure	 4.8:	Pulse	 duplicator	 footage	of	 SAPIEN	 valve	 in	 its	
fully	closed	position	indicating	twist	of	leaflet	coaptation.	
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Ideally	 the	 optimal	 design	 would	 have	 both	 the	 minimum	 peak	MPS	 and	 maximum	 CA.	
However,	 in	 reality	 the	maximum	CA	 (1.62	 cm2)	was	achieved	by	 the	design	with	a	 SF	of	
0.90625	and	CL	of	4	mm	(abbreviated	 to:	SF_0.90625_CL_4)	and	 the	minimum	peak	MPS	
(0.6	MPa)	was	achieved	by	a	design	SF_0.745_CL_3	 (Figure	4.10).	 If	minimisation	of	peak	
MPS	and	maximisation	of	CA	were	of	equal	importance,	then	the	optimal	design	would	be	
the	one	closest	to	the	origin	in	Figure	4.10	and	therefore	design	SF_0.8525_CL_4	would	be	
optimal	 (only	 7	 units	 from	 the	 origin),	 compared	 to	 the	 other	 two	 closest	 designs	
SF_0.745_CL_4	 and	 SF_0.79875_CL4,	 which	 were	 30	 and	 11	 units	 from	 the	 origin,	
respectively.	 However,	 the	 peak	 MPS	 in	 these	 three	 designs	 were	 all	 1	 MPa	 (1	 s.f.).	
Therefore,	due	to	FEA	results	for	bioprosthetic	heart	valve	leaflets	only	being	relevant	as	an	
order	 of	magnitude	 approximation	 for	 stresses,	 the	 CA	was	 used	 as	 the	 principal	 design	
criteria.		
	
	
	
	
	
	
Selection	 of	 the	 optimal	 design	 based	 on	 CA	 is	 further	 justified	 by	 its	 acute	 relevance	 in	
minimising	regurgitation,	preventing	functional	failure	and	enabling	proper	coaptation	for	a	
range	of	different	host	annulus	geometries,	the	foremost	being	of	significant	importance	in	
the	mitral	position.	Furthermore,	considering	that	transcatheter	devices	are	currently	only	
implanted	 in	 elderly	 patients,	 mostly	 for	 compassionate	 reasons	 (rather	 than	 with	 the	
intention	 of	 significantly	 increasing	 their	 life	 span);	 precision	 engineering	 the	 leaflets	 for	
maximum	 durability	 is	 arguably	 irrelevant	 compared	 to	 engineering	 them	 for	 minimal	
Figure	 4.10:	Variation	 in	 peak	maximum	 principal	 stress	 and	 coaptation	 area	 for	 17	
incrementally	different	bileaflet	designs	relative	to	the	optimal	values	achieved.	
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regurgitation.	 In	 fact,	 designing	 them	 for	minimal	 regurgitation	would	be	 the	best	design	
strategy	for	improving	the	patient’s	quality	of	life,	especially	considering	the	initial	high-risk	
patient	 population	 will	 have	 limited	 life	 expectancy	 due	 to	 various	 co-morbidities.	
Therefore	 the	 prevention	 of	 regurgitation	 was	 chosen	 as	 the	 principal	 design	 criteria.	 In	
which	 case,	 the	 design	 SF_0.745_CL_4	 was	 the	 optimal	 design;	 with	 a	 CA	 of	 1.54	 cm2	
compared	 to	 1.46	 and	 1.52	 cm2	 for	 designs	 SF_0.8525_CL_4	 and	 SF_0.79875_CL4	
respectively.	
The	 initial	 2	mm	mesh	of	 the	optimal	 leaflet	design	was	 subsequently	 refined	 to	0.5	mm	
(and	no	smaller	due	to	reasons	previously	discussed	in	section	4.4.1),	which	confirmed	the	
peak	MPS	to	be	2	MPa,	still	meeting	the	design	criteria,	and	had	a	larger	CA	of	2	cm2.	Unlike	
the	SAPIEN	FEA,	 location	of	stress	concentrations	for	both	the	MPS	and	von	Misses	stress	
were	both	located	at	the	arris	between	the	leaflets,	and	again	although	technically	different	
were	the	same	order	of	magnitude	(Figure	4.11).			
	
	
	
	
	
	
4.5 Discussion		
4.5.1 Parametric	design	
The	nature	 inspired	 conical	 design,	 implemented	using	 a	 scale	 factor,	 effectively	 reduced	
excess	material	at	the	leaflets	free	edge,	smoothing	the	central	buckle	previously	observed	
arris	between	
leaflets	 MPS	[MPa]	
arris	between	
leaflets	
mural	leaflet	
aortic	leaflet	
von	Mises	[MPa]	
Figure	 4.11:	 FEA	 results	 for	 the	 optimal	 bileaflet	 design	 with	 a	 0.5	 mm	 mesh	 (left)	 maximum	
principal	 stress	 (MPS),	 peak	 2.15	 MPa	 (right)	 von	 Mises	 stress,	 peak	 2.13	 MPa,	 arrows	 indicate	
regions	of	stress	concentration	and	location	of	peak	values.	
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in	 the	 Sheffield	 bileaflet	 valve	 (Figure	 4.12),	 thereby	 possibly	 reducing	 associated	 peak	
stresses	(Burriesci	et	al	1999).	
	
	
	
	
	
	
The	UCL	TMV	aortic	and	mural	leaflet	angles,	5.2o	and	10.4o	respectively	(Figure	4.13),	are	
in	different	proportions	compared	 to	 those	previously	quantified	 in	vivo,	which	were	8.3o	
and	5.3o	respectively	(Votta	et	al	2008).	This	highlights	the	impact	of	using	a	scale	factor	to	
angle	 the	 leaflets,	 rather	 than	 placing	 them	 at	 an	 angle	 individually.	 In	 fact	 it	 was	 not	
possible	to	angle	the	leaflets	individually	due	to	geometric	restrictions	involved	in	having	a	
coaptation	 length,	 making	 leaflets	 from	 a	 single	 flat	 sheet	 of	 pericardium	 tissue	 and	
ensuring	that	their	edges	joined	together	along	the	cuff	length	(Figure	4.3).	
	
	
	
	
	
	
4.5.2 Finite	element	simulations	
The	structural	FEAs	were	adequate	to	predict	whether	the	leaflets	closed	and	fully	occluded	
the	orifice.	However,	they	did	not	predict	leaflet	morphology	during	closure,	which	concurs	
with	Smuts	et	al	 (2011);	 that	when	modelling	the	closure	of	heart	valve	 leaflets	the	 finite	
Figure	 4.12:	 Sheffield	 valve	 indicating	 the	 central	
buckle	in	leaflets	(adapted	from	Burriesci	et	al	1999).	
Figure	 4.13:	 UCL	 transcatheter	 mitral	 valve	 leaflet	 angles	
resulting	from	a	scale	factor	between	annular	and	ventricular	
D-shapes	of	0.745:	aortic	=	5.26o	and	mural	=	10.44o.	
aortic	leaflet	
mural	
leaflet	
	
	
116	
	
element	method	 is	 limited	to	being	an	 initial	design	tool.	Reasons	for	disparities	between	
the	numerical	model	and	experimental	observations	are	discussed	below.		
4.5.2.1	Correlation	with	experimental	observations	
The	 leaflets	of	 the	surgical	version	of	 the	chosen	 leaflets	curved	 in	 the	opposite	direction	
compared	 to	 that	 predicted	 by	 the	 simulations	 (Figure	 4.11	 and	 Figure	 4.14.a)	 i.e.	 they	
curved	 towards	 the	 aortic	 leaflet.	 However,	 the	 curvature	 of	 the	 transcatheter	 leaflets	
concurred	with	the	simulations	(Figure	4.14.b),	which	also	moved	towards	the	mural	leaflet.	
	
	
	
	
	
	
	
	
	
	
	
4.6 Summary	
This	chapter	described	the	morphological	requirements	for	the	UCL	TMV	leaflets.	The	risk	
based	 design	 approach	was	 justified	 and	 expounded	 and	 its	 use	 in	 selecting	 the	 optimal	
design	 criteria,	 in	 terms	of	peak	MPS	and	CA,	was	explained	 followed	by	 the	 consequent	
aortic	leaflet	
Surgical	Mitral	Valve	
ao
rt
ic	
le
af
le
t	
Transcatheter	Mitral	Valve	
Figure	4.14:	Direction	of	curvature	of	 leaflets	 for	 the	 (a)	 surgical	and	 (b)	 transcatheter	mitral	
valves,	indicated	by	red	arrows.	Red	lines	indicate	the	free	leaflet	edge	of	the	coapting	leaflets.	
(a)	
(b)	
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parametric	 design,	 which	 was	 created	 using	 a	 scale	 factor	 and	 coaptation	 length	 in	 3-D	
modelling	 software.	 The	 conversion	 of	 these	 3-D	models	 into	 FEMs	were	 then	 described	
along	with	their	accomanying	simulations,	which	acted	as	a	design	tool,	 the	results	which	
are	discussed	and	resulted	in	the	selection	of	a	conical	bileaflet	design,	uniquely	defined	by	
two	parameters;	a	scale	factor	of	0.745	and	coaptation	length	of	4	mm.		
Chapter	 5	 will	 now	 describe	 the	 equipment	 used,	 designed	 and	 made	 to	 assess	 the	
prototypes.	This	includes	the	design	and	manufacture	of	surgical	mitral	valves,	designed	to	
provide	 a	 relevant	 reference	 valve	 for	 the	 UCL	 TMV.	 Furthermore,	 it	 describes	 the	
experimental	conditions	used	to	simulate	the	left	side	of	a	normal	healthy	adult	heart	and	
the	parameters	measured	to	assess	a	prosthetic	heart	valve’s	performance.	The	minimum	
performance	requirements	are	also	expounded	as	well	as	the	limitations	of	these	methods.	
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Chapter	5 Haemodynamic	assessment	of	valve	leaflets	
This	 chapter	 describes	 the	 equipment	 used	 to	 assess	 the	 functional	 performance	 of	 the	
surgical	and	transcatheter	mitral	valves,	including	the	successful	design	and	manufacture	of	
a	 range	 of	 different	 sized	mock	 native	mitral	 valve	 implantation	 sites	 used	 to	 assess	 the	
effect	 of	 annulus	 size	 on	 the	 functional	 performance	 of	 the	UCL	 TMV.	 The	 pulsatile	 flow	
conditions,	resulting	test	parameters	and	minimum	performance	requirements	for	surgical	
and	transcatheter	mitral	valves	are	expounded.	The	surgical	mitral	valve	(SMV)	section	then	
describes	 the	 aim	 and	 manufacture	 for	 the	 bileaflet	 and	 trileaflet	 SMVs,	 for	 which	
preliminary	flow	visualisation	of	the	left	ventricle	was	done	as	well	as	the	aforementioned	
function	assessment.	The	experimental	results	are	then	presented	and	discussed,	followed	
by	 the	 conclusions	 drawn	 and	 suggested	 future	 work.	 Finally,	 the	 limitations	 of	 the	
functional	assessments	are	outlined	along	with	current	and	future	work.		
5.1 Pulse	duplicator	
A	commercially	available	hydro-mechanical	cardiovascular	pulse	duplicator	system	(ViVitro	
Superpump	SP3891,	ViVitro,	BC,	Canada)	 (Figure	5.1)	was	used	 to	 assess	 the	mitral	 heart	
valves	made.	 Its	main	 components	 are	a	pump,	 flowmeter	 and	pressure	 transducers,	 the	
function	of	which	are	outlined	in	this	section.	The	manufacture	of	silicon	holders	designed	
to	mount	 the	 heart	 valves	 in	 the	mitral	 position	 are	 also	 described.	 All	 prototypes	were	
assessed	with	a	mechanical	bileaflet	valve	(Sorin	Bicarbon	25)	in	the	aortic	position	(Figure	
1.10)	using	phosphate-buffered	saline	(PBS)	as	the	working	fluid;	water	based	salt	solution	
with	the	same	osmolarity	and	ion	concentration	as	the	human	body	(but	different	viscosity	
and	density).		
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5.1.1 Pump	
The	hydro-mechanical	cardiovascular	pulse	duplicator	system	(ViVitro	Superpump	SP3891,	
ViVitro,	 BC,	 Canada)	 replicates	 muscular	 relaxation	 and	 contraction	 of	 the	 native	 left	
ventricle,	which	 are	 65%	 and	 35%	of	 the	 cardiac	 cycle	 respectively	 under	 rest	 conditions	
(Figure	5.2),	by	using	lateral	motion	of	a	piston	head	acting	on	a	body	of	water	to	compress	
and	expand	a	flexible	silicon	sac	(Figure	5.3).	The	piston	head	speed	determines	heart	rate	
and	 the	magnitude	 of	 stroke	 determines	 cardiac	 output/pump	 stroke	 volume;	 ultimately	
inducing	 pressure	 differences	 required	 to	 open	 and	 close	 the	 passive	 aortic	 and	 mitral	
valves.	The	pump	was	reasonably	accurate	at	replicating	the	desired	35%	systolic	duration,	
achieving	35.03%	±	0.11%.	
Mitral	Flow	
Transducer	
Free	wall	Septal	wall	
*	
Ventricular	pressure	transducer	
	
*	
Aortic	pressure	
transducer	
*	
Atrial	pressure	
transducer	
Mitral	site	
Figure	5.1:	Schematic	of	ViVitro	pulse	duplicator	(ViVitro	Superpump	SP3891,	ViVitro,	BC,	Canada)	
(adapted	from	Pulse	Duplicator	User	Manual,	ViVitro	Labs	Inc.	2015). 
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It	 is	assumed	the	 fluid	outside	 the	ventricle	sac,	 in	direct	contact	with	 the	piston	head,	 is	
incompressible	 and	 therefore	 the	 volume	 of	 fluid	 displaced	 as	 the	 piston	 head	moves	 is	
directly	correlated	to	the	volume	of	fluid	displaced	within	the	flexible	ventricle	sac,	i.e.	the	
area	of	the	piston	head	(38	cm2)	multiplied	by	the	lateral	displacement	(Figure	5.2),	which	
can	range	between	0	mm	and	40	mm	(±20	mm	from	neutral	position).	
	
Figure	5.3:	Pulse	duplicator	pump	and	peripheral	resistance	controller.	
interface	between	ventricle	chamber	(left)	and	pump	(right)	
peripheral	
resistance	
controller	
piston	head	of	pump	
Figure	5.2:	Pump	position	over	one	cardiac	cycle	at	5	 lpm;	35%	systolic,	
65%	diastolic,	representative	of	a	healthy	normal	adult	at	rest.	
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5.1.2 Magnetic	flowmeter	
The	electromagnetic	 flowmeter	(Carolina	Medical	Electronics	 Inc.)	measured	flow	through	
the	mitral	position	(Figure	5.5).	Following	Faraday’s	law	of	electromagnetic	induction,	flow	
of	 conductive	PBS	 through	 the	magnetic	 field	generated	within	 the	 cylindrical	 flowmeter,	
generates	a	 voltage	 signal	directly	proportional	 to	 flow	 rate	 i.e.	 a	 faster	 flow	generates	a	
higher	voltage,	sensed	by	electrodes	on	the	flow	tube	walls.	This	voltage,	received	by	the	
data	 acquisition	 system,	 is	 calibrated	 to	 flow	 (Figure	5.4)	with	 an	 average	 sample	 rate	of	
300	Hz,	and	achieves	high	accuracy,	as	can	be	seen	from	achieved	cardiac	outputs	and	their	
standard	deviations	(Table	5.1).	
leakage	
volume	
closing	
volume	
re-opening	
(Figure	1.4.d)	
peak	flow	
(Figure	1.4.b)	
Figure	5.4:	Exemplar	reading	from	the	mitral	flow	probe	at	5	lpm	indicating	
the	 65%	diastolic	 and	35%	 systolic	 phases,	 closing	 and	 leakage	 flows,	 the	
linear	extrapolation	between	the	latter	two	and	flow	markers	F1	to	F4.	
Figure	5.5:	ViVitro	pulse	duplicator	mitral	flow	probe	(black	cylinder).	
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Table	5.1:	Accuracy	of	flow	measurement,	exemplar	cardiac	output	statistics	for	10	cardiac	
cycles.	
Cardiac	output	(lpm)	 Standard	Deviation	Target	value	 Average	
2	 2.009	 0.029	
3	 2.996	 0.001	
4	 4.002	 0.021	
5	 4.961	 0.012	
6	 5.993	 0.062	
7	 6.959	 0.041	
	
5.1.3 Pressure	transducers		
There	 are	 three	 pressure	 transducers	 (Mikro-Tip®	 pressure	 catheter,	 Millar	 Inc.)	 (atrial,	
ventricular	and	aortic)	(Figure	5.1	and	Figure	5.6)	that	deflect	under	pressure	altering	their	
electrical	 outputs,	 which	 are	 calibrated	 to	 pressure	 in	 millimeters	 of	 mercury22	 (mmHg)	
(Figure	 5.7).	 The	 sample	 rate	 being	 the	 same	 as	 the	 flow	meters,	 300	 Hz.	 The	 pressure	
transducers	exceeded	the	required	accuracy	of	±2	mmHg;	(ISO	5840)	for	example	the	mean	
ventricular	pressure	for	10	consecutive	cardiac	cycles	was	measured	at	36.71	±	0.36	mmHg.		
																																								 																				
22	A	millimetre	of	mercury	(mmHg)	is	the	pressure	generated	by	a	column	of	mercury	one	millimetre	
high	(approximately	133	pascals	(Pa)).	
atrial	pressure	
transducer	
mitral	flow	
meter	earth	
Figure	5.6:	ViVitro	pulse	duplicator	atrial	pressure	transducer	and	earth	for	flow	meter.	
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5.1.4 Surgical	Mitral	Valve	Holders	
Holders	 were	 required	 to	 mount	 the	 surgical	 prototypes	 in	 the	 pulse	 duplicator’s	 mitral	
position,	 the	 angle	 of	 which	 can	 be	 seen	 in	 Figure	 5.1.	 They	 had	 to	 create	 a	 fluid	 seal	
between	 the	 left	 ventricle	 and	 atrium	 as	 well	 as	 between	 prototypes	 and	 their	 holders.	
Therefore,	the	SMV	stents	were	designed	with	flanges	which	slotted	into	silicon	holders.	
The	holders	were	made	by	syringing	in	a	liquid	silicone	mixture	(RTV	Silicon	Mould	Rubber	
T28	mixed	with	 5%	weight	 T6	 catalyst)	 into	 3D	 printed	moulds	 (Figure	 5.8),	 which	 were	
cured	 in	24	hours	at	 room	temperature.	To	aid	 removal	of	cured	holders,	all	mould	parts	
were	sprayed	with	Ambersil	Formula	5	prior	to	syringing	in	the	silicon.	
	
	
	
	
Figure	 5.7:	Pressure	 recorded	by	 the	 three	pressure	 transducers;	 aortic,	
ventricular	 and	 atrial,	 and	 the	 transmitral	 (atrial	 minus	 ventricular),	
indicating	the	two	pressure	markers	AT-VE1	and	AT-VE2.	
Figure	5.8:	Moulds	for	making	a	holder	for	a	circular	surgical	mitral	valve	assembled	and	
filled	 with	 silicon;	 outer	 moulds	 (Object30	 3D	 (Stratasys	 Ltd.)),	 inner	 moulds	 (Form1+	
(Formlabs	Inc.)).	
four	part	
inner	mould	
outer	mould	
part	1	
outer	mould	
part	2	
silicon	mixture	
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The	 outer	 sections	 of	 the	mould	were	made	 on	 the	Object30	 3D	 (Stratasys	 Ltd.).	 As	 the	
mould	design	developed	the	more	cost	effective	Form1+	(Formlabs	Inc.)	desktop	3D	printer	
became	 available	 and	 so	 was	 used	 to	 make	 the	 inner	 sections.	 Due	 to	 the	 Form1+’s	
limitations	 the	 inner	 sections	had	 to	be	made	 in	 four	parts	and	partially	hollowed,	which	
also	saved	material	(clear	photopolymer	resin)	and	time	required	for	printing	(Figure	5.9).	
The	same	outer	moulds	were	used	to	create	the	holders	for	both	the	D-shaped	and	circular	
SMVs,	just	different	inner	moulds	were	required,	thereby	saving	material,	money	and	time.	
	
	
	
	
	
	
	
5.1.5 Mock	native	mitral	valve	implantation	sites	
It	 is	 common	practice	 to	design	one	 sized	prosthetic	heart	 valve	 to	 fit	 a	 range	of	patient	
sized	valves.	For	example,	the	latest	SAPIEN	3,	26	mm	device	is	suitable	for	implantation	in	
annulus	 sizes	 21-25	 mm	 and	 the	 CoreValve	 Evolute	 23	 mm	 is	 for	 18-20	 mm	 annuluses	
(Table	 1.1).	 These	 interference	 fits	 anchor	 the	 devices	 and	 prevent	 paravalvular	 leakage,	
similarly	the	UCL	TMV	will	be	larger	than	the	native	mitral	valve	into	which	it	is	implanted	
and	 therefore	 will	 operate	 in	 a	 semi-folded	 configuration,	 unique	 to	 each	 patient.	 As	
previously	 reviewed,	 the	 functional	 performance	 of	 TMVs	 is	 highly	 dependent	 on	 the	
difference	between	the	size	of	the	device	and	the	implantation	site	and	indifference	to	this	
fact	 resulted	 in	 failure	of	devices	 (De	Backer	et	al	2014).	Therefore,	 the	26	mm	UCL	TMV	
prototypes	were	assessed	in	six	different	sized	mock	native	mitral	valve	implantation	sites	
with	 inter-trigonal	 diameters	 ranging	 between	 20	 and	 25	 mm	 in	 1	 mm	 intervals,	 which	
1	of	10	holes	for	
dowel	pins	
Figure	5.9:	Moulds	to	make	D-shaped	surgical	mitral	valve	holder	
(top)	two	outer	sections	(bottom)	four	hollow	inner	sections.	
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thereby	 addressed	 a	 potential	 failure	 mode	 thus	 keeping	 with	 the	 risk	 based	 approach	
outlined	in	ISO	5840-3:2013	(Annex	A,	A.1).	Increments	of	1	mm	were	chosen	because	this	
is	 the	 accuracy	 achievable	 using	 echocardiographic	 imaging23,	 and	 therefore	 smaller	
increments	would	not	have	clinical	relevance.	
Firstly	D-shaped	silicon	holders	were	made	using	similar	moulds	and	methods	as	previously	
described	(Figure	5.10.a/b),	then	mock	native	mitral	valve	leaflets	were	added	by	painting	5	
layers	of	silicone	onto	paper	templates	(Figure	5.10.c	and	Figure	5.11),	which	peeled	away	
easily	from	the	silicon	once	dry.	In	fact,	without	mock	native	leaflets	the	UCL	TMV	migrated	
into	 the	 atrium.	 Therefore	 they	 were	 essential	 to	 correctly	 model	 the	 geometry	 of	 the	
implantation	site	and	thereby	securely	anchor	the	device.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
																																								 																				
23	Acknowledgements	Pantazis	A	(Imaging	Consultant	Cardiologist,	The	Heart	Hospital,	London).	
Figure	 5.10:	Mock	native	mitral	 valves	 (a)	 silicon	 syringed	 into	 three	part	
mould	 (b)	 resulting	D-shaped	holder	 indicating	 inter-trigonal	 diameter	 ‘d’		
(c)	UCL	transcatheter	mitral	valve	2	in	a	25	mm	annulus	with	mock	leaflets.	
d	
(a)	 (b)	 (c)	
silicon	
aortic	
leaflet	
Figure	 5.11:	 Mock	 native	 mitral	 valve	 leaflet	 template	
indicating	 leaflet	 lengths	 for;	 Ca:	 anterior	 commissure,	 A:	
aortic	leaflet,	Cp:	posterior	commissure	and	M:	mural	leaflet.	
Ca	
A	
M	Cp	
region	contained	
within	holder	
one	of	two	tabs	to	
construct	paper	template	
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Numerical	 simulations	 (Bozkurt	et	al	2016)	of	 the	TMV	frame24	deployed	 inside	similar	D-
shaped	orifices	(20-25	mm)	confirmed	for	all	annulus	sizes	that	stresses	in	the	nitinol	frame	
would	be	acceptable;	the	highest	stress	being	approximately	half	of	the	yield	strength.	
5.2 Pulsatile	flow	conditions	
5.2.1 Pressure	test	
All	hydrodynamic	parameters	were	measured	at	a	heart	rate	of	70	bpm	with	a	mean	aortic	
pressure25	of	100	mmHg	and	systolic	duration	of	35%,	representative	of	a	normal	healthy	
adult	 as	 required	 by	 regulatory	 standards.	 These	 test	 parameters	 were	 achieved	 by	
combined	 adjustment	 of	 the	 peripheral	 resistance	 controller	 and	 piston	 amplifier	 (Figure	
5.3);	more	specifically	an	increase	in	the	constriction	of	the	peripheral	system	increased	the	
mean	aortic	pressure	but	reduced	flow	and	therefore	reduced	cardiac	output	(CO).	
In	vivo	CO	will	vary	between	each	individual	depending	on	their	physical	fitness	and	level	of	
activity;	maximum	values	range	from	approximately	35	lpm	for	a	trained	athlete	to	20	lpm	
for	 an	 average	 person.	 Typically	 CO	 at	 rest	 is	 5	 lpm	 and	 a	 normal	 range	 of	 outputs	 is	
between	4	 and	8	 lpm.	 Therefore	CO	was	 varied	between	2	 and	7	 lpm	 in	1	 lpm	 intervals,	
providing	 the	minimum	 of	 four	 readings	 between	 2	 and	 7	 lpm	 as	 required	 by	 ISO	 5840,	
whilst	 the	 previously	mentioned	 flow	 conditions	 were	 held	 constant.	 It	 should	 be	 noted	
that	because	 the	pulsatile	 flow	 conditions	were	held	 constant	 across	 cardiac	outputs26,	 a	
full	 set	 of	 measurements	 at	 2,	 3,	 4,	 5,	 6	 and	 7	 lpm	 (for	 the	 same	 device)	 are	 not	
representative	of	the	same	physiology.	
5.2.2 Regurgitant	test	
Minimisation	of	 regurgitation	 in	mitral	prostheses	 is	 important.	Therefore,	a	regurgitation	
test	 was	 performed	 to	 determine	 the	 regurgitant	 volumes	 associated	 with	 mean	 back	
																																								 																				
24	 Different	 software	 to	 that	 used	 for	 the	 pericardial	 leaflets	was	 required	 to	 simulate	 the	Nitinol	
frame	i.e.	one	which	used	an	implicit	code	was	required.		
25	A	mean	aortic	pressure	of	100	mmHg	is	normotensive,	compared	to	70	mmHg	for	hypotensive	and	
between	113	and	190	mmHg	for	hypertension.	
26	In	clinical	practice	a	Cardiac	Index	(l/min/m2)	is	used	to	relate	cardiac	output	(lpm)	to	body	surface	
area	 (m2),	usually	between	2.6	and	4.2	 l/min/m2	at	 rest,	and	 thus	assesses	 the	heart	performance	
relative	to	the	size	of	the	individual.		
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pressures	of	80,	 120	and	160	mmHg	and	heart	 rates	of	40,	 70	and	120	bpm	at	 a	normal	
cardiac	output	of	5	lpm	and	systolic	duration	of	35%	(ISO	5840-3:2013;	N.4.3.3).	
5.3 Test	parameters	
The	test	parameters	reported	were	selected	with	the	aim	of	characterising	diastolic,	systolic	
and	global	performance	of	the	prosthetic	mitral	valves.	The	effective	orifice	area	(EOA)	and	
mean	transmitral	diastolic	pressure	drop	characterise	forward	flow	impedance	imposed	by	
prostheses	 and	 would	 be	 maximal	 and	 minimal	 respectively	 for	 an	 optimal	 device.	 The	
regurgitant	 fraction	 (RF)	 and	 associated	 volumes	 (closing,	 leakage	 and	 total)	 characterise	
the	 incompetence	 of	 valves	 during	 systole	which	 contribute	 to	 closing,	 leakage	 and	 total	
energy	losses,	the	later	which	is	also	due	to	diastolic	losses	and	would	all	be	minimal	for	an	
optimal	device.	These	test	parameters	are	further	defined	and	described	below.	
5.3.1 Mean	transvalvular	diastolic	pressure	drop	
The	mean	transvalvular	diastolic	pressure	drop	is	the	average	pressure	difference	between	
the	left	atrium	(inflow)	and	left	ventricle	(outflow)	during	diastole,	when	the	mitral	valve	is	
open.	 This	 is	 reported,	 instead	 of	 the	 mean	 over	 the	 entire	 cardiac	 cycle,	 as	 previously	
expounded	 by	 Walker	 et	 al	 (1983),	 because	 the	 diastolic	 mean	 pressure	 measures	 the	
valves’	 resistance	to	 forward	flow.	Optimal	prosthetic	heart	valves	have	minimal	pressure	
differences,	 associated	 with	 maintaining	 a	 healthy	 blood	 pressure.	 Therefore,	 the	 mean	
transvalvular	 diastolic	 pressure	 drop	 is	 a	more	 specific	 and	 relevant	 quantification	of	 the	
devices	performance.	
5.3.2 Effective	orifice	area	
The	EOA	is	the	vena	contracta	area;	the	minimum	cross	sectional	area	associated	with	the	
jet	of	blood	 through	a	heart	valve	where	velocity	 is	maximum	and	 is	always	 smaller	 than	
anatomical/geometric	 orifice	 areas	 (Figure	 5.12)	 and	 can	 be	 estimated	 using	 Gorlin’s	
equation	(Equation	5.1).		
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	 EOA = Q/0151.6 ∆pρ 	 (5.1)	
	
where;	
EOA	=	effective	orifice	area	(cm2),	
Qrms	=	root	mean	square	forward	flow	(ml/s)	during	the	positive	differential	pressure	
period,	
Δp	=		mean	pressure	difference	(mmHg)	measured	during	the	positive	differential	pressure	
period,	
ρ	=	density	of	the	test	fluid	(g/cm2)	and		
51.6	=	non-dimensionless	constant,	therefore	it	is	only	valid	with	the	units	specified.	
																 Q/01 = 8(:)<=:><>? :<-:? 																																												(5.	2)	 					
	
Where;	Q(t)	=	instantaneous	flow	at	time	t,	t"	=	time	at	start	of	positive	pressure	(AT-VE1	in	Figure	5.13)	and	t#	=	time	at	end	of	positive	pressure	(AT-VE2	in	Figure	5.13).	
	
Figure	5.12:	2D	representation	of	the	location	of	the	geometric	
orifice	area	 (GOA)	and	effective	orifice	area	 (EOA)	 i.e.	 the	area	
of	the	vena	contracta	(adapted	from	Akins	et	al	2008).	
GOA	
EOA	
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The	 time	 interval	 used	 to	 calculate	 the	 flow	 and	 pressure	 during	 the	 positive	 differential	
pressure	period	 in	Equation	5.2	 is	determined	using	pressure	markers	AT-VE1	and	AT-VE2	
(Figure	5.13),	which	provides	 repeatable	and	consistent	 results	 compared	 to	 the	 flow	 (F),	
hybrid	(H)	and	pressure/flow	(PF)	alternatives:	
• (F)	uses	F1	and	F2	(Figure	5.13),	
• (H)	uses	AT-VE1	and	F2	and	
• (PF)	uses	the	AT-VE1	and	AT-VE2	to	calculate	the	pressure	component	and	uses	F1	
and	F2	to	calculate	the	flow	component.	
However,	there	are	 limitations	to	calculating	the	EOA	based	on	pressure,	mainly	due	to	 it	
being	based	on	a	simplified	version	of	Bernoulli’s	equation	and	therefore	will	not	equate	to	
EOAs	 calculated	 in	 vivo,	 although	 this	 formulae	 is	 also	 used	 to	 calculate	 EOAs	 in	 vivo.	
Alternative	EOA	equations	were	proposed	by	Aaslid	et	al	 (1975)	and	Gabbay	et	al	 (1978),	
which	whilst	theoretically	more	correct	are	not	clinically	practical,	due	to	the	sophisticated	
flow	measuring	device	required	(Dieter	1990)	and	so	Gorlin’s	equation	was	still	used,	which	
is	 relevant	 for	 comparison	 to	 the	 minimum	 performance	 requirements	 in	 ISO	 5840.	 It	
should	be	noted	that	in	clinical	practice	an	EOA	indexed	to	body	surface	area	is	commonly	
used	(Dumesnil	et	al	1992).	
F2	 F3	 F4	
AT-VE2	
F1	
AT-VE1	
Figure	5.13:	Average	transmitral	pressure	and	flows	across	ten	cardiac	cycles	
for	the	UCL	transcatheter	mitral	valve	prototype	2	at	a	cardiac	output	of	5	lpm	
for	one	cardiac	cycle,	systolic/diastolic	phases	marked	based	on	flow.	
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In	 summary,	 the	 EOA	 is	 a	 functional	 valve	 area	 used	 to	measure	 how	much	 a	 particular	
prosthesis	impedes	forward	flow	and	thereby	quantifies	the	quality	of	a	prosthesis;	higher	
EOAs	corresponding	with	desirable	smaller	energy	losses.	
5.3.3 Regurgitation	fraction	
The	RF	is	a	measure	of	inevitable	reverse	flow	during	one	cardiac	cycle,	defined	as	the	sum	
of	 closing	 and	 leakage	 volumes	 expressed	 as	 a	 percentage	 of	 forward	 flow	 volume	
(Equation	(5.3).	Optimal	devices	are	associated	with	minimal	RFs	because	they	have	smaller	
energy	losses	i.e.	require	less	work	from	the	left	ventricle.	
	 RF[%] = 	 closing	volume	 + 	leakage	volume *100forward	volume 	 (5.3)				
	
5.3.4 Volumes	
The	 total	 regurgitant	 volume	 is	 the	 total	 reverse	 flow	 from	 the	 left	 ventricle	 into	 the	 left	
atrium	during	one	cardiac	cycle	and	is	the	sum	of	closing	and	leakage	volumes	as	measured	
by	the	mitral	flow	meter;	being	total	reverse	flow	due	to	valve	closure	dynamics	and	total	
reverse	flow	through	the	closed	valve	respectively	(Figure	5.4).		
5.3.5 Energy	losses	
Contraction	 of	 the	 left	 ventricle	 muscle	 generates	 static	 pressure,	 which	 once	 increased	
above	the	aorta	pressure,	forces	the	aortic	valve	open	thereby	converting	pressure	energy	
into	kinetic	energy	of	 the	ejection	 fraction,	 typically	67	±	4.6	%	of	 total	 ventricle	volume,	
which	 flows	 around	 the	 body	 at	 a	 rate	 to	 enable	 normal	 cellular	 metabolism.	 This	
conversion	 of	 static	 pressure	 to	 kinetic	 energy	 during	 one	 cardiac	 cycle	 is	 commonly	
depicted	in	terms	of	the	pressure	within	and	the	volume	of	the	left	ventricle;	the	integral	of	
this	 pressure-volume	 diagram	 (Figure	 1.9)	 is	 equivalent	 to	 the	 energy	 generated	 by	 the	
ventricle	 during	 one	 cardiac	 cycle	 (Equation	 5.4).	 Similarly,	 diastolic,	 closing,	 leakage	 and	
total	 energy	 losses	 (ELD,	 ELC,	 ELL	 and	 ELT)	 are	 calculated	 by	 integrating	 flow	 times	
transvalvular	 pressure	 over	 a	 relevant	 flow	 interval;	 Equations	 5.5-5.8	 respectively.	
However,	 these	 equations	 are	 limited	 because	 they	 do	 not	 account	 for	 the	 ventricular	
compliance.	
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	 VE = 0.1333 P^ _`: ∙ DL_DT ∙ dtfgf" 	 (5.4)	
	
Where;	
0.1333	=	constant	to	convert	energy	from	mmHg.ml	to	milli	joules	(mJ)27,	
F1	 and	 F4	 =	 flow	 intervals	 defined	 in	 Figure	 5.13,	 integrals	 are	 evaluated	by	 the	ViViTest	
software	using	the	trapezoidal	rule,	P^ _`:	=	ventricular	pressure	(mmHg),	
DL_DT	=	signal	provided	by	SuperPump	Controller	indicating	pump’s	flow	rate	(ml/sec)	and	
dt	=	1/sample	rate.	
	
	 ELh = 0.1333 ∆Pi ∙ flow ∙ dtf#f" 	 (5.5)	
	
	 ELj = 0.1333 ∆Pi ∙ flow ∙ dtfkf# 	 (5.6)	
	
	 ELl = 0.1333 ∆Pi ∙ flow ∙ dtfgfk 	 (5.7)	
	
	 ELm = ELh +	ELj + 	ELl	 (5.8)					
	
Where;	
∆Pi 	=	pressure	difference	(mmHg)	across	mitral	valve	during	the	relevant	flow	interval	and	
flow	=	flow	rate	(ml/sec)	across	mitral	valve	during	the	relevant	flow	interval.	
	
In	summary,	some	of	the	pressure	energy	generated	by	the	left	ventricle	is	not	converted	to	
kinetic	 energy;	 it	 is	 lost	 as	 blood	 travels	 through	 the	 circulatory	 system.	 The	 ventricle	
compensates	 for	 additional	 losses	 due	 to	 pathologic	 conditions	 such	 as	 valvular	
regurgitation	 or	 presence	 of	 prosthesis	 by	 raising	 systolic	 pressure	 and/or	 volumetric	
																																								 																				
27	1	J	=	1	N.m	=	1	Pa.m3	=	1	(kg.m2)/s2	where	J	represents	joules	(units	of	energy),	N	is	Newtons	(units	
of	 force),	m	 is	meters	 (units	of	distance),	Pa	 is	Pascals	 (units	of	pressure),	kg	 is	kilograms	 (units	of	
mass)	and	s	is	seconds	(units	of	time).	
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capacity,	 both	 of	 which	 result	 in	 an	 undesirable	 increase	 in	 work	 on	 the	 myocardium.	
Therefore	an	optimal	prosthetic	heart	valve	would	have	minimal	energy	losses.	
5.4 Minimum	performance	requirements	
The	minimum	performance	requirements	for	prosthetic	mitral	valves	corresponding	to	the	
applied	pulsatile	flow	conditions	for	a	normal	healthy	adult	are	outlined	in	two	standards;	
one	 for	 surgical	 devices,	 ISO	 5840:2009	 ‘Cardiovascular	 implants	 –	 cardiac	 valve	
prostheses’,	and	one	for	transcatheter	devices,	ISO	5840-3:2013	‘Cardiovascular	implants	–	
cardiac	 valve	 prostheses	 Part	 3:	 Heart	 valve	 substitutes	 implanted	 by	 transcatheter	
techniques’.	 In	 both	 cases,	 just	 two	 requirements	 are	 set,	 one	 for	 diastolic	 and	 one	 for	
systolic	performances,	namely	the	EOA	and	RF	respectively.	
5.4.1 Surgical	mitral	valves	
The	minimum	performance	 requirements	 stipulated	 in	 ISO	 5840:2009	 are	 relative	 to	 the	
device	 tissue	 annulus	 diameter	 (TAD;	 the	 smallest	 flow	 area	 within	 the	 patient’s	 valve	
annulus),	which	assumes	they	are	circular.	Therefore,	 to	determine	requirements	 for	a	D-
shaped	valve	it	was	necessary	to	convert	the	TADs	to	perimeters	(Table	5.2).		
Table	 5.2:	 Minimum	 device	 performance	 requirements	 for	 surgical	 mitral	 valve	
replacements	(adapted	from	ISO	5840:2009).	
Valve	size	 TAD
1	(mm)	 25	 27	 29	 31	
Perimeter	(mm)	 79	 85	 91	 97	
Effective	orifice	area	(cm2)	≥	 1.2	 1.4	 1.6	 1.8	
Regurgitation	fraction	(%)	≤	 15	 15	 20	 20	
1Tissue	Annulus	Diameter	
	
All	the	SMVs	tested	had	the	same	outer	perimeter	of	86	mm	and	therefore	should	meet	the	
same	minimum	performance	requirements	of	an	EOA	≥	1.4-1.6	cm2	and	a	RF	≤	15-20%.	
5.4.2 Transcatheter	mitral	valves	
The	allowable	RF	for	transcatheter	valves	 is	higher	than	for	surgical	devices	because	their	
implantation	technique	inevitably	leads	to	greater	paravalvular	leakage	due	to	a	difference	
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between	the	perimeters	of	the	device	and	implantation	site.	Therefore	the	required	EOA	is	
higher	to	compensate	for	leniency	in	systolic	performance.		
The	 minimum	 performance	 requirements	 stipulated	 in	 ISO	 5840-3:2013	 are	 based	 on	
published	 literature	 (American	College	of	Cardiology	2006)(Yoganathan	et	 al	 2002)	 (Table	
5.3)	and	are	relative	to	the	deployed	valve	diameter	within	implant	site.	The	requirements	
for	 25	 and	 23	 mm	 devices	 are	 an	 EOA	 ≥	 1.25	 cm2	 and	 1.05	 cm2	 respectively	 and	 both	
require	a	RF	≤	20%.	No	requirements	are	set	for	annulus	sizes	20-22	mm.	
	
Table	 5.3:	 Minimum	 device	 performance	 requirements	 for	 transcatheter	 mitral	 valve	
replacements	(adapted	from	ISO	5840-3:2013).	
Valve	size	 Deployed	valve	diameter	within	implant	site	(mm)	 23	 25	 27	 29	 31	 33	
Effective	orifice	area	(cm2)	≥	 1.05	 1.25	 1.45	 1.65	 1.90	 2.15	
Regurgitation	fraction	(%)	≤	 20	 20	 20	 25	 25	 25	
	
5.5 Surgical	mitral	valves	
5.5.1 Aim	
There	are	no	predicate	devices	to	compare	with	the	UCL	TMV.	Therefore,	in	order	to	assess	
the	validity	of	the	design	process,	the	surgical	valve	is	used	for	comparison.	Thus,	the	aim	of	
the	SMVs	was	to	provide	a	pseudo	reference	valve	for	the	UCL	TMV	leaflets	(section	2.3.4)	
by	 comparing	 the	 conical	 bileaflet	 (CB)	 SMV	 to	 a	 replica	 of	 the	 Pericarbon	MORE	Mitral	
(PMM)	(Sorin	Group,	now	LivaNova	PLC),	named	hereafter	as	the	trileaflet	(T)	valve.	
5.5.1.1	Hypotheses	
It	 was	 hypothesised	 that	 for	 the	 same	 size	 implantation	 site	 the	 more	 physiological	
morphology	 of	 the	 bileaflet	 valves	 would	 have	 advantageous	 functional	 performance	
compared	to	the	circular	trileaflet	valves.	This	was	based	on	previous	research	into	a	similar	
bileaflet	 mitral	 valve,	 which	 demonstrated	 the	 leaflet	 length	 and	 proximity	 to	 the	
ventricular	wall	will	have	a	significant	effect	on	the	energy	dissipation	that	occurs	as	blood	
flows	from	the	left	atrium	to	the	aorta	(Kheradvar	et	al	2012)	as	well	as	evidence	previously	
discussed	in	section	5.5.3.	
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5.5.1.2	Bileaflet	valve	
The	stented,	bileaflet,	D-shaped,	conical	mitral	valves	described	in	this	section	advance	the	
study	of	SMVs	which	mimic	the	native	morphology	by	providing	an	original	set	of	features,	
combining	the	conical	design	of	the	Sheffield	(section	2.1.1)	and	stentless	mitral	valves	with	
the	 D-shape	 of	 the	 QuattroTM	 (St.	 Jude	Medical	 Inc.)	 (section	 2.1.2).	 Also,	 the	 combined	
results	 of	 the	 CB	 and	 T	 valves	 provide	 a	 solution	 to	 the	 reference	 valve	 predicament,	
discussed	below.	
The	CB	SMV	houses	the	 leaflets	chosen	for	the	UCL	TMV	(Figure	4.1Figure	4.3).	However,	
the	conicity	of	these	leaflets	 is	only	suitable	for	a	transcatheter	device;	chosen	to	address	
the	needs	of	 their	patient	population	 i.e.	severe	mitral	 regurgitation,	and	would	not	have	
been	chosen	if	designing	a	surgical	device.	In	practice,	the	leaflets	for	the	TMV	are	designed	
to	 operate	with	 some	 compression	 of	 the	 base	 (a	 size	 26	mm	 fits	 into	 a	maximum	 sized	
annulus	of	25	mm)	which	makes	the	leaflets	less	conical.	Consequently,	it	is	inevitable	that	
the	diastolic	 performance	of	 the	CB	 valve,	measured	 in	 terms	of	 its	 effective	orifice	 area	
(EOA)	will	be	significantly	surpassed	by	the	straight	T	valve.		
5.5.1.3	Trileaflet	valve	
The	 T	 valve	 was	 a	 scaled	 replica	 of	 the	 PMM	 (Figure	 1.10),	 with	 the	 same	 external	
perimeter	as	the	bileaflet	valves,	making	their	comparison	clinically	relevant	i.e.	they	could	
both	potentially	be	implanted	in	the	same	patient.	Furthermore,	a	replica	was	required	to	
enable	comparison	independently	from	stent	design,	material	selection	and	processing	and	
assembly	methods.	
More	 specifically,	 commercial	 valves	 typically	 have	multi-staged	 fixation	 resulting	 in	 their	
unstressed	state	being	the	closed	position28.	Typically,	the	flat	sheet	of	pericardium	is	firstly	
fixed	with	 0.2%	GA	 (within	 4	 hours	 of	 slaughter),	 cut	 and	 formed	 into	 leaflets	which	 are	
then	 pressurised	 to	 close	 and	 fixed	 again	 with	 0.5%	 GA.	 In	 contrast,	 the	 leaflets	 for	 the	
prototypes	were	not	subjected	to	pre-stressing	during	assembly;	therefore	their	unstressed	
state	was	the	open	position.		
																																								 																				
28	In	general,	commercially	available	valves	are	fixed	in	their	closed	position	because	surgeons	prefer	
to	see	the	valve	is	going	to	be	competent	before	implantation.	
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5.5.2 Prototyping	
5.5.2.1	Stents	
The	SMV	stents,	with	annular	perimeters	of	86	mm,	had	flanges	to	mount	them	in	the	pulse	
duplicator	 using	 specifically	 designed	 silicon	 holders	 (Figure	 5.14),	 made	 from	 clear	
photopolymer	 resin	 using	 stereolithography	 (Form	 1+,	 Formlabs	 Inc.);	 a	 form	 of	 additive	
manufacturing	that	creates	artefacts	by	directing	a	laser	across	a	tank	of	liquid	resin,	which	
polymerises	thin	layers	onto	a	build	platform	that	pulls	the	model	upwards	out	of	the	tank.	
The	 resin	 is	 not	 approved	 for	 use	 in	medical	 applications	 and	 so	 the	prototypes	 are	only	
suitable	for	in	vitro	assessment.	
	
	
	
	
	
	
	
	
	
	
Thinner	 stents	 are	 preferable	 because	 they	 maximise	 the	 geometric	 orifice	 area,	 and	
consequently	the	EOA.	The	thinnest	the	Form1+	could	make	the	stents	was	1	mm,	which	is	
0.3	mm	thicker	than	achieved	in	most	polymeric	commercial	stents	(e.g.	made	from	Delrin,	
one	commercial	form	of	polyoxymethylene),	although	the	Pericarbon	MORE	has	a	stent	1.2	
holder	
(b)	
DTH2	fabric	
(a)	
blanket	stitch	
flange	
Figure	 5.14:	 Surgical	 mitral	 valves	 (SMVs)	 (a)	 conical	 bileaflet	 valve,	
indicating	 DTH2	 fabric,	 nylon	 blanket	 stitch	 and	 flange	 which	 secure	 the	
SMVs	in	their	silicon	holders	(b)	trileaflet	valve	indicating	its	silicon	holder.	
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mm	thick	 for	 large	 sizes.	Due	 to	 this	 sub-optimal	 thickness	achievable	at	 this	prototyping	
stage,	the	usual	layer	of	material	on	the	inside	of	the	stent	was	omitted.		
5.5.2.2	Fabric	
The	 stents	 were	 covered	 in	 a	 biocompatible	 PET	 knitted	 material	 used	 for	 heart	 valve	
sewing	 rings;	 DTH2	 (Vascutek	 Ltd,	 A	 Terumo	 company).	 This	 was	 preferable	 to	 the	
alternative	 DTL1	 because	 it	 is	 0.17	mm	 thicker,	with	 a	 thickness	 of	 0.466	mm	 and	 has	 a	
water	 permeability	 of	 0.96	 ml/cm2/min	 which	 is	 0.71	 ml/cm2/min	 lower,	 both	
advantageous	 in	 terms	 of	 reducing	 intervalvular	 leakage,	 which	 may	 occur	 through	 the	
assembly	holes	of	the	stents.	Also	DTH2	has	suture	retention	of	25	N	which	is	11	N	stronger	
than	 DTL1,	 advantageous	 for	 securely	 joining	 it	 to	 the	 inner	 pericardium	 band	 using	 a	
blanket	stitch	(Figure	5.14).	
5.5.2.3	Nylon	thread	
The	name	nylon	 refers	 to	a	 family	of	 similar	artificial	aliphatic	polyamides29	and	 is	one	of	
several	 materials	 used	 to	make	 surgical	 sutures.	 At	 this	 initial	 in	 vitro	 prototyping	 stage	
non-medical	 grade	 nylon	 thread	 was	 sufficient	 and	 could	 foreseeably	 be	 replaced	 with	
biocompatible	thread	if	the	designs	progress	to	in	vivo	trials.	
5.5.2.4	Inner	band	
The	PMM	has	an	inner	band	made	from	pericardium,	which	relative	to	using	fabric	not	only	
reduces	 paravalvular	 regurgitation	 but	 also	 leaflet	 wear	 due	 to	 contact	 during	 diastole.	
Therefore	an	inner	pericardium	band	was	also	used	in	the	replica	T	design	(Figure	5.15)	and	
adapted	for	the	bileaflet	designs.		
	
5.5.2.5	Assembly	
The	 0.4	 mm	 BP	 leaflets	 and	 inner	 bands	 were	 cut	 from	 patches	 previously	 processed	
(section	3.1.3)	and	stitched	together	using	nylon	thread	along	their	 leaflet	profiles	(Figure	
5.15).	The	short	edges	were	stitched	together,	then	the	cylindrical/conical	tissue	structures	
were	stitched	to	the	main	body	of	their	stents,	flange	and	finally	the	inner	band	and	DTH2	
fabric	were	joined	using	a	blanket	stitch.		
																																								 																				
29	Polyamides	also	occur	naturally,	for	example	wool	and	silk.		
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5.5.3 Flow	visualisation	
This	 section	describes	 the	 relevance,	aims,	hypothesis	and	protocol	 for	 visualising	 flow	 in	
the	pulse	duplicator’s	ventricle	using	dye.	
5.5.3.1	Clinical	relevance	
All	 current	 heart	 valve	 prostheses	 are	 associated	with	 clinical	 complications	 due	 to	 non-
physiologic	flow	patterns	caused	by	their	 implantation	(Dasi	et	al	2009).	More	specifically,	
SMV	 replacements	 have	 been	 observed	 to	 reverse	 vertical	 flow	 inside	 the	 left	 ventricle,	
increasing	energy	dissipation,	i.e.	increasing	energy	required	by	the	left	ventricle	to	change	
the	momentum	of	fluid	within	the	ventricle,	which	in	a	normal	healthy	heart	 is	minimised	
by	 timely	 alignment	 of	 flow	 towards	 the	 aortic	 valve	 by	 the	 end	 of	 diastole	 ready	 for	
systolic	 ejection,	 which	 also	 avoids	 excessive	 regional	 wall	 stress.	 The	 reversal	 of	 the	
vertical	flow	also	effects	the	spatial	pressure	distribution,	subsequently	possibly	influencing	
post	procedural	complications	 (Pendrizzetti	et	al	2010),	such	as	blood	damage,	which	can	
be	 caused	 by	 excessive	 turbulence,	 as	 well	 as	 other	 problems	 related	 to	 blood	 flow	
including	 platelet	 activation,	 thrombus	 formation,	 hemolysis	 and	 increased	 myocardial	
stress	leading	to	left	ventricular	hypertrophy	and	remodelling.	These	changes	in	transmitral	
vortices	are	affected	by	variation	in	transmitral	pressure	gradient	(Dyverfeldt	et	al	2011)	as	
well	as	length	and	proximity	of	leaflets	to	the	ventricle	wall,	as	per	a	similar	bileaflet	mitral	
valve	design	(Kheradvar	et	al	2012).	
inner	band	
1	of	3	leaflets	
leaflet	profile	double	
stitched	with	nylon	
thread	
attaches	to	flange	of	stent	
leaflets	free	edges	
Figure	 5.15:	 Trileaflet	 surgical	 mitral	 valve	 leaflets	 and	 inner	 band	 double	 stitched	
together	with	nylon	thread,	prior	to	assembly	on	stent.	
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It	has	previously	been	 inferred	that	a	more	physiological	bileaflet	mitral	prosthesis	would	
result	 in	 flow	patterns	 that	close	 the	valve	as	efficiently	as	 the	natural	valve	 (Peskin	et	al	
1981,	Bellhouse	1980,	Lee	et	al	1979,	Reul	et	al	1979,	Laniado	et	al	1976,	Tsakiris	AG	et	al	
1976),	although	the	exact	mechanisms	are	undetermined.	Furthermore,	more	recently	the	
potential	 benefits	 of	 flow	 patterns	 resulting	 from	 a	 bileaflet	 valve	 (Kheradvar	 et	 al	 Feb	
2012,	 Kheradvar	 et	 al	 2010,	 Pasipoularides	 et	 al	 2003)	 compared	 to	 trileaflet	 valves	
(Kheradvar	et	al	2009,	Kheradvar	et	al	Jan	2007,	Kheradvar	et	al	Dec	2007,	Pasipoularides	et	
al	2003)	have	been	found.		
5.5.3.2	Aim	
The	aim	of	visualising	ventricle	flow	associated	with	the	bileaflet	and	trileaflet	SMVs	was	to	
qualitatively	compare	their	diastolic	streaklines.	Flow	visualisation	using	dye	 injection	was	
not	 feasible	 for	 the	 TMVs	 due	 to	 skirt	 porosity,	which	would	 allow	 dye	 to	 leak	 from	 the	
atrium	through	 the	 skirt	 into	 the	ventricle	prior	 to	valve	opening,	muddying	 the	ventricle	
fluid	making	diastolic	jet	streaks	unobservable.	
5.5.3.3	Hypothesis	
The	flow	patterns,	in	particular	wash	out	of	particularly	stagnant	areas	will	be	different	for	
the	bileaflet	and	trileaflet	SMVs.	
5.5.3.4	Protocol	
Ideally	 particle	 image	 velocimetry	 (PIV)	 would	 be	 used	 to	 visualise	 and	 quantify	 the	
ventricle	flow,	however	due	to	technical	limitations	(section	0)	dye	injection	was	used	as	a	
preliminary	method	of	obtaining	qualitative	streak	line	data.	
Once	the	pulsatile	flow	conditions	representative	of	a	normal	healthy	adult	were	set	for	a	
CO	of	4	lpm30	and	a	high	speed	camera	(TSI)	had	begun	recording	whilst	linked	with	Insight	
Experiment	MVUR	 VI	 software,	 blue	 dye	 (Cole-Parmer	 blue	 tracer	 dye	 concentrate)	 was	
injected	into	the	atrium	just	above	the	mitral	valve	(Figures	5.4	and	Figure	5.16).	A	few	free	
standing	light	sources	were	used	to	help	illuminate	the	flow.	
	
																																								 																				
30	A	cardiac	output	of	5	lpm	was	attempted	but	the	quality	of	the	images	was	worse	than	at	4	lpm.	
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5.5.4 Results	
This	 section	 presents	 the	 functional	 performance	 and	 flow	 visualisation	 results	 for	 the	
SMVs.	
5.5.4.1	Anomalies	
Most	 of	 the	 data	 plotted	 in	 section	 5.5.4	 is	 the	 average	 of	 three	 prototypes	 and	 their	
associated	standard	deviation.	However,	there	were	some	anomalies	for	the	trileaflet	valve	
2	(T2),	identified	because	they	caused	the	standard	deviation	for	the	three	prototypes	to	be	
larger	 than	 the	 average	 value	 for	 the	 parameter	 i.e.	 the	 standard	 deviation	 statistic	
spanned	 into	 the	 negative	 regions	 of	 leakage	 volume	 and	 energy	 loss,	 which	 are	
nonsensical	and	so	were	removed.	The	anomalies	identified	were	as	follows.	
		
At	3	lpm	T2	had	an	abnormally	high	leakage	volume	of	2.1	ml	compared	to	0.2	and	0.1	ml	
for	T1	and	T3	respectively,	and	similarly	 for	a	CO	of	4lpm	(Figure	5.23).	This	was	also	 the	
case	 for	 the	total	energy	 losses	at	 these	COs,	 for	example	at	3	 lpm	T2	had	a	 total	energy	
loss	 of	 52	 mJ	 (6	 %VE)	 compare	 to	 25	 mJ	 (3	 %VE)	 and	 14	 mJ	 (2	 %VE)	 for	 T1	 and	 T3	
respectively	(Figure	5.29).	These	elevated	 leakages	and	consequently	higher	energy	 losses	
are	most	likely	due	to	inaccuracy	of	the	assembly	of	T3.	More	specifically	the	leaflets	were	
atrial	injection	site	
TSI	high	speed	camera	
ventricle	observation	window	
insight	experiment	
software	
Figure	5.16:	Dye	 injection	flow	visualisation	ViVitro	pulse	duplicator	 left	ventricle	using	
TSI	high	speed	camera	and	insight	experiment	software.	
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not	perfectly	 aligned	due	 to	 inaccuracy	of	 the	 suturing,	 the	 consequent	 elevated	 leakage	
was	exacerbated	by	 lower	ventricular	pressure	at	 lower	COs	which	meant	 the	 leaflets	did	
not	coapt	as	firmly,	enabling	more	fluid	to	pass	back	into	the	atrium.	
	
The	forward	energy	losses	for	prototypes	1	and	2	at	COs	of	2	and	3	lpm	were	negative	and	
therefore	were	 removed,	which	 is	 why	 there	 are	 no	 error	 bars	 plotted	 (Figure	 5.26,	 the	
standard	deviation	across	ten	cardiac	cycles	for	prototype	3	for	the	forward	energy	losses	
were	±0.61	mJ	and	±0.11	%VE).	These	negative	energy	losses	occurred	due	to	errors	in	the	
position	of	the	flow	markers	used	by	the	software	to	calculate	energy	losses	(Equations	5.5-
5.8	and	Figure	5.13).	
	
5.5.4.2	Functional	performance	
The	 holders	 designed	 for	 the	 SMVs	 successfully	mounted	 them	with	 a	 seal	 between	 the	
pulse	duplicator	atrium	and	ventricle	chambers	and	prevented	paravalvular	leakage	(Figure	
5.17	and	Figure	5.18).	
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Conical	Bileaflet	 Trileaflet	
location	of	aortic	valve	
Figure	 5.17:	 Open	 and	 closed	 morphology	 of	 the	 conical	 bileaflet	 and	 trileaflet	 designs	 at	 a	
cardiac	output	of	5	 lpm,	viewed	 in	a	pulse	duplicator	 from	 (top	 row)	 atrium	and	 (bottom	row)	
ventricle.	
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5.5.4.2.1	Effective	orifice	area		
The	effective	orifice	area	(EOA)	increased	slightly	with	cardiac	output	(CO)	and	was	larger	in	
the	 trileaflet	 design	 ranging	 between	 1.99	 and	 3.07	 cm2	 compared	 to	 between	 1.43	 and	
2.07	cm2	for	the	bileaflet	design	(Figure	5.20).	When	the	EOA	is	analysed	as	a	percentage	of	
the	geometric	orifice	area	(GOA),	ideally	100%,	(Figure	5.19)	the	designs	perform	to	a	more	
similar	 standard	 (Figure	 5.21).	 Furthermore,	 when	 the	 EOA	 of	 the	 bileaflet	 design	 is	
analysed	as	a	percentage	of	its	design	orifice	area	(DOA)	(Figure	5.19)	it	in	fact	exceeds	that	
achieved	 by	 the	 trileaflet	 design	 (Figure	 5.21).	 Both	 designs	 met	 the	 minimum	 EOA	
performance	requirements	for	a	CO	of	5	lpm,	i.e.	they	open	sufficiently	well.	
	
	
Figure	5.18:	Pressure-volume	diagram	for	 two	surgical	mitral	valve	designs	
for	a	cardiac	output	of	5	 lpm.	(Irregular	 in	shape	compare	with	a	“normal”	
native	valve	in	Figure	1.9,	which	is	rectangular).	
GOA	
DOA	
EOA	
Conical	Bileaflet	 Trileaflet	
open	
leaflets	
flow	
flow	
Figure	5.19:	Definition	of	areas	for	the	conical	bileaflet	and	trileaflet	mitral	valves	(GOA)	
Geometric	Orifice	Area	(DOA)	Design	Orifice	Area	and	(EOA)	Effective	Orifice	Area.	
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Figure	5.21:	Effective	orifice	area	(P)	as	a	percentage	of	geometric/design	
orifice	 areas	 for	 two	 surgical	 mitral	 valve	 designs,	 average	 of	 three	
prototypes	each.	
Figure	 5.20:	 Effective	 orifice	 area	 for	 two	 surgical	 mitral	 valve	 designs,	
average	of	three	prototypes	each.	
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5.5.4.2.2	Reverse	flow	volumes	
For	a	CO	of	5	lpm,	in	general,	there	was	no	statistically	significant	difference	between	the	
reverse	flow	volumes	for	the	two	designs	(Figure	5.22).	Although	on	average	the	trileaflet	
design	 had	 a	 larger	 closing	 volume	 than	 the	 bileaflet	 design	 but	 had	 less	 leakage	 and	
therefore	 the	 total	 regurgitant	 flow	was	 less;	 however,	 the	 performance	 of	 the	 trileaflet	
design	 was	 more	 variable	 i.e.	 had	 larger	 standard	 deviations	 across	 cardiac	 cycles.	 In	
general,	this	pattern	was	observed	for	all	COs.	
	
	
	
	
	
The	closing	volume,	i.e.	the	total	reverse	flow	due	to	valve	closure	dynamics,	decreased	as	
the	CO	increased	(Error!	Reference	source	not	found.),	ranging	between	approximately	4.5	
and	 1.5	 ml,	 and	 was	 more	 variable	 (larger	 standard	 deviations	 across	 cardiac	 cycles)	 at	
lower	COs	 for	 the	trileaflet	design	compared	to	the	bileaflet	design,	 for	which	the	closing	
volume	was	significantly	less	for	COs	between	4	and	7	lpm.		
For	COs	between	3	and	7	lpm	leakage	volume,	i.e.	the	total	reverse	flow	through	the	closed	
valve	 increased	 as	 CO	 increased	 (Figure	 5.23),	 ranging	 between	 0.1	 and	 4.5	ml,	 and	was	
more	 variable	 at	 higher	 COs	 for	 the	 trileaflet	 design	 and	 overall	 less	 variable	 for	 the	
bileaflet	 design,	 which	 was	 significantly	 less	 for	 COs	 of	 3	 and	 4	 lpm.	 Furthermore,	 the	
leakage	 volumes	 for	 the	 Trileaflet	 valve	were	 statistically	 significantly	 lower	 than	 for	 the	
Bileaflet	valve	at	COs	of	3	and	4	lpm,	for	no	apparent	reason.	The	leakage	volumes	for	a	CO	
at	2	lpm	were	in	between	those	at	4	and	5	lpm.	
	
	
Figure	5.22:	Reverse	flow	volumes	for	a	cardiac	output	of	5	lpm,	for	
two	surgical	mitral	valve	designs,	average	of	three	prototypes	each.	
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The	 total	 regurgitant	 volume	 ranged	 between	 approximately	 2.3	 and	 6.6	 ml,	 which	
occurred	 at	 COs	 of	 3	 and	 2	 lpm	 respectively.	 The	 total	 regurgitant	 volume	 at	 4	 lpm	was	
similar	 to	 that	 at	 3	 lpm	 and	 was	 slightly	 higher	 and	 approximately	 constant	 for	 COs	
between	5	and	7	lpm.	
Figure	 5.23:	 (top)	 closing	 volumes	 for	 two	 surgical	 mitral	 valve	 designs	 at	 six	 different	 cardiac	
outputs,	average	of	 three	prototypes	each	 (bottom)	 leakage	 volume	 for	 two	surgical	mitral	 valve	
designs	at	six	different	cardiac	outputs,	average	of	three	prototypes	each.	
	
	
145	
	
5.5.4.2.3	Mean	transmitral	diastolic	pressure	difference	
In	 general,	 the	 mean	 transmitral	 diastolic	 pressure	 difference	 increased	 with	 CO	 (Figure	
5.24)	 ranging	 between	 approximately	 1	 and	 4	mmHg	 and	was	 significantly	 higher	 in	 the	
bileaflet	compared	to	the	trileaflet	design	for	COs	of	3,	6	and	7	lpm.	
	
	
	
	
	
	
	
	
	
	
	
5.5.4.2.4	Energy	losses		
At	a	CO	of	5	lpm,	in	general	most	energy	loss	occurred	during	forward	flow	phase	with	
minimal	contribution	due	to	closing	(Figure	5.25),	ranging	between	85	and	15	mJ	(i.e.	1-6	
percent	of	ventricular	energy	(%VE)),	with	intermediate	values	for	energy	loss	due	to	
leakage.	The	total	energy	loss	for	the	trileaflet	design	was	significantly	lower	compared	to	
the	bileaflet	design.	In	general,	these	patterns	were	observed	for	all	COs.		
	
	 	
Figure	 5.24:	Mean	 transmitral	 diastolic	 pressure	 difference	 for	 two	
surgical	mitral	valve	designs,	average	of	three	prototypes	each.	
	
	
146	
	
	
	
	
	
Figure	5.25:	(bottom)	energy	losses	in	millijoules	for	two	surgical	mitral	valve	designs	for	a	cardiac	
output	of	5	 lpm,	average	of	3	prototypes	each	(top)	energy	 losses	as	a	percentage	of	ventricular	
energy	 for	 two	 surgical	 mitral	 valve	 designs	 for	 a	 cardiac	 output	 of	 5	 lpm,	 average	 of	 three	
prototypes	each.	
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The	diastolic	energy	losses	increased	with	CO	ranging	between	1	and	196	mJ	(i.e.	0.1	and	
9.1	%VE)	(Figure	5.26).		
	 	
Figure	 5.26:	diastolic	 energy	 losses	 for	 two	surgical	mitral	 valve	designs	at	 six	different	 cardiac	
outputs,	average	of	three	prototypes	each.	Omitted	error	bars	for	trileaflet	results	at	2	and	3	lpm	
discussed	in	section	5.5.5	(top)	in	millijoules	(bottom)	as	a	percentage	of	ventricular	energy.	
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The	closing	energy	losses	were	approximately	constant	for	all	COs	with	average	values	of	18	
mJ,	2	%VE	(Figure	5.27).		
	
	
	
	
	
	
	
	 	
Figure	5.27:	Closing	energy	losses	for	two	surgical	mitral	valve	designs	at	six	different	
cardiac	outputs,	average	of	 three	prototypes	 each	 (top)	 in	millijoules	 (bottom)	as	a	
percentage	of	ventricular	energy.	
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The	leakage	energy	losses	increased	as	CO	increased	from	3	to	7	lpm	ranging	between	0.3	
and	79	mJ	i.e.	0.04	and	4	%VE	(Figure	5.28),	with	losses	at	2	lpm	between	those	at	4	and	5	
lpm.	In	general	the	total	energy	loss	increased	with	CO	ranging	between	approximately	11	
and	265	mJ	i.e.	1	and	12	%VE	(Figure	5.29).	
	
Figure	 5.28:	 Leakage	 energy	 losses	 for	 two	 surgical	mitral	 valve	 designs	 at	 six	 different	 cardiac	
outputs,	 average	 of	 three	 prototypes	 each	 (top)	 in	 millijoules	 (bottom)	 as	 a	 percentage	 of	
ventricular	energy.	
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Figure	 5.29:	 Total	 energy	 losses	 for	 two	 surgical	 mitral	 valve	 designs	 at	 six	 different	 cardiac	
outputs,	 average	 of	 three	 prototypes	 each	 (top)	 in	 millijoules	 (bottom)	 as	 a	 percentage	 of	
ventricular	energy.	
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5.5.4.2.4	Regurgitant	fraction	
The	regurgitant	fractions	decreased	with	CO	ranging	between	2.9	and	17.2%	and	were	not	
significantly	different	for	the	two	designs	(Figure	5.30).	
	
	
		
	
	
	
	
	
	
	
	
5.5.4.3	Flow	visualisation	
The	streakline	(Figure	5.31,	frame	1)	for	the	trileaflet	SMV	jet	at	the	beginning	of	diastole	
was	 narrow,	 short	 and	 straight.	 As	 the	 streakline	 became	 longer	 and	 wider	 it	 drifted	
towards	the	free	wall	and	once	it	came	in	contact	with	the	ventricle	apex	a	vortex	formed	
directing	flow	towards	the	aortic	valve.	Later	lack	of	circulation	of	dye	can	be	observed	at	
the	base	of	ventricle	near	the	free	wall.	
	 	
Figure	5.30:	Regurgitation	fraction	for	two	surgical	mitral	valve	designs	
for	a	cardiac	output	of	5	lpm,	average	of	three	prototypes	each.	
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1	BEGINNING	OF	VENTRICLE	FILLING	
T	SMV	aortic	valve	
2	
streaklines	of	jet	
through	mitral	orifice	
vortex	at	apex	of	left	ventricle	sac	
free	wall	location	of	septum	in	vivo	
3	 4	 5	
6	 7	 8	
9	 10	 11	
12	 13	 14	END	OF	VENTRICULAR	EXPANSION	
Figure	5.31:	Dye	injection	flow	visualisation	of	the	trileaflet	(T)	surgical	mitral	valve	(SMV)	prototype	2	at	
4	 lpm,	time	between	frames	is	10	ms,	taken	using	a	TSI	high	speed	camera,	which	produces	black	and	
white	images.	
	
	
153	
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9	 10	 11	
12	 13	 14	END	OF	VENTRICLE	EXPANSION	
1	BEGINNING	OF	VENTRICLE	FILLING	 2	
CB	SMV	aortic	valve	
wide	jet	through	mitral	
orifice	
vortex	at	apex	of	left	ventricle	sac	
free	wall	location	of	septum	in	vivo	
Figure	5.32:	Dye	injection	flow	visualisation	of	the	conical	bileaflet	(CB)	surgical	mitral	valve	(SMV)	prototype	
2	at	4	 lpm,	 time	between	 frames	 is	10	ms,	 taken	using	a	TSI	high	speed	camera,	which	produces	black	and	
white	images.	
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The	 streakline	 (Figure	5.32,	 frame	1)	 for	 the	 conical	 bileaflet	 SMV	 jet	 at	 the	beginning	of	
diastole	was	wide,	long	and	divergent,	immediately	coming	into	contact	with	the	ventricle	
apex	and	generating	a	vortex	directing	the	flow	towards	the	aortic	valve.		After	which,	the	
ventricle	fluid	was	circulated	to	such	an	extent	that	no	more	streaklines	could	be	observed.	
5.5.5 Discussion	
This	 section	 provides	 a	 discussion	 of	 the	 experimental	 results	 for	 the	 surgical	 prototypes	
including	 their	 functional	 performance	 and	 associated	 flow	 visualisation.	 The	 reasons	 for	
translating	a	bileaflet	design	to	the	transcatheter	device	are	then	discussed.		
5.5.5.1	Functional	performance	
The	trileaflet	and	bileaflet	valves	were	the	same	size	i.e.	had	the	same	external	perimeter,	
and	so	had	the	same	minimum	performance	requirements	of	an	effective	orifice	area	(EOA)	
≥	 1.4-1.6	 cm2	 and	 a	 regurgitant	 fraction	 (RF)	 ≤	 15-20%.	 These	 were	 exceeded	 by	 the	
trileaflet	valve	with	values	of	2.5	cm2	and	5.7%,	which	performed	better	 than	 the	conical	
bileaflet	valve	which	also	exceeded	the	minimum	requirements	with	values	of	1.8	cm2	and	
5.9%.	 In	 words,	 the	 bileaflet	 design	 successfully	 matched	 the	 systolic	 performance	 of	 a	
commercially	 available	 valve,	 although	 performed	 less	 well	 during	 diastole.	 However,	 as	
discussed	previously,	 the	heart	 is	 resilient	 to	 reduction	 in	mitral	 valve	orifice	area	 (Figure	
1.12)	and	therefore	the	relatively	lower	EOA	of	the	bileaflet	design	is	not	cause	for	rejecting	
it.		
The	 RF	 was	 lower	 at	 higher	 cardiac	 outputs	 (COs),	 most	 likely	 due	 to	 higher	 systolic	
transmitral	pressure	difference	coapting	the	leaflets	more	tightly.	Despite	this	total	energy	
loss	(TEL)	 increased	with	CO,	most	 likely	because	of	 losses	due	to	viscosity31;	 turbulence32	
and	flow	separation33	all	 increase	as	CO	 increases	 (Akins	et	al	2008),	 indicating	TEL	 is	 less	
affected	by	regurgitation	compared	to	other	sources	of	loss.	Although	the	two	designs	had	
similar	 RFs	 the	 origin	 of	 reverse	 flow	 differed,	 mostly	 due	 to	 closing	 and	 leakage	 for	
trileaflet	and	bileaflet	valves	respectively	(for	all	COs).	
																																								 																				
31	Viscous	energy	 losses	are	directly	proportional	 to	 the	 flow	rate,	vessel	 length	and	 fluid	viscosity	
(Akins	et	al	2008).	
32	Energy	loss	due	to	turbulence	is	proportional	to	the	square	of	the	flow	rate	(Akins	et	al	2008).	
33	Energy	loss	due	to	flow	separation	is	proportional	to	the	square	of	the	flow	rate	(Akins	et	al	2008).	
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The	 trileaflet	valve	presented	a	significantly	advantageously	smaller	 resistance	 to	 forward	
flow	 for	 COs	 of	 3,	 6	 and	 7	 lpm,	 i.e.	 had	 a	 smaller	 mean	 diastolic	 transmitral	 pressure	
difference,	although	did	not	perform	significantly	different	to	the	bileaflet	valve	for	COs	of	
2,	4	and	5	lpm.	
The	 smaller	 closing	 volume	 associated	with	 the	 conical	 bileaflet	 valves,	 compared	 to	 the	
trileaflet	valves,	supports	previous	studies	which	state	that	flow	patterns	associated	with	a	
bileaflet	 valve	will	 result	 in	 efficient	 closure	 (Peskin	 et	 al	 1981,	 Bellhouse	1980,	 Lee	 et	 al	
1979,	Reul	et	al	1979,	Laniado	et	al	1976,	Tsakiris	et	al	1976).	
The	bileaflet	valves	caused	greater	energy	losses	compared	to	the	trileaflet	design,	mostly	
due	to	higher	diastolic	losses,	as	well	as	higher	leakage	losses.	Although	the	bileaflet	design	
had	favourably	smaller	closing	energy	losses	in	millijoules	(also	reflected	as	smaller	closing	
volume),	when	considered	as	a	percentage	of	ventricular	energy	(%VE)	it	was	in	fact	larger	
compared	to	the	trileaflet	valves.		
The	 exemplar	 data	 (Figure	 5.18)	 shows	 an	 instance	 where	 the	 bileaflet	 valve	 had	 a	
marginally	 lower	VE	 compared	 to	 the	 trileaflet	 valve.	However,	due	 to	variation	between	
cardiac	 cycles	 of	 individual	 prototypes	 and	 even	 greater	 variation	 between	 prototypes,	
overall	 there	was	 no	 significant	 difference	 between	 designs	 as	 it	 increased	with	 CO.	 The	
isovolumic	contraction	and	relaxation	that	occur	in	a	healthy	heart	with	competent	valves	
clearly	does	not	occur	for	the	prosthetic	devices	i.e.	lines	from	F4	to	F1	and	F2	to	F3	are	not	
vertical	(Figure	5.18).	This	was	caused	by	leakage	though	both	the	mitral	prototypes	as	well	
as	the	mechanical	aortic	valve.		
	
5.5.5.1.1	Comparison	with	in	vivo	data	
The	 EOA,	 RF,	 transmitral	 pressure	 difference	 and	 energy	 loss	 are	 commonly	 understood	
and	used	 in	 clinical	practice	as	well	 as	 in	 laboratory	 studies.	Despite	 in	 vitro	 assessments	
being	relevant	only	in	terms	of	comparative	performance	for	two	or	more	devices	tested	in	
any	particular	pulse	duplicator	set-up	(Simenauer	et	al	1987),	the	trileaflet	valve,	a	27	mm	
diameter	replica	of	the	Pericarbon	MORE	Mitral,	had	a	similar	pressure	gradient	and	EOA	to	
those	 observed	 in	 vivo	 for	 an	 actual	 29	mm	 bioprosthesis	 (based	 on	 postoperative	 data	
from	 21	 patients	 in	 stable	 conditions,	 Table	 5.4,	 Caimmi	 et	 al	 1998).	 However,	 this	
comparison	is	limited	due	to	the	inevitably	different	pulsatile	flow	conditions,	most	notably	
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the	 EOA	 for	 the	 larger	 device	 in	 vivo	 is	 smaller	 than	 that	 for	 the	 smaller	 device	 in	 vitro,	
which	is	likely	to	be	due	to	the	higher	pressure	gradients	in	vivo	and/or	could	also	be	due	to	
a	 lower	 CO.	 Also,	 most	 notably	 there	 is	 a	 difference	 in	 fluid	 viscosity;	 blood	 being	
approximately	four	times	more	viscous	than	water.	
Table	5.4:	Comparison	between	in	vitro	data	for	a	27	mm	replica	Pericarbon	MORE	Mitral	
(PMM)	i.e.	the	trileaflet	valve	and	in	vivo	data	for	an	actual	29	mm	PMM.	
Variable	 In	vivo	echo-color	doppler	study	(Caimmi	et	al	1998)		
In	vitro	pulse	duplicator	
study	at	5	lpm		
Size	(mm)	 29	 27	
Peak	gradient	(mmHg)	 10.2	±	1.0	 8.2	±	1.7	
Mean	gradient	(mmHg)	 3.4	±	0.2	 2.1	±	0.2	
Effective	orifice	area	(cm2)	 2.1	±	0.2	 2.5	±0.1	
	
5.5.5.1.2	Comparison	with	in	vitro	data	
In	absence	of	a	reference	valve	for	the	bileaflet	valve	a	comparison	is	made	here	with	the	
only	other	known	reported	data	for	a	bileaflet	mitral	valve,	the	‘bubble	valve’	(BV,	Walker	
et	al	1983,	section	2.1.3,	Table	5.5,	 the	EOA	was	not	 reported).	The	BV	had	 lower	energy	
losses,	 most	 likely	 due	 to	 the	 conicity	 of	 the	 bileaflet	 design,	 although	 the	 latter	 had	
favourably	 smaller	 regurgitant	 volume	 thereby	 demonstrating	 that	 it	 achieved	 its	 main	
design	 aim.	 However	 this	 comparison	 is	 limited	 because,	 as	 previously	 stated,	 data	 for	
valves	tested	in	different	pulse	duplicator	set-ups	are	not	strictly	comparable	(Simenauer	et	
al	1987)	and,	furthermore,	the	only	pulsatile	flow	condition	stated	by	Walker	et	al	1983	was	
heart	rate.		
Table	 5.5:	 The	 functional	 performance	 of	 the	 bileaflet	 design	 compared	 to	 the	 'bubble	
valve'	in	terms	of	regurgitant	volume,	diastolic	and	total	energy	losses.	
Variable	 ‘Bubble	valve’	(Walker	et	al	1983)	
Bileaflet	valve	at	a	cardiac	
output	of	5	lpm	
Size	(nominal	diameter)	(mm)	 29	 27	
Heart	rate	(bpm)	 60	 80	 70	
Regurgitant	volume	(ml)	 6±1	 7±1	 4±1	
Diastolic	energy	loss	(%	of	
ventricular	energy)	 1.5±1	 5.5±0.7	
Total	energy	loss	(%	of	
ventricular	energy)	 6.5±0.8	 7±1	 9.6±0.9	
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5.5.5.2	Flow	visualisation	
Both	valves	were	associated	with	formation	of	vortices	when	their	mitral	jets	made	contact	
with	 the	 ventricle	 apex,	 directing	 flow	 towards	 the	 aortic	 valve,	 although	 the	 timings	 of	
their	generation	and	dissipation	varied	and	their	direction	prior	to	aortic	valve	opening	was	
not	 determinable.	 For	 the	 trileaflet	 design,	 stagnation	 of	 flow	 was	 observable	 near	 the	
ventricle	 free	wall	 (Figure	5.31,	please	 refer	 to	 the	electronic	 version	 for	 clearer	 images),	
which	 is	 undesirable	 because	 blood	 stasis	 was	 associated	 with	 platelet	 activation	 and	
thrombus	 formation	 (Lowe	 2003).	 However,	 the	 Pericarbon	MORE	Mitral	 has	 been	 used	
successfully	 for	 the	 past	 16	 years	 with	 no	 significant	 haemolytic	 consequences.	 Further	
investigation	(section	8.4)	may	therefore	indicate	relatively	low	residence	times.	
5.5.5.3	Translation	to	a	transcatheter	device	
The	 bileaflet	 design	 successfully	 fulfilled	 its	 targeted	 optimal	 systolic	 performance	 i.e.	
minimal	regurgitation,	demonstrated	by	having	near	equivalent	RF	to	the	trileaflet	valve	(a	
replica	of	a	commercially	available	device).	Also,	 its	 two	 instead	of	 three	stent	posts	may	
make	 it	 preferable	 for	 specific	 patients	whom	 are	 declined	 circular	 replacements	 due	 to	
their	 specific	 anatomical	 requirements	 (Walker	 et	 al	 1983,	 Figure	 1.2).	 Although	 the	
bileaflet	 design	was	 surpassed	by	 the	 trileaflet	 design	 in	 its	 EOA,	 it	was	 still	 used	 for	 the	
leaflets	of	the	transcatheter	prototype	for	several	reasons.	
Translation	 of	 a	 bileaflet	 design	 to	 the	 transcatheter	 device	 is	 supported	 by	 previous	
evidence	 which	 demonstrates	 that	 a	 bileaflet	 design	 is	 preferable	 to	 the	more	 common	
trileaflet	solutions	due	to	 its	ability	to	have	proper	 leaflet	coaptation	for	a	wider	range	of	
anatomical	configurations	(Burriesci	and	Zervides	et	al	2010)	and	it	has	also	been	inferred	
that	it	will	generate	more	physiological	left	ventricle	haemodynamics	(Carmody	et	al	2006,	
Burriesci	 et	 al	 2003,	 Peskin	 et	 al	 1981,	 Bellhouse	 1980,	 Lee	 et	 al	 1979,	 Reul	 et	 al	 1979,	
Laniado	et	 al	 1976,	Tsakiris	 et	 al	 1976),	 unsurprising	 considering	native	mitral	 valves	 also	
have	two	leaflets.	Therefore	the	proposed	TMV	is	expected	to	exceed	the	performance	of	
other	devices	in	development	because	it	has	two	rather	than	three	leaflets.		
A	D-shaped	device	would	present	less	restriction	of	the	LVOT	compared	to	a	circular	device	
(Figure	5.33),	and	although	a	D-shaped	device	would	have	a	smaller	geometric	orifice	area	
compared	 to	 circular	 device	 with	 the	 same	 perimeter,	 it	 would	 in	 fact	 use	 the	 space	
available	more	efficiently.	
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Developers	 of	 other	 TMV	 designs	 most	 likely	 choose	 trileaflet	 circular	 configurations	
because	 they	 are	 relatively	 easier	 to	 design	 for	 minimal	 crimped	 profiles,	 which	 are	
necessary	 for	delivery	 through	narrow	vascular	passages.	Three	 leafleted,	 circular	devices	
also	tend	to	have	repeatable	uniform	deployment.	
5.5.6 Conclusions		
5.5.6.1	Nature-inspired	design	
The	functional	assessment	of	the	bileaflet	surgical	mitral	valves	(SMVs),	supports	previous	
work	(Burriesci	G	et	al	1999),	showing	a	stented	bileaflet	bioprosthetic	mitral	prosthesis	is	
feasible.	In	fact,	the	bileaflet	SMVs	also	have	an	original	combination	of	geometric	features	
which	mimic	 native	 valve	morphology	 and	 thereby	 advance	 the	 study	 of	 nature-inspired	
mitral	 valve	 designs	 (section	 2.1).	 Due	 to	 them	 exceeding	 minimum	 performance	
requirements	 (ISO	 5840:2009)	 they	 have	 potential	 for	 technology	 transfer	 and	 therefore	
may	initiate	a	new	generation	of	surgical	replacements	designed	specifically	 for	the	mitral	
position.	 Thus,	 the	 D-shaped	 bileaflet	 SMV,	 which	 requires	 minimal	 distortion	 to	 the	 D-
shaped	native	mitral	annulus	compared	to	a	circular	device,	potentially	presents	a	paradigm	
shift	 from	prioritising	commercial	profit	over	preservation	of	healthy	natural	physiological	
flow.	
5.5.6.2	Bileaflet	vs.	trileaflet	valves	
For	 the	 first	 time	 functional	 performance	 of	 two	 and	 three	 leafleted	 bioprosthetic	mitral	
valves	 were	 compared	 in	 vitro,	 opposed	 to	 in	 silico	 (Kheradvar	 et	 al	 2012),	 thereby	
Circular	mitral	device	
Aortic	
valve	
\\\\	
D-shape	mitral	device	
Aortic	
valve	
Potential	impingement	of	LVOT	
Figure	 5.33:	 Advantage	 of	 D-shaped	 mitral	 valve	 replacements	
compared	 to	 circular	 (left)	 potential	 impingement	 of	 left	 ventricular	
outflow	 tract	 by	 circular	 device	 (right)	 efficient	 use	 of	 space	 by	 a	 D-
shaped	device.	
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advancing	 the	 study	 of	 bileaflet	 mitral	 valves.	 The	 in	 vitro	 data	 obtained	 cannot	 be	
compared	precisely	with	in	vitro	data	from	another	pulse	duplicator,	nor	with	in	vivo	data,	
although,	in	a	broad	sense,	test	parameters	reported	for	similar	devices	in	vivo	and	in	vitro	
support	the	data	obtained	for	the	trileaflet	and	bileaflet	valves	respectively.		
The	proposed	bileaflet	valve	was	expected	to	exceed	the	trileaflet	valve	performance	and,	
therefore,	 demonstrate	 its	 superiority	 compared	 to	 a	 commercially	 available	 circular	
alternative	(Figure	1.10	and	Figure	1.11).	Although	this	was	not	shown	to	be	the	case	it	still	
exceeded	minimum	performance	 requirements	 (ISO	 5840:2009).	 However,	 these	 findings	
relate	only	 to	 their	 functional	performance	and	 therefore	do	not	necessarily	 conflict	with	
previous	 research	 which	 shows	 that	 two	 leaflets,	 rather	 than	 three,	 will	 generate	 more	
physiological	 left	 ventricle	 haemodynamics	 (Carmody	 et	 al	 2006,	 Burriesci	 et	 al	 2003).	
Furthermore,	 a	 two	 stent	 post	 design	 may	 be	 preferable	 due	 to	 relatively	 minimal	
disturbance	to	surrounding	anatomy,	most	notably	 to	 the	native	mitral	valve	sub	valvular	
apparatus,	and	associated	mechanics,	which	crucially	connect	the	native	mitral	valve	to	the	
left	 ventricle	 (Figure	 1.1Figure	 1.7Figure	 1.8)	 and	 would	 theoretically	 lead	 to	 more	
physiological	flow	patterns	(Figure	1.4Figure	1.9)	and,	therefore,	 less	 likely	to	cause	blood	
damage.	Furthermore,	a	D-shaped	design	is	less	likely	to	impede	the	aortic	annulus	(Figure	
5.33).		
In	 summary	 although	 the	 hypothesis	 (section	 5.5.1)	 was	 not	 shown	 to	 be	 true	 for	 the	
surgical	mitral	valves	made;	overall	the	trileaflet	valve	had	optimal	functional	performance,	
although	 the	bileaflet	 valve	was	not	worse	 for	 all	 of	 the	bulk	haemodynamic	parameters	
measured.	 Furthermore,	 there	 are	 other	 expected	 advantages	 of	 a	 bileaflet,	 opposed	 to	
trileaflet,	 design	 in	 terms	 of	 more	 physiological	 left	 ventricle	 flow	 patterns,	 minimal	
interaction	with	myocardial	morphology	and	dynamics	and	reduced	risk	of	haemolysis	and	
therefore	a	surgical	bileaflet	mitral	valve	device	may	still	be	preferable.	
	
5.5.6.3	Solution	to	transcatheter	reference	valve	predicament		
Together,	 the	 two	 SMVs	 present	 an	 original	 and	 in	 fact	 first	 approach	 to	 providing	 a	
reference	valve	 for	a	TMV	(section	2.3.4).	The	trileaflet	valve	was	 indirectly	 the	reference	
valve,	i.e.	it	had	to	be	compared	to	a	surgical	version	of	the	UCL	TMV	to	mitigate	disparities	
in	 transvalvular	 regurgitation.	 The	 results	 demonstrated	 the	 bileaflet	 design	 strategy	was	
successful	 in	 achieving	 optimal	 systolic	 performance,	 although	 consequently	 had	 poorer	
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diastolic	 performance,	 which	 is	 also	 likely	 if	 compared	 to	 circular	 TMVs	 in	 development	
(section	2.2).	
In	summary,	 the	SMVs	assessed	present	a	design	method	for	a	bileaflet	valve	 in	 line	with	
international	 standards,	 and	 compare	 its	 functional	 performance	 to	 a	 commercially	
available	and	potentially	relevant	alternative	prosthesis.	The	SMVs	designed	highlighted	the	
difference	 in	 requirements	 of	 surgical	 and	 transcatheter	 devices,	 namely	 that	 a	 conical	
bileaflet	design	 is	best	 suited	 to	a	 transcatheter	device	 rather	 than	a	 surgical	device,	and	
provided	 sufficient	 comparison	 with	 a	 relevant	 reference	 valve	 which	 confirmed	 the	
suitability	of	the	UCL	TMV	leaflets.	
5.5.6.4	Limitations	
5.5.6.4.1	Left	atrium	
The	effect	of	larger	closing	volumes,	and	therefore	also	energy	losses	(mJ),	on	the	function	
of	the	left	atrium	(LA)	in	the	trileaflet	valve	are	unknown	because	the	current	rigid	atrium	
prevents	study	of	the	extent	to	which	smaller	closing	volumes	in	the	bileaflet	valve	(section	
5.5.1)	are	advantageous.	More	specifically,	 if	 the	LA	were	capable	of	contraction,	 then	 its	
pressure-volume	 diagram	 would	 enable	 a	 more	 complete	 energy	 assessment	 of	 the	
devices,	previously	shown	to	be	relevant	by	MacIsaac	et	al	 (1992)	and	Teien	et	al	 (1997).	
The	former	studied	impact	of	mitral	regurgitation	on	energy	transfer	from	the	left	ventricle	
to	LA	and	the	 latter	showed	energy	associated	with	 the	LA	to	be	at	 least	as	 important	as	
regurgitant	 volume	 in	 determining	 ventricular	 work	 required.	 Therefore,	 ideally	 atrial	
contraction	would	be	 included,	which	 in	 fact	 is	 still	emitted	 in	even	most	 recent	pulsatile	
flow	system	designs	(Leopaldi	et	al	2015).		
5.5.6.4.2	Flow	visualisation	
Flow	visualisation	using	the	current	pulse	duplicator	ventricle	sac	will	not	replicate	 in	vivo	
flow	patterns,	most	 notably	 due	 to	 there	being	no	 sub-valvular	 components	 (Figure	 1.2).	
Despite	 this	 it	 is	 still	 a	 valid	 tool	 for	 comparing	 devices,	 and	 as	 previously	 discussed	 can	
replicate	pressures	and	flows	observed	in	vivo	(Table	5.4).	Also	as	mentioned	at	the	outset,	
dye	injection	is	limited	to	providing	a	qualitative	indication	of	flow	patterns,	a	quantitative	
alternative	is	discussed	in	the	following	section.	
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5.6 Summary	
This	 chapter	 described	 the	 equipment	 used	 and	 made	 to	 assess	 the	 prototypes,	 which	
included	 the	 design	 and	 manufacture	 of	 surgical	 mitral	 valves,	 designed	 to	 provide	 a	
relevant	 reference	 valve	 for	 the	 UCL	 TMV.	 Furthermore,	 it	 described	 the	 experimental	
conditions	 used	 to	 simulate	 the	 left	 side	 of	 a	 normal	 healthy	 adult	 heart	 and	 the	
parameters	 measured	 to	 assess	 prosthetic	 heart	 valve’s	 performance,	 namely	 effective	
orifice	 area	 and	 regurgitation	 fraction.	 The	minimum	performance	 requirements	 are	 also	
expounded	as	well	as	the	limitations	of	these	methods.	
The	 following	 chapter,	 chapter	 6,	 will	 outline	 the	main	 aim	 of	 the	 UCL	 TMVs,	 that	 is,	 to	
assess	 its	 potential	 as	 a	 treatment	 option	 for	 high-risk	 patients	 with	 severe	 mitral	
regurgitation.	 The	 design	 of	 the	 prototypes	 and	 their	 functional	 assessment	 are	 then	
described	and	the	results	presented	and	discussed.		
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Chapter	6 Transcatheter	mitral	valves	1st	generation	
This	section	describes	the	aim	for	the	UCL	TMV	prototypes	and	the	materials	and	methods	
used	to	make	three	prototypes.	The	aim	of	the	functional	assessment	is	clarified,	details	for	
which	 are	 in	 0.	 The	 experimental	 results	 are	 presented,	 followed	 by	 a	 discussion	 and	
summary.	
6.1 Aim	
The	aim	of	prototyping	the	UCL	TMV	(Figure	3.1)	was	to	assess	its	potential	as	a	treatment	
option	 for	 high-risk	 patients	 with	 severe	 mitral	 regurgitation,	 who	 are	 refused	 surgical	
interventions	because	they	are	too	weak	to	undergo	such	an	invasive	procedure.	
6.2 Design	
This	 section	 describes	 advances	made	 to	 the	 initial	 concept	 for	 the	UCL	 TMV,	 previously	
described	(section	1.4.4).		
6.2.1 Leaflets	
The	 pericardial	 leaflets	 were	 designed	 for	 optimal	 systolic	 performance,	 with	 acceptable	
levels	of	stress	and	maximal	coaptation	area	(Chapter	4).		
6.2.2 Wireframe	
The	wireframe	was	subsequently	designed	to	fit	the	leaflets	and	was	optimised	(Bozkurt	et	
al	2016)	 to	provide	adequate	matching	to	the	mitral	valve	anatomy,	while	minimising	the	
stresses	during	loading	in	the	delivery	system	(Figure	6.1).		
The	 UCL	 TMV	 frames	 were	 thermo-mechanically	 formed	 (Lithotech	 Group	 Inc.)	 from	 a	
single	 0.58	 mm	 nitinol	 wire	 (Fort	 Wayne	 Metals).	 This	 manufacturing	 method	 is	
advantageous	 compared	 to	 laser-cutting	 them	 from	metal	 tubes	 because	 laser	 cut	 tubes	
have	heat	affected	 zones	 susceptible	 to	micro-cracking,	which	expose	 intrinsic	draw	 lines	
resulting	from	the	manufacturing	process,	serving	as	 initiation	sites	for	crack	propagation.	
The	wireframe	was	then	collated	in	five	locations	using	crimping	sleeves	to	prevent	rotation	
(Figure	6.1).	Four	sections	of	wire	are	held	together	with	the	annular	medial	sleeve,	where	
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the	wire	begins	and	ends	and	just	two	sections	of	wire	are	contained	within	the	other	four	
sleeves.	
	
	
	
	
	
	
	
	
	
	
	
	
At	present	Af	is	4.8	oC,	i.e.	the	transition	temperature	to	which	martensitic	nitinol	must	be	
heated	 to	 completely	 transform	 it	 into	 its	 austenitic	 structure	 (section	 3.3).	 This	 means	
when	the	frames	are	cooled	below	this	transformation	temperature	its	structure	changes,	
enabling	it	to	deform	easily	to	fit	 inside	the	catheter,	and	then	when	later	re-expanded	 in	
vivo	at	37	oC	it	will	return	to	the	original	shape.	However,	Af	is	dependent	on	manufacturing	
processes	and	therefore	will	be	subject	to	change	as	they	are	optimised.		
left	atrium	
left	ventricle	
*	*	
*	
*	
*	
5	crimping	sleeve	locations	*	
annular	medial	
crimping	sleeve	
view	from	atrium	
Figure	 6.1:	Optimised	 nitinol	 wireframe	 for	 the	 UCL	 transcatheter	mitral	 valve,	
(top	left)	view	from	atrium,	(bottom	left)	side	view,	(bottom	right)	made	from	a	
single	wire	starting	and	finishing	at	the	annular	medial	crimping	sleeve,	and	(top	
right)	collated	at	four	other	points.	
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6.2.3 Auxiliary	parts	
A	pericardial	sealing	cuff	 (Figure	3.1)	was	designed	to	reduce	paravalvular	 leakage	and	an	
appropriate	 polymeric	 mesh	 was	 sourced	 and	 selected	 for	 the	 skirt	 (section	 3.2),	 which	
gently	 distributes	 an	 anchoring	 force	 over	 the	 annulus.	 Finally,	 as	 previously	 discussed	
(section	5.5.2),	nylon	was	selected	as	the	most	appropriate	thread	for	assembly.	
6.3 Prototype	
The	 cutting	 patterns	 for	 the	 leaflets	 (Figure	 6.2),	 sealing	 cuff	 and	 skirt	 (Figure	 6.3)	 were	
drawn	using	computer-aided	design	(CAD)	3-D	modelling	software	Rhinoceros	4.0	 (Robert	
McNeel	&	Associates)	and	printed	onto	the	sticky	side	of	overhead	projector	(OHP)	acetate,	
except	 for	 the	 skirt	 pattern	which	was	 printed	 onto	 ordinary	 acetate.	 The	 patterns	were	
then	transferred	onto	their	respective	materials,	cut	out	and	assembled	as	follows.	
	
	
	
	
	
	
	
	
The	0.4	mm	thick	BP	 leaflets	 (section	3.1.3)	were	double	stitched	 to	 the	skirt	using	nylon	
thread	and	the	sides	joined	together,	prior	to	inserting	it	inside	the	wireframe.	The	leaflet	
profile	and	skirt	were	then	attached	to	the	wireframe	using	nylon	thread	followed	by	the	
sealing	cuff.	
aortic	
leaflet	
mural	
leaflet	
line	attaches	to	
skirt	
dashed	line	
attaches	to	
sealing	cuff	
dotted	line	
attaches	to	
wireframe	
Figure	6.2:	UCL	transcatheter	mitral	valve	leaflet	cutting	pattern	indicating	attachment	
sites	to	other	parts.	
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6.4 Functional	Assessment	
6.4.1 Aims	
The	aim	of	the	functional	assessment	of	the	UCL	TMV	was	to	determine	firstly	whether	 it	
met	 the	 international	 standard	 requirements	 and	 secondly	 to	 determine	 the	 effect	 of	
annulus	size	on	its	performance.	
6.5 Results	
This	 section	presents	 the	 functional	performance	and	 regurgitant	 test	 results	 for	 the	UCL	
TMV.		
6.5.1 Functional	performance	
The	mock	native	mitral	valves	(section	5.1.5)	designed	for	assessing	the	TMVs	successfully	
created	a	seal	between	the	pulse	duplicator’s	atrium	and	ventricle	chambers	and	prevented	
migration	of	the	prototypes	(Figure	6.4,	please	see	electronic	version	for	a	clearer	image).	
The	characteristic	pressures	and	flows	observed	for	a	single	cardiac	cycle	were	previously	
shown	in	Figure	5.13	and	the	resulting	test	parameters	for	all	tests	are	described	below.	
	
axial	
00	
from	
patch	
transverse		
line	
attaches	to	leaflets		
top	edge	attaches	to	
wireframe	
Figure	 6.3:	 Skirt	 cutting	 pattern	 for	 PETKM2004,	 axial	
direction	 aligned	 with	 the	 0o	 orientation	 of	 the	 patch	
sample	(section	3.2.2).	
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6.5.1.1	Regurgitation	fraction		
The	TMVs	exceeded	ISO	5840-3:2013	requirements	at	5	lpm	and,	in	general,	the	regurgitant	
fraction	(RF)	decreased	as	the	CO	increased	(Figure	6.5).	There	was	no	significant	difference	
between	holder	sizes	although,	on	average,	the	RF	was	higher	in	a	25	mm	annulus.	
6.5.1.2	Effective	orifice	area	
The	TMVs	exceeded	the	ISO	5840-3:2013	requirements	and	in	general	the	effective	orifice	
area	 (EOA)	 increased	with	CO	and	was	 larger	 in	 larger	 holders,	 although	 these	 variations	
were	 not	 significant	 due	 to	 the	 large	 variation	 in	 performance	 between	 the	 three	
prototypes	made	(Figure	6.5).		
Figure	6.4:	The	UCL	transcatheter	mitral	valve	in	the	pulse	duplicator	functioning	
at	a	cardiac	output	of	5	lpm	in	a	24	mm	holder	(left)	closed	(systolic)	and	(right)	
open	(diastolic).	
Figure	6.5:	(left)	regurgitation	fraction	(right)	effective	orifice	area;	average	of	3	UCL	transcatheter	
mitral	valve	prototypes	in	holder	sizes	20-25	mm	at	cardiac	outputs	2-7	lpm,	arrow	indicates	that	
holder	sizes	25	and	23	exceed	ISO	5840-3:2013	requirements.	
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6.5.1.3	Mean	diastolic	transmitral	pressure	difference	
In	 general	 the	mean	 diastolic	 transmitral	 pressure	 difference	 (MDPD)	 increased	with	 CO,	
although	there	was	no	statistically	significant	difference	between	holder	sizes	(Figure	6.6).	
	
	
	
	
	
	
	
6.5.1.4	Reverse	flow	volumes	
Most	 of	 the	 reverse	 flow	 volume	 (RFV)	 was	 due	 to	 leakage	 with	 more	 variable	 and	 in	
general	 higher	 RFVs	 in	 smaller	 holders	 (Appendix	 E,	 Figure	 E.1).	 For	 a	 CO	 of	 5	 lpm	 the	
minimum	 total	RFV	 (5.7	±	0.6	ml)	occurred	 in	 transcatheter	mitral	 valve	 two	 in	 a	21	mm	
holder	and	the	maximum	(12.2	±	0.8	ml)	was	in	transcatheter	mitral	valve	three	in	a	25	mm	
holder.	
There	was	no	significant	difference	in	the	closing,	leakage	or	total	regurgitant	volumes	for	
COs	between	2	and	7	lpm,	with	average	values	of	1.7	±	0.4	ml,	8.1	±	2.7	ml	and	9.8	±	2.9	ml	
respectively	(Appendix	E,	Figures	E.2-E.4).	Although,	based	on	average	values,	the	 leakage	
and	total	regurgitant	volumes	followed	the	same	pattern,	with	maximum	values	in	25	mm	
holders	with	a	peak	value	at	7	lpm	and	minimum	values	in	24	mm	holders	with	higher	and	
more	variable	performance	in	smaller	holders.	
6.5.1.5	Energy	losses		
Most	 of	 the	 energy	 loss	 (EL)	 occurs	 during	 diastole	 with	 minimal	 contribution	 from	 the	
closing	phase	 (Appendix	E,	 Figures	E.5	and	E.6).	 For	a	CO	of	5	 lpm	the	maximum	total	EL	
Figure	 6.6:	 Mean	 diastolic	 transmitral	 pressure	 difference;	
average	of	 3	UCL	 transcatheter	mitral	 valves	 in	 holder	 sizes	
20-25	mm	at	cardiac	outputs	2-7	lpm.	
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(456	±	10	mJ,	27	±	1	%VE)	occurred	in	TMV1	in	a	20	mm	holder	and	minimal	losses	(193	±	9	
mJ,	 14	 ±	 1	 %VE)	 occurred	 in	 TMV3	 in	 a	 24	 mm	 holder,	 and	 decreased	 as	 holder	 size	
increased	 although	 losses	 in	 a	 25	 mm	 were	 similar	 to	 a	 21	 mm	 with	 more	 variable	
performance	in	a	20	mm.	Similar	patterns	were	observed	for	ELs	across	all	COs,	as	well	as	
for	the	diastolic	and	leakage	ELs.	
The	diastolic	EL	increased	with	CO	(Appendix	E,	Figures	E.7	and	E.8).		
The	closing	EL	in	millijoules	did	not	vary	significantly	with	CO,	with	an	average	value	of	15	±	
4	mJ,	although	as	a	%VE	it	tended	to	decrease	as	CO	increased	(Appendix	E,	Figures	E.9	and	
E.10).		
In	general	 the	 leakage	EL	was	not	affected	by	CO,	with	an	average	value	of	123	±	47	mJ,	
however	as	a	%VE	it	tended	to	decrease	with	CO	(Appendix	E,	Figures	E.11	and	E.12).		
The	 total	 EL	 in	 millijoules	 tended	 to	 increase	 with	 CO	 however	 as	 a	 %VE	 it	 tended	 to	
remained	approximately	constant	(19	±	3	%VE)	(Appendix	E,	Figures	E.13	and	E.14).	
6.5.2 Regurgitation	tests	
6.5.2.1	Reverse	flows	
The	closing	volume	was	not	significantly	affected	by	heart	rate	(HR)	or	mean	back	pressure	
(MBP),	with	an	average	value	of	1.9	±	0.3	ml	(Appendix	E,	Figure	E.15).		
The	leakage	and	total	regurgitant	volumes	tended	to	decrease	as	heart	rate	increased	and	
was	higher	for	higher	MBPs,	with	total	minimum	value	for	TMV2	at	a	HR	of	120	bpm	and	
MBP	80	mmHg	(4.1	±	0.6	ml)	and	a	maximum	value	for	TMV3	at	a	HR	of	45	bpm	and	a	MBP	
of	160	mmHg	(57.8	±	1.0	ml)	(Appendix	E,	Figures	E.16	and	E.17).		
In	 general	 the	 RF	 was	 not	 affected	 by	 HR	 and	 tended	 to	 increase	 with	 MBP,	 with	 a	
maximum	 value	 for	 TMV3	 at	 a	 HR	 of	 120	 bpm	 and	MBP	 of	 160	mmHg	 (39	 ±	 1%)	 and	 a	
minimum	value	for	TMV2	at	a	HR	of	120	bpm	and	MBP	of	80	mmHg	(9	±	1%)	(Appendix	E,	
Figure	E.18).	
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6.5.2.2	Effective	orifice	area	
The	 EOA	 tended	 to	 decrease	 as	HR	 increased	 and	was	 not	 significantly	 affected	by	MBP,	
with	a	maximum	value	for	TMV3	at	a	HR	of	45	bpm	and	MBP	of	 	120	mmHg	(1.73	±	0.01	
cm2)	and	a	minimum	value	for	TMV2	at	a	HR	of	120	bpm	and	MBP	of	 	160	mmHg	(1.30	±	
0.03	cm2)	(Appendix	E,	Figure	E.19).	
6.5.2.3	Diastolic	energy	losses	
In	general	diastolic	EL	in	millijoules	decreased	as	HR	increased	and	tended	to	be	higher	for	
higher	MBPs,	with	a	maximum	value	for	TMV3	at	a	HR	of	45	bpm	and	MBP	of	160	mmHg	
(399	±	4	mJ)	and	a	minimum	value	for	TMV1	at	a	HR	of	120	bpm	and	MBP	of	160	mmHg	(70	
±	6	mJ)	(Appendix	E,	Figure	E.20).		
	
However,	as	a	%VE,	the	diastolic	EL	decreased	as	MBP	increased	with	a	maximum	value	for	
TMV3	at	a	HR	of	45	bpm	and	MBP	of	80	mmHg	(13.8	±	0.1	%VE)	and	a	minimum	value	for	
TMV1	at	a	HR	of	120	bpm	and	MBP	of	160	mmHg	(5.4	±	0.2	%VE)	(Appendix	E,	Figure	E.21).	
	
6.5.2.4	Closing	energy	losses	
In	general	closing	EL	increased	with	HR	and	for	HRs	of	70	and	120	bpm	also	increased	with	
MBP,	with	a	maximum	value	for	TMV3	at	a	HR	of	120	bpm	and	MBP	of	160	mmHg	(67	±	3	
mJ)	and	a	minimum	value	for	TMV3	at	a	HR	of	45	bpm	and	a	MBP	of	80	mmHg	(6.5	±	0.5	
mJ)	(Appendix	E,	Figure	E.22).		
The	 closing	EL	as	a	%VE	also	 increased	with	HR,	but	 there	was	no	 significant	 relationship	
with	MBP,	with	a	maximum	value	for	TMV1	at	a	HR	of	120	bpm	and	MBP	120	mmHg	(3.2	±	
0.3	%VE)	and	a	minimum	for	TMV3	at	a	HR	45	bpm	and	MBP	160	mmHg	(0.2	±	0.1	%VE)	
(Appendix	E,	Figure	E.23).	
6.5.2.5	Leakage	energy	losses	
In	general	leakage	energy	losses	decreased	as	HR	increased	and	increased	with	MBP,	with	a	
minimum	value	in	TMV2	at	a	HR	of	120	bpm	and	a	MBP	80	mmHg	(33	±	5	mJ,	4.7	±	0.6	%VE)	
and	a	maximum	for	TMV3	at	a	HR	of	45	bpm	and	a	MBP	160	mmHg	(1244	±	19	mJ,	28.4	±	
0.5	%VE)	(Appendix	E,	Figures	E.24	and	E.25).	
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6.5.2.6	Total	energy	loss	
The	 total	EL	decreased	as	HR	 increased	and	 tended	 to	 increase	as	MBP	 increased,	with	a	
minimum	value	for	TMV1	at	a	HR	of	120	bpm	and	a	MBP	of	80	mmHg	(124	±	23	mJ)	and	a	
maximum	 value	 for	 TMV3	 at	 a	 HR	 of	 45	 bpm	 and	 a	MBP	 of	 160	mmHg	 (1657	 ±	 17	mJ)	
(Appendix	E,	Figure	E.26).		
However,	in	general,	as	a	%VE	total	EL	was	not	significantly	affected	by	HR	or	MBP	with	an	
average	value	of	23	±	1	%VE	(Appendix	E,	Figure	E.27).	
6.6 Discussion	
In	 this	 section	 the	 functional	 performance	 of	 the	 UCL	 TMV	 prototypes	 are	 discussed	 in	
terms	 of	 their	 systolic,	 diastolic	 and	 global	 performance,	 anomalies	 and	 comparison	 to	
another	 TMV	 in	 terms	 of	 transmitral	 pressure	 difference	 and	 implantation	 range	 is	 also	
discussed.	 After	 this,	 the	 failure	modes	 and	 design	 flaws	 observed	 and	 their	 subsequent	
effect	on	test	parameters	are	explained.		
6.6.1 Functional	performance	
As	expected,	the	functional	performance	of	the	UCL	TMV	was	affected	by	annulus	size.	The	
TMV	anchored	securely	in	all	holder	sizes	20-25	mm	and	had	optimal	performance	in	a	24	
mm	 holder	 in	 terms	 of	 regurgitation	 fraction	 and	 effective	 orifice	 area	 (Figure	 6.5).	 On	
average	the	test	parameters	were	ten	times	more	variable	between	prototypes	than	across	
cardiac	 cycles,	 this	 is	 due	 to	 both	 the	 accuracy	 to	 which	 they	 were	 made	 as	 well	 as	
variability	in	placement	in	the	annuluses,	the	latter	being	the	main	cause	for	this	disparity	
being	larger	than	observed	in	the	SMVs,	discussed	in	more	detail	below.		
6.6.1.1	Systolic	performance	
The	 systolic	 performance	of	 the	UCL	 TMV	 is	 described	by	 the	RF,	which	 includes	 reverse	
flow	volumes	in	its	calculation,	and	the	leakage	energy	losses.		
The	prototypes	met	and	exceeded	the	minimum	performance	requirements	set	for	25	mm	
and	23	mm	devices34	 i.e.	RFs	≤	20%,	with	values	of	16	±	1.4%	and	9.5	±	1.2%	respectively	
(no	 requirements	 are	 set	 for	 annulus	 sizes	 20-22	mm).	 In	 fact,	 as	 previously	mentioned,	
																																								 																				
34	Minimum	performance	requirements	are	not	set	for	24	mm	devices.		
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despite	the	variability	of	performance	between	individual	valves	being	larger	than	between	
cardiac	 cycles,	 even	 the	 worst	 performing	 valves	 exceeded	 the	 standard;	 which	 were	
prototypes	one	and	three	when	in	holder	sizes	25	and	23	mm	respectively,	associated	with	
RFs	of	17.5	±	2.8%	and	10.9	±	0.5%	respectively.		However,	the	elderly	patients	in	whom	the	
device	 would	 initially	 be	 implanted	 tend	 to	 have	 lower	 resting	 COs	 of	 around	 3	 l/min	
(Brandfonbrener	et	al	1955)	and	so	 in	practice	 the	TMV	will	be	 functioning	at	suboptimal	
COs.	The	regurgitation	tests	demonstrated	that	the	RF	is	relatively	constant	for	mean	back	
pressures	(MBP)	80-160	mmHg	and	heart	rates	45-120	bpm	on	average	being	18	±	2%.			
The	leakage	energy	loss	as	a	percentage	of	ventricular	energy	follows	a	similar	pattern	to	RF	
and	therefore	 is	arguably	an	equally	good	measure	of	systolic	performance	with	values	of	
11.4	±	1.1	%VE	and	6.3	±	1.1	%VE	for	25	and	23	mm	holders	respectively.		
6.6.1.2	Diastolic	performance	
The	 diastolic	 performance	 of	 the	 TMV	 is	 described	 by	 EOA,	 mean	 transmitral	 diastolic	
pressure	difference	(MDPD),	and	diastolic	energy	losses.	
The	prototypes	exceeded	the	minimum	performance	requirements	set	 for	25	and	23	mm	
TMVs	i.e.	EOAs	≥	1.25	cm2	and	1.05	cm2	respectively,	with	values	of	1.8	±	0.2	cm2	and	1.5	±	
0.1	cm2	respectively	(no	requirements	are	set	for	annulus	sizes	20-22	mm).	
The	 diastolic	 performance	 is	 arguably	 best	 described	 by	 diastolic	 energy	 loss	 rather	 than	
MDPD	 because,	 although	 pressure	 difference	 during	 diastole	 quantifies	 resistance	 to	
forward	 flow,	 this	 pressure	 is	 not	 directly	 reflected	 in	 the	 peripheral	 circulatory	 system	
(unlike	 the	 ventricular	 pressure	 whilst	 the	 aortic	 valve	 is	 open),	 whereas	 the	 diastolic	
energy	loss	(mJ)	is	directly	related	to	how	much	energy	is	required	by	the	left	ventricle	and,	
therefore,	 is	of	more	clinical	relevance.	Furthermore,	the	apparent	advantageous	increase	
in	EOA	with	increased	CO	is	misleading;	the	diastolic	energy	loss	(%VE)	on	the	other	hand	
better	 represents	 true	 diastolic	 performance	 i.e.	 greater	 forward	 flow	 energy	 losses	 at	
higher	COs.	
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6.6.1.3	Global	performance	
The	 global	 performance	 of	 the	 UCL	 TMV	 is	 described	 by	 total	 energy	 losses	 and	 was	
minimum	for	the	24	mm	holder	for	COs	between	2	and	6	lpm	(Appendix	E,	Figures	E.13	and	
E.14).	The	total	energy	loss	was	relatively	constant	for	MBPs	80-160	mmHg	and	heart	rates	
45-120	bpm	on	average	being	23	±	1%VE,	measured	at	5	lpm	which,	as	would	be	expected,	
is	higher	than	the	15	±	1%VE	for	normal	healthy	pulsatile	flow	conditions.	
6.6.1.4	Anomalies	
The	majority	 of	 data	 plotted	 in	 section	 6.5	 is	 the	 average	 of	 three	 prototypes	 and	 their	
associated	standard	deviation.	However,	there	were	some	anomalies,	all	relating	to	TMV3	
in	 a	 21	mm	holder.	 These	particular	 data	points	were	 identified	because	 if	 included	 they	
caused	the	standard	deviation	for	the	three	prototypes	to	be	larger	than	the	average	value	
for	the	parameter	i.e.	the	standard	deviation	statistic	spanned	into	the	negative	regions	of	
energy	 loss	 and	 closing	 volume,	 which	 are	 nonsensical	 and	 so	 were	 removed.	 The	
anomalies	identified	were	as	follows.	
	
At	5	lpm	TMV3	had	an	abnormally	high	closing	energy	loss	of	73	mJ	(4.6	%VE)	compared	to	
14	and	10	mJ	(0.7	and	0.9	%VE)	for	TMV1	and	2	respectively	and	therefore	these	were	not	
included	(Appendix	E,	Figures	E.9	and	E.10).	For	similar	disparities	between	data	points	the	
closing	energy	losses	(mJ	and	%VE)	at	2	and	3	lpm	and	closing	volume	at	3	lpm	(Appendix	E,	
Figure	 E.2)	 and	 were	 also	 treated	 as	 anomalies	 and	 removed.	 All	 other	 data	 for	 TMV3,	
which	 also	 caused	 the	 three	 largest	 standard	 deviations	 between	 prototypes;	 for	 closing	
volumes	 in	21	mm	holders	at	2,	5	and	6	 lpm	(Appendix	E,	Figure	E.2),	were	not	 removed	
because	 although	 very	 large,	 the	 standard	 deviation	 statistic	 still	 spanned	 meaningful	
closing	volumes.	
	
These	elevated	closing	energy	losses	and	closing	volumes	are	most	likely	due	to	the	native	
leaflets	of	the	21	mm	holder	not	covering	the	TMV3	skirt	mesh	in	a	consistent	way	for	all	
COs	 (Figure	6.7)	and	therefore,	elevated	paravalvular	 leakage	occurred	 from	the	ventricle	
through	the	skirt	mesh	into	the	atrium	as	the	leaflets	closed.	The	greater	significance	of	this	
feature	 in	 TMV3	 compared	 to	 TMV2	 and	 1	 may	 have	 been	 exacerbated	 by	 the	 slightly	
thinner	sealing	cuff	and	its	assembly.	
	
	
	
	
173	
	
	
	
	
	
	
	
	
	
	
	
	
6.6.1.5	Comparisons	to	other	transcatheter	mitral	valves	
6.6.1.5.1	Functional	performance	
Pulse	duplicator	data	for	other	TMVs	have	not	been	published.	However,	due	to	inevitable	
differences	 in	 pulse	 duplicators	 and	 exact	 testing	 parameters	 used,	 direct	 comparison	
would	still	not	be	appropriate	(Simenauer	et	al	1987).	The	only	comparative	data	available	
is	for	the	Fortis	(Edwards)	TMV,	which	is	reported	to	achieve	a	mean	transmitral	pressure	
difference	 (MPD)	 of	 ≤	 4	 mmHg	 (Altisent	 et	 al	 2015);	 however,	 no	 other	 pulsatile	 flow	
conditions	were	 specified.	Therefore,	 comparison	with	 the	MPD	 for	 the	UCL	TMV	 in	a	24	
mm	holder	at,	for	example,	5	lpm	(6	±	1	mmHg),	is	limited,	although	they	do	appear	to	have	
the	same	order	of	magnitude.	
6.6.1.5.2	Implantation	range	
In	 terms	 of	 A2-P2	 diameter	 (orthogonal	 to	 the	 inter-trigonal	 diameter,	 Figure	 1.2),	 the	
proposed	TMV	is	a	20	mm	device	suitable	for	annuluses	between	15	and	19	mm,	which	is	
different	 to	 the	 29	 mm	 Fortis	 (Edwards)	 TMV	 which,	 due	 to	 its	 atrial	 flange,	 is	 only	
implanted	into	relatively	larger	native	valves,	between	30	and	44	mm	(Bapat	et	al	2014)	i.e.	
the	major	difference	being	that	the	UCL	TMV	requires	an	interference	fit	for	anchorage.	It	is	
predicted	 that	 a	 greater	 interference	 fit	 between	 the	 UCL	 TMV	 and	 annulus	 will	 have	 a	
greater	 effect	 on	 the	 native	 valve/leaflets	 potentially	 leading	 to	 greater	 damage	 and	
increased	risk	of	native	leaflets	occluding	the	left	ventricle	outflow	tract	(LVOT),	depending	
on	each	patients’	specific	anatomy.	
increased	skirt	
exposure	
skirt	exposed	
end	of	systole		
Figure	 6.7:	 Skirt	 of	 TMV3	 not	 covered	 by	 mock	 native	 leaflets	
associated	 with	 a	 21	 mm	 holder	 (left)	 exacerbated	 during	 systole	
(right)	on	bench	top.	
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The	 Fortis	 was	 suitable	 for	 aortic	 and	 mural	 leaflet	 lengths	 <	 23	 mm	 and	 >	 5	 mm	
respectively.	In	fact,	anatomical	criteria	for	the	left	atrium	minor	and	major	diameters,	left	
ventricle	 outflow	 tract	 width,	 aorta	 to	 device	 plane	 angle,	 left	 ventricular	 outflow	 tract	
clearance,	left	ventricle	diameter	at	papillary	muscle	plane	and	left	atrium	height	were	also	
specified.	The	UCL	TMV	performed	well	for	aortic,	mural	and	commissure	lengths	of	17-23	
mm,	9-12	mm,	and	9-13	mm	respectively.	These	lengths	were	associated	with	inter-trigonal	
holder	sizes	20-25	mm	and	the	24	mm	holder.	The	26	mm	TMV	performed	optimally	in	the	
24	 mm	 holder,	 which	 had	 aortic,	 mural	 and	 commissure	 lengths	 of	 22,	 11	 and	 12	 mm	
respectively.	The	commissure	length	of	the	UCL	TMV	was	of	critical	importance	in	reducing	
regurgitant	 flow.	 This	 was	 unlike	 the	 Fortis,	 which	 in	 fact	 is	 unsuitable	 for	 patients	 with	
predominantly	 commissural	 mitral	 regurgitation	 (Bapat	 et	 al	 2014).	 Therefore,	 the	
commissure	 length	 should	 be	 included	 in	 the	 echocardiography	 inclusion	 criteria	 for	 the	
UCL	 TMV,	which	would	 be	used	 to	 determine	patient	 suitability,	 discussed	 further	 in	 the	
following	section.	
6.6.2 Design	issues	
6.6.2.1	Interaction	between	sealing	cuff	and	mock	native	commissures	
The	main	source	of	regurgitant	flow	was	due	to	native	leaflets	not	covering	the	skirt	mesh	
(Figure	6.7),	or	there	being	a	gap	between	them.	In	the	first	instance	this	was	observed	as	
elevated	RF	and	total	regurgitant	volume	in	holder	sizes	20	and	21	mm	and	secondly	for	a	
25	mm	holder,	most	 notable	 at	 7	 lpm	 for	which	 they	were	 also	 elevated	 for	 the	 24	mm	
holder.		
	
Additional	reverse	flow	occasionally	occurred	due	to	the	sealing	cuff	being	pushed	towards	
the	 atrium	 during	 systole	 (Figure	 6.8),	 which	 occurred	 in	 TMV1,	 with	 a	 most	 notably	
elevated	RF	in	a	20	mm	holder	at	2	lpm	(35	±	1%)	compared	to	TMV2	and	3	(22	±	1%	and	19	
±	1%	respectively),	for	which	this	did	not	occur.	
	
6.6.2.2	Interaction	with	ventricle	
The	TMV	wireframe	contacted	the	ventricle	during	systole	for	TMV2	and	3	for	COs	of	5,	6	
and	7	lpm	for	all	holder	sizes	as	well	as	for	TMV1	for	all	COs	apart	from	2	lpm	(Figure	6.9).	
Considering	that	in	vivo	the	ventricle	sac	would	also	be	smaller	for	smaller	annulus	sizes	this	
problem	is	likely	to	be	more	severe	in	smaller	annuluses.		
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skirt	moved	inwards	
during	systole	
sealing	cuff	up	
during	systole	
sealing	cuff	down	
during	diastole	
Figure	 6.8:	 Dysfunction	 of	 sealing	 cuff	 in	 UCL	 transcatheter	 mitral	
valve	one,	in	a	25	mm	holder	at	5	lpm	(top)	atrial	view	(bottom):	left;	
ventricular	view	during	systole,	right;	ventricular	view	during	diastole.	
no	contact		
end	of	systole	2	lpm		
contact		
end	of	systole	7	lpm	
Figure	6.9:	 Interaction	between	 the	frame	of	TMV2	in	a	22	
mm		holder	and	ventricle	sac	at	the	end	of	systole	(left)	no	
contact	at	2	lpm	(right)	most	severe	contact	at	7	lpm.	
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6.7 Summary	
This	 chapter	 outlined	 the	main	 aim	of	 the	UCL	 TMVs,	 that	 is,	 to	 assess	 its	 potential	 as	 a	
treatment	option	for	high-risk	patients	with	severe	mitral	regurgitation.	The	design	of	the	
prototypes,	in	terms	of	their	leaflets,	wireframe,	sealing	cuff	and	skirt,	and	their	functional	
assessment	were	described.	The	results	were	presented	and	discussed	in	terms	of	both	the	
achievement	of	working	prototypes	and	the	design	issues	that	still	required	attention.	
The	 following	 chapter	 7	 further	 describes	 how	 and	 why	 the	 1st	 generation	 device	 was	
developed	 into	 a	 2nd	 generation	 device,	 for	 which	 preliminary	 results	 and	 discussion	 are	
provided.	
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Chapter	7 Transcatheter	mitral	valves	2nd	generation	
As	discussed	in	section	6.6.2	and	0	a	smaller	frame	for	the	UCL	TMV	was	developed.	In	this	
chapter,	the	new	wireframe	design	and	initial	results	of	the	functional	assessment	of	three	
prototypes	 are	 expounded	 and	 compared	 to	 the	 1st	 generation	 of	 UCL	 TMVs.	 (The	
functional	assessment	conducted	was	the	same	as	previously	described	in	Chapter	6).	
7.1 Design	
The	 aim	 of	 the	 new	 wireframe	 design	 (Figure	 7.1)	 was	 mainly	 to	 reduce	 interaction	
between	 the	 ventricle	 sac	 and	 frame	 during	 systole	 (Figure	 6.9)	 and	 also	 has	 the	 added	
benefit	 that	 if	 a	 transseptal	 version	 is	 designed	 it	 would	 reduce	 vascular	 damage	 during	
implantation.	 This	 was	 achieved	 by	 making	 the	 petal	 shaped	 hoops	 smaller	 (Figure	 6.1	
compared	to	Figure	7.1).	
	
	
	
	
	
	
	
	
	
	
left	atrium	
left	ventricle	
view	from	atrium	
petal	shaped	hoop	
Figure	 7.1:	2nd	 generation	 nitinol	 wireframe	 for	 the	 UCL	 transcatheter	 mitral	
valve	 with	 reduced	 size	 of	 petal	 shaped	 hoops,	 (top	 left)	 view	 from	 atrium,	
(bottom	left)	side	view,	(bottom	right)	front	view	(top	right)	perspective	view.	
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The	2nd	generation	UCL	TMV	houses	the	same	sized	leaflets,	and	so	is	the	same	size	device.	
However,	 the	 2nd	 generation	 frame	 is	 shorter	 than	 the	 first;	 its	 deployed	 and	 crimped	
lengths	 being	 33	 and	 45	 mm,	 which	 are	 7	 and	 8	 mm	 shorter	 than	 the	 1st	 generation	
respectively	 (Bozkurt	 et	 al	 2016).	 Thus	making	 potential	 vascular	 damage	 caused	 by	 the	
length	of	the	2nd	generation	UCL	TMV	frame	less	compared	to	the	1st	as	well	as	compared	
to	the	much	longer	CoreValve,	which	has	a	deployed	height	of	50-53	mm	(Table	1.1).	
7.2 Preliminary	results	and	discussion	
In	this	section	the	results	for	a	cardiac	output	of	5	lpm	are	presented	and	discussed.	
7.2.1 Effective	orifice	area	
The	 2nd	 generation	 UCL	 TMV	 still	 met	 and	 exceeded	 the	 ISO	 requirements	 for	 effective	
orifice	area	(EOA)	(Figure	7.2).	However,	on	average	it	had	a	smaller	EOA	compared	to	the	
first	generation	and	overall	there	were	similar	standard	deviations	between	prototypes.	For	
example,	for	the	24	mm	holder,	the	EOA	for	the	1st	generation	was	1.61	±	0.18	cm2	and	for	
the	2nd	generation	it	was	only	1.32	±	0.14	cm2.	
7.2.2 Regurgitant	fraction	
The	2nd	generation	UCL	TMV	still	met	and	exceeded	 the	 ISO	requirements	 for	 regurgitant	
fraction	 (RF)	 (Figure	 7.2).	 However,	 on	 average	 it	 had	 larger	 RFs	 compared	 to	 the	 1st	
generation	and	overall	there	was	a	smaller	standard	deviation	between	the	2nd	generation	
prototypes.	For	example,	for	the	24	mm	holder	at	a	cardiac	output	of	5lpm,	the	RF	for	the	
Figure	7.2:	(left)	effective	orifice	area	(right)	regurgitation	fraction;	for	two	generations	of	the	UCL	
transcatheter	mitral	valve,	both	averages	and	standard	deviations	are	for	three	prototypes.	
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1st	generation	was	9.1	±	0.8%	and	for	the	2nd	generation	it	was	11.7	±	1.4%.	
7.3 Summary	
This	 chapter	 demonstrated	 that	 the	 2nd	 generation	 wireframe	 design	 for	 the	 UCL	 TMV	
achieved	its	aim	to	reduce	interaction	between	the	ventricle	sac	and	frame	during	systole,	
as	determined	from	visual	observations.	The	new	design	also	had	the	added	benefit	that	if	
a	transseptal	version	were	designed	it	would	reduce	vascular	damage	during	implantation	
and	still	meet	the	Internal	Standard	requirements	(ISO	5840-3:2013).	However,	in	terms	of	
EOA	 and	 RF	 its	 performance	 was	 surpassed	 by	 the	 first	 generation.	 Although	 its	
performance	could	foreseeably	improve	as	assembly	methods	are	refined.	
The	following	chapter,	discusses	the	limitations	of	the	work	and	future	work.	This	includes	a	
discussion	of	materials,	leaflet	design,	prototyping,	in	vitro	assessment	as	well	as	the	future	
delivery	system	for	the	UCL	TMV.	 	
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Chapter	8 	Conclusions	&	Recommendations	for	Future	Work	
The	 aim	 of	 this	 project	 was	 to	 develop	 a	 proof	 of	 concept	 prototype	 of	 the	 UCL	
transcatheter	mitral	valve	 (TMV)	by	completing	an	 initial	design	cycle	consisting	of	design	
(Chapter	 3	 and	 4),	 prototyping	 and	 testing	 (Chapters	 6	 and	 7).	 This	 aim	 was	 achieved	
demonstrating	 both	 promising	 hydrodynamic	 performance	 (section	 6.6.1)	 and	 durability	
(Chapters	6	and	7).	 In	 fact	 the	 in	vitro	 results	 for	 the	proof	of	concept	1st	generation	UCL	
TMV	prototypes	(Chapter	6)	have	already	been	utilised	in	the	2nd	design	cycle	(Chapter	7),	
analysis	for	which	is	ongoing.	
This	final	chapter	discusses	the	main	findings,	limitations	and	recommendations	for	future	
work,	 including	 a	 discussion	 of	 the	 materials,	 leaflet	 design,	 prototyping	 and	 in	 vitro	
assessment.		
8.1 Main	findings	
Conclusions	in	this	section	are	discussed	in	the	context	of	background	information	provided	
in	3,	as	well	as	other	major	concepts	and	recent	developments,	and	advances	made	in	the	
study	 of	 various	 subject	 areas.	 Areas	 of	 original	 contribution	 are	 highlighted	 and	 where	
broad	conclusions	support,	add	to	or	conflict	with	previous	work	are	indicated.		
The	following	sections	8.1.1	and	8.1.2	discuss	the	main	contributions	to	the	following	areas	
of	research:	
• Nature-inspired	conical	leaflet	design	(Chapter	1,	Figure	1.5,	section	1.4.4)	
• Thermomechanical	properties	of	pericardium	(Chapter	3,	section	3.1.2.1)	
• Design	and	making	of	mock	native	mitral	valves	(Chapter	5,	section	5.1)	
• Proof	of	concept	and	effective	adaptation	of	the	TAV	frame	for	the	UCL	TMV,	
including	optimal	implantation	site	size	and	surpassing	ISO	5840-3:2013	minimum	
performance	requirements	(Chapter	6,	section	6.6)	
8.1.1 Design		
The	 two	 leafleted	 UCL	 TMV	 is	 a	 viable	 alternative	 to	 transcatheter	 repair	 techniques	
(section	1.4.1)	for	treating	mitral	regurgitation	(Figure	1.8)	in	high-risk	patients	and	due	to	
its	 geometric	 similarity	 to	 the	 human	mitral	 valve	 (Figure	 1.1	 and	 1.3),	may	 prove	more	
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appropriate	compared	to	circular	TMVs	in	development	(Table	2.1),	minimising	disturbance	
to	 natural	 kinetics	 of	 native	mitral	 apparatus	 (Figure	 1.7)	 and	 possibly	 resulting	 in	more	
natural	 pressures	 and	 flows	 (Figure	 1.4	 and	 1.9),	 thereby	 significantly	 advancing	 their	
development.	 Furthermore,	 there	 are	 only	 three	 other	 devices,	 the	 AccuFit,	 Direct	 Flow	
Mitral	and	Tresillo	(Figure	2.8)	which,	like	the	UCL	TMV,	are	retrievable	and	repositionable,	
features	which	were	inherited	for	their	success	in	the	UCL	TAV	wireframe	(section	1.4.3).	
A	 novel	 design	 strategy,	 using	 a	 failure	 mode	 and	 effects	 analysis,	 was	 used	 to	 select	
optimal	 leaflets	 for	 the	 UCL	 TMV,	 which	 supports	 the	 approach	 suggested	 in	 ISO	 5840-
3:2013,	 this	 led	 to	 addition	 of	 conicity	 to	 the	 parametric	 leaflet	 design,	which	 as	well	 as	
design	of	the	sealing	cuff	and	selection	of	skirt	material,	was	an	original	contribution	to	the	
initial	design	(section	1.4.4).	In	fact,	the	methods	used	to	characterise	the	skirt	mesh	were	
also	novel	and	could	enable	a	more	advanced	study	of	mesh	structures	for	other	biological	
purposes.		
In	 terms	 of	 the	 experimental	 design	 there	were	 two	major	 original	 contributions.	 Firstly,	
investigation	 into	 thermo-mechanical	 properties	 of	 pericardium	was	 the	 first	 justification	
for	 in	 vitro	 testing	 of	 bioprosthetic	 heart	 valves	 at	 room	 temperature.	 In	 fact,	 the	
constitutive	equation	derived	to	show	this	improved	on	the	accuracy	achieved	by	previous	
equations	used	to	describe	the	behaviour	of	pericardium.	Secondly,	design	and	methods	for	
making	mock	native	mitral	valve	implantation	sites	were	an	effective	novel	development	in	
in	 vitro	 assessment	 of	 TMVs,	 for	 which	 no	 experimental	 equipment	 has	 previously	 been	
suggested.	
8.1.2 Functional	performance	
For	 the	 first	 time,	 hydrodynamic	 functional	 performance	 data	 for	 a	 TMV,	 using	
internationally	 recognised	pulsatile	 flow	 conditions	 are	 reported.	 The	proposed	TMV	was	
shown	to	exceed	minimum	performance	requirements	set	for	nominal	diameters	of	23	and	
25	 mm	 (ISO	 5840-3:2013)	 i.e.	 effective	 orifice	 areas	 (EOAs)	 ≥	 1.05	 and	 1.25	 cm2	 and	
regurgitation	fractions	(RFs)	≤	20%.	It	performed	optimally	 in	a	24	mm	mock	native	mitral	
valve	holder,	with	minimum	total	energy	loss	of	14.7	±	1.6%	of	ventricular	energy,	an	EOA	
of	1.61	±	0.18	cm2	and	a	RF	of	9.1	±	0.8%	(here,	the	average	values	are	for	a	cardiac	output	
of	 5	 lpm	and	 the	 standard	 deviations	 are,	 in	worse	 cases,	 between	 three	 prototypes).	 In	
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other	words,	 it	 achieved	an	EOA	41%	greater	and	a	RF	55%	 less	 than	 required.	 	 These	 in	
vitro	 assessments	 support	 previous	 research	 (section	 2.2.4)	 which	 indicates	 TMVs	 can	
achieve	 good	 anchoring	 in	 a	 mitral	 orifice	 and	 have	 healthy	 diastolic	 and	 systolic	
performance.	 For	 the	 UCL	 TMV,	 regurgitation	 prevention	 using	 a	 sealing	 cuff	 was	
paramount	 to	 its	 good	 performance.	 The	 tests	 demonstrated	 the	 effective	 adaptation	 of	
the	UCL	TAV	frame	for	the	mitral	position	and	that	 its	functional	performance	was	largely	
determined	 by	 native	 leaflet	 geometry,	 highlighting	 that	more	 complex	 sizing	 algorithms	
are	required	for	TMVs	compared	to	TAVs	and	will	be	different	for	different	TMV	designs.	
8.1.3 Summary	of	main	achievements	
To	summarise,	 to	address	a	currently	untreated	patient	population	of	elderly	people	with	
severe	mitral	regurgitation	a	proof	of	concept	for	a	26	mm	UCL	transcatheter	mitral	valve	
has	 been	 provided	 which	 exceeds	 international	 standards	 and	 would	 foreseeably	 be	
suitable	for	patients	with	annulus	sizes	between	20	and	25	mm	and	to	date	has	achieved	in	
vitro	 durability	 up	 to	 two	 years.	 Furthermore,	 the	 in	 vitro	 results	 indicated	 design	
improvements	 required,	 which	were	 implemented	 in	 the	 2nd	 generation	 UCL	 TMV	which	
still	meets	 the	 international	 standards.	 In	 addition,	 the	 following	 three	 papers	 and	 three	
conferences	resulted	from	the	research:	
• Preston-Maher	GL,	Torii	R	and	Burriesci	G.	A	technical	review	of	minimally	invasive	
mitral	valve	replacements.	Cardiovascular	Engineering	and	Technology.	6(2):174-
184.	Jun	2015.	URL:	http://dx.doi.org/10.1007/s13239-014-0203-9.	(Chapter	2,	
section	2.4).	
• Sturla	F,	Ronzoni	M,	Vitali	M,	Dimasi	A,	Vismara	R,	Preston-Maher	G,	Burriesci	G,	
Votta	E	and	Redaelli	A.	Impact	of	different	aortic	valve	calcification	patterns	on	
the	outcome	of	transcatheter	aortic	valve	implantation:	a	finite	element	study.	
Journal	of	Biomechanics.	49(12):2520-2530,	Aug	2016.	URL:	
http://dx.doi.org/10.1016/	j.jbiomech.2016.03.036.	(Chapter	3,	section	3.1.2).		
• Bozkurt	S,	Preston-Maher	GL,	Torii	R	and	Burriesci	G.	Design,	analysis	and	testing	
of	a	novel	mitral	valve	for	transcatheter	implantation.	Annals	of	Biomedical	
Engineering.	Mar	2017.	URL:	http://dx.doi.org/10.1007/s10439-017-1828-2.	
(Chapter	6).	
• Preston-Maher	G,	Bozkurt	S,	Rahmani	B,	Torii	R,	Mullen	M	and	Burriesci	G.	
Development	and	hydrodynamic	assessment	of	a	novel	transcatheter	mitral	
valve.	European	Society	for	Vascular	Surgery	Spring	Meeting,	London,	UK,	13	May	
2016	–	14	May	2016.	14	May	2016.	(Chapter	6).	
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• Bozkurt	S,	Preston-Maher	G,	Torii	R	and	Burriesci	G.	A	novel	mitral	valve	for	
transcatheter	implantation.	European	Society	of	Biomechanics	Conference,	Lyon,	
France,	10	Jul	2016	–	13	Jul	2016.	10	Jul	2016.	(Chapter	6).	
• Bozkurt	S,	Preston-Maher	GL,	Rahmani	B,	Torii	R,	Burriesci	G.	Design,	Analysis	and	
Hydrodynamic	Assessment	of	a	Novel	Transcatheter	Mitral	Valve.	28th	
Conference	of	the	International	Society	for	Medical	Innovation	and	Technology,	
Delft,	Netherland,	5-8	Oct	2016.	7	Oct	2016.	(Chapter	6).	
8.2 Limitations	and	recommendations	for	future	work	
8.2.1 Materials	
8.2.1.1	Pericardium	
The	main	limitation	of	using	pericardium	tissue	in	bioprosthetic	heart	valves	is	its	durability	
and	 in	 the	 case	 of	 transcatheter	 valves	maybe	 affected	 by	 crimping	 inside	 a	 catheter	 for	
delivery.	More	 specifically,	 crimping	 duration	 is	 correlated	with	 structural	 changes	which	
maybe	of	 clinical	 significance	 and	 therefore	 the	duration	 and	 severity	 of	 crimping	 should	
ideally	 be	 minimised	 (Kiefer	 et	 al	 2011).	 However,	 Kiefer	 et	 al	 (2011)	 did	 not	 study	 the	
influence	 of	 temperature	 at	 which	 the	 leaflets	 are	 crimped,	 therefore	 a	 further	 thermo-
mechanical	study	of	pericardium	is	required	to	determine	the	effect	of	crimping	pericardial	
leaflets	at	4	 oC,	and	of	particular	 relevance	 for	 retrievable	devices,	 the	effect	of	 repeated	
crimping	and	unfolding	at	37	oC.		
The	 UCL	 Cardiovascular	 Engineering	 Group	 is	 currently	 investigating	 two	 alternatives	 to	
pericardial	 leaflets;	 genetically	modified	 sources	 and	nanocomposite	polymers.	 The	 latter	
has	 shown	promising	 results	 for	 the	UCL	 TAV	 (Rahmani	 et	 al	 2013,	 Rahmani	 et	 al	 2012),	
achieving	more	than	400	million	cardiac	cycles	in	vitro	and	could	foreseeably	be	applied	to	
the	UCL	TMV.	Most	recently,	a	simpler	approach	was	taken	by	Anssari-Benam	et	al	(2016),	
whom	 simply	 addressed	 the	 durability	 issue	 by	 suggesting	 an	 alternative	 chemical	
treatment.	
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8.2.1.2	Polyester	mesh	
The	current	polyester	mesh	used	for	the	UCL	TMV	skirt	is	sufficient	for	in	vitro	assessments.	
However	further	investigation	is	required	to	select	a	mesh	structure	that	will	be	optimal	in	
terms	of	tissue	ingrowth,	whilst	still	achieving	the	required	extensibility.	
8.2.1.3	Nitinol	wire	
The	UCL	TMV,	 like	most	other	TMVs	 in	development	 (Table	2.1),	has	nitinol	 components.	
Unfortunately,	 this	will	 limit	 the	number	of	patients	 suitable	 for	 the	devices	due	 to	some	
having	hypersensitivity	to	the	nickel	content	of	nitinol	which	occurs	 in	approximately	15%	
of	the	population	(Marks	Jr.	et	al	2003),	research	into	how	to	mitigate	this	is	required.	
8.2.2 Leaflet	design	using	finite	element	analyses	
All	 finite	 element	models	 have	 a	 certain	 amount	 of	 unavoidable	 uncertainty	 due	 to	 their	
narrow	 depiction	 of	 reality	 partly	 due	 to	 omission	 of	 natural	 variability	 in	 mechanical	
properties	of	materials.	Similarly,	despite	quality	measures	in	place,	there	will	be	variations	
between	mechanical	properties	in	bioprosthetic	heart	valve	leaflets.	
In	 fact,	pericardium	tissue	has	an	 innate	range	of	maximum	tensile	strengths	and	general	
tensile	behaviour;	mean	tensile	stress	at	rupture	for	porcine	pericardium	was	reported	to	
range	between	2	 and	 20	MPa	 (Paez	 et	 al	 2003,	 Zioupos	 et	 al	 Apr	 1994)	 and	 the	 Young’s	
Modulus	of	decellularized	bovine	pericardium	was	reported	(even	though	it	has	a	nonlinear	
relationship	between	strain	and	stress)	to	range	between	60	and	100	MPa	(Hulsmann	et	al	
2012).	 Variability	 also	 occurs	 due	 to	 manufacturing	 methods,	 including	 variation	 in	
geometry	 of	 these	 handmade	 devices,	 operating	 environment	 and	 subsequent	 loading	
conditions.	 Therefore,	 the	 exact	 leaflet	 shape	 observable	 in	 vitro	 will	 differ	 from	 those	
predicted	by	 FEA	and	 subsequently	 so	will	 predicted	 stress	distributions.	Despite	 this	 the	
FEAs	of	the	bioprosthetic	heart	valve	 leaflets	provided	a	useful	prediction	of	their	general	
ability	 to	 close,	 occlude	 the	 orifice	 and	 stress	 states	 are	 meaningful	 as	 an	 order	 of	
magnitude	approximation.	Furthermore,	the	simulations	correctly	predicted	the	curvature	
of	the	fully	closed	leaflets	being	towards	the	mural	leaflet	in	the	case	of	the	transcatheter	
mitral	valve	prototype	(Figure	4.14).		
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The	boundary	 conditions	 for	 diseased	native	mitral	 valves	 and	 surrounding	 anatomy	 into	
which	the	TMV	would	be	implanted	i.e.	their	structure,	material	properties	and	forces	they	
exert,	 were	 not	 modelled	 because,	 in	 general,	 their	 high	 complexity	 and	 variability	
throughout	 the	 cardiac	 cycle	 have	not	 been	quantified.	 In	 fact,	 exact	 values	 for	 forces	 in	
native	 mitral	 valves	 have	 only	 recently	 been	 recorded	 (Askov	 et	 al	 2013)	 and	 although	
predictions	 for	 patient	 specific	 configuration	 of	 transcatheter	 aortic	 valves	 has	 recently	
been	 investigated	 (Bailey	et	al	2016,	Capelli	et	al	2012)	a	patient	 specific	approach	 is	not	
appropriate	when	designing	one	device	 for	a	whole	patient	population.	 Instead	boundary	
conditions	 were	 applied	 to	 the	 leaflets	 in	 their	 manufactured	 configuration,	 which	 still	
predicted	 the	 order	 of	 magnitude	 of	 the	 maximum	 principal	 stress	 (MPS),	 as	 recently	
expounded	by	Abbasi	et	al	(2015)	who	reported	that	although	the	MPS	for	the	SAPIEN	TAV	
leaflets	varies	non-linearly	with	its	expanded	diameter,	 it	remained	within	the	same	order	
of	magnitude	 as	 1	MPa.	 Also,	 simulating	 the	 leaflets	 in	 their	manufactured	 configuration	
would	still	provide	comparative	values	for	coaptation	areas.	Furthermore,	the	native	mitral	
valve	 boundary	 conditions	 may	 be	 subject	 to	 change	 once	 the	 proposed	 device	 is	
implanted.	For	example,	the	once	reduced	left	ventricular	systolic	torsion,	associated	with	
mitral	regurgitation	(Ennis	et	al	2009),	may	increase	as	the	ventricle	re-models.		
The	absence	of	the	frame35	is	a	limitation	of	the	simulations,	causing	an	over	estimation	of	
the	 stresses	 that	will	occur	due	 to	 the	additional	 rigidity	of	 the	boundary	conditions.	 It	 is	
also	limited	because	the	simulations	do	not	predict	the	opening	and	closing	dynamics.	
	
The	 shell	 elements	 used	were	 limited	 in	 that	 they	 could	 not	 represent	 shear,	 a	 possible	
alternative	 would	 be	 membrane	 or	 brick	 elements.	 However,	 the	 former	 were	 not	
appropriate	for	modelling	the	heart	valve	leaflets	because	they	do	not	account	for	bending	
and	the	latter	were	unsuitable	because	five	brick	elements	would	be	required	to	have	five	
integration	 points	 through	 the	 thickness	 of	 the	 pericardium	 tissue	 (as	 done	 in	 the	 shell	
elements	for	representation	of	out-of-plane	stresses);	this	would	quintuplet	the	number	of	
elements	 introducing	bricks	with	a	very	 small	dimension,	 the	 latter	being	associated	with	
very	small	time	steps	and	subsequently	long	analysis	times	(Burriesci	et	al	1999).	
	
																																								 																				
35	Modelling	the	frame	was	beyond	the	scope	of	this	project.		
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The	 structural	 models	 were	 inherently	 limited	 in	 their	 ability	 to	 represent	 the	 physics	
involved	in	heart	valve	leaflet	closure,	which	treated	the	geometry	and	pressure	difference	
as	 inputs	 and	 resulting	morphology	 and	 stress	 states	 as	outputs.	 In	 reality,	 the	physics	 is	
different;	the	working	fluid	interacts	with	the	valve	geometry	and	pressure	differences	are	
what	 result.	 Therefore,	 ideally	 pressure	 difference	 should	 be	 an	 output	 rather	 than	 an	
imposed	boundary	condition,	which	could	be	achieved	by	modelling	a	body	of	fluid	moving	
in	a	closed	system.		
A	structural	model	may	also	be	surpassed	by	a	fluid	structure	interaction	(FSI)	model	in	its	
ability	 to	 simulate	 the	 formation	of	 vortices	 (Lau	et	 al	 2010);	 however	 the	 shear	 stresses	
induced	 on	 the	 leaflet	 surface	 by	 fluid	 flow	 are	 an	 order	 of	 magnitude	 less	 than	 shear	
stresses	 generated	 due	 to	 structural	 deformation.	 Therefore,	 pressure	 difference	 is	
considered	to	be	the	principal	 load	causing	leaflet	deformation	and,	despite	ignoring	local	
pressure	variation	and	 fluid	shear	 stresses	due	 to	blood	 flow,	a	 time-dependent,	 spatially	
uniform	pressure	 distribution	 across	 the	 leaflet	 surface,	 should	 yield	 reasonably	 accurate	
results	 (Chandran	 2010).	 Omission	 of	 the	 ventricular	 vortex	 generated	 behind	 the	 aortic	
leaflet	 (Charonko	et	al	2013)	 is	a	 likely	explanation	for	why	the	model	predicted	opposite	
curvature	 of	 the	 closed	 leaflets	 in	 the	 case	 of	 the	 surgical	 mitral	 valve,	 which	 curved	
convexly	towards	the	aortic	leaflet	rather	than	concaved	(Figure	4.14).	
Furthermore,	 leaflet	 closure	duration	 in	 silico	and	 in	vitro	were	not	expected	 to	correlate	
either	because	it	was	previously	demonstrated	that	due	to	lack	of	fluid	inertia,	a	structural	
simulation	of	mitral	leaflets	will	close	approximately	16	times	faster	and	take	twice	as	long	
to	 open	 compared	 to	 experimental	 results,	 the	 latter	 being	 400	 and	 40	 ms	 respectively	
(Burriesci	et	al	1999).	Nevertheless,	 the	structural	model	did	not	entirely	 fail	 to	represent	
the	presence	of	a	 fluid;	 firstly,	 contact	between	 leaflets	was	modelled	as	 frictionless	and,	
secondly,	 the	 role	of	 inertia	 in	 reducing	oscillations	was	 represented	by	multiplying	node	
velocities	by	a	damping	coefficient	of	0.9965,	previously	used	successfully	by	Burriesci	et	al	
(1999).		
It	is	unlikely	that	numerical	simulations	would	be	able	to	predict	a	maximum	leaflet	length.	
More	specifically,	they	fail	to	replicate	the	point	at	which	further	increase	in	leaflet	length,	
and	therefore	also	 in	their	coaptation	area,	will	 result	 in	a	reduction	of	pressure	between	
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them.	Once	this	pressure	reaches	zero,	any	further	increase	in	length	would	in	fact	actively	
separate	the	leaflets	(Figure	8.1)	reducing	the	coaptation	area.	
8.2.3 Haemodynamic	assessment	of	valve	leaflets	
8.2.3.1	Software	
The	 current	 ViViTest	 software	 does	 not	 calculate	 pressure-volume	 diagrams	 (Figure	 1.9)	
automatically;	 manual	 processing	 of	 data	 is	 required.	 However,	 previous	 research	 has	
shown	 that	 altering	 the	 pressure-volume	 relationship	 directly	 is	 possible	 and	 useful	 for	
simulating	both	healthy	and	disease	sates	(Yokoyama	et	al	2010).	
	
8.2.3.1.1	Mitral	valve	implantation	sites	
The	mock	native	mitral	valve	implantation	sites	successfully	assessed	effect	of	annulus	size	
on	the	functional	performance	of	the	UCL	TMV.	However,	clinical	relevance	of	the	data	 is	
limited	because	the	highly	likely	corresponding	change	in	size	of	the	patients’	ventricle	was	
not	 represented;	 the	 same	 standard	 ventricle	 sac	was	 used	 for	 all	 annulus	 sizes.	 Ideally,	
ventricles	 with	 a	 smaller	 volume	would	 be	 used	 for	 the	 smaller	 geometric	 orifice	 areas;	
scaled	according	to	averaged	native	morphological	findings	(not	published	to	date).		
8.2.4 Bileaflet	surgical	mitral	valve	
This	section	discusses	the	future	work	for	the	bileaflet	surgical	mitral	valve	and	adaptations	
to	 the	 pulse	 duplicator	 required	 to	 obtain	 flow	 visualisation	 data	 using	 particle	 image	
velocimetry	(PIV).	
The	 novel	 bileaflet	 surgical	 mitral	 valve	 (SMV)	 met	 the	 minimum	 performance	
requirements	 (section	 5.4)	 and	 therefore,	 following	 durability	 assessment	 as	 per	 the	
requirements	and	protocol	outlined	in	section	0,	could	eventually	proceed	to	animal	trials.	
If	 this	were	 the	 case	 then	 the	 flange,	designed	 specifically	 for	 in	 vitro	 assessment,	would	
have	to	be	converted	to	a	suture	ring,	similar	to	that	used	for	the	Pericarbon	MORE	Mitral	
(Figure	1.10)	and	biocompatible	materials	for	the	stent	and	thread	would	be	required.	
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8.2.4.1	Flow	visualisation	
The	 functional	 assessment	of	 the	 SMVs	 showed	 they	 can	 replicate	healthy	pressures	 and	
flows	and	qualitative	macro-scale	features	of	the	latter	were	viewed	experimentally	(Figure	
5.31Figure	5.32).	Further	work	is	required	to	determine	the	quantitative	micro-scale36	fluid	
mechanics.	 For	 example,	 instantaneous	 velocity	 measurements	 would	 be	 essential	 for	
assessing	 the	 hemolytic37	 and	 thrombogenic38	 potential	 of	 prosthetic	 heart	 valves	 (ISO	
14708,	Adrian	1991).	 In	the	case	of	the	SMVs	presented	 in	this	thesis,	more	detailed	flow	
visualisation	would	be	essential	 for	 investigating	the	effect	of	conicity	on	flow	separation,	
which	 according	 to	 Akins	 et	 al	 (2008)	 is	 heavily	 dependent	 on	 the	 ratio	 of	 the	 cross-
sectional	area	from	a	smaller	to	larger	vessel.	
8.2.4.2	Particle	image	velocimetry		
Particle	image	velocimetry	(PIV)	has	previously	been	used	to	compare	the	ventricular	flow	
associated	 with	 different	 mechanical	 mitral	 valve	 designs	 (Querzoli	 et	 al	 2010).	 In	 PIV	
velocity	 data	 for	 a	 fluid	 is	 obtained	 by	 seeding	 it	 with	 tracer	 particles	 which	 can	 be	
illuminated	 using	 a	 laser.	 The	 displacement	 patterns	 of	 the	 particles	 are	 observed	 using	
video	footage	from	a	high	speed	camera,	which	 is	combined	with	the	time	between	 laser	
pulses	 to	 provide	 velocity	 data.	 This	 enables	 the	 quantification	 of	 stagnation	 zones	 as	
regions	with	 low	velocity	and	 long	residence	times	(Toninato	et	al	2016),	which	“promote	
the	formation	of	thrombi	and	concur	to	the	development	of	lesions	of	embolic	origin	”	in	a	
TAV	 device,	 and	 which	 in	 general	 occur	 more	 frequently	 in	 transcatheter	 replacements	
compared	to	surgical	(Ducci	et	al	2013).	
Optical	distortions,	observable	using	calibration	grids	(Barannyk	et	al	2015),	will	occur	if	the	
index	of	refraction	(IR)	of	the	materials	through	which	the	laser	sheet	passes	do	not	match.	
For	the	current	pulse	duplicator	(section	5.1),	there	are	two	materials,	the	acrylic	housing	
and	 silicon	 ventricle	 sac,	 and	 two	 fluids,	 the	 distilled	 water	 outside	 the	 ventricle	 and	
buffered	saline	inside	the	ventricle,	which	should	ideally	have	identical	indices	of	refraction	
(Figure	8.2).		
																																								 																				
36	Opossed	to	the		attempted	macro-scale	observation.	
37	Red	blood	cell	damage.	
38	Formation	of	blood	clots	which	cause	blockages	and	damage	surrounding	tissue.	
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In	 general	 there	are	algorithms	 to	account	 for	optical	distortions;	however	 these	will	 not	
work	well	with	the	spherical,	cylindrical	and	highly	nonlinear	deformations	of	the	ventricle,	
which	occur	under	typical	operating	conditions	as	it	expands	and	contracts	in	less	than	one	
second	for	a	complete	cardiac	cycle.		
	
	
	
	
	
	
RI	 matching	 has	 previously	 been	 achieved	 by	 replacing	 the	 fluid	 in	 the	 ventricle	 with	 a	
mixture	 of	 deionized	 water	 (water	 with	 almost	 all	 of	 its	 mineral	 ions	 removed),	 viscous	
sugar	alcohol	(glycerin)	and	salt	(sodium	iodide	(NaI),	Barannyk	et	al	2015).	However,	NaI	is	
not	 compatible	 with	 pericardium	 soft	 tissue	 and	 if	 used	 outside	 the	 ventricle	 its	 highly	
corrosive	properties	would	damage	the	piston	seal	and	viscoelastic	impedance	adapter.	In	
fact,	according	to	the	manufactures	manual	the	area	outside	the	ventricle	should	only	ever	
be	filled	with	distilled	water;	any	other	fluid	may	cause	damage.	The	ventricle	sac	could	be	
replaced	with	one	made	from	silicone	that	has	the	same	RI	as	the	housing	stock	acrylic	or	
vice	versa.	Either	way,	 the	RI	of	all	 four	materials	must	match	and	appropriate	 fluids	and	
materials	 compatible	 with	 the	 machine	 parts	 and	 pericardial	 valves39	 remain	 undefined	
therefore	conducting	PIV	would	 require	 the	design	and	making	of	a	new	pulse	duplicator	
system	that	also	ideally	includes	clear	visual	access	to	the	ventricle	from	numerous	angles,	
similar	to	the	rectangular	tank	set-up	used	by	Falahatpisheh	et	al	(2012).	
	 	
																																								 																				
39	Fluorecent	dyes	could	theoretically	be	used	with	lasers	(or	seeding	particles)	despite	not	achieving	
RI	 matching,	 and	 would	 still	 give	 a	 better	 visualisation.	 However,	 they	 are	 not	 compatible	 with	
pericardium	and	so	were	not	used.	
housing	
acrylic	
RI	=	1.48	
ventricle	sac	
silicon	
RI	>	1.48	
outside	ventricle	
distilled	water	
RI	=	1.33	
piston	
inside	ventricle	
buffered	saline	
RI	=	1.332	
pericardium	
	
particle	laser	
sheet	
Figure	 8.1:	 Refractive	 index	 (RI)	 matching	 problem	 for	 the	 current	 pulse	 duplicator,	
indicating	the	parts	the	fluids	contact.	
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8.2.4.3	Clinical	relevance	
The	analysis	of	blood	 flow	dynamics	 is	 common	 in	 laboratories	and	 is	only	 recently	being	
developed	into	flow-based	indexes	for	early	diagnosis	of	cardiac	pathologies	(Sengupta	et	al	
2012).	 In	 fact,	 in	 a	 more	 general	 sense,	 Moraldo	 et	 al	 (2013)	 used	 doppler	
echocardiography40	 to	 measure	 the	 effective	 regurgitant	 orifice	 area	 (EROA)	 in	 patients	
with	mitral	regurgitation	using	the	proximal	isovelocity	surface	area	(PISA)	technique,	which	
incidentally,	 as	mentioned	 previously	 (section	 2.3.1),	 is	 also	 a	more	 relevant	method	 for	
assessing	 the	 diastolic	 performance	 of	 mitral	 valves.	 Therefore,	 development	 of	 flow	
visualisation	 techniques	 for	 the	mitral	 valves	 in	 vitro	would	 enable	 the	 effective	 surface	
area	to	be	measured	rather	than	the	current	effective	orifice	area	making	their	assessment	
more	clinically	relevant.		
8.2.5 Pulse	duplicator	
The	Cardiovascular	Engineering	Group	at	UCL	is	currently	developing	a	more	physiologically	
similar	ventricular	sac.	This	was	made	by	firstly	extracting	the	shape	of	the	outer	surface	of	
a	 human	 left	 ventricle	 in	 the	 fully	 contracted	 position	 from	 a	 computerised	 tomographic	
(CT)	scan	(Figure	8.2).	This	was	then	printed	as	a	solid	artefact	 in	3D	to	act	as	a	moulding	
surface	which	was	dipped	in	liquid	silicon	to	form	a	transparent	silicon	sac	(Figure	8.2).	
	
	
																																								 																				
40	 Doppler	 echocardiography	 is	 an	 ultrasound	 technology,	 i.e.	 high	 frequency	 sound	waves,	which	
enables	one	to	see	inside	the	body	from	the	outside.	
Figure	8.2:	Human	 left	 ventricle	 (left)	 computerised	 Tomographic	 (CT)	
scan	in	its	fully	contracted	state	(right)	left:	mould	to	make	ventricle	sac	
right:	silicon	ventricle	sac	formed	using	mould.	
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Furthermore,	 the	 ventricle	 was	 adapted	 to	 incorporate	 artificial	 papillary	 muscles	 for	
tethering	 the	 chordae	 tendineae	 of	 animal	 heart	 valves,	 the	 orientation	 of	which	 can	 be	
adjusted	(Figure	8.3).		
	
8.2.6 Transcatheter	mitral	valve	
This	 section	 discusses	 the	 ongoing	 development	 of	 the	 UCL	 TMV	 in	 terms	 of	 the	 new	
wireframe	 design	 and	 the	 functional	 assessment;	 more	 specifically	 the	 test	 temperature	
and	anatomical	inclusion	criteria,	the	delivery	system	and	lastly	durability	assessments.		
	 	
Figure	 8.3:	 Physiologically	 similar	 ventricle	 sac	 with	 adaptable	 papillary	 muscles	 (left)	
schematic	 (right)	 adapted	 hydro-mechanical	 cardiovascular	 pulse	 duplicator	 system	
(ViVitro	Superpump	SP3891,	ViVitro,	BC,	Canada).	
Mitral	Valve	
Left	Ventricle	
Papillary	
Muscle	
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8.2.6.1	Wireframe	design	
As	 discussed	 in	 section	 6.6.2,	 the	 ventricle	 sac	 frequently	 touched	 the	 UCL	 TMV	 frame	
during	 systole	and	 therefore	 to	minimise	 this	 interaction,	a	 smaller	 frame	was	developed	
and	 is	currently	being	 tested	 (6.7).	However,	 repeated	contact	does	not	necessarily	 imply	
the	frame	is	unsuitable;	there	are	other	commercially	available	surgical	approaches,	such	as	
left	 ventricle	 assist	 devices	 (LVAD),	 which	 repeatedly	 connect	 with	 the	 ventricle	 wall	
without	significant	damage.	In	the	case	of	the	UCL	TMV,	in	vivo	assessment	in	animals	will	
be	 required	 to	 determine	 whether	 this	 causes	 significant	 damage	 to	 the	 left	 ventricle	
and/or	device.	
8.2.6.2	Functional	assessment	
8.2.6.2.1	Test	temperature	
As	per	the	 investigation	into	thermo-mechanical	properties	of	pericardium	(section	3.1.2),	
assessing	 the	 functional	 performance	of	 bioprosthetic	 heart	 valves	 at	 room	 temperature,	
rather	 than	 body	 temperature,	 does	 not	 significantly	 affect	 the	mechanical	 properties	 of	
the	 pericardial	 leaflets.	 However,	 elevated	 temperatures	 will	 substantially	 affect	 the	
mechanical	 properties	 (rigidity)	 of	 nitinol	 frames	 and,	 therefore,	 once	 the	 optimal	 frame	
design	and	processing	techniques	(e.g.	electropolishing	or	alternatives	(Rokicki	et	al	2015))	
have	been	finalised,	new	UCL	TMV	prototypes	should	be	assessed	at	37	oC.	
8.2.6.2.2	Anatomical	inclusion	criteria	
The	UCL	TMVs	were	tested	in	mock	native	mitral	valve	holders	with	inter-trigonal	diameters	
between	 20	 and	 25	 mm,	 which	 identified	 the	 native	 commissural	 length	 as	 a	 critical	
parameter	 affecting	 their	 performance	 (section	 6.6.2),	 i.e.	 if	 they	 are	 too	 short	 then	 the	
porous	skirt	mesh	is	exposed,	greatly	increasing	regurgitant	volumes.	In	the	event	of	in	vivo	
assessment,	further	clarification	of	native	anatomy	inclusion	criteria,	including	when	in	the	
cardiac	 cycle	 these	 parameters	 should	 be	measured,	 is	 required,	 some	 of	which	may	 be	
similar	to	that	reported	for	the	Fortis	device	(Bapat	et	al	2014).	
	
8.2.6.3	Delivery	system		
The	 catheter	 based	 delivery	 system	 which	 facilitates	 crimping,	 multi-stage	 expansion	
(Figure	 1.15),	 repositioning	 and	 retrieval	 of	 the	 proposed	 TMV,	 will	 be	 based	 on	 that	
developed	for	the	UCL	TAV	(Rahmani	et	al	2016,	Burriesci	et	al	2012),	the	main	adaptation	
	
	
193	
	
being	 increasing	 catheter	 diameter.	 A	minimal	 girth	would	minimise	 the	 invasivity	 of	 the	
transapical	 access	 required	 and	 if	 a	 transseptal	 version	 were	 designed,	 would	 minimise	
vascular	 damage.	 	 Therefore,	 further	 experimental	 work	 is	 required	 to	 determine	 the	
minimal	crimped	diameter	achievable	without	damage	to	device	or	delivery	system	whilst	
maintaining	ease	of	loading.		
The	proposed	26	mm	UCL	TMV	had	a	deployed	 length	of	40	mm	and	will	be	53	mm	long	
when	crimped	to	a	diameter	of	8	mm	(Bozkurt	et	al	2016).	The	same	sized	device	but	with	a	
shorter	 frame	which	 is	 only	 33	mm	 long	when	 deployed	 and	 45	mm	when	 crimped	 has	
been	made	and	initial	functional	assessment	results	obtained	(6.7).	The	aim	of	this	design	
change	was	mainly	 to	 reduce	 interaction	between	ventricle	 sac	and	 frame	during	systole,	
but	 also	 has	 the	 added	 benefit	 that	 if	 a	 transseptal	 version	 is	 designed	 would	 reduce	
vascular	 damage	 during	 implantation.	 In	 fact,	 potential	 vascular	 damage	 caused	 by	 the	
length	of	either	of	the	UCL	TMV	frames	would	still	be	optimal	compared	to	the	much	longer	
CoreValve,	which	has	a	deployed	height	of	50-53	mm	(Table	1.1).	
8.2.6.4	Durability	assessment	
8.2.6.4.1	Requirements	
Further	to	the	functional	assessment	of	the	UCL	TMVs	(0),	the	international	standards	(ISO	
5840-3:2013)	 require	 that	 transcatheter	 heart	 valves	 remain	 functional	 for	 at	 least	 200	
million	 in	vitro	 test	cycles,	equivalent	 to	approximately	5	years	 in	vivo.	However,	 to	meet	
the	CE	directive	requirements,	on	route	to	acquiring	the	CE	marking	(Conformite	Europeene	
i.e.	European	Conformity),	only	8	million	 in	vitro	 test	cycles	 (90	days	 in	vivo)	are	required	
prior	 to	 animal	 testing.	 In	 the	 United	 States	 the	 FDA	 (Food	 and	 Drug	 Administration;	 a	
federal	agency	of	 the	United	States	Department	of	Health	and	Human	Services)	 require	a	
longer	durability	 assessment	of	 12	million	 cycles	 (140	days	 in	 vivo)	 before	 animal	 studies	
can	 be	 undertaken.	 These	 regulations	 currently	 have	 to	 be	 satisfied	 independently,	
however,	the	WHO	(World	Health	Organisation;	a	specialized	agency	of	the	United	Nations)	
continues	to	promote	the	harmonization	of	regulations	(Lamph	2012).		
8.2.6.4.2	Protocol	
The	durability	of	the	UCL	TMV	prototypes	is	currently	being	assessed	inside	optimal	24	mm	
mock	 native	 mitral	 valve	 holders	 using	 the	 BDC	 Laboratories’	 VDT-3600i	 heart	 valve	
durability	 tester	 (Figure	 8.4)	whilst	 in	 saline	 solution	 at	 37	 oC.	 The	 accelerated	wear	 test	
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system	is	set	to	generate	a	heart	rate	of	20	Hz	and	peak	differential	pressure	of	130	mmHg,	
which	is	slightly	higher	than	the	required	normotensive	120	mmHg	to	account	for	machine	
oscillations	and	is	maintained	for	at	least	5%	of	each	cycle	for	95%	or	more	of	all	test	cycles.	
This	 higher	 than	 natural	 heart	 rate	 means	 that	 in	 vitro	 it	 takes	 only	 three	 months	 to	
simulate	five	years	of	in	vivo	function.		
8.2.6.4.3	Results	to	date	
TMV1	and	TMV3	have	passed	80	million	cycles	(equivalent	to	two	years	in	vivo)	and	are	still	
functional.	 Therefore,	 they	 would	 be	 considered	 durable	 enough	 for	 animal	 trials.	 The	
frame	of	TMV2	failed	prior	to	reaching	one	million	cycles,	however	this	premature	failure	
will	foreseeably	be	rectified	once	the	frames	are	electropolished,	which	will	remove	micro-
cracks	which	act	as	 initiation	sites	for	 failure.	Tests	are	estimated	to	be	completed	by	the	
end	of	2016.	
	
	
	
	
	
8.2.6.4.4	Future	work	
The	durability	testing	will	continue	until	200	million	cycles/device	failure	and	will	continue	
to	be	paused	every	40	million	cycles,	approximately	18	days,	equivalent	to	1	year	in	vivo,	at	
which	 point	 the	 devices	 will	 be	 placed	 back	 in	 the	 pulse	 duplicator	 to	 confirm	 they	 are	
maintaining	acceptable	functional	performance.	Once	the	frame	design	and	manufacturing	
methods	 have	 been	 optimised	 (namely,	 electropolishing	 methods)	 and	 the	 catheter	
delivery	 system	 is	 made,	 the	 devices	 will	 be	 crimped	 and	 released	 three	 times	 prior	 to	
repeating	 the	 durability	 assessment	 outlined	 above.	 Therefore,	 the	 current	 durability	
assessment	is	predominantly	testing	the	leaflets	and	general	assembly	methods.	
Ventricle	side	
Atrial	side	
Figure	8.4:	Heart	valve	durability	tester	(BDC	Laboratories)	(left)	6	stations	
of	tester	and	the	UCL	TMV	mounted	viewed	from	(middle)	ventricular	side	
(right)	side	view.	
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On	 successful	 completion	 of	 the	 durability	 assessments	 to	 the	 required	 standards,	
estimated	 to	 be	 completed	 by	 the	 end	 of	 2016,	 animal	 trials	 could	 foreseeably	 be	
performed	followed	by	human	trials	within	the	next	2-4	years.	
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Appendix	A 	
 
% This script analyses the data from a cyclic tensile test, with ten 
% conditioning cycles and ten main cycles. 
% The excel file should contain three columns; cycle number, nominal 
strain 
% standard force in columns A, B and C respectively, with no titles. 
close all; 
clear all; 
%% Reading in the data and predefined variables  
% input file name 
str = input('Please enter the name of your excel file:  ' ,'s'); 
test_data = xlsread(str); 
test_data_for_editing = test_data; 
area = input('Please enter the cross sectional area of your specimen 
in millimetres squared:  '); 
original_length = input('Please enter the original length of the 
gauge section your specimen in millimetres:  '); 
% Input initial estimates for the parameters of the equation 
display('Your data will be described with the following equation: 
stress = Aln(1 + exp(B*strain – C)) + D*strain)') 
A = input('Please enter an initial estimate for parameter A:  '); 
B = input('Please enter an initial estimate for parameter B:  '); 
C = input('Please enter an initial estimate for parameter C:  '); 
D = input('Please enter an initial estimate for parameter D:  '); 
% Definition of matrices and creation of separate matrices for 
separate    % cycles. Define two matrices for the data that is 
associated with the     % zeroth cycle.  
cycle_zero_start = zeros(length(test_data), 2); 
cycle_zero_middle = zeros(length(test_data), 2); 
% Define ten matrices, one for each conditioning cycle. 
cycle_conditioning_1 = zeros(length(test_data), 2); 
cycle_conditioning_2 = zeros(length(test_data), 2); 
cycle_conditioning_3 = zeros(length(test_data), 2); 
cycle_conditioning_4 = zeros(length(test_data), 2); 
cycle_conditioning_5 = zeros(length(test_data), 2); 
cycle_conditioning_6 = zeros(length(test_data), 2); 
cycle_conditioning_7 = zeros(length(test_data), 2); 
cycle_conditioning_8 = zeros(length(test_data), 2); 
cycle_conditioning_9 = zeros(length(test_data), 2); 
cycle_conditioning_10 = zeros(length(test_data), 2); 
% Define ten matrices, one for each main cycle. 
cycle_1 = zeros(length(test_data), 2); 
cycle_2 = zeros(length(test_data), 2); 
cycle_3 = zeros(length(test_data), 2); 
cycle_4 = zeros(length(test_data), 2); 
cycle_5 = zeros(length(test_data), 2); 
cycle_6 = zeros(length(test_data), 2); 
cycle_7 = zeros(length(test_data), 2); 
cycle_8 = zeros(length(test_data), 2); 
cycle_9 = zeros(length(test_data), 2); 
cycle_10 = zeros(length(test_data), 2); 
% Fill in the first row of the zeroth cycle. 
cycle_zero_start(1,1:2)= test_data_for_editing(1,2:3); 
% Remove this row from the test data. It has now been filed in the 
correct 
% place. 
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test_data_for_editing = removerows(test_data_for_editing, 1); 
% Go through each row adding it to the zeroth cycle if there is a 
zero in 
% the first column. 
% Fill the cycle zero start matrix 
% This i denotes the row number of the cycle_zero_start matrix 
i = 1; 
while ((test_data_for_editing(1,1)) == 0) 
cycle_zero_start(i+1,1:2)= test_data_for_editing(1,2:3); 
  test_data_for_editing = removerows(test_data_for_editing, 1); 
  i=i+1; 
end 
% Fill the conditioning cycle 1 matrix 
i = 1; 
while ((test_data_for_editing(1,1)) == 1)  
 cycle_conditioning_1(i,1:2)= test_data_for_editing(1,2:3); 
 test_data_for_editing = removerows(test_data_for_editing, 1); 
 i=i+1; 
end 
% Fill the conditioning cycle 2 matrix 
i = 1; 
while ((test_data_for_editing(1,1)) == 2)  
 cycle_conditioning_2(i,1:2)= test_data_for_editing(1,2:3); 
 test_data_for_editing = removerows(test_data_for_editing, 1); 
 i=i+1; 
end 
% Fill the conditioning cycle 3 matrix 
i = 1; 
while ((test_data_for_editing(1,1)) == 3) 
 cycle_conditioning_3(i,1:2)= test_data_for_editing(1,2:3); 
 test_data_for_editing = removerows(test_data_for_editing, 1); 
 i=i+1; 
end 
% Fill the conditioning cycle 4 matrix 
i = 1; 
while ((test_data_for_editing(1,1)) == 4) 
 cycle_conditioning_4(i,1:2)= test_data_for_editing(1,2:3); 
 test_data_for_editing = removerows(test_data_for_editing, 1); 
 i=i+1; 
end 
% Fill the conditioning cycle 5 matrix 
i = 1; 
while ((test_data_for_editing(1,1)) == 5)  
 cycle_conditioning_5(i,1:2)= test_data_for_editing(1,2:3); 
 test_data_for_editing = removerows(test_data_for_editing, 1); 
 i=i+1; 
end 
% Fill the conditioning cycle 6 matrix 
i = 1; 
while ((test_data_for_editing(1,1)) == 6) 
 cycle_conditioning_6(i,1:2)= test_data_for_editing(1,2:3); 
 test_data_for_editing = removerows(test_data_for_editing, 1); 
 i=i+1 
end 
% Fill the conditioning cycle 7 matrix 
i = 1; 
while ((test_data_for_editing(1,1)) == 7)   
 cycle_conditioning_7(i,1:2)= test_data_for_editing(1,2:3); 
 test_data_for_editing = removerows(test_data_for_editing, 1); 
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 i=i+1; 
end 
% Fill the conditioning cycle 8 matrix 
i = 1; 
while ((test_data_for_editing(1,1)) == 8) 
 cycle_conditioning_8(i,1:2)= test_data_for_editing(1,2:3); 
 test_data_for_editing = removerows(test_data_for_editing, 1); 
 i=i+1; 
end 
% Fill the conditioning cycle 9 matrix 
i = 1; 
while ((test_data_for_editing(1,1)) == 9) 
 cycle_conditioning_9(i,1:2)= test_data_for_editing(1,2:3); 
 test_data_for_editing = removerows(test_data_for_editing, 1); 
 i=i+1; 
end 
% Fill the conditioning cycle 10 matrix 
i = 1; 
while ((test_data_for_editing(1,1)) == 10)  
 cycle_conditioning_10(i,1:2)= test_data_for_editing(1,2:3); 
 test_data_for_editing = removerows(test_data_for_editing, 1); 
 i=i+1; 
end 
% Fill the cycle zero middle 
i = 1; 
while ((test_data_for_editing(1,1)) == 0) 
 cycle_zero_middle(i,1:2)= test_data_for_editing(1,2:3); 
 test_data_for_editing = removerows(test_data_for_editing, 1); 
 i=i+1; 
end 
% Fill the main cycle 1 matrix 
i = 1; 
while ((test_data_for_editing(1,1)) == 1) 
 cycle_1(i,1:2)= test_data_for_editing(1,2:3); 
 test_data_for_editing = removerows(test_data_for_editing, 1); 
 i=i+1; 
end 
% Fill the main cycle 2 matrix 
i = 1; 
while ((test_data_for_editing(1,1)) == 2) 
 cycle_2(i,1:2)= test_data_for_editing(1,2:3); 
 test_data_for_editing = removerows(test_data_for_editing, 1); 
 i=i+1; 
end 
% Fill the main cycle 3 matrix 
i = 1; 
while ((test_data_for_editing(1,1)) == 3) 
 cycle_3(i,1:2)= test_data_for_editing(1,2:3); 
 test_data_for_editing = removerows(test_data_for_editing, 1); 
 i=i+1; 
end 
% Fill the main cycle 4 matrix 
i = 1; 
while ((test_data_for_editing(1,1)) == 4) 
 cycle_4(i,1:2)= test_data_for_editing(1,2:3); 
 test_data_for_editing = removerows(test_data_for_editing, 1); 
 i=i+1; 
end 
% Fill the main cycle 5 matrix 
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i = 1; 
while ((test_data_for_editing(1,1)) == 5) 
 cycle_5(i,1:2)= test_data_for_editing(1,2:3); 
 test_data_for_editing = removerows(test_data_for_editing, 1); 
 i=i+1; 
end 
% Fill the main cycle 6 matrix 
i = 1; 
while ((test_data_for_editing(1,1)) == 6) 
 cycle_6(i,1:2)= test_data_for_editing(1,2:3); 
 test_data_for_editing = removerows(test_data_for_editing, 1); 
 i=i+1; 
end 
% Fill the main cycle 7 matrix 
i = 1; 
while ((test_data_for_editing(1,1)) == 7) 
 cycle_7(i,1:2)= test_data_for_editing(1,2:3); 
 test_data_for_editing = removerows(test_data_for_editing, 1); 
 i=i+1; 
end 
% Fill the main cycle 8 matrix 
i = 1; 
while ((test_data_for_editing(1,1)) == 8) 
 cycle_8(i,1:2)= test_data_for_editing(1,2:3); 
 test_data_for_editing = removerows(test_data_for_editing, 1); 
 i=i+1; 
end 
% Fill the main cycle 9 matrix 
i = 1; 
while ((test_data_for_editing(1,1)) == 9) 
 cycle_9(i,1:2)= test_data_for_editing(1,2:3); 
 test_data_for_editing = removerows(test_data_for_editing, 1); 
 i=i+1; 
end 
% Fill the main cycle 10 matrix 
% This is what is left in the test_data_for_editing. 
 cycle_10(1:(length(test_data_for_editing)),1:2)= 
test_data_for_editing(:,2:3); 
%% Extract just the loading data from the main cycles 
% The end of the loading will occur at the maximum value of force, 
which 
% is the maximum value in column 2. 
% Loading data for cycle  1 
[num, idx] = max(cycle_1(:,2)); 
loading_cycle_1(1:idx,:) = cycle_1(1:idx,:); 
% Loading data for cycle  2 
[num, idx] = max(cycle_2(:,2)); 
loading_cycle_2(1:idx,:) = cycle_2(1:idx,:); 
% Loading data for cycle  3 
[num, idx] = max(cycle_3(:,2)); 
loading_cycle_3(1:idx,:) = cycle_3(1:idx,:); 
% Loading data for cycle  4 
[num, idx] = max(cycle_4(:,2)); 
loading_cycle_4(1:idx,:) = cycle_4(1:idx,:); 
% Loading data for cycle  5 
[num, idx] = max(cycle_5(:,2)); 
loading_cycle_5(1:idx,:) = cycle_5(1:idx,:); 
% Loading data for cycle  6 
[num, idx] = max(cycle_6(:,2)); 
	
	
230	
	
loading_cycle_6(1:idx,:) = cycle_6(1:idx,:); 
% Loading data for cycle  7 
[num, idx] = max(cycle_7(:,2)); 
loading_cycle_7(1:idx,:) = cycle_7(1:idx,:); 
% Loading data for cycle  8 
[num, idx] = max(cycle_8(:,2)); 
loading_cycle_8(1:idx,:) = cycle_8(1:idx,:); 
% Loading data for cycle  9 
[num, idx] = max(cycle_9(:,2)); 
loading_cycle_9(1:idx,:) = cycle_9(1:idx,:); 
% Loading data for cycle  10 
[num, idx] = max(cycle_1(:,2)); 
loading_cycle_10(1:idx,:) = cycle_10(1:idx,:); 
%% Smoothing the force data points to remove noise 
% Only need to smooth the force data. 
% Smoothing loading cycle 1 data 
loading_cycle_1_smooth = loading_cycle_1; 
loading_cycle_1_smooth(:,2) = smooth(loading_cycle_1_smooth(:,2), 
10); 
% Smoothing loading cycle 2 data 
loading_cycle_2_smooth = loading_cycle_2; 
loading_cycle_2_smooth(:,2) = smooth(loading_cycle_2_smooth(:,2), 
10); 
% Smoothing loading cycle 3 data 
loading_cycle_3_smooth = loading_cycle_3; 
loading_cycle_3_smooth(:,2) = smooth(loading_cycle_3_smooth(:,2), 
10); 
% Smoothing loading cycle 4 data 
loading_cycle_4_smooth = loading_cycle_4; 
loading_cycle_4_smooth(:,2) = smooth(loading_cycle_4_smooth(:,2), 
10); 
% Smoothing loading cycle 5 data 
loading_cycle_5_smooth = loading_cycle_5; 
loading_cycle_5_smooth(:,2) = smooth(loading_cycle_5_smooth(:,2), 
10); 
% Smoothing loading cycle 6 data 
loading_cycle_6_smooth = loading_cycle_6; 
loading_cycle_6_smooth(:,2) = smooth(loading_cycle_6_smooth(:,2), 
10); 
% Smoothing loading cycle 7 data 
loading_cycle_7_smooth = loading_cycle_7; 
loading_cycle_7_smooth(:,2) = smooth(loading_cycle_7_smooth(:,2), 
10); 
% Smoothing loading cycle 8 data 
loading_cycle_8_smooth = loading_cycle_8; 
loading_cycle_8_smooth(:,2) = smooth(loading_cycle_8_smooth(:,2), 
10); 
% Smoothing loading cycle 9 data 
loading_cycle_9_smooth = loading_cycle_9; 
loading_cycle_9_smooth(:,2) = smooth(loading_cycle_9_smooth(:,2), 
10); 
% Smoothing loading cycle 10 data 
loading_cycle_10_smooth = loading_cycle_10; 
loading_cycle_10_smooth(:,2) = smooth(loading_cycle_10_smooth(:,2), 
10); 
%% Zero the smoothed loading data 
% Zeroing the data for cycle 1 
for i=1:length(loading_cycle_1_smooth) 
% Zero extension data 
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loading_cycle_1_smooth_zeroed (i,1) = loading_cycle_1_smooth(i,1)-
loading_cycle_1_smooth(1,1); 
% Zero force data 
loading_cycle_1_smooth_zeroed (i,2) = loading_cycle_1_smooth(i,2)-
loading_cycle_1_smooth(1,2); 
end 
% Zeroing the data for cycle 2 
for i=1:length(loading_cycle_2_smooth)  
% Zero extension data 
loading_cycle_2_smooth_zeroed (i,1) = loading_cycle_2_smooth(i,1)-
loading_cycle_2_smooth(1,1); 
% Zero force data 
loading_cycle_2_smooth_zeroed (i,2) = loading_cycle_2_smooth(i,2)-
loading_cycle_2_smooth(1,2); 
end 
% Zeroing the data for cycle 3 
for i=1:length(loading_cycle_3_smooth) 
% Zero extension data 
loading_cycle_3_smooth_zeroed (i,1) = loading_cycle_3_smooth(i,1)-
loading_cycle_3_smooth(1,1); 
% Zero force data 
loading_cycle_3_smooth_zeroed (i,2) = loading_cycle_3_smooth(i,2)-
loading_cycle_3_smooth(1,2); 
end 
% Zeroing the data for cycle 4 
for i=1:length(loading_cycle_4_smooth) 
% Zero extension data 
loading_cycle_4_smooth_zeroed (i,1) = loading_cycle_4_smooth(i,1)-
loading_cycle_4_smooth(1,1); 
% Zero force data 
loading_cycle_4_smooth_zeroed (i,2) = loading_cycle_4_smooth(i,2)-
loading_cycle_4_smooth(1,2); 
end 
% Zeroing the data for cycle 5 
for i=1:length(loading_cycle_5_smooth) 
% Zero extension data 
loading_cycle_5_smooth_zeroed (i,1) = loading_cycle_5_smooth(i,1)-
loading_cycle_5_smooth(1,1); 
% Zero force data 
loading_cycle_5_smooth_zeroed (i,2) = loading_cycle_5_smooth(i,2)-
loading_cycle_5_smooth(1,2); 
end 
% Zeroing the data for cycle 6 
for i=1:length(loading_cycle_6_smooth) 
% Zero extension data 
loading_cycle_6_smooth_zeroed (i,1) = loading_cycle_6_smooth(i,1)-
loading_cycle_6_smooth(1,1); 
% Zero force data 
loading_cycle_6_smooth_zeroed (i,2) = loading_cycle_6_smooth(i,2)-
loading_cycle_6_smooth(1,2); 
end 
% Zeroing the data for cycle 7 
for i=1:length(loading_cycle_7_smooth) 
% Zero extension data 
loading_cycle_7_smooth_zeroed (i,1) = loading_cycle_7_smooth(i,1)-
loading_cycle_7_smooth(1,1); 
% Zero force data 
loading_cycle_7_smooth_zeroed (i,2) = loading_cycle_7_smooth(i,2)-
loading_cycle_7_smooth(1,2); 
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end 
% Zeroing the data for cycle 8 
for i=1:length(loading_cycle_8_smooth) 
% Zero extension data 
loading_cycle_8_smooth_zeroed (i,1) = loading_cycle_8_smooth(i,1)-
loading_cycle_8_smooth(1,1); 
% Zero force data 
loading_cycle_8_smooth_zeroed (i,2) = loading_cycle_8_smooth(i,2)-
loading_cycle_8_smooth(1,2); 
end 
% Zeroing the data for cycle 9 
for i=1:length(loading_cycle_9_smooth) 
% Zero extension data 
loading_cycle_9_smooth_zeroed (i,1) = loading_cycle_9_smooth(i,1)-
loading_cycle_9_smooth(1,1); 
% Zero force data 
loading_cycle_9_smooth_zeroed (i,2) = loading_cycle_9_smooth(i,2)-
loading_cycle_9_smooth(1,2); 
end 
% Zeroing the data for cycle 10 
for i=1:length(loading_cycle_10_smooth) 
% Zero extension data 
loading_cycle_10_smooth_zeroed (i,1) = loading_cycle_10_smooth(i,1)-
loading_cycle_10_smooth(1,1); 
% Zero force data 
loading_cycle_10_smooth_zeroed (i,2) = loading_cycle_10_smooth(i,2)-
loading_cycle_10_smooth(1,2); 
end 
%% Convert extension to strain and force to stress 
% Converting extensions to strain by dividing by the original 
length; for example 20 mm.  
cycle_1_strain_stress(:,1)= 
loading_cycle_1_smooth_zeroed(:,1)/original_length; 
cycle_2_strain_stress(:,1)= 
loading_cycle_2_smooth_zeroed(:,1)/original_length; 
cycle_3_strain_stress(:,1)= 
loading_cycle_3_smooth_zeroed(:,1)/original_length; 
cycle_4_strain_stress(:,1)= 
loading_cycle_4_smooth_zeroed(:,1)/original_length; 
cycle_5_strain_stress(:,1)= 
loading_cycle_5_smooth_zeroed(:,1)/original_length; 
cycle_6_strain_stress(:,1)= 
loading_cycle_6_smooth_zeroed(:,1)/original_length; 
cycle_7_strain_stress(:,1)= 
loading_cycle_7_smooth_zeroed(:,1)/original_length; 
cycle_8_strain_stress(:,1)= 
loading_cycle_8_smooth_zeroed(:,1)/original_length; 
cycle_9_strain_stress(:,1)= 
loading_cycle_9_smooth_zeroed(:,1)/original_length; 
cycle_10_strain_stress(:,1)= 
loading_cycle_10_smooth_zeroed(:,1)/original_length; 
% Converting force to stress by dividing by area. This area will be 
% different for each sample tested and should be defined at the 
beginning  % of this script. 
cycle_1_strain_stress(:,2)= loading_cycle_1_smooth_zeroed(:,2)/area; 
cycle_2_strain_stress(:,2)= loading_cycle_2_smooth_zeroed(:,2)/area; 
cycle_3_strain_stress(:,2)= loading_cycle_3_smooth_zeroed(:,2)/area; 
cycle_4_strain_stress(:,2)= loading_cycle_4_smooth_zeroed(:,2)/area; 
cycle_5_strain_stress(:,2)= loading_cycle_5_smooth_zeroed(:,2)/area; 
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cycle_6_strain_stress(:,2)= loading_cycle_6_smooth_zeroed(:,2)/area; 
cycle_7_strain_stress(:,2)= loading_cycle_7_smooth_zeroed(:,2)/area; 
cycle_8_strain_stress(:,2)= loading_cycle_8_smooth_zeroed(:,2)/area; 
cycle_9_strain_stress(:,2)= loading_cycle_9_smooth_zeroed(:,2)/area; 
cycle_10_strain_stress(:,2)= 
loading_cycle_10_smooth_zeroed(:,2)/area; 
%% Plot the real data for cycle 10 
strain = cycle_10_strain_stress(:,1); 
stress = cycle_10_strain_stress(:,2); 
fig1 = figure(1); 
set(fig1,'name', 'Real Data'); 
plot(strain,stress, 'r'); 
title('Real Data: Stress vs Strain', 'FontWeight', 'bold'); 
xlabel('Strain'); 
ylabel('Stress [MPa]'); 
%% Solving nonlinear curve fitting (data-fitting) problems in least-
squares % sense.'lsqcurvefit' enables you to fit a parameterised 
nonlinear function % to data easily. You can use lsqnonlin as well, 
lsqcurvefit is simply a   % convenient way to call lsqnonlin for 
curve fitting. 
% Define a fitting function 
% In order to fit the parameters to the data using lsqcurvefit you 
need to 
% define a fitting function. Define the fitting function PREDICTED 
as an 
% anonymous function. 
strain_predicted_solver = 0:0.0001:0.4; 
predicted = @(a,strain_predicted_solver) a(1)*log(1 + 
exp(a(2)*strain_predicted_solver - a(3))) + 
a(4)*strain_predicted_solver; 
% provide initial estimates for parameters 
% To fit the model to the data, lsqcurvefit needs an initial 
estimate 'a0' 
% for the parameters 
a0 = [A;B;C;D]; 
% Run the solver 
 
[ahat,resnorm,residual,exitflag,output,lambda,jacobian] = 
lsqcurvefit(predicted,a0,strain,stress); 
% View the resulting least-squares estimate 
ahat; 
%% plot the predicted data using the equation derived in 
sigmoid_curve.m 
% The 'sigmoid_curve.m' script is available on request. 
% Note; the real values of strain are used to predict the values of 
stress 
strain_predicted = 0:0.0001:0.4; 
stress_predicted = ahat(1)*log(1 + exp(ahat(2)*strain_predicted - 
ahat(3))) + ahat(4)*strain_predicted; 
'FontWeight', 'bold'); 
fig3 = figure(3); 
set(fig3,'name', 'Comparison Between the Real Data and Predicted 
Data'); 
plot(strain,stress, 'r'); 
hold on; 
plot(strain_predicted,stress_predicted, 'g'); 
title('Comparison Between the Real Data (red) and Predicted Data 
(green)', 'FontWeight', 'bold'); 
xlabel('Strain'); 
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ylabel('Stress [MPa]'); 
%% Plot the derivative the derived equation 
derivative = diff(stress_predicted)./diff(strain_predicted); 
derivative = derivative'; 
% Slight adjustment to the strain range in order to make the 
matrices the 
% same size to let us plot the derivative 
strain_predicted_derivative = 0.0001:0.0001:0.4; 
strain_predicted_derivative = strain_predicted_derivative'; 
fig4 = figure(4); 
set(fig4,'name', 'Derivative of Derived Equation'); 
plot(strain_predicted_derivative, derivative); 
title('Derivative of Derived Equation', 'FontWeight', 'bold'); 
xlabel('Strain'); 
ylabel('Derivative'); 
x_start = strain_predicted_derivative(1); 
y_start = derivative(1); 
text(x_start,y_start , ['(x = ',num2str(x_start), ' , y = ', 
num2str(y_start), 
')\rightarrow\bullet'],'HorizontalAlignment','right', 'Color',[1 0.5 
0]); 
x_end =  strain_predicted_derivative(end); 
y_end = derivative(end); 
text(x_end,y_end , ['(x = ',num2str(x_end), ' , y = ', 
num2str(y_end), 
')\rightarrow\bullet'],'HorizontalAlignment','right', 'Color',[1 0.5 
0]); 
%% Plot the second derivative the derived equation 
second_derivative = 
diff(derivative)./diff(strain_predicted_derivative); 
second_derivative = second_derivative'; 
strain_predicted_derivative_derivative = 0.0002:0.0001:0.4; 
fig5 = figure(5); 
set(fig5,'name', 'Second Derivative of Derived Equation'); 
plot(strain_predicted_derivative_derivative, second_derivative); 
title('Second Derivative of Derived Equation', 'FontWeight', 
'bold'); 
xlabel('Strain'); 
ylabel('Second Derivative'); 
%% Find where the maximum of the second derivative occurs 
% pks gives the maximum y-value 
[pks, locs] = findpeaks(second_derivative); 
% We want the strain value at this maximum y value 
strain_at_which_maximum_occurs = 
strain_predicted_derivative_derivative(second_derivative==max(second
_derivative(:))); 
text(strain_at_which_maximum_occurs, pks, ['Maximum: (x = ', 
num2str(strain_at_which_maximum_occurs), ', y = ', num2str(pks), ') 
\rightarrow\bullet'],'HorizontalAlignment','right', 'Color',[1 0.5 
0]); 
X = ['The strain at which the maximum of the second derivative 
occurs is: ', strain_at_which_maximum_occurs]; 
disp(X); 
%% Plot the derived equation 
% This has been moved here so that this figure appears first on the 
screen 
fig2 = figure(2); 
set(fig2,'units', 'normalized', 'OuterPosition', [0 0 1 1],'name', 
'Derived Equation'); 
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plot(strain_predicted,stress_predicted, 'g'); 
axis([0 0.4 0 3]); 
title('Predicted Stress vs Strain', 'FontWeight', 'bold'); 
xlabel('Strain'); 
ylabel('Stress [MPa]'); 
text('units', 'normalized', 'position', [0.1, 0.75], 
'string','General Equation: \sigma = Alog(1 + exp(B\epsilon - C) + 
D\epsilon)', 'Color',[1 0.5 0]); 
text('units', 'normalized', 'position', [0.1, 0.7], 
'string',['Derived Equation: \sigma =' , num2str(ahat(1)), 'log(1 + 
exp(', num2str(ahat(2)),'\epsilon - ', num2str(ahat(3)),') + ', 
num2str(ahat(4)), '\epsilon)'], 'Color',[1 0.5 0]); 
text('units', 'normalized','position', [0.1, 0.55],'string','Final 
Parameters:', 'Color',[1 0.5 0]); 
text('units', 'normalized','position', [0.1, 0.5],'string',['A: ', 
num2str(ahat(1))], 'Color',[1 0.5 0]); 
text('units', 'normalized','position', [0.1, 0.45],'string',['B: ', 
num2str(ahat(2))], 'Color',[1 0.5 0]); 
text('units', 'normalized','position', [0.1, 0.4],'string',['C: ', 
num2str(ahat(3))], 'Color',[1 0.5 0]); 
text('units', 'normalized','position', [0.1, 0.35],'string',['D: ', 
num2str(ahat(4))], 'Color',[1 0.5 0]); 
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Appendix	B 	
	 	
Figure	 B.1:	 Thermo-mechanical	 properties	 of	 bovine	 pericardium,	 relationship	 between	 the	
gradient	of	the	linear	region	and	temperature	for	dumbbell	2	on	day	21.	
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Table	B.1:	Thermo-mechanical	properties	of	bovine	pericardium,	statistical	significance	of	the	third	order	polynomial	relationship	between	the	gradient	of	
the	linear	region	and	temperature.	
Hypothesis	rejected	based	on	a	paired	Student’s	t-test	 Number	of	cycles	per	data	set	 p-value	
T1040	=	T1232	 6	 4.8	×	10()	
T1232	=	T1328	 5	 3.7	×	10()	
T1328	=	T1520	 5	 1.5	×	10(-	
T1520	=	T194	 5	 4.0	×	10()	
T1136	=	T1424	 6	 9.9	×	10(/	
T1424	=	T1616	 6	 6.2×	10(/	
T1616	=	T188	 5	 2.3	×	10(-	
T1616	=	T194	 5	 1.9	×	10(/	
T194	=	T1712	 4	 5.2	×	10(2	
Key:	T1040	=	test	10	at	40	oC.	
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Figure	 B.2:	 Relationship	 between	 temperature	 and	 the	 strain	 at	 transition	 point	 for	 sample	 1	when	 cycled	
between	3	different	temperatures	twice.	
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Figure	B.3:	Relationship	between	temperature	and	the	transition	point	for	sample	2	when	cycled	between	3	different	
temperatures	twice.	
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Figure	B.4:	Relationship	between	temperature	and	the	transition	point	for	sample	3	when	cycled	between	3	different	
temperatures	twice.	
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Table	B.2:	Thermo-mechanical	properties	of	bovine	pericardium,	Student's	t-tests	for	significance	of	the	increase	in	transition	point	with	temperature	for	
three	dumbbells.	
Dumbbell	number	 Hypothesis	rejected	based	on	a	paired	Student’s	t-test	
Number	of	cycles	included	in	
calculation	 p-values	
1	
TP4	=	TP21	
13	
1.5	×	10(34	
TP21	=	TP37	 8.5	×	10(3)	
TP4	=	TP37	 9.2	×	10(3)	
2	
TP4	=	TP21	
14	
3.0		×	10(33	
TP21	=	TP37	 1.5	×	10(34	
TP4	=	TP37	 1.4		×	10(33	
2	(21	days	later)	
TP4	=	TP20	
10	
1.7		×	10(5	
TP20	=	TP36	 1.8		×	10(5	
TP4	=	TP36	 3.1		×	10(6	
3	
TP4	=	TP21	
11	
4.6	×	10(5	
TP21	=	TP37	 8.2	×	10(7	
TP4	=	TP37	 4.7	×	10(8	
Key:	TP4	=	strain	at	the	transition	point	for	4oC	
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Figure	B.5:	Transition	point	for	three	different	temperatures	and	dumbbells	from	two	different	patches	of	pericardium.	
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Table	 B.3:	 Thermo-mechanical	 properties	 of	 bovine	 pericardium	 statistical	 significance	 of	 variation	 in	 transition	 point	 between	 dumbbells	 and	 greater	
variation	between	patches.	
Temperature	(oC)	 Hypothesis	rejected	based	on	a	paired	Student’s	t-test	 p-values	
4	
TPdb1	=	TPdb2	 9.5	×	10(3)	
TPdb1	=	TPdb3	 2.6	×	10(35	
TPdb2	=	TPdb3	 1.1	×	10(37	
21	
TPdb1	=	TPdb2	 3.2	×	10(37	
TPdb1	=	TPdb3	 3.3	×	10(36	
TPdb2	=	TPdb3	 2.7	×	10(35	
37	
TPdb1	=	TPdb2	 3.1	×	10(32	
TPdb1	=	TPdb3	 3.6	×	10(-3	
TPdb2	=	TPdb3	 1.6	×	10(--	
Key:	TPdb1	=	strain	at	transition	point	for	dumbbell	1.	
Note:	dumbbell		1	and	2	are	from	the	same	patch	and	dumbbell	3	is	from	a	different	patch.	
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	 Figure	B.6:	Relationship	between	temperature	and	the	transition	point	for	sample	2	when	cycled	between	10	different	
temperatures	once	on	day	21.	
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Table	B.4:	Thermo-mechanical	properties	of	bovine	pericardium;	increase	in	transition	point	due	to	cyclic	temperature	changes.	
Temperature	 Dumbbell	number	
p-value	for	null	hypothesis41		
TPc1	=	TPrc	
4	
1	 7.0	×	10()	
2	 5.8	×	10(/	
2	(day21)	 6.0	×	10(2	
3	 8.9×	10(/	
21	
1	 2.0	×	10(-	
2	 2.2	×	10(-	
2	(day21)	 3.8	×	10(/	
3	 6.2	×	10(/	
TPc1	=	transition	point	for	cycle	1,	TPrc	=	transition	point	for	remaining	cycles.	
	
Table	B.5:	Change	in	thermo-mechanical	properties	of	bovine	pericardium	in	terms	of	its	transition	point	(increases)	after	21	days	stored	in	PBS	at	4oC.	
Hypothesis	rejected	based	on	a	paired	Student’s	t-test	 p-values	
TP4d1	=	TP4d21	 6.6	×	10(38	
TP21/20d1	=	TP21/20d21	 6.2	×	10(38	
TP36/37d1	=	TP36/37d21	 2.5×	10(3/	
Key:	TP4d1	=	strain	at	transition	point	at	4oC	on	day	1,	TP36/37	=	on	day	1	it	was	measured	at	36	oC	and	on	day	21	it	was	measured	at	37	oC,	however	the	
temperature	error	was	±1	oC	so	was	not	significant.	
	
																																								 																				
41	A	null	hypothesis	is	a	general	statement	that	there	is	no	relationship	between	two	measured	phenomena.	
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Table	B.6:	Thermo-mechanical	properties	of	bovine	pericardium	statistical	significance	of	variation	in	hysteresis	between	dumbbells	and	greater	variation	
between	patches.	
Temperature	(oC)	 Hypothesis	rejected	based	on	a	paired	Student’s	t-test	 p-values	
4	
Hdb1	=	Hdb2	 1.4	×	10(-	
Hdb1	=	Hdb3	 	2.5	×	10(5	
Hdb2	=	Hdb3	 	7.3	×	10(34	
21	
Hdb1	=	Hdb2	 4.7	×	10(-	
Hdb1	=	Hdb3	 1.2	×	10(3-	
Hdb2	=	Hdb3	 	1.5×	10(3)	
37	
Hdb1	=	Hdb2	 2.5	×	10(-	
Hdb1	=	Hdb3	 4.4	×	10(8	
Hdb2	=	Hdb3	 	1.6×	10(7	
Key:	Hdb1	=	hysteresis	for	dumbbell	1.	
Note:	dumbbell	1	and	2	are	from	the	same	patch	and	dumbbell	3	is	from	a	different	patch.	
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Appendix	C 	
	
Figure	C.1:	Effect	of	fixation	on	the	thickness	of	bovine	pericardium	patch	3	in	12	
locations.	
Figure	C.2:	Effect	of	fixation	on	the	thickness	of	bovine	pericardium	patch	2	in	12	
locations.	
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Figure	C.3:	Effect	of	fixation	on	the	thickness	of	bovine	pericardium	patch	4	in	12	
locations.	
Figure	C.4:	Effect	of	fixation	on	the	thickness	of	bovine	pericardium	patch	5	in	12	
locations.	
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Figure	C.5:	Effect	of	fixation	on	the	thickness	of	bovine	pericardium	patch	8	in	12	
locations.	
Figure	C.6:	Effect	of	fixation	on	the	thickness	of	bovine	pericardium	patch	6	in	12	
locations.	
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Figure	C.7:	Effect	of	fixation	on	the	thickness	of	bovine	pericardium	patch	7	in	12	
locations.	
Figure	C.8:	Effect	of	fixation	on	the	thickness	of	bovine	pericardium	patch	9	in	12	
locations.	
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Appendix	D 	
$# LS-DYNA Keyword file 
*KEYWORD 
*TITLE 
This keyword file will simulate the closure of a pair of pericardial mitral valve 
leaflets  
*DATABASE_FORMAT 
$ Define the output format for binary files 
$[1] output format  
$[2] word size of the binary output files 
$--------1---------2--------------------------------------- 
$------IFORM---IBINARY------------------------------------- 
         0         0                                                             
$ 
$******************************************************************************** 
$****************************** CONTROL CARDS ***********************************  
$******************************************************************************** 
$  
*CONTROL_TERMINATION 
$ Stop the job 
$[1] termination time  
$[2] termination cycle  
$[3] reduction factor for initial time step size to determine minimum time step 
TSMIN. 
$[4] percent change in energy ratio for termination of calculation 
$[5] percent change in the total mass for termination of calculation 
$[6] flag for a non-solution run 
$--------1---------2---------3---------4---------5---------6--------- 
$------ENDTIM----ENDCYC----DTMIN----ENDENG----ENDMAS-----NOSOL------- 
  6.82E-01                            
*CONTROL_TIMESTEP 
$ Set structural time step size control using different options 
$ CARD1 
$[1] initial time step size 
$[2] scale factor for computed time step 
$[3] basis of time size calculation for 4-node shell elements 
$[4] shell element minimum time step assignment 
$[5] time step size for mass scaled solutions 
$[6] load curve ID that limits the maximum time step size (optional) 
$[7] erosion flag for solid, t-shell and SPH elements when TSMIN (see 
*CONTROL_TERMINATION) is reached 
$[8] limit mass scaling to the first step and fix the mass vector according to the 
time steps once 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$-----DTINIT----TSSFAC------ISDO-----TSLIMT----DT2MS-----LCTM------ERODE-----MSIST---
---- 
         0       0.9         1  
$ CARD2 
$[1] reduction factor for initial time step size to determine the minimum time step 
size permitted 
$[2] load curve specifying DT2MS as a function of time during the explicit solutions 
phase 
$[3] flag for selective mass scaling if and only if mass scaling active 
$--------1---------2---------3--------- 
$-----DT2MSF----DT2MSL-----IMSCL-------    
         0         0         0                                                   
*CONTROL_CONTACT 
$ Change defaults for computation with contact surfaces 
$ CARD1 
$[1] scale factor for sliding interface penalties, SLSFAC. (default = 0.1) 
$[2] scale factor for rigid wall penalties, which treat nodal points interacting with 
rigid walls, RWPNAL. 
$[3] initial penetration check in contact surfaces with indication of initial 
penetration in output files. (1 - no checking) 
$[4] shell thickness considered in type surface to surface and node to surface type 
contact options, where options 1 and 2 below activate the new contact algorithms. (0 
= thickness is not considered) 
$[5] penalty stiffness value option. (0 - the default is set to 1) 
$[6] shell thickness changes considered in single surface contact. (0 = no 
consideration (default)) 
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$[7] optional automatic reorientation of contact interface segments during 
initialization (1 - active for automated (part) input only. Contact surfaces are 
given by *PART definitions.) 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$-----SLSFAC----RWPNAL----ISLCHK----SHLTHK----PENOPT----THKCHG-----ORIEN----ENMASS---
---- 
  0.100000     0.000         1         0         0         0         1         0 
$ CARD2 
$[1] storage per contact interface for user supplied interface control subroutine, 
see Appendix F. 
$[2] storage per contact interface for user supplied interface friction subroutine, 
see Appendix G. 
$[3] number of cycles between contact searching using three dimensional bucket 
searches. 
$[4] flag for intermittent searching in old surface-to-surface contact using the 
interval specified as NSBCS above. (0 = off) 
$[5] contact surface maximum penetration check multiplier (0 - default is set to 4) 
$[6] flag for using actual shell thickness in single surface contact logic-types 4, 
13, 15 and 26. (0 = actual shell thickness is not used in the contacts (default)) 
$[7] time step size override for eroding contact. (0 = contact time size may control 
Dt) 
$[8] bypass projection of slave nodes to master surface in types (0 = eliminate gaps 
by projection nodes) 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$----USRSTR-----USRFRC-----NSBCS----INTERM-----XPENE-----SSTHK------ECDT---TIEDPRJ---
---- 
         0         0         0         0  4.000000         0         0         0 
$ CARD3 
$[1] default static coefficient of friction (see *PART_CONTACT) 
$[2] default dynamic coefficient of friction (see *PART_CONTACT) 
$[3] default exponential decay coefficient (see *PART_CONTACT) 
$[4] default viscous friction coefficient (see *PART_CONTACT) 
$[5] default contact thickness (see *PART_CONTACT) 
$[6] default thickness scale factor (see *PART_CONTACT) 
$[7] default local penalty scale factor (see *PART_CONTACT) 
$--------1---------2---------3---------4---------5---------6---------7--------- 
$------SFRIC-----DFRIC------EDC-------VFC-------TH-------TH_SF----PEN_SF------- 
     0.000     0.000     0.000     0.000     0.000     0.000     0.000 
$ CARD4 
$[1] ignore initial penetrations in the *CONTACT_AUTOMATIC options. (0 = move nodes 
to eliminate initial penetrations in the model definition) 
$[2] flag to activate the calculation of frictional sliding energy. (0 = do not 
calculate) 
$[3] flag not to display stationary rigid wall by default. (0 = generate 4 extra 
nodes and 1 shell element to visualize stationary planar rigid wall) 
$[4] flag to output each beam spot weld slave node and its master segment for contact 
type: *CONTACT_SPOTWELD into the D3HSP file. (0 = no, do not write out this 
information) 
$[5] if a spot weld node or face, which is related to a *MAT_SPOTWELD beam or solid 
element, respectively, cannot be found on the master surface, should an error 
termination occur? (0 = no, continue calculation) 
$[6] if the nodes of a spot weld beam or solid element are attached to a shell 
element that fails and are deleted, then the attached spot weld element is deleted if 
this flag is on. (0 = no, do not delete the spot weld beam or solid element) 
$[7] optional thickness scale factor 
$--------1---------2---------3---------4---------5---------6---------7--------- 
$-----IGNORE----FRCENG---SKIPRWG----OUTSEG---SPOTSTP---SPOTDEL---SPOTHIN------- 
         0         0         0         0         0         0     0.000 
$ CARD5 
$[1] symmetry plane option default for automatic segment generation when contact is 
defined by part IDs. (0 = off) 
$[2] flag to use one-way node to surface erosion. (0 = use one way algorithm) 
$[3] flag to add rigid wall gap stiffness, see parameter RWGDTH below. (1 = add gap 
stiffness, 2  = do not add gap stiffness) 
$[4] death time for gap stiffness. After this time the gap stiffness is no longer 
added. 
$[5] rigid wall penalty scale factor for contact with deformable parts during 
implicit calculations. 
$[6] invokes the covariant formulation of Konyukhov and Schweizerhof in the FORMING 
contact option. (0 = standard formulation (default)) 
$[7] spot weld radius scale factor for neighbour segment thinning. (0 = neighbour 
segments not thinned (default)). 
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$[8] flag for offsetting thermal contact surfaces for thick thermal shells. (0 = no 
offset) 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$-------ISYM----NSEROD----RWGAPS----RWGDTH-----RWKSF-----ICOV-----SWRADF-------
ITHOFF---- 
         0         0         0     0.000  1.000000         0     0.000         0 
$ CARD6 
$[1] flag for assuming edge shape for shells when measuring penetration. (0 = shells 
are assumed round (default)) 
$[2] flag to choose the method for calculating the penalty stiffness. (0 = based on 
material density and segment dimensions (default)) 
$[3] thermal contact heat transfer methodology. ( 0 = default set to 1) 
$[4] tied constraint offset contact update option. (0 = update velocities and 
displacements from accelerations) 
$[5] option to output contact forces to RDFORC for all 2 surface force transducer 
surfaces overlap. (0 = output to the first force transducer that matches (default)) 
$[6] unused 
$[7] optional shell thickness scale factor for contact with rigid walls. 
$--------1---------2---------3---------4---------5---------6---------7--------- 
$-----SHLEDG----PSTIFF----ITHCNT----TDCNOF-----FTALL----UNUSED----SHLTRW------- 
         0         0         0         0         0         0     0.000                         
*CONTROL_ENERGY 
$ Provides control for energy dissipation options 
$CARD1 
$[1] Hourglass energy calculation option. This option requires significant additional 
storage and increases cost by ten percent. (1 - hourglass energy is not computed - 
default) 
$[2] Rigidwall energy (a.k.a. stonewall energy) dissipation option. (1 - energy 
dissipation is not computed) 
$[3] Sliding interface energy dissipation option (this parameter is always set to 2 
if contact is active. The option SLNTEN=1 is not available). (1 - energy dissipation 
is not computed) 
$[4] Rayleigh energy dissipation option (damping energy dissipation). (1 - energy 
dissipation is not computed - default) 
$--------1---------2---------3---------4--------- 
$-------HGEN------RWEN----SLNTEN-----RYLEN-------  
         2         2         1         1                                                    
*CONTROL_ACCURACY 
$ Define control parameters that can improve the accuracy of the calculation 
$ CARD1 
$[1] Global flag for 2nd order objective stress updates. 
$[2] Invariant node numbering for shell and solid elements. (4 - on for shell, thick 
shell and solid elements) 
$[3] Part set ID for objective stress updates 
$--------1---------2---------3---------- 
$-------OSU-------INN-----PIDOSU-------- 
         1         4         0                                                 0                                               
0 
*CONTROL_BULK_VISCOSITY 
$ Reset the default values of the bulk viscosity coefficients globally. This may be 
advisable for shock wave propagation and some materials. 
$ CARD1 
$[1] default quadratic viscosity coefficient 
$[2] default linear viscosity coefficient 
$[3] default bulk viscosity type, IBQ (Default = 1). (-2 - internal energy 
dissipation by the viscosity in the shell elements is computed and included in the 
overall energy balance) 
$[4] beam bulk viscosity type (Default = 0) 
$--------1---------2---------3---------4--------- 
$-------Q1---------Q2-------TYPE-----BTYPE------- 
       1.5      0.06        -2                                                   
*CONTROL_SHELL 
$ Provide controls for computing shell response 
$ CARD1 
$[1] shell element warpage angle in degrees 
$[2] automatic sorting of triangular shell elements to treat degenerate quadrilateral 
shell elements as CO or DKT triangular shells 
$[3] shell normal update option 
$[4] shell thickness change option for deformable shells 
$[5] default shell formulation 
$[6] warping stiffness for Belytschko-Tsay shells 
$[7] plane stress plasticity option (applies to materials 3, 18, 19 and 24) 
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$[8] projection method for the warping stiffness in the Belytschko-Tsay shell (the 
BWC option above) and the Belytschko-Wong-Chiang elements 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$-----WRPANG-----ESORT-----IRNXX----ISTUPD----THEORY------BWC------MITER------PROJ---
---- 
     0.000         1                   1         2 
$ CARD2 
$[1] define a scale factor for the rotary shell mass 
$[2] default shell through thickness numerical integration rule 
$[3] laminated shell theory is available for all thin shell and thick shell materials 
except those that use the Green-Lagrange strain 
$[4] coordinate system for the type 6 shell element 
$[5] thermal shell option 
$--------1---------2---------3---------4---------5---------6---------7--------- 
$----ROTASCL----INTGRD----LAMSHT----CSTYP6----THSHEL----NFAIL1----NFAIL4------- 
  0.000000         0         0         0                                                                                 
*CONTROL_OUTPUT 
$ Set miscellaneous output parameters. This keyword does not control the information, 
such as the stress and strain tensors, which is written into the binary databases. 
$ For the latter, see the keyword *DATABASE_EXTENT_BINARY 
$ CARD1 
$[1] print suppression during input phase flag for the "d3hsp" file 
$[2] print suppression during input phase flag for echo file 
$[3] flag to update reference node coordinates for beam formulations 1, 2 and 11 
$[4] flag to average or filter nodal accelerations output to file "nodout" and the 
time history database "d3thdt"  
$[5] output interval for interface file written per *INTERFACE_COMPONENT_option 
$[6] flag controlling output of initial time step sizes for elements to d3hsp 
$[7] problem status report interval steps to the "d3hsp" file. This flag is ignored 
if the "glstat" file is written, see *DATABASE_GLSTAT 
$[8] number of time steps interval for flushing I/O buffers 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$------NPOPT----NEECHO----NREFUP----IACCOP-----OPIFS----IPNINT----IKEDIT----IFLUSH---
---- 
         0         0         0         0         0         0       125         0 
$ CARD2 
$[1] default print flag for "rbdout" and "matsum" files 
$[2] output erode internal and kinetic energy into the "matsum" file 
$[3] output ten connectivity nodes into "d3plot" database 
$[4] maximum number of each error/warning message 
$[5] flag to output digitized curve data to message and d3hsp files 
$[6] output interval for recorded motions from *INTERFACE_SSI_AUX 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$------IPRTF----IERODE-----TET10----MSGMAX----IPCURV------GMDT------- 
         0         0         0         0         0        
*CONTROL_HOURGLASS 
$ Redefine values of hourglass control type and coefficient 
$[1] default hourglass type (1 - standard LSDYNA, 3 - Flanagan-Belytschko with exact 
volume integration) for shells viscous type (1=2=3) for explicit or stiffness 
hourglass control (4=5) 
$[2] default hourglass coefficient (0.1 - default). Note QH that exceeds 0.15 may 
cause instabilities. 
$--------1---------2--------- 
$-------IHQ-------QH--------- 
         3    0.2475           
*DAMPING_GLOBAL 
$ define mass weighted nodal damping that applies globally to the nodes of deformable 
bodies and to the mass center of the rigid bodies 
$[1] load curve ID which specifies the system damping constant. EQ.0: a constant 
damping factor as defined by VALDMP is used 
$[2] system damping constant 
$[3] scale factor  
$[4] scale factor 
$[5] scale factor 
$[6] scale factor 
$[7] scale factor 
$[8] scale factor 
$--------1---------2---------3---------4---------5---------6---------7---------8 
$------LCID-----VALDMP------STX-------STY-------STZ-------SRX-------SRY-------SRZ 
         0    0.9965    
$ 
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$******************************************************************************** 
$****************************** SECTION *****************************************  
$******************************************************************************** 
$   
*SECTION_SHELL 
$ define section properties for shell elements 
$ CARD1 
$[1] section ID 
$[2] element formulation options (2 - Belytschko-Tsay) 
$[3] shear correction factor which scales the transverse shear stress. A suggested 
value is 5/6 for isotropic materials. 
$[4] number of through thickness integration points (3 - 3 point) 
$[5] printout option (2 - resultants at plan points and fibre lengths) 
$[6] quadrature rule or integration rule ID, see *INTEGRATION_SHELL 
$[7] flag for orthotropic/anisotropic layered composite material model 
$[8] not used (obsolete) 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$------SECID----ELFORM------SHRF------NIP------PROPT---QR/IRID-----ICOMP-----SETYP---
---- 
         1         2  0.833333         5         2       
$ CARD2 
$[1] shell thickness at node n1, unless the thickness is defined on the 
*ELEMENT_SHELL_OPTION card 
$[2] shell thickness at node n2 
$[3] shell thickness at node n3 
$[4] shell thickness at node n4 
$[5] location of reference surface for three dimensional shell elements 
$[6] non-structural mass per unit area  
$[7] treatment of through thickness strain 
$[8] edge node set required for shell type seatbelts 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$--------T1--------T2--------T3--------T4-------NLOC-----MAREA------IDOF----EDGSET---
----  
       0.4       0.4       0.4       0.4                   
*SECTION_SHELL 
$ Define section properties for shell elements 
$ CARD1 
$[1] section ID 
$[2] element formulation options (2 - Belytschko-Tsay) 
$[3] shear correction factor which scales the transverse shear stress. A suggested 
value is 5/6 for isotropic materials. 
$[4] number of through thickness integration points (3 - 3 point) 
$[5] printout option (2 - resultants at plan points and fibre lengths) 
$[6] quadrature rule or integration rule ID, see *INTEGRATION_SHELL 
$[7] flag for orthotropic/anisotropic layered composite material model 
$[8] not used (obsolete) 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$------SECID----ELFORM------SHRF------NIP------PROPT---QR/IRID-----ICOMP-----SETYP---
---- 
         2         2  0.833333         5         2        
$ CARD2 
$[1] shell thickness at node n1, unless the thickness is defined on the 
*ELEMENT_SHELL_OPTION card 
$[2] shell thickness at node n2 
$[3] shell thickness at node n3 
$[4] shell thickness at node n4 
$[5] location of reference surface for three dimensional shell elements 
$[6] non-structural mass per unit area  
$[7] treatment of through thickness strain 
$[8] edge node set required for shell type seatbelts 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$--------T1--------T2--------T3--------T4-------NLOC-----MAREA------IDOF----EDGSET---
----  
       0.4       0.4       0.4       0.4     
$  
$********************************************************************************** 
$****************************** MATERIALS *****************************************
  
$********************************************************************************** 
$  
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*MAT_OGDEN_RUBBER_TITLE 
Pericardium parameters from experimental data 
$ This is also material type 77. This material provides the Ogden [1984] rubber model 
combined optionally with linear viscoelasticity as outlines by Christensen [1980] 
$ CARD1 
$[1] material identification 
$[2] mass density 
$[3] poissons ratio (>=0.49 is recommended; smaller values may not work and should 
not be used.) 
$[4] order of fit to the Ogden model 
$[5] number of prony series terms in fit 
$[6] shear modulus for frequency independent damping 
$[7] limit stress for frequency independent frictional damping 
$--------1---------2---------3---------4---------5---------6---------7--------- 
$-------MID-------RO--------PR---------N--------NV---------G--------SIGF------- 
         1 1.2000E-9  0.499900         0         0     0.000     0.000 
$ CARD2 
$[1-8] the ith shear modulus 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$-------MU1-------MU2-------MU3-------MU4-------MU5-------MU6-------MU7-------MU8----
---- 
 7.5600E-6 5.6700E-4     0.000     0.000     0.000     0.000     0.000     0.000 
$ CARD3 
$[1-8] the ith exponent 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$-----ALPHA1----ALPHA2----ALPHA3----ALPHA-----ALPHA-----ALPHA-----ALPHA7----ALPHA8---
---- 
 26.255711 26.255711     0.000     0.000     0.000     0.000     0.000     0.000 
$  
$******************************************************************************** 
$****************************** PART ********************************************  
$******************************************************************************** 
$  
*PART 
                                                                        Shell                                                                         
$ Define parts, i.e., combine material information, section properties, hourglass 
type, thermal properties, and a flag for part adaptivity 
$ CARD1 
$[1] part identification 
$[2] section identification defined in the *SECTION section 
$[3] material identification defined in the *MAT section 
$[4] equation of state identification in the *EOS section 
$[5] hourglass/bulk viscosity identification defined in the *HOURGLASS section 
$[6] part initialization for gravity loading 
$[7] indication if this part is adapted or not 
$[8] thermal material property identification defined in the *MAT_THERMAL section 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$-------PID------SECID------MID------EOSID------HGID------GRAV----ADPOPT------TMID---
----   
         1         1         1         0         0         0         0         0                                        
*PART 
                                                                           Shell 
$ Define parts, i.e., combine material information, section properties, hourglass 
type, thermal properties, and a flag for part adaptivity 
$ CARD1 
$[1] part identification 
$[2] section identification defined in the *SECTION section 
$[3] material identification defined in the *MAT section 
$[4] equation of state identification in the *EOS section 
$[5] hourglass/bulk viscosity identification defined in the *HOURGLASS section 
$[6] part initialization for gravity loading 
$[7] indication if this part is adapted or not 
$[8] thermal material property identification defined in the *MAT_THERMAL section 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$-------PID------SECID------MID------EOSID------HGID------GRAV----ADPOPT------TMID---
----   
         2         2         1         0         0         0         0         0 
$  
$******************************************************************************** 
$****************************** NODES *******************************************  
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$******************************************************************************** 
$  
*NODE 
$ Define a node and its coordinates in the global coordinate system 
$ CARD1 
$[1] node number 
$[2] x coordinate 
$[3] y coordinate 
$[4] z coordinate 
$[5] translational constraint 
$[6] rotational constraint 
$------1---------------2---------------3---------------4----------5----------6-------
--- 
$-----NID--------------X---------------Y---------------Z---------TC---------RC-------
--- 
… etc.                                      
$  
$ ******************************************************************************* 
$****************************** ELEMENTS *****************************************  
$ ******************************************************************************* 
$  
*ELEMENT_SHELL 
$ Define three, four, six and eight node elements including 3D shells, membranes, 2D 
plane stress, plane strain and axisymmetric solids 
$ CARD1 
$[1] element ID 
$[2] part ID, see *PART 
$[3] nodal point 1 
$[4] nodal point 2 
$[5] nodal point 3 
$[6] nodal point 4 
$[7-10] mid-side nodes for eight node shell  
$------1-------2-------3-------4-------5-------6-------7-------8---------9------10---
---- 
$-----EID-----PID-----N1------N2------N3------N4------N5------N6--------N7------N8---
---- 
… etc. 
*DEFINE_COORDINATE_SYSTEM 
$ Define a local coordinate system 
$ CARD1 
$[1] coordinate system ID 
$[2] X-coordinate of origin 
$[3] Y-coordinate of origin 
$[4] Z-coordinate of origin 
$[5] X-coordinate of point on local x-axis 
$[6] Y-coordinate of point on local x-axis 
$[7] Z-coordinate of point on local x-axis 
$[8] coordinate system ID applied to the coordinates used to define the current 
system 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$-------CID-------XO--------YO--------ZO--------XL--------YL--------ZL--------CIDL---
---- 
        26         0         0         0         1         0         0        
$ CARD2 
$[1] X-coordinate of point in local x-y plane 
$[2] Y-coordinate of point in local x-y plane 
$[3] Z-coordinate of point in local x-y plane 
$--------1---------2---------3--------- 
$-------XP--------YP--------ZP---------    
         0         1         0                                                   
$  
$******************************************************************************** 
$****************************** SETS ********************************************  
$******************************************************************************** 
$  
*SET_SEGMENT 
$ Define a set of quadrilateral and triangular segments with optional identical or 
unique attributes 
$ CARD1 
$[1] set identification  
$[2] first nodal attribute default value 
$[3] second nodal attribute default value 
$[4] third nodal attribute default value 
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$[5] fourth nodal attribute default value 
$[6] this field is used by a non-mechanics solver to create a set defined on that 
solver's mesh. By default, the set refers to the mechanics mesh (MECH) 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$-------SID-------DA1-------DA2-------DA3-------DA4-----SOLVER------ 
$----leaflet_1_aortic---- 
         1 
$ CARD2 
$[1-6] Node ID n 
$--------1---------2---------3---------4--------- 
$-------N1--------N2--------N3--------N4--------- 
… etc. 
*SET_SEGMENT 
$ Define a set of quadrilateral and triangular segments with optional identical or 
unique attributes 
$ CARD1 
$[1] set identification  
$[2] first nodal attribute default value 
$[3] second nodal attribute default value 
$[4] third nodal attribute default value 
$[5] fourth nodal attribute default value 
$[6] this field is used by a non-mechanics solver to create a set defined on that 
solver's mesh. By default, the set refers to the mechanics mesh (MECH) 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$-------SID-------DA1-------DA2-------DA3-------DA4-----SOLVER------ 
$----leaflet_2_mural---- 
         2 
$ CARD2 
$[1-6] Node ID n 
$--------1---------2---------3---------4--------- 
$-------N1--------N2--------N3--------N4--------- 
… etc. 
*SET_NODE_LIST_TITLE 
Edges of leaflets fixed to frame 
$ Define a nodal set with some identical or unique attributes 
$ CARD1 
$[1] set identification 
$[2] first nodal attribute default value 
$[3] second nodal attribute default value 
$[4] third nodal attribute default value 
$[5] fourth nodal attribute default value 
$[6] this field is used by a non-mechanics solver to create a set defined on that 
solver's mesh. By default, the set refers to the mechanics mesh (MECH) 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$-------SID-------DA1-------DA2-------DA3-------DA4-----SOLVER------ 
         3 
$ CARD2 
$[1-6] Node ID n 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$-------NID1------NID2------NID3------NID4------NID5------NID6------NID7------NID8---
---- 
… etc. 
$ 
$******************************************************************************** 
$****************************** CURVES ******************************************  
$******************************************************************************** 
$  
*DEFINE_CURVE 
$ Define a curve [for example, load (ordinate value) versus time (abscissa value)], 
often referred to as a load curve 
$ This is the pressure difference across the mitral valve, derived from pulse 
duplicator data  
$ CARD1 
$[1] load curve ID 
$[2] stress initialization by dynamic relaxation 
$[3] scale factor for abscissa value 
$[4] scale factor for ordinate value (function) 
$[5] offset for abscissa values 
$[6] offset for ordinate values (function) 
$[7] data type 
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$--------1---------2---------3---------4---------5---------6---------7--------- 
$-------LCID------SIDR------SFA-------SFO-------OFFA------OFFO----DATTYP------- 
         1         0         0         0         0         0         0    
$CARD2 
$[1] abscissa values 
$[2] ordinate (function) values 
$------------------1-------------------2------------------- 
$-----------------A1------------------O1-------------------     
… etc. 
*DEFINE_CURVE 
$ Define a curve [for example, load (ordinate value) versus time (abscissa value)], 
often referred to as a load curve 
$ CARD1 
$[1] load curve ID 
$[2] stress initialization by dynamic relaxation 
$[3] scale factor for abscissa value 
$[4] scale factor for ordinate value (function) 
$[5] offset for abscissa values 
$[6] offset for ordinate values (function) 
$[7] data type 
$--------1---------2---------3---------4---------5---------6---------7--------- 
$-------LCID------SIDR------SFA-------SFO-------OFFA------OFFO----DATTYP------- 
         2         0         0         0         0         0         0    
$CARD2 
$[1] abscissa values 
$[2] ordinate (function) values 
$------------------1-------------------2------------------- 
$-----------------A1------------------O1-------------------     
… etc. 
$  
$************************************************************************************
******** 
$****************************** LOADING CONDITIONS 
****************************************** 
$************************************************************************************
******** 
$ 
*LOAD_SEGMENT_SET 
$ APPLYS TRANSMITRAL PRESSURE DIFFERENCE TO LEAFLET1 
$ Apply the distributed pressure load over each segment in a segment set.  
$ CARD1 
$[1] Segment set ID, see *SET_SEGMENT 
$[2] Load curve ID (see *DEFINE_CURVE) or function ID (see *DEFINE_FUNCTION) 
$[3] Load curve scale factor 
$[4] Arrival time for pressure or birth time of pressure  
$--------1---------2---------3---------4--------- 
$-------SSID------LCID------SF--------AT--------- 
         1         1         0         0         0    
*LOAD_SEGMENT_SET 
$ APPLYS TRANSMITRAL PRESSURE DIFFERENCE TO LEAFLET2 
$ Apply the distributed pressure load over each segment in a segment set.  
$ CARD1 
$[1] Segment set ID, see *SET_SEGMENT 
$[2] Load curve ID (see *DEFINE_CURVE) or function ID (see *DEFINE_FUNCTION) 
$[3] Load curve scale factor 
$[4] Arrival time for pressure or birth time of pressure  
$--------1---------2---------3---------4--------- 
$-------SSID------LCID------SF--------AT--------- 
         2         2         0         0         0        
$  
$************************************************************************************
******** 
$****************************** BOUNDARY CONDITIONS & CONTACT 
******************************* 
$************************************************************************************
******** 
$ Key word *BOUNDARY provides a way of defining imposed motions on boundary nodes. 
*BOUNDARY_SPC_SET 
$ Define nodal single point constraints for the edge of the leaflets fixed onto the 
frame 
$ CARD1 
$[1] node ID or nodal set ID, see *SET_NODE 
$[2] coordinate system ID, see *DEFINE-COORDINATE_SYSTEM 
$[3] insert 1 for translational constraint in local x-direction 
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$[4] insert 1 for translational constraint in local y-direction 
$[5] insert 1 for translational constraint in local z-direction 
$[6] insert 1 for rotational constraint about local x-axis 
$[7] insert 1 for rotational constraint about local y-axis 
$[8] insert 1 for rotational constraint about local z-axis 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$-----NID/NSI-----CID-------DOFX------DOFY------DOFZ-----DOFRX-----DOFRY-----DOFRZ---
---- 
         3        26         1         1         1                            
*CONTACT_AUTOMATIC_SINGLE_SURFACE 
$ Define a contact interface 
$ Contact type - AUTOMATIC 
$ CARD1 
$[1] slave segment, node set ID, par set ID, part ID or shell element set ID. (0 = 
all part IDs are included for single surface contact, automatic single surface and 
eroding single surface) 
$[2] master segment set IC, part set ID, part ID or shell element set ID. (0 = for 
single surface contact, automatic single surface, and eroding single surface)  
$[3] ID type of SSID (5 - include all for single surface definition) 
$[4] ID type of MSID (0 - segment set ID) 
$[5] include in contact definition only those slave nodes/segments within box SBOXID 
$[6] include in contact definition only those master segments within box MBOXID 
$[7] include the slave side in the *DATABASE_NCFORC and the *DATABASE _BINARY_INTFOR 
interface force files (1 = slave side forces included) 
$[8] include the master side in the *DATABASE_NCFORC and the *DATABASE_BINARY_INTFOR 
interface force files (1 = master side forces included) 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$-------SSID------MSID-----SSTYP-----MSTYP----SBOXID----MBOXID------SPR-------MPR----
---- 
         0         0         5         0         0         0         0         0 
$ CARD2 
$[1] static coefficient of friction if FS is >0 and not equal to 2 
$[2] dynamic coefficient of friction 
$[3] exponential decay coefficient 
$[4] coefficient for viscous friction 
$[5] viscous damping coefficient in percent of critical 
$[6] small penetration in contact search option 
$[7] birth time (contact surface becomes active at this time) (0 = birth time is 
inactive, i.e. contact is always active) 
$[8] death time (contact surface is deactivated at this time) 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$-------FS--------FD--------DC--------VC--------VDC-----PENCHK------BT--------DT-----
---- 
         0         0         0         0        10         0         0         0 
$ CARD3 
$[1] scale factor on default slave penalty stiffness when SOFT=0 or SOFT=2, see also 
*CONTROL_ CONTACT 
$[2] scale factor on default master penalty stiffness when SOFT=0 or SOFT=2, see also 
*CONTROL_CONTACT 
$[3] optional thickness for slave surface (overrides true thickness) 
$[4] optional thickness for master surface (overrides true thickness) 
$[5] scale factor for slave surface thickness (scales default thickness) 
$[6] scale factor for master surface thickness (scales default thickness) 
$[7] coulomb friction scale factor 
$[8] viscous friction scale factor 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$-------SFS-------SFM-------SST-------MST-------SFST------SFMT------FSF-------VSF----
---- 
         0         0         0         0         0         0         0         0 
$ CARD4  
$--------1---------2---------3---------4---------5---------6---------7--------- 
         2       0.1         0         0         3         5         0         0 
$ CARD5 
$--------1---------2---------3---------4---------5---------6---------7--------- 
         0         0         0         0         0         0         0         0 
$ 
$******************************************************************************** 
$****************************** DATABASE ******************************************
  
$******************************************************************************** 
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$ 
*DATABASE_EXTENT_BINARY 
$ Control to some extent the content of specific output databases 
$ CARD1 
$[1] number of additional integration point history variables written to the binary 
database for solid elements 
$[2] number of additional integration point history variables written to the binary 
database for both shell and thick shell elements for each integration point, see 
NEIPH above  
$[3] number of shell integration points written to the binary database, see also 
*INTEGRATION_SHELL  
$[4] set to 1 to dump strain tensors for solid, shell and thick shell elements for 
plotting by LS-PREPOST and ASCII file ELOUT  
$[5] flag for including stress tensor in the shell LS-DYNA database  
$[6] flag for including the effective plastic strains in the shell LS-DYNA database 
$[7] flag for including stress resultants in the shell LS-DYNA database  
$[8] flag for including shell internal energy density and thickness in the LS-DYNA 
database 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$------NEIPH-----NEIPS----MAXINT----STRFLG----SIGFLG----EPSFLG----RLTFLG----ENGFLG---
--- 
         0         0         5         1        
$ CARD2 
$[1] orthotropic and anisotropic material stress and strain output in local material 
coordinate system for solids, shells and thick shells 
$[2] every plot state for "d3plot" database is written to a separate file  
$[3] number of beam integration points for output 
$[4] data compression to eliminate rigid body data 
$[5] output shell hourglass energy density 
$[6] output shell element time step, mass or added mass 
$[7] material energy write option for D3THDT database 
$[8] output solid part ID list containing ale materials 
$--------1---------2---------3---------4---------5---------6---------7---------8-----
---- 
$-----CMPFLG----IEVERP----BEAMIP-----DCOMP------SHGE-----STSSZ----N3THDT---IALEMAT---
---- 
         1                     
*DATABASE_BINARY_D3PLOT 
$ Options for binary output files with the default names given 
$ D3PLOT - Dt for complete output states. See also *DATABASE_EXTENT_BINARY 
$ CARD1 
$[1] DT - time interval between outputs. CYCL - output interval in time steps (a time 
step is a cycle). (1 - i.e. one result for each second of the simulation) 
$[2] NR - number of running restart files, RUNRSF, written in a cyclical fashion. 
LCDT - optional load curve ID specifying time interval between dumps 
$[3] option flag for *DATABASE_BINARY_D3PLOT or D3PART  
$[4] DT=ENDTIME/NPLTC applies to D3PLOT and D3PART only. This overrides the DT 
specified in the first field 
$[5] SET_PART ID for D3PART and D3PLOT only 
$--------1---------2---------3---------4---------5--------- 
$----DT/CYCL---LCDT/NR------BEAM-----NPLTC----PSETID------- 
   1.00E-3         0         1         0         0           
$ CARD2 
$[1] This option applies to the D3PLOT file only. Flag to govern behaviour of the 
plot frequency load curve defined by LCDT 
$--------1--------- 
$------IOOPT-------  
         0                                                                                                 
*DATABASE_BINARY_D3DUMP 
$ Options for binary output files with default names 
$ D3DUMP - binary output files. Define output frequency in cycles 
$ CARD1 
$[1] DT - time interval between outputs. CYCL - output interval in time steps (a time 
step is a cycle) 
$[2] NR - number of running restart files, RUNRSF, written in a cyclical fashion. 
LCDT - optional load curve ID specifying time interval between dumps 
$[3] option flag for *DATABASE_BINARY_D3PLOT or D3PART  
$[4] DT=ENDTIME/NPLTC applies to D3PLOT and D3PART only. This overrides the DT 
specified in the first field 
$[5] SET_PART ID for D3PART and D3PLOT only 
$--------1---------2---------3---------4---------5--------- 
$----DT/CYCL---LCDT/NR------BEAM-----NPLTC----PSETID------- 
     20000  
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*DATABASE_BINARY_D3THDT 
$ Options for binary output files with default names 
$ D3THDT - dt for time history data of element subsets. See *DATABASE_HISTORY 
$ CARD1 
$[1] DT - time interval between outputs. CYCL - output interval in time steps (a time 
step is a cycle) 
$--------1---------2--------- 
$----DT/CYCL---LCDT/NR------ 
 2.0000E-4 
*DATABASE_BINARY_RUNRSF 
$ Options for binary output files with default names 
$ RUNRSF - binary output restart file. Define output frequency in cycles 
$ CARD1 
$[1] DT - time interval between outputs. CYCL - output interval in time steps (a time 
step is a cycle) 
$--------1--------- 
$----DT/CYCL--- 
     99999 
*DATABASE_BINARY_XTFILE 
$ Options for binary output files with default names 
$ XTFILE - flag to specify output of extra time  history data to XTFILE at same time 
as D3THDT file. The following card is left black for this option 
$ CARD1 
$[1] DT - time interval between outputs. CYCL - output interval in time steps (a time 
step is a cycle) 
$--------1---------2---------3---------4--------- 
$----DT/CYCL---LCDT/NR------BEAM-----NPLTC------- 
     0.000         0         0         0 
*DATABASE_GLSTAT 
$ Global data. Always obtained if SSSTAT file is activated 
  0.000682         0         0         0         0         0                   0   
*END 
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Appendix	E 	
Figure	E.1:	Reverse	flow	volumes	in	millilitres;	average	of	3	UCL	 transcatheter	mitral	
valves	in	holder	sizes	20-25	mm	at	a	cardiac	output	of	5	lpm.	
Figure	 E.2:	 Closing	 volumes	 for	 the	 UCL	 transcatheter	 mitral	 valve	 at	 six	 different	
cardiac	outputs	in	holder	sizes	20-25	mm,	average	of	three	prototypes.	
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Figure	E.3:	Leakage	volume	for	 the	UCL	transcatheter	mitral	valve	at	six	different	cardiac	
outputs	in	holder	sizes	20-25	mm,	average	of	three	prototypes.	
Figure	E.4:	Total	regurgitant	volume	for	the	UCL	transcatheter	mitral	valve	at	six	different	
cardiac	outputs	in	holder	sizes	20-25	mm,	average	of	three	prototypes.	
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Figure	 E.6:	 Energy	 losses	 as	 a	 percentage	 of	 ventricular	 energy;	 average	 of	 3	 UCL	
transcatheter	mitral	valves	in	holder	sizes	20-25	mm	at	a	cardiac	output	of	5	lpm.	
Figure	 E.5:	 Energy	 losses	 in	 millijoules;	 average	 of	 3	 UCL	 transcatheter	 mitral	 valves	 in	
holder	sizes	20-25	mm	at	a	cardiac	output	of	5	lpm.	
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Figure	E.7:	Diastolic	energy	losses	in	millijoules	for	the	UCL	transcatheter	mitral	valve	at	six	
different	cardiac	outputs	in	holder	sizes	20-25	mm,	average	of	three	prototypes.	
Figure	 E.8:	 Diastolic	 energy	 losses	 as	 a	 percentage	 of	 ventricular	 energy	 for	 the	 UCL	
transcatheter	 mitral	 valve	 at	 six	 different	 cardiac	 outputs	 in	 holder	 sizes	 20-25	 mm,	
average	of	three	prototypes.	
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Figure	E.10:	Closing	energy	losses	in	millijoules	for	the	UCL	transcatheter	mitral	valve	at	six	
different	cardiac	outputs	in	holder	sizes	20-25	mm,	average	of	three	prototypes.	
Figure	 E.9:	 Closing	 energy	 losses	 as	 a	 percentage	 of	 ventricular	 energy	 for	 the	 UCL	
transcatheter	 mitral	 valve	 at	 six	 different	 cardiac	 outputs	 in	 holder	 sizes	 20-25	 mm,	
average	of	three	prototypes.	
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Figure	 E.12:	 Leakage	 energy	 losses	 as	 a	 percentage	 of	 ventricular	 energy	 for	 the	 UCL	
transcatheter	 mitral	 valve	 at	 six	 different	 cardiac	 outputs	 in	 holder	 sizes	 20-25	 mm,	
average	of	three	prototypes.	
Figure	E.113:		Leakage	energy	losses	in	millijoules	for	the	UCL	transcatheter	mitral	valve	at	
six	different	cardiac	outputs	in	holder	sizes	20-25	mm,	average	of	three	prototypes.	
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Figure	E.14:		Total	energy	 losses	in	millijoules	for	the	UCL	transcatheter	mitral	valve	at	six	
different	cardiac	outputs	in	holder	sizes	20-25	mm,	average	of	three	prototypes.	
Figure	 E.13:	 Total	 energy	 losses	 as	 a	 percentage	 of	 ventricular	 energy	 for	 the	 UCL	
transcatheter	 mitral	 valve	 at	 six	 different	 cardiac	 outputs	 in	 holder	 sizes	 20-25	 mm,	
average	of	three	prototypes.	
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Figure	E.15:	Closing	volume	for	three	mean	back	pressures	for	three	simulated	heart	rates,	
average	of	three	UCL	transcatheter	mitral	valve	prototypes	in	a	24	mm	holder.	
Figure	 E.16:	 Leakage	 volume	 for	 three	 mean	 back	 pressures	 for	 three	 simulated	 heart	
rates,	average	of	three	UCL	transcatheter	mitral	valve	prototypes	in	a	24	mm	holder.	
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Figure	E.17:	Total	regurgitant	volumes	for	three	mean	back	pressures	for	three	simulated	
heart	rates,	average	of	three	UCL	transcatheter	mitral	valve	prototypes	in	a	24	mm	holder.	
Figure	 E.18:	 Regurgitation	 fraction	 for	 three	 mean	 back	 pressures	 for	 three	 simulated	
heart	rates,	average	of	three	UCL	transcatheter	mitral	valve	prototypes	in	a	24	mm	holder.	
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Figure	 E.19:	 Effective	 orifice	 area	 for	 three	 different	 mean	 back	 pressures	 for	 three	
simulated	heart	rates,	average	of	three	UCL	transcatheter	mitral	valve	prototypes	 in	a	24	
mm	holder.	
Figure	 E.204:	Diastolic	energy	 loss	 in	millijoules	 for	 three	mean	back	pressures	 for	 three	
simulated	heart	rates,	average	of	three	UCL	transcatheter	mitral	valve	prototypes	 in	a	24	
mm	holder.	
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Figure	 E.21:	Diastolic	 energy	 loss	 as	 a	 percentage	 of	 ventricular	 energy	 for	 three	 mean	
back	pressures	for	three	simulated	heart	rates,	average	of	three	UCL	transcatheter	mitral	
valve	prototypes	in	a	24	mm	holder.	
Figure	 E.22:	 Closing	 energy	 loss	 in	 millijoules	 for	 three	 mean	 back	 pressures	 for	 three	
simulated	heart	rates,	average	of	three	UCL	transcatheter	mitral	valve	prototypes	 in	a	24	
mm	holder.	
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Figure	E.23:	Closing	energy	loss	as	a	percentage	of	ventricular	energy	for	three	mean	back	
pressures	for	three	simulated	heart	rates,	average	of	three	UCL	transcatheter	mitral	valve	
prototypes	in	a	24	mm	holder.	
Figure	 E.24:	 Leakage	 energy	 loss	 in	 millijoules	 for	 three	 mean	 back	 pressures	 for	 three	
simulated	heart	rates,	average	of	three	UCL	transcatheter	mitral	valve	prototypes	 in	a	24	
mm	holder.	
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Figure	 E.255:	 Leakage	 energy	 loss	 as	 a	 percentage	of	 ventricular	 energy	 for	 three	mean	
back	pressures	for	three	simulated	heart	rates,	average	of	three	UCL	transcatheter	mitral	
valve	prototypes	in	a	24	mm	holder.	
Figure	 E.26:	 Total	 energy	 loss	 in	 millijoules	 for	 three	 mean	 back	 pressures	 for	 three	
simulated	heart	rates,	average	of	three	UCL	 transcatheter	mitral	valve	prototypes	 in	a	24	
mm	holder.	
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Figure	E.27:	Total	 energy	 loss	as	a	percentage	of	ventricular	energy	 for	 three	mean	back	
pressures	for	three	simulated	heart	rates,	average	of	three	UCL	transcatheter	mitral	valve	
prototypes	in	a	24	mm	holder.	
